0001551152country:USabbv:EyeCareMemberabbv:RestasisMember2020-01-012020-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K
|
| | | | | | | |
| (MARK ONE) | | |
x☒ | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2021
OR | | | | | | | | |
OR |
o☐ | | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2018 |
For the transition period from to
Commission file number 001-35565
AbbVie Inc.
(Exact name of registrant as specified in its charter) |
| | | | | | | |
Delaware | | 32-0375147 |
| (State or other jurisdiction of
incorporation or organization)
| | 32-0375147
(I.R.S. employer
identification number)
|
| | |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices) (Zip Code)
| | (847) 932-7900
(Telephone number)
|
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(847) 932-7900
(Address, including zip code, and telephone number of principal executive offices)
Securities Registered Pursuant to Section 12(b) of the Act:
|
| | | | | | | | | | | | | |
| Title of Each Class | | Trading Symbol(s) | | Name of Each Exchange on Which Registered |
| Common Stock, par value $0.01 per share | | ABBV | | New York Stock Exchange |
| | | | Chicago Stock Exchange |
| 1.500% Senior Notes due 2023 | | ABBV23B | | New York Stock Exchange |
| 1.375% Senior Notes due 2024 | | ABBV24 | | New York Stock Exchange |
| 1.250% Senior Notes due 2024 | | ABBV24B | | New York Stock Exchange |
| 0.750% Senior Notes due 2027 | | ABBV27 | | New York Stock Exchange |
| 2.125% Senior Notes due 2028 | | ABBV28 | | New York Stock Exchange |
| 2.625% Senior Notes due 2028 | | ABBV28B | | New York Stock Exchange |
| 2.125% Senior Notes due 2029 | | ABBV29 | | New York Stock Exchange |
| 1.250% Senior Notes due 2031 | | ABBV31 | | New York Stock Exchange |
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes x ☒ No o☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.
Yes o☐ No x☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes x☒ No o☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x☒ No o☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. |
| | | | | | | | | | |
Large Accelerated Filerx | ☒ | Accelerated Filero | | Non-accelerated Filer o
☐ |
Non-Accelerated Filer | ☐ | Smaller Reporting Company oreporting company | ☐ |
| | Emerging Growth Company ogrowth company | | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes o☐ No x☒
The aggregate market value of the 1,498,817,4591,751,117,802 shares of voting stock held by non-affiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of AbbVie Inc.'s most recently completed second fiscal quarter (June 30, 2018)2021), was $138,865,437,576.$197,245,909,217. AbbVie has no non-voting common equity.
Number of common shares outstanding as of February 8, 2019: 1,475,083,514January 31, 2022: 1,768,753,829
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the 20192022 AbbVie Inc. Proxy Statement are incorporated by reference into Part III. The Definitive Proxy Statement will be filed on or about March 22, 2019.21, 2022.
ABBVIE INC.
FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 20182021
TABLE OF CONTENTS
| | | | | | | | |
| | Page No. |
| | |
| Item 1. | | |
| Item 1A. | | |
| Item 1B. | | |
| Item 2. | | |
| Item 3. | | |
| Item 4. | | |
| | |
| | |
| | Page No. |
| | |
Item 1. | | |
Item 1A. | | |
Item 1B. | | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
| | |
| | |
| | |
| Item 5. | | |
| Item 6. | | |
| Item 7. | | |
| Item 7A. | | |
| Item 8. | | |
| Item 9. | | |
| Item 9A. | | |
| Item 9B. | | |
| | |
| | |
| Item 10. | | |
| Item 11. | | |
| Item 12. | | |
| Item 13. | | |
| Item 14. | | |
| | |
| | |
| Item 15. | | |
| Item 16. | | |
| | |
| | |
PART I
ITEM 1. BUSINESS
Overview
AbbVie(1)is a global, diversified research-based biopharmaceutical company.company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, hematologic oncology, neuroscience, aesthetics and eye care. AbbVie developsuses its expertise, dedicated people and marketsunique approach to innovation to develop and market advanced therapies that address some of the world'sworld’s most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.
Impact of the Coronavirus Disease 2019 (COVID-19)
The novel coronavirus (COVID-19) pandemic continues to spread throughout the United States and around the world. As COVID-19 continues to have an impact worldwide, AbbVie is focused on the health and safety of its employees, health care professionals and patients and communities. In the continued operation of its business, AbbVie has followed health and safety guidance from relevant health authorities, managed manufacturing and supply chain resources and monitored closely its clinical trial sites. See Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations—Impact of the Coronavirus Disease 2019 (COVID-19)."
Segments
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in oneorder to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, development, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment—pharmaceutical products.segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. See Note 1516, "Segment and Geographic Area Information" to the Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data" and the sales information related to HUMIRA, IMBRUVICAAbbVie's key products and MAVYRETgeographies included under Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."
(1)As used throughout the text of this report on Form 10-K, the terms "AbbVie" or "the company" refer to AbbVie Inc., a Delaware corporation, or AbbVie Inc. and its consolidated subsidiaries, as the context requires.
| | | | | | | | | | | |
1 |  |2021 Form 10-K | | |
Products
AbbVie's portfolio of products includes a broad line of therapies that address some of the world's most complex and serious diseases.
HUMIRA. HUMIRAImmunology products. AbbVie maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology. AbbVie's immunology products address unmet needs for patients with autoimmune diseases. These products are:
Humira. Humira (adalimumab) is a biologic therapy administered as a subcutaneous injection. It is approved to treat the following autoimmune diseases in the United States, Canada and Mexico (collectively, North America) and in the European Union:
|
| | | | | | | |
| Condition | | Principal Markets |
| Rheumatoid arthritis (moderate to severe) | | North America, European Union |
| Psoriatic arthritis | | North America, European Union |
| Ankylosing spondylitis | | North America, European Union |
| Adult Crohn's disease (moderate to severe) | | North America, European Union |
| Plaque psoriasis (moderate to severe chronic) | | North America, European Union |
| Juvenile idiopathic arthritis (moderate to severe polyarticular) | | North America, European Union |
| Ulcerative colitis (moderate to severe) | | North America, European Union |
| Axial spondyloarthropathy | | European Union |
| Pediatric Crohn's disease (moderate to severe) | | North America, European Union |
Hidradenitis Suppurativasuppurativa (moderate to severe) | | North America, European Union |
| Pediatric enthesitis-related arthritis | | European Union |
| Non-infectious intermediate, posterior and panuveitis | | North America, European Union |
| Pediatric ulcerative colitis (moderate to severe) | | U.S., Canada, European Union |
| Pediatric uveitis | | North America, European Union |
HUMIRAHumira is also approved in Japan for the treatment of intestinal Behçet's disease.disease and pyoderma gangrenosum.
HUMIRAHumira is sold in numerous other markets worldwide, including Japan, China, Brazil and Australia, and accounted for approximately 61%37% of AbbVie's total net revenues in 2018.2021.
Skyrizi. Skyrizi (risankizumab) is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. It is a biologic therapy administered as a quarterly subcutaneous injection following two induction doses. Skyrizi is approved in the United States, Canada, Mexico and the European Union and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In the United States and the European Union, Skyrizi is additionally approved for the treatment of active psoriatic arthritis in adult patients who have an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). In Japan, Skyrizi is approved for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.
Rinvoq. Rinvoq (upadacitinib) is an oral, once-daily selective and reversible JAK inhibitor that is approved to treat the following inflammatory diseases in North America, Japan and the European Union:
| | | | | | | | |
(1)Condition | As used throughout the text of this report on Form 10-K, the terms "AbbVie" or "the company" refer | Principal Markets |
Rheumatoid arthritis (moderate to AbbVie Inc.severe) | | North America, European Union, Japan |
| Psoriatic arthritis | | U.S., a Delaware corporation, or AbbVie Inc. and its consolidated subsidiaries, as the context requires.Canada, European Union, Japan |
| Ankylosing spondylitis | | European Union |
| Atopic dermatitis (moderate to severe) | | U.S., Canada, European Union, Japan |
In the United States, Rinvoq is indicated for both the treatment of moderate to severe active rheumatoid arthritis, and for active psoriatic arthritis, in adult patients who have an inadequate response or intolerance to one or more TNF blockers. It is also indicated for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |1
| 2 |
Oncology products.AbbVie’s oncology products target some of the most complex and difficult-to-treat cancers. These products are:
IMBRUVICA.IMBRUVICAImbruvica.Imbruvica (ibrutinib) is an oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). IMBRUVICAkinase. Imbruvica was one of the first medicines to receive a United States Food and Drug Administration (FDA) approval after being granted a Breakthrough Therapy Designation and is one of the few therapies to receive four separate designations. IMBRUVICAImbruvica currently is approved for the treatment of adult patients with:
Chronicwith blood cancers such as chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) and CLL/SLL with 17p deletion;, as well as certain forms of non-Hodgkin lymphoma.
Mantle cell lymphoma (MCL) who have received at least one prior therapy*;
Waldenström’s macroglobulinemia (WM);
Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy*; and
Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
* Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
VENCLEXTA.VENCLEXTAVenclexta/Venclyxto. Venclexta (venetoclax) is a BCL-2B-cell lymphoma 2 (BCL-2) inhibitor used to treat hematological malignancies. Venclexta is approved by the FDA for adults with CLL or SLL, with or without 17p deletion, who have received at least one prior treatment.SLL. In addition, VENCLEXTAVenclexta is usedapproved in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who are 75 years of age or older orhave other medical conditions that prevent the use of standard chemotherapy.
Virology Products. Aesthetics products. AbbVie’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring and skincare products, which hold market-leading positions in the U.S. and in key markets around the world. These products are:
Botox Cosmetic. Botox Cosmetic is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for treatment in three areas: temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows), moderate to severe crow's feet and moderate to severe forehead lines in adults. Having received its initial FDA approval in 2002, Botox Cosmetic is now approved for use in all major markets around the world and has become one of the world’s most recognized and iconic brands.
The Juvederm Collection of Fillers. The Juvederm Collection of Fillers is a portfolio of hyaluronic acid-based dermal fillers with a variety of approved indications in the U.S. and in other major markets around the world to augment or treat volume loss in the cheeks, chin, lips and lower face.
Other aesthetics. Other aesthetics products include, but are not limited to, Coolsculpting body contouring technology, Alloderm regenerative dermal tissue, Natrelle breast implants, the SkinMedica skincare line and DiamondGlow dermabrasion technology.
Neuroscience products. AbbVie’s neuroscience products address some of the most difficult-to-treat neurologic diseases. These products are:
Botox Therapeutic. Botox Therapeutic (onabotulinumtoxinA injection) is a neuromuscular blocking agent that is injected into muscle tissue in treatment for the following indications in the United States:
•Prophylaxis of headaches in adult patients with chronic migraine (≥ 15 days per month with headache lasting 4 hours a day or longer).
•Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
•Urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
•Spasticity in patients 2 years of age and older.
•Cervical dystonia in adults to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
•Strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.
•Severe primary axillary hyperhidrosis that is inadequately managed with topical agents. Licenses around the world vary.
•Focal spasticity associated with dynamic equinus foot deformity due to spasticity in ambulant pediatric cerebral palsy patients 2 years of age or older.
| | | | | | | | | | | |
3 | |2021 Form 10-K | | |
•Focal spasticity of the wrist and hand in adult post stroke patients.
•Focal spasticity of the ankle and foot in adult post stroke patients.
Vraylar. Vraylar (cariprazine) is a dopamine D3-preferring D3/D2 receptor partial agonist and a 5-HT1A receptor partial agonist. Its D3 binding profile may be linked to observed improvements in the negative symptoms of schizophrenia and to antidepressant effects in bipolar I disorder (bipolar depression). Vraylar is indicated for acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar disorder in adults and acute treatment of depressive episodes associated with bipolar I disorder in adults.
Duopa and Duodopa (carbidopa and levodopa). AbbVie's virologylevodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States.
Ubrelvy. Ubrelvy (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults and is only commercialized in the United States.
Other neuroscience. Other neuroscience products includeQulipta (atogepant), which is indicated for preventive treatment of episodic migraine in adults.
Eye care products. AbbVie’s eye care products address unmet needs and new approaches to help preserve and protect patients’ vision. These products are:
Lumigan/Ganfort. Lumigan (bimatoprost ophthalmic solution) 0.01% is a once daily, topical prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). Ganfort is a once daily topical fixed combination of bimatoprost 0.03% and timolol 0.5% for the reduction of IOP in adult patients with OAG or OHT. Lumigan is sold in the United States and numerous markets around the world, while Ganfort is approved in the European Union and some markets in South America, the Middle East and Asia.
Alphagan/Combigan. Alphagan (brimonidine tartrate ophthalmic solution) is an alpha-adrenergic receptor agonist indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) is approved for reducing elevated IOP in patients with glaucoma who require additional or adjunctive IOP-lowering therapy. Both Alphagan and Combigan are available for sale in the United States and numerous markets around the world.
Restasis. Restasis is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Restasis is approved in the United States and a number of other markets in South America, the Middle East and Asia.
Other eye care. Other eye care products include Xen, Durysta, Ozurdex, Refresh/Optive and Vuity.
Women's health products. AbbVie’s women's health products are:
Lo Loestrin. Lo Loestrin Fe is an oral contraceptive. It is indicated for prevention of pregnancy with the lowest dose of estrogen with only 10mcg and is dispensed in a unique 24/2/2 regimen with a two-day hormone-free interval. It is marketed in the U.S. as Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) and in select markets outside the U.S. as Lolo.
Orilissa/Oriahnn. Orilissa (elagolix) is the first and only orally-administered, nonpeptide small molecule gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain. It represents the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade. Orilissa inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, leading to decreased blood concentrations of ovarian sex hormones, estradiol and progesterone. Outside the United States, Orilissa is also launched in Canada. Oriahnn (elagolix, estradiol and norethindrone acetate capsules; elagolix capsules) is a combination prescription medicine used to control heavy menstrual bleeding related to uterine fibroids in women before menopause.
Other women's health. Other women's health includes Liletta, a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to six years.
Other key products. AbbVie’s other key products include, among other things, treatments for patients living with HCVhepatitis C virus (HCV), metabolic and HIV.hormone products that target a number of conditions, including exocrine pancreatic insufficiency and hypothyroidism, as well as endocrinology products for the palliative treatment of advanced prostate
HCV products. AbbVie's HCV | | | | | | | | | | | |
| | 2021 Form 10-K | | 4 |
cancer, treatment of endometriosis and central precocious puberty and for the preoperative treatment of patients with anemia caused by uterine fibroids. These products are:
MAVYRET/MAVIRET. MAVYRETMavyret/Maviret. Mavyret (glecaprevir/pibrentasvir) is approved in the United States and European Union (MAVIRET)(Maviret) for the treatment of adult and pediatric patients (12 years and older or weighing at least 45 kilograms) with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). It is also indicated for the treatment of adult and pediatric patients (12 years and older or weighing at least 45 kilograms) with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. It is an 8-week, pan-genotypic treatment for patients without cirrhosis and following the EXPEDITION-8 study, also in patients with compensated cirrhosis who are new to treatment.
VIEKIRA PAK AND TECHNIVIE. VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including those with compensated cirrhosis. In Europe, VIEKIRA PAK is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV. AbbVie's TECHNIVIE (ombitasvir, paritaprevir and ritonavir) is FDA-approved for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.
Additional Virology products. AbbVie's additional virology products include:
SYNAGIS. SYNAGIS (palivizumab) is a product marketed by AbbVie outside of the United States that protects at-risk infants from severe respiratory disease caused by respiratory syncytial virus (RSV).
KALETRA. KALETRA (lopinavir/ritonavir), which is also marketed as Aluvia in emerging markets, is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. KALETRA is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1.
NORVIR. NORVIR (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
|
| | |
2  |2018 Form 10-K
| | |
Metabolics/Hormones products. Metabolic and hormone products target a number of conditions, including testosterone deficiency due to certain underlying conditions, exocrine pancreatic insufficiency and hypothyroidism. These products include:
CREON. CREONCreon. Creon (pancrelipase) is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis and several other conditions.
Synthroid. Synthroid (levothyroxine sodium tablets, USP) is used in the treatment of hypothyroidism.
AndroGel. AndroGel (testosterone gel) is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone due to certain underlying conditions.
AbbVie has the rights to sell AndroGel, CREON and Synthroid only in the United States.
Endocrinology products.Lupron. Lupron (leuprolide acetate), which is also marketed as Lucrin and LUPRON DEPOT,Lupron Depot, is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection.
Other products. AbbVie's other products include:
ORILISSA. ORILISSA (elagolix)Linzess/Constella. Linzess (linaclotide) is the firsta once-daily guanylate cyclase-C agonist used in adults to treat irritable bowel syndrome with constipation (IBS‑C) and only orally-administered, nonpeptide small molecule gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.chronic idiopathic constipation (CIC). The FDA approved ORILISSA under priority review. It represents the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade. ORILISSA inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, leading to decreased blood concentrations of ovarian sex hormones, estradiol and progesterone.
Duopa and Duodopa (carbidopa and levodopa). AbbVie's levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's diseaseproduct is marketed as DuopaLinzess in the United States and as DuodopaConstella outside of the United States.
Sevoflurane. Sevoflurane (sold underSynthroid. Synthroid (levothyroxine sodium tablets, USP) is used in the trademarks Ultanetreatment of hypothyroidism.
AbbVie has the rights to sell Creon and Sevorane) is an anesthesia product that AbbVie sells worldwide for human use.Synthroid only in the United States.
Marketing, Sales and Distribution Capabilities
AbbVie utilizes a combination of dedicated commercial resources, regional commercial resources and distributorships to market, sell and distribute its products worldwide.
AbbVie directs its primary marketing efforts toward securing the prescription, or recommendation, of its brand of products by physicians, key opinion leaders and other health care providers. Managed care providers (for example, health maintenance organizations and pharmacy benefit managers), hospitals and state and federal government agencies (for example, the United States Department of Veterans Affairs and the United States Department of Defense) are also important customers. AbbVie also markets directly to consumers themselves, although in the United States allmany of the company's products must be sold pursuant to a prescription. Outside of the United States, AbbVie focuses its marketingpromotional and market access efforts on key opinion leaders, payers, physicians and country regulatory bodies.health systems. AbbVie also provides patient support programs closely related to its products. Throughout the COVID-19 pandemic AbbVie has maintained its promotional activities with key stakeholders by leveraging digital engagement where permitted and in compliance with the locally applicable government guidance.
AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. Although AbbVie's business does not have significant seasonality, AbbVie's product revenues may be affected by end customer and retail buying patterns, fluctuations in wholesaler inventory levels and other factors.
In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, and patients.patients or other customers. In 2018,2021, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and AmerisourceBergen Corporation) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. No individual wholesaler accounted for greater than 42%37% of AbbVie's 20182021 gross revenues in the United States. Outside the United States, AbbVie sells products are sold primarily to customers or through distributors, depending on the market served. These wholesalers purchase product from AbbVie under standard terms and conditions of sale.
Certain products are co-marketed or co-promoted with other companies. AbbVie has no single customer that, if the customer were lost, would have a material adverse effect on the company's business. No material portion of AbbVie's
|
| | |
| | 2018 Form 10-K | 3
|
business is subject to renegotiation of profits or termination of contracts at the election of the government. Orders are generally filled on a current basis and order backlog is not material to AbbVie's business.
Competition
The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies
| | | | | | | | | | | |
5 | |2021 Form 10-K | | |
and biologics. For example, HUMIRAHumira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and AbbVie's virology products competeMavyret/Maviret competes with other available HCV treatment options. In addition, in the past few years, a number of other companies have started to develop, have successfully developed and/or are currently marketing products that are being positioned as competitors to Botox. The search for technological innovations in pharmaceutical products is a significant aspect of competition. The introduction of new products by competitors and changes in medical practices and procedures can result in product obsolescence. Price is also a competitive factor. In addition, the substitution of generic pharmaceutical products for branded conventional (small-molecule) pharmaceutical products creates competitive pressures on AbbVie's products that do not have patent protection. New products or treatments brought to market by AbbVie’s competitors could cause revenues for AbbVie’s products to decrease due to price reductions and sales volume decreases.
Biosimilars. Competition for AbbVie’s biologic products is affected by the approval of follow-on biologics, also known as “biosimilars.” Biologics have added major therapeutic options for the treatment of many diseases, including some for which therapies were unavailable or inadequate. The cost of developing and producing biologic therapies is typically dramatically higher than for conventional (small molecule)small molecule medications, and many biologic medications are used for ongoing treatment of chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of previously untreatable cancer. Significant investments in biologics infrastructure and manufacturing are necessary to produce biologic products.
HUMIRAHumira is now facing direct biosimilar competition in Europe and other countries, which represent approximately 75% of AbbVie's international HUMIRA business or approximately 25% of total global HUMIRA revenues.and AbbVie will continue to face competitive pressure from these biologics and from orally administered products.
In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act (the FFDCA), the Public Health Service Act (PHSA) and the regulations implementing regulations.these statutes. The enactment of federal health care reform legislation in March 2010 provided a pathway for approval of biosimilars under the Public Health Service Act,PHSA, but the approval process for, and science behind, biosimilars is more complex than the approval process for, and science behind, generic or other follow-on versions of small molecule products.complex. Approval by the FDA is dependent upon many factors, including a showing that the biosimilar is "highly similar" to the original product and has no clinically meaningful differences from the original product in terms of safety, purity and potency. The types of data that could ordinarily be required in an application to show similarity may include analytical data, bioequivalence studies and studies to demonstrate chemical similarity, animal studies (including toxicity studies) and clinical studies.
Furthermore, the law provides that only a biosimilar product that is determined to be "interchangeable" will be considered by the FDA as substitutable for the original biologic product without the intervention of the health care provider who prescribed the original biologic product. To prove that a biosimilar product is interchangeable, the applicant must demonstrate that the product can be expected to produce the same clinical results as the original biologic product in any given patient, and if the product is administered more than once in a patient, that safety risks and potential for diminished efficacy of alternating or switching between the use of the interchangeable biosimilar biologic product and the original biologic product is no greater than the risk of using the original biologic product without switching. The law continues to be interpreted and implemented by the FDA. As a result, its full ultimate impact, implementation and meaning remains subject to substantial uncertainty.
Intellectual Property Protection and Regulatory Exclusivity
Generally, upon approval, products may be entitled to certain kinds of exclusivity under applicable intellectual property and regulatory regimes. AbbVie’s intellectual property is materially valuable to the company, and AbbVie seeks patent protection, where available, in all significant markets and/or countries for each product in development. In the United States, the expiration date for patents is 20 years after the filing date. Given that patents relating to pharmaceutical products are often obtained early in the development process and given the amount of time needed to complete clinical trials and other development activities required for regulatory approval, the length of time between product launch and patent expiration is significantly less than 20 years. The Drug Price Competition and Patent Term Restoration Act of 1984 (commonly known as the Hatch-Waxman Act) permits a patent holder to seek a patent extension, commonly called a “patent term restoration,” for patents on products (or processes for making the product) regulated by the Federal Food, Drug, and Cosmetic Act.FFDCA. The length of the patent extension is roughly based on 50 percent of the period of time from the filing of an Investigational New Drug Application (NDA) for a compound to the submission of the NDA for such compound, plus 100 percent of the time period from NDA submission to regulatory approval. The extension, however, cannot exceed five years and the patent term remaining after
|
| | |
4 |2018 Form 10-K
| | |
regulatory approval cannot exceed 14 years. Biological products licensed under the Public Health Service ActPHSA are similarly eligible for terms of patent restoration.
Pharmaceutical products may be entitled to other forms of legal or regulatory exclusivity upon approval. The scope, length and requirements for each of these exclusivities vary both in the United States and in other jurisdictions. In the United States, if the FDA approves a conventional drug product that contains an active ingredient not previously approved, the product is typically entitled to five years of non-patent regulatory exclusivity. OtherSpecific conditions of use approved for
| | | | | | | | | | | |
| | 2021 Form 10-K | | 6 |
individual products may also be entitled to three years of exclusivity if approval was based on the FDA’s reliance on new clinical studies essential to approval submitted by the NDA applicant. If the NDA applicant studies the product for use by children, the FDA may grant pediatric exclusivity, which extends by 180 days all existing exclusivities (patent and regulatory) related to the product. For products that are either used to treat conditions that afflict a relatively small population or for which there is not a reasonable expectation that the research and development costs will be recovered, the FDA may designate the pharmaceutical as an orphan drug and grant it seven years of market exclusivity. Other types of regulatory exclusivity may also be available, such as Generating New Antibiotic Incentives Now (GAIN) exclusivity, which can provide new antibiotic or new antifungal drugs an additional five years of exclusivity to be added to certain exclusivities already provided for by law.
Applicable laws and regulations dictate the scope of any exclusivity to which a product or particular characteristics of a product is entitled upon its approval in any particular country. In certain instances, regulatory exclusivity may protect a productoffer protection where patent protection is no longer available or for a period of time in excess of patent protection. It is not possible to estimate for each product in development the total period and scope of exclusivity to which it may become entitled until regulatory approval is obtained.obtained or sometimes even later. However, given the length of time required to complete clinical development of a pharmaceutical product, the periods of exclusivity that might be achieved in any individual case would not generally be expected to exceed a minimum of three years and a maximum of 14 years. These estimates do not consider other factors, such as the difficulty of recreating the manufacturing process for a particular product or other proprietary knowledge that may delay the introduction of a generic or other follow-on product after the expiration of applicable patent and other regulatory exclusivity periods.
Biologics may be entitled to exclusivity under the Biologics Price Competition and Innovation Act, which was passed on March 23, 2010 as Title VII to the Patient Protection and Affordable Care Act. The law provides a pathway for approval of biosimilars following the expiration of 12 years of regulatory exclusivity for the innovator biologic and a potential additional 180 day-extension term for conducting pediatric studies. Biologics are also eligible for orphan drug exclusivity, as discussed above. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity and enforceability. The European Union has also created a pathway for approval of biosimilars and has published guidelines for approval of certain biosimilar products. The more complex nature of biologics and biosimilar products has led to close regulatory scrutiny over and more rigorous requirements for approval of, follow-on biosimilar products, which can reduce the effect of biosimilars on sales of the innovator biologic as compared to the sales erosion caused by generic versions of small molecule pharmaceutical products.
AbbVie owns or has licensed rights to a substantial number of patents and patent applications. AbbVie licenses or owns a patent portfolio of thousands of patent families, each of which includes United States patent applications and/or issued patents and may also contain the non-United States counterparts to these patents and applications.
These patents and applications, including various patents that expire during the period 20192022 to the late 2030s,early 2040s, in aggregate are believed to be of material importance in the operation of AbbVie’s business. However, AbbVie believes that no single patent, license, trademark (or related group of patents, licenses, or trademarks), except for those related to adalimumab (which is sold under the trademark HUMIRA)Humira), are material in relation to the company’s business as a whole. The United States composition of matter (that is, compound) patent covering adalimumab expired in December 2016, and the equivalent European Union patent expired in October 2018 in the majority of European Union countries. In the United States, non-composition of matter patents covering adalimumab expire no earlier than 2022. AbbVie has entered into settlement and license agreements with several adalimumab biosimilar manufactures. Under the agreements, the licenses in the United States will begin in 2023 and the licenses in Europe began in 2018.
In addition, the following patents, licenses and trademarks are significant: those related to ibrutinib (which is sold under the trademark IMBRUVICA)Imbruvica) and those related to glecaprevir and pibrentasvirrisankizumab (which areis sold under the trademarks MAVYRET and MAVIRET)trademark Skyrizi). The United States composition of matter patent covering ibrutinib is expected to expire in 2027.2027, however no generic entry for any ibrutinib product is expected prior to March 30, 2032, assuming pediatric exclusivity is granted. The United States composition of matter patentspatent covering glecaprevir and pibrentasvir arerisankizumab is expected to expire in 2032.
2033.
AbbVie may rely, in some circumstances, on trade secrets to protect its technology. However, trade secrets are difficult to protect. AbbVie seeks to protect its technology and product candidates, in part, by confidentiality agreements with its employees, consultants, advisors, contractors and collaborators. These agreements may be breached and AbbVie may not have adequate remedies for any breach. In addition, AbbVie’s trade secrets may otherwise become known or be independently discovered by competitors. To the extent that AbbVie’s employees, consultants, advisors, contractors and collaborators use intellectual property owned by others in their work for the company, disputes may arise as to the rights in related or resulting know-how and inventions.
|
| | | | | | | | | | |
| 7 | 2018|2021 Form 10-K| 5
| | |
Licensing, Acquisitions and Other Arrangements
In addition to its independent efforts to develop and market products, AbbVie enters into arrangements such as acquisitions, option-to-acquire agreements, licensing arrangements, option-to-license arrangements, strategic alliances, co-promotion arrangements, co-development and co-marketing agreements and joint ventures. TheseThe acquisitions and option-to-acquire agreements typically include, among other terms and conditions, non-refundable purchase price payments or option fees, option exercise payments, milestones or earn-outs and other customary terms and obligations. The licensing and other arrangements typically include, among other terms and conditions, non-refundable upfront license fees, option fees and option exercise payments, (if applicable), milestone payments and royalty and/or profit sharing obligations. See Note 5, "Licensing, Acquisitions and Other Arrangements—Other Licensing & Acquisitions Activity," to the Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data."
Third Party Agreements
AbbVie has agreements with third parties for process development, product distribution, analytical services and manufacturing of certain products. AbbVie procures certain products and services from a limited number of suppliers and, in some cases, a single supply source. In addition, AbbVie has agreements with third parties for active pharmaceutical ingredient and product manufacturing, formulation and development services, fill, finish and packaging services, transportation and distribution and logistics services for certain products. AbbVie does not believe that these manufacturing related agreements are material because AbbVie's business is not substantially dependent on any individual agreement. In most cases, AbbVie maintains alternate supply relationships that it can utilize without undue disruption of its manufacturing processes if a third party fails to perform its contractual obligations. AbbVie also maintainsseeks to maintain sufficient inventory of product to minimize the impact of any supply disruption.
AbbVie is also party to certain collaborations and other arrangements, as discussed in Note 5, "Licensing, Acquisitions and Other Arrangements—Other Licensing & Acquisitions Activity," to the Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data."
Sources and Availability of Raw Materials
AbbVie purchases, in the ordinary course of business, raw materials and supplies essential to its operations from numerous suppliers around the world. In addition, certain medical devices and components necessary for the manufacture of AbbVie products are provided by unaffiliated third party suppliers. Despite the disruption to the global supply chain caused by COVID-19, AbbVie has not experienced any recent significant availability problems orcontinued to supply patients with no material supply impact, except for the previously-disclosed near-term supply issues impacting Lupron. Given the general increased global volatility due to the pandemic, AbbVie is monitoring and taking actions to mitigate potential supply shortages that impactedwhich may impact the fulfillment of product demand.
Research and Development Activities
AbbVie makes a significant investment in research and development and has numerous compounds (and complementary devices) in clinical development, including potential treatments for complex, life-threatening diseases. AbbVie's ability to discover and develop new compounds is enhanced by the company's use of integrated discovery and development project teams, which include chemists, biologists, physicians and pharmacologists who work on the same compounds as a team. AbbVie also partners with third parties, such as biotechnology companies, other pharmaceutical companies and academic institutions to identify and prioritize promising new treatments that complement and enhance AbbVie’s existing portfolio. AbbVie also supplements its research and development efforts with acquisitions.
The research and development process generally begins with discovery research which focuses on the identification of a molecule that has a desired effect against a given disease. If preclinical testing of an identified compound proves successful, the compound moves into clinical development which generally includes the following phases:
•Phase 1—involves the first human tests in a small number of healthy volunteers or patients to assess safety, tolerability and potential dosing.doses for later phases.
•Phase 2—tests different doses of the drug's efficacy against the diseasedrug in a relatively small group of patients.disease state in order to assess efficacy.
•Phase 3—tests a drug that demonstrates favorable results in the earlier phases in a significantly larger patient population to further demonstrate efficacy and safety based on regulatory criteria.in order to meet requirements to enable global approval.
ThePreclinical data and clinical trials from all of the development phases provide the data required to prepare and submit an NDA, a Biological License Application (BLA) or other submission for regulatory approval to the FDA or similar government agencies outside the United States. The specific requirements (e.g., scope of clinical trials) for obtaining regulatory approval vary across different countries and geographic regions.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 8 |
The research and development process from discovery through a new drug launch typically takes 8 to 12 years and can be even longer. The research and development of new pharmaceutical products has a significant amount of inherent uncertainty. There is no guarantee when, or if, a molecule will receive the regulatory approval required to launch a new drug or indication.
|
| | |
6 |2018 Form 10-K
| | |
In addition to the development of new products, delivery devices, and new formulations, research and development projects also may include Phase 4 trials, sometimes called post-marketing studies. For such projects, clinical trials are designed and conducted to collect additional data regarding, among other parameters, the benefits and risks of an approved drug.
Regulation—Discovery and Clinical Development
United States. Securing approval to market a new pharmaceutical product in the United States requires substantial effort and financial resources and takes several years to complete. The applicant must complete preclinical tests and submit protocols to the FDA before commencing clinical trials. Clinical trials are intended to establish the safety and efficacy of the pharmaceutical product and typically are conducted in sequential phases, although the phases may overlap or be combined. If the required clinical testing is successful, the results are submitted to the FDA in the form of an NDA or BLA requesting approval to market the product for one or more indications. The FDA reviews an NDA or BLA to determine whether a product is safe and effective for its intended use and whether its manufacturing is compliant with current Good Manufacturing Practices (cGMP).
Compliance with regulatory requirements is assured through periodic, announced or unannounced inspections by the FDA and other regulatory authorities, and these inspections associated with clinical development may include the sponsor, investigator sites, laboratories, hospitals and manufacturing facilities of AbbVie's subcontractors or other third-party manufacturers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, including rejection of an NDA or BLA.
Even if an NDA or a BLA receives approval, the applicant must comply with post-approval requirements. For example, holders of an approval must report adverse reactions, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional materials and activities. Also, quality control and manufacturing procedures must continue to conform to cGMP after approval, and certain changes to the manufacturing procedures and finished product must be included in the NDA or BLAsubmitted and approved by the FDA prior to implementation. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural and record keeping requirements. In addition, as a condition of approval, the FDA may require post-marketing testing and surveillance to further assess and monitor the product's safety or efficacy after commercialization, which may require additional clinical trials, patient registries, observational data or additional work on chemistry, manufacturing and controls. Any post-approval regulatory obligations, and the cost of complying with such obligations, could expand in the future. Further, the FDA continues to regulate product labeling, and prohibits the promotion of products for unapproved or “off-label” uses along with other labeling restrictions.
Outside the United States. AbbVie is subject to similar regulatory requirements outside the United States for approval and marketing of pharmaceutical products. AbbVie must obtain approval of a clinical trial application or product from the applicable supervising regulatory authorities before it can commence clinical trials or marketing of the product.product in target markets. The approval requirements and process for each country can vary, and the time required to obtain approval may be longer or shorter than that required for FDA approval in the United States. For example, AbbVie may submit marketing authorizations in the European Union under either a centralized or decentralized procedure. The centralized procedure is mandatory for the approval of biotechnology products and many pharmaceutical products and provides for a single marketing authorization that is valid for all European Union member states. Under the centralized procedure, a single marketing authorization application is submitted to the European Medicines Agency (EMA).Agency. After the agency evaluates the application, it makes a recommendation to the European Commission, which then makes the final determination on whether to approve the application. The decentralized procedure provides for mutual recognition of individual national approval decisions and is available for products that are not subject to the centralized procedure.
In Japan, applications for approval of a new product are made through the Pharmaceutical and Medical Devices Agency (PMDA). BridgingJapan-specific trials and/or bridging studies to demonstrate that the non-Japanese clinical data applies to Japanese patients may be required. After completing a comprehensive review, the PMDA reports to the Ministry of Health, Labour and Welfare, which then approves or denies the application.
Similarly, applications for a new product in China are submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for technical review and approval of a product for marketing in China. Clinical data in Chinese subjects are usually required to support approval in China, requiring the inclusion of China in global pivotal studies, or a separate China/Asian clinical trial.
| | | | | | | | | | | |
9 | |2021 Form 10-K | | |
The regulatory process in many emerging markets continues to evolve. Many emerging markets, including those in Asia, generally require regulatory approval to have been obtained in a large developed market (such as the United States or Europe) before the country will begin or complete its regulatory review process. SomeSimilar to the requirements in Japan and China, certain countries (notably South Korea, Taiwan, India and Russia) also generally require that local clinical studies be conducted in order to obtainsupport regulatory approval in the country.
The requirements governing the conduct of clinical trials and product licensing also vary. In addition, post-approval regulatory obligations such as adverse event reporting and cGMP compliance generally apply and may vary by country. For example, after a marketing authorization has been granted in the European Union, periodic safety reports must be submitted and other pharmacovigilance measures may be required (such as Risk Management Plans).
Regulation—Commercialization, Distribution and Manufacturing
The manufacture,manufacturing, marketing, sale, promotion and distribution of AbbVie's products are subject to comprehensive government regulation. Government regulation by various national, regional, federal, state and local agencies, both in the United States and other countries, addresses (among other matters) inspection of, and controls over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, labeling, packaging, marketing and promotion, pricing and reimbursement, sampling, distribution, quality control, post-marketing surveillance, record keeping, storage and disposal practices. AbbVie's operations are also affected by trade regulations in many countries that limit the import of raw
|
| | |
| | 2018 Form 10-K | 7
|
materials and finished products and by laws and regulations that seek to prevent corruption and bribery in the marketplace (including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, which provide guidance on corporate interactions with government officials) and require safeguards for the protection of personal data. In addition, AbbVie is subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-kickback and false claims laws in the United States. Prescription drug manufacturers such as AbbVie are also subject to taxes, as well as application, product, user and other fees.
Compliance with these laws and regulations is costly and materially affects AbbVie's business. Among other effects, health care regulations substantially increase the time, difficulty and costs incurred in obtaining and maintaining approval to market newly developed and existing products. AbbVie expects compliance with these regulations to continue to require significant technical expertise and capital investment to ensure compliance. Failure to comply can delay the release of a new product or result in regulatory and enforcement actions, the seizure or recall of a product, the suspension or revocation of the authority necessary for a product's production and sale and other civil or criminal sanctions, including fines and penalties.
In addition to regulatory initiatives, AbbVie's business can be affected by ongoing studies of the utilization, safety, efficacy and outcomes of health care products and their components that are regularly conducted by industry participants, government agencies and others. These studies can call into questionlead to updates to the data regarding utilization, safety and efficacy of previously marketed products. In some cases, these studies have resulted, and may in the future result, in the discontinuance of, or limitations on, marketing of such products domestically or worldwide, and may give rise to claims for damages from persons who believe they have been injured as a result of their use.
Access to human health care products continues to be a subject of oversight, investigation and action by governmental agencies, legislative bodies and private organizations in the United States and other countries. A major focus is cost containment. Efforts to reduce health care costs are also being made in the private sector, notably by health care payers and providers, which have instituted various cost reduction and containment measures. AbbVie expects insurers and providers to continue attempts to reduce the cost of health care products. Outside the United States, many countries control the price of health care products directly or indirectly, through reimbursement, payment, pricing, coverage limitations, or compulsory licensing. Political and budgetary pressures in the United States and in other countries may also heighten the scope and severity of pricing pressures on AbbVie's products for the foreseeable future.
United States. Specifically, U.S. federal laws require pharmaceutical manufacturers to pay certain statutorily-prescribed rebates to state Medicaid programs on prescription drugs reimbursed under state Medicaid plans, and the efforts by states to seek additional rebates may affect AbbVie's business. Similarly, the Veterans Health Care Act of 1992, as a prerequisite to participation in Medicaid and other federal health care programs, requires that manufacturers extend additional discounts on pharmaceutical products to various federal agencies, including the United States Department of Veterans Affairs, Department of Defense and Public Health Service entities and institutions. In addition, recent legislative changes would require similarly discounted prices to be offered to TRICARE program beneficiaries. The Veterans Health Care Act of 1992 also established the 340B drug discount program, which requires pharmaceutical manufacturers to provide products at reduced prices to various designated health care entities and facilities.
In the United States, most states also have generic substitution legislation requiring or permitting a dispensing pharmacist to substitute a different manufacturer's generic version of a pharmaceutical product for the one prescribed. In
| | | | | | | | | | | |
| | 2021 Form 10-K | | 10 |
addition, the federal government follows a diagnosis-related group (DRG) payment system for certain institutional services provided under Medicare or Medicaid and has implemented a prospective payment system (PPS) for services delivered in hospital outpatient, nursing home and home health settings. DRG and PPS entitle a health care facility to a fixed reimbursement based on the diagnosis and/or procedure rather than actual costs incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many health care products. Medicare reimburses Part B drugs based on average sales price plus a certain percentage to account for physician administration costs, which have been reduced in the hospital outpatient setting. Medicare enters into contracts with private plans to negotiate prices for most patient-administered medicine delivered under Part D.
Under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (together, the Affordable Care Act), AbbVie pays a fee related to its pharmaceuticals sales to government programs. In addition, AbbVie provides a discount of 50%70% for branded prescription drugs sold to patients who fall into the Medicare Part D coverage gap, or "donut hole."
The Affordable Care Act also includes provisions known as the Physician Payments Sunshine Act, which require manufacturers of drugs and biologics covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data to the Centers for Medicare and Medicaid Services for subsequent public disclosure. Similar reporting requirements have also been enacted on the state level in the United States, and an increasing number of
|
| | |
8 |2018 Form 10-K
| | |
countries worldwide either have adopted or are considering similar laws requiring disclosure of interactions with health care professionals. Failure to report appropriate data may result in civil or criminal fines and/or penalties.
AbbVie expects debate to continue during 20192022 at all government levels worldwide over the marketing, availability, method of delivery and payment for health care products and services. AbbVie believes that future legislation and regulation in the markets it serves could affect access to health care products and services, increase rebates, reduce prices or the rate of price increases for health care products and services, change health care delivery systems, create new fees and obligations for the pharmaceuticals industry, or require additional reporting and disclosure. It is not possibledifficult to predict the extent to which AbbVie or the health care industry in general might be affected by the matters discussed above.
European Union. The European Union has adopted directives and other legislation governing labeling, advertising, distribution, supply, pharmacovigilance and marketing of pharmaceutical products. Such legislation provides mandatory standards throughout the European Union and permits member states to supplement these standards with additional regulations. European governments also regulate pharmaceutical product prices through their control of national health care systems that fund a large part of the cost of such products to consumers. As a result, patients are unlikely to use a pharmaceutical product that is not reimbursed by the government. In many European countries, the government either regulates the pricing of a new product at launch or subsequent to launch through direct price controls or reference pricing. In recent years, many countries have also imposed new or additional cost containment measures on pharmaceutical products. Differences between national pricing regimes create price differentials within the European Union that can lead to significant parallel trade in pharmaceutical products.
Most governments also promote generic substitution by mandating or permitting a pharmacist to substitute a different manufacturer's generic version of a pharmaceutical product for the one prescribed and by permitting or mandating that health care professionals prescribe generic versions in certain circumstances. Many governments are also following a similar path for biosimilar therapies. In addition, governments use reimbursement lists to limit the pharmaceutical products that are eligible for reimbursement by national health care systems.
Japan. In Japan, the National Health Insurance system maintains a Drug Price List specifying which pharmaceutical products are eligible for reimbursement, and the Ministry of Health, Labour and Welfare sets the prices of the products on this list. The government generally introduces price cut rounds every other year and also mandates price decreases for specific products. New products judged innovative or useful, that are indicated for pediatric use, or that target orphan or small population diseases, however, may be eligible for a pricing premium. The government has also promoted the use of generics, where available.
Emerging Markets. Many emerging markets take steps to reduce pharmaceutical product prices, in some cases through direct price controls and in others through the promotion of generic/biosimilar alternatives to branded pharmaceuticals.
Since AbbVie markets its products worldwide, certain products of a local nature and variations of product lines must also meet other local regulatory requirements. Certain additional risks are inherent in conducting business outside the United States, including price and currency exchange controls, changes in currency exchange rates, limitations on participation in local enterprises, expropriation, nationalization and other governmental action.
| | | | | | | | | | | |
11 | |2021 Form 10-K | | |
Regulation – Medical Devices
Medical devices are subject to regulation by the FDA, state agencies and foreign government health authorities. FDA regulations, as well as various U.S. federal and state laws, govern the development, clinical testing, manufacturing, labeling, record keeping and marketing of medical device products agencies in the United States. AbbVie’s medical device product candidates, including AbbVie’s breast implants,must undergo rigorous clinical testing and an extensive government regulatory clearance or approval process prior to sale in the United States and other countries. The lengthy process of clinical development and submissions for clearance or approval, and the continuing need for compliance with applicable laws and regulations, require the expenditure of substantial resources. Regulatory clearance or approval, when and if obtained, may be limited in scope, and may significantly limit the indicated uses for which a product may be marketed. Cleared or approved products and their manufacturers are subject to ongoing review, and discovery of previously unknown problems with products may result in restrictions on their manufacture, sale and/or use or require their withdrawal from the market.
United States. AbbVie’s medical device products are subject to extensive regulation by the FDA in the United States. Unless an exemption applies, each medical device AbbVie markets in the United States must have a 510(k) clearance or a Premarket Approval Application (PMA) in accordance with the FFDCA and its implementing regulations. The FDA classifies medical devices into one of three classes, depending on the degree of risk associated with each medical device and the extent of controls that are needed to ensure safety and effectiveness. Devices deemed to pose a lower risk are placed in either Class I or Class II, and devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or a device deemed to be not substantially equivalent to a previously cleared 510(k) device, are placed in Class III. In general, a Class III device cannot be marketed in the United States unless the FDA approves the device after submission of a PMA, and any changes to the device subsequent to initial FDA approval must also be reviewed and approved by the FDA. The majority of AbbVie’s medical device products, including AbbVie’s breast implants, are regulated as Class III medical devices. A Class III device may have significant additional obligations imposed in its conditions of approval, and the time in which it takes to obtain approval can be long. Compliance with regulatory requirements is assured through periodic, unannounced facility inspections by the FDA and other regulatory authorities, and these inspections may include the manufacturing facilities of AbbVie’s subcontractors or other third-party manufacturers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: warning letters or untitled letters; fines, injunctions and civil penalties; recall or seizure of AbbVie’ products; operating restrictions, partial suspension or total shutdown of production; refusing AbbVie’ request for 510(k) clearance or PMA approval of new products; withdrawing 510(k) clearance or PMA approvals that are already granted; and criminal prosecution.
A clinical trial is almost always required to support a PMA application and is sometimes required for a 510(k) premarket notification. Clinical trials generally require submission of an application for an investigational device exemption (IDE), which must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. A study sponsor must obtain approval for its IDE from the FDA, and it must also obtain approval of its study from the Institutional Review Board overseeing the trial. The results of clinical testing may not be sufficient to obtain approval of the investigational device.
Once a device is approved, the manufacture and distribution of the device remains subject to continuing regulation by the FDA, including Quality System Regulation requirements, which involve design, testing, control, documentation and other quality assurance procedures during the manufacturing process. Medical device manufacturers and their subcontractors are required to register their establishments and list their manufactured devices with the FDA and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with regulatory requirements. Manufacturers must also report to the FDA if their devices may have caused or contributed to a death or serious injury or malfunctioned in a way that could likely cause or contribute to a death or serious injury, or if the manufacturer conducts a field correction or product recall or removal to reduce a risk to health posed by a device or to remedy a violation of the FFDCA that may present a health risk. Further, the FDA continues to regulate device labeling, and prohibits the promotion of products for unapproved or “off-label” uses along with other labeling restrictions.
European Union. Medical device products that are marketed in the European Union must comply with the requirements of the Medical Device Regulation (the MDR), which came into effect in May 2021. The MDR provides for regulatory oversight with respect to the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices to ensure that medical devices marketed in the European Union are safe and effective for their intended uses. Medical devices that comply with the MDR are entitled to bear a Conformité Européenne marking evidencing such compliance and may be marketed in the European Union. Failure to comply with these domestic and international regulatory requirements could affect AbbVie’s ability to market and sell AbbVie’s products in these countries.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 12 |
Environmental Matters
AbbVie believes that its operations comply in all material respects with applicable laws and regulations concerning environmental protection. Regulations under federal and state environmental laws impose stringent limitations on emissions and discharges to the environment from various manufacturing operations. AbbVie's capital expenditures for pollution control in 20182021 were approximately $20$17 million and operating expenditures were approximately $31$33 million. In 2019,2022, capital expenditures for pollution control are estimated to be approximately $26$14 million and operating expenditures are estimated to be approximately $33$34 million.
Abbott was identified as one of many potentially responsible parties in investigations and/or remediations at several locations in the United States, including Puerto Rico, under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund. Some of these locations were transferred to AbbVie in connection with the separation and distribution, and AbbVie has become a party to these investigations and remediations. Abbott was also engaged in remediation at several other sites, some of which have been transferred to AbbVie in connection with the separation and distribution, in cooperation with the Environmental Protection Agency or similar agencies. While it is not feasible to predict with certainty the final costs related to those investigations and remediation activities, AbbVie believes that such costs, together with other expenditures to maintain compliance with applicable laws and regulations concerning environmental protection, should not have a material adverse effect on the company's financial position, cash flows, or results of operations.
|
| | |
| | 2018 Form 10-K | 9
|
Employees
AbbVie employed approximately 30,000 persons50,000 employees in over 70 countries as of January 31, 2019.2022. Outside the United States, some of AbbVie's employees are represented by unions or works councils. AbbVie believes that it has good relations with its employees.
Human Capital Management
Attracting, retaining and providing meaningful growth and development opportunities to AbbVie's employees is critical to the company's success in making a remarkable impact on people’s lives around the world. AbbVie leverages numerous resources to identify and enhance strategic and leadership capability, foster employee engagement and create a culture where diverse talent is productive and engaged. AbbVie invests in its employees through competitive compensation, benefits and employee support programs and offers best-in-class development and leadership opportunities. AbbVie has developed a deep talent base through ongoing investment in functional and leadership training and by sourcing world-class external talent, ensuring a sustainable talent pipeline. AbbVie continuously cultivates and enhances its working culture and embraces equality, diversity and inclusion as fundamental to the company's mission.
Attracting and Developing Talent. Attracting and developing high-performing talent is essential to AbbVie’s continued success. AbbVie implements detailed talent attraction strategies, with an emphasis on STEM skill sets, a diverse talent base and other critical skillsets, including drug discovery, clinical development, market access and business development. AbbVie also invests in competitive compensation and benefits programs. In addition to offering a comprehensive suite of benefits ranging from medical and dental coverage to retirement, disability and life insurance programs, AbbVie also provides health promotion programs, mental health awareness campaigns and employee assistance programs in several countries, financial wellness support, on-site health screenings and immunizations in several countries and on-site fitness and rehabilitation centers. In addition, the AbbVie Employee Assistance Fund (a part of the AbbVie Foundation) supports two programs for global employees: the AbbVie Possibilities Scholarship for children of employees, which is an annual merit-based scholarship for use at accredited colleges, universities or vocational-technical schools; and the Employee Relief Program, which is financial assistance to support short term needs of employees when faced with large-scale disasters (e.g. a hurricane), individual disasters (e.g. a home fire) or financial hardship (e.g. the death of a spouse). Finally, AbbVie empowers managers and their teams with tools, tips and guidelines on effectively managing workloads, managing teams from a distance and supporting flexible work practices.
New AbbVie employees are given a tailored onboarding experience for faster integration and to support performance. AbbVie's mentorship program allows employees to self-nominate as mentors or mentees and facilitates meaningful relationships supporting employees’ career and development goals.
AbbVie also provides structured, broad-based development opportunities, focusing on high-performance skills and leadership training. AbbVie's talent philosophy holds leaders accountable for building a high-performing organization, and the company provides development opportunities to all levels of leadership. AbbVie's Learn, Develop, Perform program offers year-long, self-directed leadership education, supplemented with tools and resources, and leverages leaders as role models and teachers. In addition, the foundation to AbbVie's leadership pipeline is the company's Professional Development
| | | | | | | | | | | |
13 | |2021 Form 10-K | | |
Programs, which attract graduates, postgraduates and post-doctoral talent to participate in formal development programs lasting up to three years, with the objective of strengthening functional and leadership capabilities.
Culture. AbbVie’s shared values of transforming lives, acting with integrity, driving innovation, embracing diversity and inclusion and serving the community form the core of the company's culture. AbbVie articulates the behaviors associated with these values in the Ways We Work, a core set of working behaviors that emphasize how the company achieves results is equally as important as achieving them. The Ways We Work are designed to ensure that every AbbVie employee is aware of the company's cultural expectations. AbbVie integrates the Ways We Work into all talent processes, forming the basis for assessing performance, prioritizing development and ultimately rewarding employees. AbbVie believes its culture creates strong engagement, which is measured regularly through a confidential, third party all-employee survey, and this engagement supports AbbVie’s mission of making a remarkable impact on people’s lives.
Equity, Equality, Diversity & Inclusion (EED&I). A cornerstone of AbbVie’s human capital management approach is to prioritize fostering an inclusive and diverse workforce. In 2019, AbbVie adopted a five-year Equality, Diversity & Inclusion roadmap that defines key global focus areas, objectives and associated initiatives, and includes implementation plans organized by business function and geography. AbbVie’s senior leaders have adopted formal goals aligned with executing this strategy. In recent years, AbbVie's board of directors has prioritized oversight of AbbVie's response to the U.S. racial justice movement, including overseeing internal programs designed to ensure that AbbVie is attracting, retaining and developing diverse talent. Through December 2021, women represented 51 percent of management positions globally and in the United States, 35 percent of AbbVie's workforce was comprised of members of historically underrepresented populations, an increase from 2020. Further, AbbVie is committed to pay equity and conducts pay equity analyses annually. A critical component of AbbVie's strategy is to instill an inclusive mindset in all AbbVie leaders and employees, so the company can realize the full value of a diverse workforce from recruitment through retirement. AbbVie recently launched a new resource for people who manage others to reinforce the importance of EED&I to the business, educate leaders on inclusive recruiting practices and modeling inclusive behavior, and encourage participation in the company's inclusive culture learning opportunities. AbbVie's Employee Resource Groups also help the company nurture an inclusive culture by building community, hosting awareness events and providing leadership and career opportunities. In 2021, AbbVie reiterated its commitment to racial equality and social justice by, among other things, expanding its employee matching program to $3-to-$1 for donations to civil rights nonprofits fostering racial equity and by reaffirming its commitment to clinical trial diversity. Additional information about AbbVie's efforts on racial equality and social justice is provided on the company's website at: https://abbvie.com/our-company/equality-inclusion-diversity/our-commitment-to-racial-justice.html.
COVID-19 Health and Safety.AbbVie has effectively prioritized the health and safety of its employees during the COVID-19 pandemic, while continuing to drive strong business performance. AbbVie implemented, among other things, temporary office and facility closures and establishment of new safety and cleaning protocols and procedures; regular communication regarding the effect of the pandemic on AbbVie's business and employees; establishment of physical distancing procedures, modification of workspaces and provision of personal protective equipment and cleaning supplies for employees; provision of on-site vaccinations and temperature screenings; a variety of testing and vaccination resources including on-site vaccinations and on-site and at-home testing and COVID case management programs; and remote working accommodations and related services to support employees’ needs for flexibility. In addition, COVID-19 is a covered event under the AbbVie Employee Assistance Fund's Employee Relief Program, entitling eligible AbbVie employees and their families to financial assistance to pay for mortgage/rent, utilities, food, childcare and medical expenses not covered by insurance. AbbVie also provided paid leave and other support and accommodations to the company's employees with relevant medical, pharmaceutical, research and development, science, public health and public safety skills, knowledge, training and experience who desired or were requested or mandated to serve as volunteers during the pandemic. Lastly, AbbVie’s commitment to employees has been evidenced by no workforce reductions and no salary reductions associated with COVID-19.
Internet Information
Copies of AbbVie's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are available free of charge through AbbVie's investor relations website (www.abbvieinvestor.cominvestors.abbvie.com) as soon as reasonably practicable after AbbVie electronically files the material with, or furnishes it to, the Securities and Exchange Commission (SEC).
AbbVie's corporate governance guidelines, outline of directorship qualifications, code of business conduct and the charters of AbbVie's audit committee, compensation committee, nominations and governance committee and public policy committee are all available on AbbVie's investor relations website (www.abbvieinvestor.cominvestors.abbvie.com).
| | | | | | | | | | | |
| | 2021 Form 10-K | | 14 |
ITEM 1A. RISK FACTORS
You should carefully consider the following risks and other information in this Form 10-K in evaluating AbbVie and AbbVie's common stock. Any of the following risks could materially and adversely affect AbbVie's results of operations, financial condition or cash flows. The risk factors generally have been separated into two groups: risks related to AbbVie's business and risks related to AbbVie's common stock. Based on the information currently known to it, AbbVie believes that the following information identifies the most significant risk factors affecting it in each of these categories of risks. However, the risks and uncertainties AbbVie faces are not limited to those set forth in the risk factors described below and may not be in order of importance or probability of occurrence. Additional risks and uncertainties not presently known to AbbVie or that AbbVie currently believes to be immaterial may also adversely affect its business. In addition, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.
If any of the following risks and uncertainties develops into actual events, these events could have a material adverse effect on AbbVie's business, results of operations, financial condition or cash flows. In such case, the trading price of AbbVie's common stock could decline.
Risks Related to AbbVie's Business
Public health outbreaks, epidemics or pandemics, such as the coronavirus (COVID-19), have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition.
Public health outbreaks, epidemics or pandemics have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition. The continuing pandemic caused by the novel strain of coronavirus (COVID-19) has caused many countries, including the United States, to declare national emergencies and implement preventive measures such as travel bans and shelter in place or total lock-down orders, some of which have eased. The continuation or re-implementation of these bans and orders remains uncertain. The COVID-19 pandemic has caused AbbVie to modify its business practices (including instituting remote work for many of AbbVie’s employees), and AbbVie may take further actions as may be required by government authorities or as AbbVie determines are in the best interests of AbbVie’s employees, patients, customers and business partners.
While the impact of COVID-19 on AbbVie’s operations, including, among others, its manufacturing and supply chain, sales and marketing, commercial and clinical trial operations, to date has not been material, AbbVie has experienced lower new patient starts in certain products and markets. The impact of COVID-19 on AbbVie over the long-term is uncertain and cannot be predicted with confidence. The extent of the adverse impact of COVID-19 on AbbVie’s operations will depend on the extent and severity of the continued spread of COVID-19 globally, the timing and nature of actions taken to respond to COVID-19 and the resulting economic consequences. Ultimately, efforts to mitigate the impact of COVID-19 may not completely prevent AbbVie's business from being adversely affected and future impacts remain uncertain.
The expiration or loss of patent protection and licenses may adversely affect AbbVie's future revenues and operating earnings.
AbbVie relies on patent, trademark and other intellectual property protection in the discovery, development, manufacturing and sale of its products. In particular, patent protection is, in the aggregate, important in AbbVie's marketing of pharmaceutical products in the United States and most major markets outside of the United States. Patents covering AbbVie products normally provide market exclusivity, which is important for the profitability of many of AbbVie's products.
As patents for certain of its products expire, AbbVie will or could face competition from lower priced generic or biosimilar products. The expiration or loss of patent protection for a product typically is followed promptly by substitutes that may significantly reduce sales for that product in a short amount of time. If AbbVie's competitive position is compromised because of generics, biosimilars or otherwise, it could have a material adverse effect on AbbVie's business and results of operations. In addition, proposals emerge from time to time for legislation to further encourage the early and rapid approval of generic drugs or biosimilars. Any such proposals that are enacted into law could increase the impact of generic competition.
AbbVie's principal patents and trademarks are described in greater detail in Item 1, "Business—Intellectual Property Protection and Regulatory Exclusivity" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations," and litigation regarding these patents is described in Item 3, "Legal Proceedings." The United States composition of matter patent for HUMIRA,Humira, which is AbbVie's largest product and had worldwide net revenues of approximately $19.9$20.7 billion in 2018,2021, expired in December 2016, and the equivalent European Union patent expired in the majority of European Union countries in October 2018.
|
| | | | | | | | | | |
1015
| |20182021 Form 10-K
| | |
AbbVie's major products could lose patent protection earlier than expected, which could adversely affect AbbVie's future revenues and operating earnings.
Third parties or government authorities may challenge or seek to invalidate or circumvent AbbVie's patents and patent applications. For example, manufacturers of generic pharmaceutical products file, and may continue to file, Abbreviated New Drug Applications with the FDA seeking to market generic forms of AbbVie's products prior to the expiration of relevant patents owned or licensed by AbbVie by asserting that the patents are invalid, unenforceable and/or not infringed. In addition, petitioners have filed, and may continue to file, challenges to the validity of AbbVie patents under the 2011 Leahy-Smith America Invents Act, which created inter partes review and post grant review procedures for challenging patent validity in administrative proceedings at the United States Patent and Trademark Office.
Although most of the challenges to AbbVie's intellectual property have come from other businesses, governments may also challenge intellectual property rights. For example, court decisions and potential legislation relating to patents, such as legislation regarding biosimilars, and other regulatory initiatives may result in further erosion of intellectual property protection. In addition, certain governments outside the United States have indicated that compulsory licenses to patents may be sought to further their domestic policies or on the basis of national emergencies, such as HIV/AIDS. If triggered, compulsory licenses could diminish or eliminate sales and profits from those jurisdictions and negatively affect AbbVie's results of operations.
AbbVie normally responds to challenges by vigorously defending its patents, including by filing patent infringement lawsuits. Patent litigation, administrative proceedings and other challenges to AbbVie's patents are costly and unpredictable and may deprive AbbVie of market exclusivity for a patented product. To the extent AbbVie's intellectual property is successfully challenged, circumvented or circumventedweakened, or to the extent such intellectual property does not allow AbbVie to compete effectively, AbbVie's business will suffer. To the extent that countries do not enforce AbbVie's intellectual property rights or require compulsory licensing of AbbVie's intellectual property, AbbVie's future revenues and operating earnings will be reduced.
A third party's intellectual property may prevent AbbVie from selling its products or have a material adverse effect on AbbVie's future profitability and financial condition.
Third parties may claim that an AbbVie product infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require AbbVie to enter into license agreements. AbbVie cannot guarantee that it would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject AbbVie to significant damages or an injunction preventing the manufacture, sale, or use of the affected AbbVie product or products. Any of these events could have a material adverse effect on AbbVie's profitability and financial condition.
Any significant event that adversely affects HUMIRAHumira revenues could have a material and negative impact on AbbVie's results of operations and cash flows.
HUMIRAHumira accounted for approximately 61%37% of AbbVie's total net revenues in 2018.2021. Any significant event that adversely affects HUMIRA'sHumira's revenues could have a material adverse impact on AbbVie's results of operations and cash flows. These events could include loss of patent protection for HUMIRA,Humira (as described further in “—The expiration or loss of patent protection and licenses may adversely affect AbbVie’s future revenues and operating earnings” above), the commercialization of biosimilars of HUMIRA,Humira, the discovery of previously unknown side effects or impaired efficacy, increased competition from the introduction of new, more effective or less expensive treatments and discontinuation or removal from the market of HUMIRAHumira for any reason.
AbbVie's research and development efforts may not succeed in developing and marketing commercially successful products and technologies, which may cause its revenues and profitability to decline.
To remain competitive, AbbVie must continue to launch new products and new indications and/or brand extensions for existing products, and such launches must generate revenue sufficient both to cover its substantial research and development costs and to replace revenues of profitable products that are lost to or displaced by competing products or therapies. Failure to do so would have a material adverse effect on AbbVie's revenue and profitability. Accordingly, AbbVie commits substantial effort, funds, and other resources to research and development and must make ongoing substantial expenditures without any assurance that its efforts will be commercially successful. A high rate of failure in the biopharmaceutical industry is inherent in the research and development of new products, and failure can occur at any point in the research and development process, including after significant funds have been invested. Products that appear promising in development may fail to reach the market for numerous reasons, including failure to demonstrate effectiveness, safety concerns, superior safety or efficacy of
|
| | |
| | 2018 Form 10-K | 11
|
competing therapies, failure to achieve positive clinical or pre-clinical outcomes beyond the current standards of care,
| | | | | | | | | | | |
| | 2021 Form 10-K | | 16 |
inability to obtain necessary regulatory approvals or delays in the approval of new products and new indications, limited scope of approved uses, excessive costs to manufacture, the failure to obtain or maintain intellectual property rights, or infringement of the intellectual property rights of others.
Decisions about research studies made early in the development process of a pharmaceutical product candidate can affect the marketing strategy once such candidate receives approval. More detailed studies may demonstrate additional benefits that can help in the marketing, but they also consume time and resources and may delay submitting the pharmaceutical product candidate for approval. AbbVie cannot guarantee that a proper balance of speed and testing will be made with respect to each pharmaceutical product candidate or that decisions in this area would not adversely affect AbbVie's future results of operations.
Even if AbbVie successfully develops and markets new products or enhancements to its existing products, they may be quickly rendered obsolete by changing clinical preferences, changing industry standards, or competitors' innovations. AbbVie's innovations may not be accepted quickly in the marketplace because of existing clinical practices or uncertainty over third-party reimbursement. AbbVie cannot state with certainty when or whether any of its products under development will be launched, whether it will be able to develop, license, or otherwise acquire compounds or products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause AbbVie's products to become obsolete, causing AbbVie's revenues and operating results to suffer.
A portion of AbbVie's near-term pharmaceutical pipeline relies on collaborations with third parties, which may adversely affect the development and sale of its products.
AbbVie depends on alliances and joint ventures with pharmaceutical and biotechnology companies for a portion of the products in its near-term pharmaceutical pipeline. Failures by these parties to meet their contractual, regulatory, or other obligations to AbbVie, or any disruption in the relationships between AbbVie and these third parties, could have an adverse effect on AbbVie's pharmaceutical pipeline and business. In addition, AbbVie's collaborative relationships for research and development extend for many years and may give rise to disputes regarding the relative rights, obligations and revenues of AbbVie and its collaboration partners, including the ownership of intellectual property and associated rights and obligations. This could result in the loss of intellectual property rights or protection, delay the development and sale of potential pharmaceutical products and lead to lengthy and expensive litigation, administrative proceedings or arbitration.
Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.
The successful discovery, development, manufacturing and sale of biologics is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell biologics—including HUMIRA—Humira—could adversely impact AbbVie's business and results of operations.
AbbVie's biologic products are subject to competition from biosimilars.
The Biologics Price Competition and Innovation Act creates a framework for the approval of biosimilars in the United States and could allow competitors to reference data from biologic products already approved. In Europe, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies are developing biosimilars in other countries that could and do compete with AbbVie’s biologic products, including HUMIRA.Humira. As competitors obtain marketing approval for biosimilars referencing AbbVie’s biologic products, AbbVie’s products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. Expiration or successful challenge of AbbVie’s applicable patent rights could also trigger competition from other products, assuming any relevant exclusivity period has expired. As a result, AbbVie could face more litigation and administrative proceedings with respect to the validity and/or scope of patents relating to its biologic products.
|
| | |
12 |2018 Form 10-K
| | |
New products and technological advances by AbbVie's competitors may negatively affect AbbVie's results of operations.
AbbVie competes with other research-based pharmaceutical and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products and biologics. For example, HUMIRAHumira competes with anti-TNF products
| | | | | | | | | | | |
17 | |2021 Form 10-K | | |
and other competitive products intended to treat a number of disease states and AbbVie’s virology products competeMavyret/Maviret competes with other available hepatitis C treatment options. TheseIn addition, in the past few years, a number of other companies have started to develop, have successfully developed and/or are currently marketing products that are being positioned as competitors to Botox. All of these competitors may introduce new products or develop technological advances that compete with AbbVie’s products in therapeutic areas such as immunology, virology/liver disease,hematologic oncology, aesthetics, neuroscience, eye care and neuroscience.women's health. AbbVie cannot predict with certainty the timing or impact of the introduction by competitors of new products or technological advances. Such competing products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than AbbVie’s products, and this could negatively impact AbbVie’s business and results of operations.
The manufacture of many of AbbVie's products is a highly exacting and complex process, and if AbbVie or one of its suppliers encounters problems manufacturing AbbVie's products, AbbVie's business could suffer.
The manufacture of many of AbbVie's products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or the expansion of existing facilities, including those intended to support future demand for AbbVie's products, changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in the types of products produced, physical limitations that could inhibit continuous supply, man-made or natural disasters and environmental factors. If problems arise during the production of a batch of product, that batch of product may have to be discarded and AbbVie may experience product shortages or incur added expenses. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.
AbbVie uses a number of products in its pharmaceutical and biologic manufacturing processes that are sourced from single suppliers, and an interruption in the supply of those products could adversely affect AbbVie's business and results of operations.
AbbVie uses a number of products in its pharmaceutical and biologic manufacturing processes that are sourced from single suppliers. The failure of these single-source suppliers to fulfill their contractual obligations in a timely manner or as a result of regulatory noncompliance or physical disruption at a manufacturing site may impair AbbVie's ability to deliver its products to customers on a timely and competitive basis, which could adversely affect AbbVie's business and results of operations. Finding an alternative supplier could take a significant amount of time and involve significant expense due to the nature of the products and the need to obtain regulatory approvals. AbbVie cannot guarantee that it will be able to reach agreement with alternative providers or that regulatory authorities would approve AbbVie's use of such alternatives. AbbVie does, however, carry business interruption insurance, which provides a degree of protection in the case of a failure by a single-source supplier.
Certain aspects of AbbVie’s operations are highly dependent upon third party service providers.
AbbVie relies on suppliers, vendors and other third party service providers to research, develop, manufacture, commercialize, promote and sell its products. Reliance on third party manufacturers reduces AbbVie’s oversight and control of the manufacturing process. Some of these third party providers are subject to legal and regulatory requirements, privacy and security risks and market risks of their own. The failure of a critical third party service provider to meet its obligations could have a material adverse impact on AbbVie’s operations and results. If any third party service providers have violated or are alleged to have violated any laws or regulations during the performance of their obligations to AbbVie, it is possible that AbbVie could suffer financial and reputational harm or other negative outcomes, including possible legal consequences.
Significant safety or efficacy issues could arise for AbbVie's products, which could have a material adverse effect on AbbVie's revenues and financial condition.
Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety or efficacy issues are reported or if new scientific information becomes available (including results of post-marketing Phase 4 trials), or if governments change standards regarding safety, efficacy or labeling, AbbVie may be required to amend the conditions of use for a product. For example, AbbVie may voluntarily provide or be required to provide updated information on a product's label or narrow its approved indication, either of which could reduce the product's market acceptance. If safety or efficacy issues with an AbbVie product arise, sales of the product could be halted by AbbVie or by regulatory authorities and regulatory action could be
| | | | | | | | | | | |
| | 2021 Form 10-K | | 18 |
taken by such regulatory authorities. Safety or efficacy issues affecting suppliers' or competitors' products also may reduce the market acceptance of AbbVie's products.
New data about AbbVie's products, or products similar to its products, could negatively impact demand for AbbVie's products due to real or perceived safety issues or uncertainty regarding efficacy and, in some cases, could result in product
|
| | |
| | 2018 Form 10-K | 13
|
withdrawal. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of AbbVie's products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of AbbVie's products.
AbbVie is subject to product liability claims and other lawsuits that may adversely affect its business and results of operations.
In the ordinary course of business, AbbVie is the subject of product liability claims and lawsuits alleging that AbbVie's products or the products of other companies that it promotes have resulted or could result in an unsafe condition for or injury to patients. For example, lawsuits are pending against Allergan, AbbVie’s recently acquired subsidiary, and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan’s textured breast implants. Product liability claims and lawsuits and safety alerts or product recalls, regardless of their ultimate outcome, may have a material adverse effect on AbbVie's business, results of operations and reputation and on its ability to attract and retain customers. Consequences may also include additional costs, a decrease in market share for the product in question, lower income and exposure to other claims. Product liability losses are self-insured.
AbbVie is also the subject of other claims, legal proceedings and investigations in the ordinary course of business, which relate to the intellectual property, commercial, securities and other matters. Adverse outcomes in such claims, legal proceedings and investigations may also adversely affect AbbVie’s business and results of operations. Additionally, Allergan has been named as a defendant in approximately 3,130 matters relating to the promotion and sale of prescription opioid pain relievers and additional suits may be filed. See Note 15, "Legal Proceedings and Contingencies" to the Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data." AbbVie cannot predict the outcome of these proceedings.
AbbVie is subject to cost-containment efforts and pricing pressures that could cause a reduction in future revenues and operating earnings, and changes in the terms of rebate and chargeback programs, which are common in the pharmaceuticals industry, could have a material adverse effect on AbbVie's operations.
Cost-containment efforts by governments and private organizations are described in greater detail in Item 1, "Business—Regulation—Commercialization, Distribution and Manufacturing." To the extent these cost containment efforts are not offset by greater demand, increased patient access to health care, or other factors, AbbVie's future revenues and operating earnings will be reduced. In the United States, the European Union and other countries, AbbVie's business has experienced downward pressure on product pricing, and this pressure could increase in the future.
AbbVie is subject to increasing public and legislative pressure with respect to pharmaceutical pricing. In the United States, practices of managed care groups, and institutional and governmental purchasers, and United States federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug Improvement and Modernization Act of 2003 and the Patient Protection and Affordable Care Act, contribute to pricing pressures. The potential for continuing changes to the health care system in the United States and the increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid and private sector beneficiaries could result in additional pricing pressures.
In numerous major markets worldwide, the government plays a significant role in funding health care services and determining the pricing and reimbursement of pharmaceutical products. Consequently, in those markets, AbbVie is subject to government decision-making and budgetary actions with respect to its products. In particular, many European countries have ongoing government-mandated price reductions for many pharmaceutical products, and AbbVie anticipates continuing pricing pressures in Europe. Differences between countries in pricing regulations could lead to third-party cross-border trading in AbbVie's products that results in a reduction in future revenues and operating earnings.
Rebates related to government programs, such as fee-for-service Medicaid or Medicaid managed care programs, arise from laws and regulations. AbbVie cannot predict if additional government initiatives to contain health care costs or other factors could lead to new or modified regulatory requirements that include higher or incremental rebates or discounts. Other rebate and discount programs arise from contractual agreements with private payers. Various factors, including market factors and the ability of private payers to control patient access to products, may provide payers the leverage to negotiate higher or additional rebates or discounts that could have a material adverse effect on AbbVie's operations.
| | | | | | | | | | | |
19 | |2021 Form 10-K | | |
AbbVie is subject to numerous governmental regulations, and it can be costly to comply with these regulations and to develop compliant products and processes.
AbbVie's products are subject to rigorous regulation by numerous international, supranational, federal and state authorities, as described in Item 1, "Business—Regulation—Discovery and Clinical Development."Development,” “Business—Regulation—Commercialization, Distribution and Manufacturing,” and “Business—Regulation—Medical Devices.” The process of obtaining regulatory approvals to market a pharmaceutical product can be costly and time consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, future products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues and substantial additional costs.
In addition, AbbVie cannot guarantee that it will remain compliant with applicable regulatory requirements once approval has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling and advertising and post-marketing reporting, including adverse event reports and
|
| | |
14 |2018 Form 10-K
| | |
field alerts due to manufacturing quality concerns. AbbVie must incur expense and spend time and effort to ensure compliance with these complex regulations.
Possible regulatory actions could result in substantial modifications to AbbVie's business practices and operations; refunds, recalls or seizures of AbbVie's products; a total or partial shutdown of production in one or more of AbbVie's or its suppliers' facilities while AbbVie or its supplier remedies the alleged violation; the inability to obtain future approvals; and withdrawals or suspensions of current products from the market. Any of these events could disrupt AbbVie's business and have a material adverse effect on its business and results of operations.
Laws and regulations affecting government benefit programs could impose new obligations on AbbVie, require it to change its business practices, and restrict its operations in the future.
The health care industry is subject to various federal, state and international laws and regulations pertaining to government benefit programs reimbursement, rebates, price reporting and regulation and health care fraud and abuse. In the United States, these laws include anti-kickback and false claims laws, the Medicaid Rebate Statute, the Veterans Health Care Act, the U.S. Physician Payments Sunshine Act, the TRICARE program, the government pricing rules applicable to the Medicaid, Medicare Part B, 340B Drug Pricing Program and individual state laws relating to pricing and sales and marketing practices. Violations of these laws may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, imprisonment and exclusion from participation in federal and state health care programs, including Medicare, Medicaid and Veterans Administration health programs. These laws and regulations are broad in scope and they are subject to change and evolving interpretations, which could require AbbVie to incur substantial costs associated with compliance or to alter one or more of its sales or marketing practices. In addition, violations of these laws, or allegations of such violations, could disrupt AbbVie's business and result in a material adverse effect on its business and results of operations.
The international nature of AbbVie's business subjects it to additional business risks that may cause its revenue and profitability to decline.
AbbVie's business is subject to risks associated with doing business internationally, including in emerging markets. Net revenues outside of the United States makemade up approximately 34%23% of AbbVie's total net revenues in 2018.2021. The risks associated with AbbVie's operations outside the United States include:
•fluctuations in currency exchange rates;
•changes in medical reimbursement policies and programs;
•multiple legal and regulatory requirements that are subject to change and that could restrict AbbVie's ability to manufacture, market and sell its products;
•differing local product preferences and product requirements;
•trade protection measures and import or export licensing requirements;
•international trade disruptions or disputes;
•difficulty in establishing, staffing and managing operations;
•differing labor regulations;
•potentially negative consequences from changes in or interpretations of tax laws;
| | | | | | | | | | | |
| | 2021 Form 10-K | | 20 |
•political and economic instability, including as a result of the United Kingdom’s exit from the European Union and the COVID-19 pandemic;
•sovereign debt issues;
•price and currency exchange controls, limitations on participation in local enterprises, expropriation, nationalization and other governmental action;action and regulation;
•inflation, recession and fluctuations in interest rates;
•restrictions on transfers of funds;
•potential deterioration in the economic position and credit quality of certain non-U.S. countries, including in Europecountries; and Latin America; and
•potential penalties or other adverse consequences for violations of anti-corruption, anti-bribery and other similar laws and regulations, including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act.
Events contemplated by these risks may, individually or in the aggregate, have a material adverse effect on AbbVie's revenues and profitability.
|
| | |
| | 2018 Form 10-K | 15
|
If AbbVie does not effectively and profitably commercialize its products, AbbVie's revenues and financial condition could be adversely affected.
AbbVie must effectively and profitably commercialize its principal products by creating and meeting continued market demand; achieving market acceptance and generating product sales; ensuring that the active pharmaceutical ingredient(s) for a product and the finished product are manufactured in sufficient quantities and in compliance with requirements of the FDA and similar foreign regulatory agencies and with acceptable quality and pricing to meet commercial demand; and ensuring that the entire supply chain efficiently and consistently delivers AbbVie's products to its customers. The commercialization of AbbVie products may not be successful due to, among other things, unexpected challenges from competitors, new safety issues or concerns being reported that may impact or narrow approved indications, the relative price of AbbVie's product as compared to alternative treatment options and changes to a product's label that further restrict its marketing. If the commercialization of AbbVie's principal products is unsuccessful, AbbVie's ability to generate revenue from product sales will be adversely affected.
AbbVie may acquire other businesses, license rights to technologies or products, form alliances, or dispose of assets, which could cause it to incur significant expenses and could negatively affect profitability.
AbbVie may pursue acquisitions, technology licensing arrangements, joint ventures and strategic alliances, or dispose of some of its assets, as part of its business strategy. AbbVie may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If AbbVie is successful in making an acquisition, the products and technologies that are acquired may not be successful or may require significantly greater resources and investments than originally anticipated. AbbVie may not be able to integrate acquisitions successfully into its existing business and could incur or assume significant debt and unknown or contingent liabilities. AbbVie could also experience negative effects on its reported results of operations from acquisition or disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets. These effects could cause a deterioration of AbbVie's credit rating and result in increased borrowing costs and interest expense.
Additionally, changes in AbbVie's structure, operations, revenues, costs, or efficiency resulting from major transactions such as acquisitions, divestitures, mergers, alliances, joint ventures, restructurings or other strategic initiatives, may result in greater than expected costs, may take longer than expected to complete or encounter other difficulties, including the need for regulatory approval where appropriate.
AbbVie is dependent on wholesale distributors for distribution of its products in the United States and, accordingly, its results of operations could be adversely affected if they encounter financial difficulties.
In 2018,2021, three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and AmerisourceBergen Corporation) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. If one of its significant wholesale distributors encounters financial or other difficulties, such distributor may decrease the amount of business that it does with AbbVie, and AbbVie may be unable to collect all the amounts that the distributor owes it on a timely basis or at all, which could negatively impact AbbVie's business and results of operations.
| | | | | | | | | | | |
21 | |2021 Form 10-K | | |
AbbVie has debt obligations that could adversely affect its business and its ability to meet its obligations.
The amount of debt that AbbVie has incurred and intends to incur could have important consequences to AbbVie and its investors. These consequences include, among other things, requiring a portion of AbbVie's cash flow from operations to make interest payments on this debt and reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow AbbVie's business. In particular, AbbVie incurred significant debt in connection with its acquisition of Allergan. AbbVie’s substantially increased indebtedness and higher debt to equity ratio as a result of the acquisition may exacerbate these risks and have the effect of, among other things, reducing its flexibility to respond to changing business and economic conditions and/or lowering its credit ratings. To the extent AbbVie incurs additional indebtedness or interest rates increase, these risks could increase.increase further. In addition, AbbVie's cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and AbbVie may not be able to borrow money, sell assets, or otherwise raise funds on acceptable terms, or at all, to refinance its debt.
AbbVie may need additional financing in the future to meet its capital needs or to make opportunistic acquisitions, and such financing may not be available on favorable terms, if at all.
AbbVie may need to seek additional financing for its general corporate purposes. For example, it may need to increase its investment in research and development activities or need funds to make acquisitions. AbbVie may be unable to obtain any desired additional financing on terms favorable to it, if at all. If AbbVie loses its investment grade credit rating or adequate
|
| | |
16 |2018 Form 10-K
| | |
funds are not available on acceptable terms, AbbVie may be unable to fund its expansion, successfully develop or enhance products, or respond to competitive pressures, any of which could negatively affect AbbVie's business. If AbbVie raises additional funds by issuing debt or entering into credit facilities, it may be subject to limitations on its operations due to restrictive covenants. Failure to comply with these covenants could adversely affect AbbVie's business.
AbbVie depends on information technology and a failure of those systems could adversely affecthave a material adverse effect on AbbVie's business.
AbbVie relies on sophisticated software applications and complex information technology systems to operate its business. These systems are potentially vulnerable to malicious intrusion, random attack, loss of data privacy, disruption, degradation or breakdown. Data privacy or security breaches by employees or others may in the future result in the failure of critical business operations oroperations. Such breaches may cause sensitive data, including intellectual property, trade secrets or personal information belonging to AbbVie, its patients, customers or business partners, to be exposed to unauthorized persons or to the public. To date, AbbVie’s business or operations have not been materially impacted by such incidents. Although AbbVie has invested in the protection of its data and information technology and also monitors its systems on an ongoing basis, there can be no assurance that these efforts will prevent material breakdowns or breaches in AbbVie's information technology systems that could adversely affect AbbVie's business. Such adverse consequences could include loss of revenue, or the loss of critical or sensitive information from AbbVie’s or third-party providers’ databases or IT systems and could also result in legal, financial, reputational or business harm to AbbVie and potentially substantial remediation costs.
In connection with the acquisition of Allergan, AbbVie’s balances of intangible assets, including developed product rights and goodwill acquired, have increased significantly. Such balances are subject to impairment testing and may result in impairment charges, which will adversely affect AbbVie’s results of operations and financial condition.
A significant amount of AbbVie’s total assets is related to acquired intangibles and goodwill. As of December 31, 2021, the carrying value of AbbVie’s developed product rights and other intangible assets was $76.0 billion and the carrying value of AbbVie’s goodwill was $32.4 billion.
AbbVie’s developed product rights are stated at cost, less accumulated amortization. AbbVie determines original fair value and amortization periods for developed product rights based on its assessment of various factors impacting estimated useful lives and cash flows of the acquired products. Significant adverse changes to any of these factors require AbbVie to perform an impairment test on the affected asset and, if evidence of impairment exists, require AbbVie to take an impairment charge with respect to the asset. For assets that are not impaired, AbbVie may adjust the remaining useful lives. Such a charge could have a material adverse effect on AbbVie’s results of operations and financial condition.
AbbVie’s other significant intangible assets include in-process research and development (IPR&D) intangible projects, acquired in recent business combinations, which are indefinite-lived intangible assets.
Goodwill and AbbVie’s IPR&D intangible assets are tested for impairment annually, or when events occur or circumstances change that could potentially reduce the fair value of the reporting unit or intangible asset. Impairment testing compares the fair value of the reporting unit or intangible asset to its carrying amount. A goodwill or IPR&D impairment, if any, would be recorded in operating income and could have a material adverse effect on AbbVie’s results of operations and financial condition.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 22 |
Failure to attract, develop and retain highly qualified personnel could affect AbbVie’s ability to successfully develop and commercialize products.
AbbVie’s success is largely dependent on its continued ability to attract, develop and retain diverse, highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development (R&D), governmental regulation and commercialization. Competition for qualified personnel in the biopharmaceutical field is intense. AbbVie cannot be sure that it will be able to attract and retain quality personnel or that the costs of doing so will not materially increase.
Other factors can have a material adverse effect on AbbVie's profitability and financial condition.
Many other factors can affect AbbVie's results of operations, cash flows and financial condition, including:
•changes in or interpretations of laws and regulations, including changes in accounting standards, taxation requirements, product marketing application standards, data privacy laws, particularly in the European Union and the United States, and environmental laws;
•differences between the fair value measurement of assets and liabilities and their actual value, particularly for pension and post-employment benefits, stock-based compensation, intangibles and goodwill; and for contingent liabilities such as litigation and contingent consideration, the absence of a recorded amount, or an amount recorded at the minimum, compared to the actual amount;
•changes in the rate of inflation (including the cost of raw materials, commodities and supplies), interest rates, market value of AbbVie's equity investments and the performance of investments held by it or its employee benefit trusts;
•changes in the creditworthiness of counterparties that transact business with or provide services to AbbVie or its employee benefit trusts;
•environmental liabilities in connection with AbbVie’s manufacturing processes and distribution logistics, including the handling of hazardous materials;
•changes in the ability of third parties that provide information technology, accounting, human resources, payroll and other outsourced services to AbbVie to meet their contractual obligations to AbbVie;
•business interruptions stemming from natural disasters, such as climate change, earthquakes, hurricanes, flooding, fires, or efforts taken by third parties to prevent or mitigate such disasters; and
•changes in business, economic and political conditions, including: war, political instability, terrorist attacks, the threat of future terrorist activity and related military action; natural disasters; the cost and availability of insurance due to any of the foregoing events; labor disputes, strikes, slow-downs, or other forms of labor or union activity; and pressure from third-party interest groups.
Risks Related to AbbVie's Common Stock
AbbVie cannot guarantee the timing, amount, or payment of dividends on its common stock.
Although AbbVie expects to pay regular cash dividends, the timing, declaration, amount and payment of future dividends to stockholders will fall within the discretion of AbbVie's board of directors. The board's decisions regarding the payment of dividends will depend on many factors, such as AbbVie's financial condition, earnings, capital requirements, debt service obligations, industry practice, legal requirements, regulatory constraints and other factors that the board deems relevant. For more information, see Item 5, "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities." AbbVie's ability to pay dividends will depend on its ongoing ability to generate cash from operations and access capital markets. AbbVie cannot guarantee that it will continue to pay a dividend in the future.
|
| | |
| | 2018 Form 10-K | 17
|
An AbbVie stockholder's percentage of ownership in AbbVie may be diluted in the future.
In the future, a stockholder's percentage ownership in AbbVie may be diluted because of equity issuances for capital market transactions, equity awards that AbbVie will be granting to AbbVie's directors, officers and employees, acquisitions or other purposes. AbbVie's employees have options to purchase shares of its common stock as a result of conversion of their Abbott stock options (in whole or in part) to AbbVie stock options. AbbVie anticipates its compensation committee will grant additional stock options or other stock-based awards to its employees. Such awards will have a dilutive effect on AbbVie's earnings per share, which could adversely affect the market price of AbbVie's common stock. From time to time, AbbVie will issue additional options or other stock-based awards to its employees under AbbVie's employee benefits plans.
| | | | | | | | | | | |
23 | |2021 Form 10-K | | |
In addition, AbbVie's amended and restated certificate of incorporation authorizes AbbVie to issue, without the approval of AbbVie's stockholders, one or more classes or series of preferred stock having such designation, powers, preferences and relative, participating, optional and other special rights, including preferences over AbbVie's common stock respecting dividends and distributions, as AbbVie's board of directors generally may determine. The terms of one or more classes or series of preferred stock could dilute the voting power or reduce the value of AbbVie's common stock. For example, AbbVie could grant the holders of preferred stock the right to elect some number of AbbVie's directors in all events or on the happening of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences AbbVie could assign to holders of preferred stock could affect the residual value of the common stock.
Certain provisions in AbbVie's amended and restated certificate of incorporation and amended and restated by-laws, and of Delaware law, may prevent or delay an acquisition of AbbVie, which could decrease the trading price of AbbVie's common stock.
AbbVie's amended and restated certificate of incorporation and amended and restated by-laws contain, and Delaware law contains, provisions that are intended to deter coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the bidder and to encourageencouraging prospective acquirors to negotiate with AbbVie's board of directors rather than to attempt a hostile takeover. These provisions include, among others:
•the inability of AbbVie's stockholders to call a special meeting;
•the division of AbbVie's board of directors into three classes of directors, with each class serving a staggered three-year term;
•a provision that stockholders may only remove directors for cause;
•the ability of AbbVie's directors, and not stockholders, to fill vacancies on AbbVie's board of directors; and
•the requirement that the affirmative vote of stockholders holding at least 80% of AbbVie's voting stock is required to amend certain provisions in AbbVie's amended and restated certificate of incorporation and AbbVie's amended and restated by-laws relating to the number, term and election of AbbVie's directors, the filling of board vacancies, the calling of special meetings of stockholders and director and officer indemnification provisions.
In addition, Section 203 of the Delaware General Corporation Law provides that, subject to limited exceptions, persons that acquire, or are affiliated with a person that acquires, more than 15% of the outstanding voting stock of a Delaware corporation shall not engage in any business combination with that corporation, including by merger, consolidation or acquisitions of additional shares, for a three-year period following the date on which that person or its affiliates becomes the holder of more than 15% of the corporation's outstanding voting stock.
AbbVie believes these provisions protect its stockholders from coercive or otherwise unfair takeover tactics by requiring potential acquirors to negotiate with AbbVie's board of directors and by providing AbbVie's board of directors with more time to assess any acquisition proposal. These provisions are not intended to make the company immune from takeovers. However, these provisions apply even if the offer may be considered beneficial by some stockholders and could delay or prevent an acquisition that AbbVie's board of directors determines is not in the best interests of AbbVie and AbbVie's stockholders. These provisions may also prevent or discourage attempts to remove and replace incumbent directors.
|
| | | | | | | | | | |
| | 18 |20182021 Form 10-K| | | 24 |
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains certain forward looking statements regarding business strategies, market potential, future financial performance and other matters. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify "forward looking statements," which speak only as of the date the statements were made. The matters discussed in these forward looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward looking statements. In particular, information included under Item 1, "Business," Item 1A, "Risk Factors," and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" contain forward looking statements. Where, in any forward looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of AbbVie management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Factors that could cause actual results or events to differ materially from those anticipated include the matters described under Item 1A, "Risk Factors" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations." AbbVie does not undertake any obligation to update the forward-looking statements included in this Annual Report on Form 10-K to reflect events or circumstances after the date hereof, unless AbbVie is required by applicable securities law to do so.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
AbbVie's corporate offices are located at 1 North Waukegan Road, North Chicago, Illinois 60064-6400. As of December 31, 2021, AbbVie owns or leases approximately 645 facilities worldwide, containing an aggregate of approximately 20 million square feet of floor space dedicated to production, distribution, and administration. AbbVie's significant manufacturing facilities are in the following locations:
|
| | | | | | | |
| United States | | Outside the United States |
| Abbott Park, Illinois* | | Campoverde di Aprilia, Italy |
| Barceloneta, Puerto Rico | | Cork,Clonshaugh, Ireland |
Jayuya, Puerto RicoBranchburg, New Jersey* | | Ludwigshafen, GermanyLa Aurora, Costa Rica |
| Campbell, California | | Ludwigshafen, Germany |
| Cincinnati, Ohio | | Pringy, France |
| Dublin, California* | | Singapore* |
| Irvine, California | | Sligo, Ireland |
| North Chicago, Illinois | | Singapore*Westport, Ireland* |
Worcester, Massachusetts*Waco, Texas | | Sligo, Ireland |
Wyandotte, Michigan*Worcester, Massachusetts* | | |
| |
*Wyandotte, Michigan* | Leased property. | |
In addition to the above, AbbVie has other manufacturing facilities worldwide. * Leased property.
AbbVie believes its facilities are suitable and provide adequate production capacity.capacity for its current and projected operations. There are no material encumbrances on AbbVie's owned properties.
In the United States, including Puerto Rico, AbbVie has onetwo central distribution center.centers. AbbVie also has research and development facilities in the United States located at: Abbott Park, Illinois; Branchburg, New Jersey; Cambridge, Massachusetts; Irvine, California; Madison, New Jersey; North Chicago, Illinois; Redwood City,Pleasanton, California; Santa Cruz, California; South San Francisco, California; Sunnyvale, California; Cambridge, Massachusetts; and Worcester, Massachusetts. Outside the United States, AbbVie's principal research and development facilities are located in Ludwigshafen, Germany.
| | | | | | | | | | | |
25 | |2021 Form 10-K | | |
ITEM 3. LEGAL PROCEEDINGS | | |
| | 2018 Form 10-K | 19
|
ITEM 3. LEGAL PROCEEDINGS
Information pertaining to legal proceedings is provided in Note 14,15, "Legal Proceedings and Contingencies" to the Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data," and is incorporated by reference herein.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
|
| | | | | | | | | | |
| | 20 |20182021 Form 10-K| | | 26 |
INFORMATION ABOUT OUR EXECUTIVE OFFICERS OF THE REGISTRANT
The following table lists AbbVie's executive officers, each of whom was first appointed as an AbbVie corporate officer in December 2012, except as otherwise indicated:
|
| | | | | | | | | | | | | |
| Name | | Age | | Position |
| Richard A. Gonzalez | | 6568 | | Chairman of the Board and Chief Executive Officer |
Carlos AlbanRobert A. Michael | | 5651 | | Vice Chairman, Finance and Commercial Operations and Chief CommercialFinancial Officer |
| Laura J. Schumacher | | 5558 | | Vice Chairman, External Affairs and Chief Legal Officer |
Michael E. Severino, M.D.* | | 5356 | | Vice Chairman and President |
William J. ChaseHenry O. Gosebruch | | 5149 | | Executive Vice President, Finance and Administration |
Henry O. Gosebruch* | | 46 | | Executive Vice President and Chief Strategy Officer |
| Timothy J. Richmond | | 5255 | | Executive Vice President, Chief Human Resources Officer |
| Azita Saleki-Gerhardt, Ph.D. | | 5558 | | Executive Vice President, Operations |
Nicholas Donoghoe,Jeffrey R. Stewart | | 53 | | Executive Vice President, Chief Commercial Officer |
Thomas J. Hudson, M.D.* | | 3860 | | Senior Vice President, Enterprise InnovationResearch & Development and Chief Scientific Officer |
Robert A. Michael*Elaine K. Sorg | | 4855 | | Senior Vice President, Chief Financial Officer |
Jeffrey R. Stewart* | | 50 | | Senior Vice President, U.S. Commercial Operations |
| Carrie Strom | | 44 | | Senior Vice President, AbbVie and President, Global Allergan Aesthetics |
Brian L. Durkin*Durkin | | 5861 | | Vice President, Controller |
| |
* | Dr. Severino was first appointed as a corporate officer in June 2014; Mr. Gosebruch was first appointed as a corporate officer in December 2015; Dr. Donoghoe was first appointed as a corporate officer in January 2019; Mr. Michael was first appointed as a corporate officer in December 2015; Mr. Stewart was first appointed as a corporate officer in December 2018; and Mr. Durkin was first appointed as a corporate officer in October 2018. |
Mr. Gonzalez is the Chairman and Chief Executive Officer of AbbVie. He served as Abbott’s Executive Vice President of the Pharmaceutical Products Group from July 2010 to December 2012, and was responsible for Abbott’s worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President, Abbott Ventures Inc., Abbott’s medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions.
He was first appointed as an AbbVie corporate officer in December 2012.
Mr. AlbanMichael is AbbVie’s Vice Chairman, Finance and Commercial Operations and Chief Commercial Officer, responsible for global commercial operations of the company, including the Pharmacyclics commercial functions. HeFinancial Officer. Mr. Michael previously served as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019, and as Vice President, Controller from 2017 to 2018. He served as AbbVie’s Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2018. He2015 and Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Abbott’s Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial OperationsDivision Controller, Nutrition Supply Chain from 20112010 to 2012, as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Western Europe and Canada from 2007 to 2009, and as Vice President, European Operations from 2006 to 2007.2012. Mr. AlbanMichael joined Abbott in 1986.1993 and was first appointed as an AbbVie corporate officer in December 2015.
Ms. Schumacher is AbbVie’s Vice Chairman, External Affairs and Chief Legal Officer, responsible for global legal, ethics and compliance, corporate governance, corporate aviation, and all externally-facing functions including health economics outcomes research, government affairs, corporate responsibility, brand and communications.communications and government affairs. Prior to her current appointment in 2018, she served as AbbVie’s Executive Vice President, External Affairs, General Counsel and Corporate Secretary. Prior to AbbVie’s separation from Abbott, Ms. Schumacher served as Executive Vice President, General Counsel and Corporate Secretary from 2007 to 2012. Both at Abbott and AbbVie, Ms. Schumacher also led Licensing and AcquisitionBusiness Development and Ventures and Early Stage Collaborations. At Abbott, Ms. Schumacher was also responsible for its Office of Ethics and Compliance. Ms. Schumacher joined Abbottfirst appointed as an AbbVie corporate officer in 1990.December 2012. She serves on the board of General Dynamics Corporation.Corporation and CrowdStrike Holdings, Inc.
Dr. Severino is AbbVie’s Vice Chairman and President, responsible for research and development human resources, operations, and the corporate strategy office. He served as Executive Vice President, Research and Development and Chief Scientific Officer from 2014 to 2018. Dr. Severino served at Amgen Inc. as Senior Vice President, Global Development and Corporate Chief Medical Officer from 2012 to 2014, as Vice President, Global Development from 2010 to 2012 and as Vice President, Therapeutic Area Head, General Medicine and Inflammation Global Clinical Development from 2007 to 2012. He joined AbbVie in 2014.
|
| | |
| | 2018 Form 10-K | 21
|
Mr. Chase is AbbVie’s Executive Vice President, Finance2014 and Administration, responsible for all financial and administrative functionswas first appointed as an AbbVie corporate officer in June 2014. Dr. Severino also serves on the board of the company. He previously served as Executive Vice President, Chief Financial Officer from 2013 to 2018. He served as Abbott’s Vice President, Licensing and Acquisitions from 2010 to 2012, as Vice President, Treasurer from 2007 to 2010, and as Divisional Vice President, Controller of Abbott International from 2004 to 2007. Mr. Chase joined Abbott in 1989.Avantor, Inc.
Mr. Gosebruch is AbbVie's Executive Vice President, and Chief Strategy Officer. He worked for more than 20 years in the Mergers & Acquisitions Group at J.P. Morgan Securities LLC, serving as Managing Director since 2007 and as Co-Head of M&A North America during 2015. Mr. Gosebruch joined AbbVie in 2015 and was first appointed as an AbbVie corporate officer in December 2015. He serves on the board of Aptinyx Inc.
Mr. Richmond is AbbVie’s Executive Vice President, Chief Human Resources Officer. He served as Senior Vice President, Human Resources from 2013 to 2018. Mr. Richmond served as Abbott’s Divisional Vice President of Compensation & Benefits from 2008 to 2012, as Group Vice President of Talent and Rewards from 2007 to 2008, and as Divisional Vice President of
| | | | | | | | | | | |
27 | |2021 Form 10-K | | |
Talent Acquisition from 2006 to 2007. Mr. Richmond joined Abbott in 2006.2006 and was first appointed as an AbbVie corporate officer in December 2012.
Dr. Saleki-Gerhardt is AbbVie’s Executive Vice President, Operations. She served as Senior Vice President, Operations from 2013 to 2018. Dr. Saleki-Gerhardt served as Abbott’s Vice President, Pharmaceuticals Manufacturing and Supply from 2011 to 2012, and as Divisional Vice President, Quality Assurance, Global Pharmaceutical Operations from 2008 to 2011. Dr. Saleki-Gerhardt joined Abbott in 1993.1993 and was first appointed as an AbbVie corporate officer in December 2012. She serves on the board of Entegris Inc.
Dr. DonoghoeMr. Stewart is AbbVie's SeniorAbbVie’s Executive Vice President, Enterprise Innovation.Chief Commercial Officer. He previously served as a Partner at McKinsey & Company, leading the firm's West Coast pharma and biotechnology practice. Dr. Donoghoe joined the firm in 2007 and supported multiple successful launches in therapeutic areas such as oncology, immunology, and primary care. He joined AbbVie in 2019.
Mr. Michael is AbbVie’s Senior Vice President, Chief Financial Officer. Mr. Michael previously served as Vice President, Controller from March 2017 to October 2018. He became an AbbVie officer in 2015 and served as AbbVie’s Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993.
Mr. Stewart is AbbVie’s Senior Vice President, U.S. Commercial Operations. Mr. Stewart previously servedOperations from 2018 to 2020 and as AbbVie’s President, Commercial Operations from 2013 to 2018. Prior to AbbVie’s separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States. Mr. Stewart joined Abbott in 1992.1992 and was first appointed as an AbbVie corporate officer in December 2018.
Dr. Hudson is AbbVie's Senior Vice President, Research & Development and Chief Scientific Officer. He previously served as Vice President, Head of Oncology Discovery and Early Development from 2016 to 2019. Prior to joining AbbVie, Dr. Hudson served at the Ontario Institute for Cancer Research as President and Scientific Director. He also previously served as Founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research. Dr. Hudson was first appointed as an AbbVie corporate officer in July 2019.
Ms. Sorg is AbbVie’s Senior Vice President, U.S. Commercial Operations. She previously served as AbbVie’s President, U.S. Immunology and Patient Services from 2019 to 2020 and as Vice President, Immunology and Oncology from 2016 to 2018. She served as Vice President, Immunology prior to AbbVie’s separation from Abbott and until 2016 at AbbVie. Ms. Sorg joined Abbott in 2012 and was first appointed as an AbbVie corporate officer in November 2020. Prior to joining Abbott, Ms. Sorg served in management roles at Eli Lilly and Company for 23 years.
Ms. Strom is AbbVie’s Senior Vice President, AbbVie, and President, Global Allergan Aesthetics, responsible for the worldwide operations of the aesthetics franchise. She was appointed to the position upon AbbVie’s acquisition of Allergan in 2020 and was first appointed as an AbbVie corporate officer in May 2020. At Allergan, Ms. Strom previously served as Senior Vice President, U.S. Medical Aesthetics from 2018 to 2020. She joined Allergan in 2011.
Mr. Durkin is AbbVie’s Vice President, Controller. Mr. Durkin previously served as Vice President, Internal Audit from 2016 to 2018. Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbott’s Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009. Mr. Durkin joined Abbott in 1986.1986 and was first appointed as an AbbVie corporate officer in October 2018.
The executive officers of AbbVie are elected annually by the board of directors. All other officers are elected by the board or appointed by the Chairman of the Board. All officers are either elected at the first meeting of the board of directors held after the annual stockholder meeting or appointed by the Chairman of the Board after that board meeting. Each officer holds office until a successor has been duly elected or appointed and qualified or until the officer's death, resignation, or removal. There are no family relationships between any of the executive officers listed above.
|
| | | | | | | | | | |
| | 22 |20182021 Form 10-K| | | 28 |
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Principal Market
The principal market for AbbVie's common stock is the New York Stock Exchange (Symbol: ABBV). AbbVie's common stock is also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges.
Stockholders
There were 48,51646,139 stockholders of record of AbbVie common stock as of January 31, 2019.2022.
Dividends
On November 2, 2018, AbbVie's board of directors declared an increase in the quarterly cash dividend from $0.96 per share to $1.07 per share, payable on February 15, 2019 to stockholders of record as of January 15, 2019. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie's financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie's debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors. Moreover, if AbbVie determines to pay any dividend in the future, there can be no assurance that it will continue to pay such dividends or the amount of such dividends.
Performance Graph
The following graph compares the cumulative total returns of AbbVie, the S&P 500 Index and the NYSE Arca Pharmaceuticals Index for the period from December 31, 20132016 through December 31, 2018.2021. This graph assumes $100 was invested in AbbVie common stock and each index on December 31, 20132016 and also assumes the reinvestment of dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.
|
| | |
| | 2018 Form 10-K | 23
|
This performance graph is furnished and shall not be deemed "filed" with the SEC or subject to Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any of AbbVie's filings under the Securities Act of 1933, as amended.
| | | | | | | | | | | |
29 | |2021 Form 10-K | | |
Dividends
On October 29, 2021, AbbVie's board of directors declared an increase in the quarterly cash dividend from $1.30 per share to $1.41 per share, payable on February 15, 2022 to stockholders of record as of January 14, 2022. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie's financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie's debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors. Moreover, if AbbVie determines to pay any dividend in the future, there can be no assurance that it will continue to pay such dividends or the amount of such dividends.
Issuer Purchases of Equity Securities | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Period | (a) Total
Number
of Shares
(or Units)
Purchased | | (b) Average
Price
Paid per Share
(or Unit) | | (c) Total
Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced
Plans or
Programs | | (d) Maximum Number (or
Approximate Dollar Value) of
Shares (or Units) that May
Yet Be Purchased Under the
Plans or Programs | |
| October 1, 2021 - October 31, 2021 | 3,808 | | (1) | $ | 108.90 | | (1) | — | | | $ | 2,643,316,927 | | |
| November 1, 2021 - November 30, 2021 | 845 | | (1) | $ | 116.08 | | (1) | — | | | $ | 2,643,316,927 | | |
| December 1, 2021 - December 31, 2021 | 904,176 | | (1) | $ | 136.23 | | (1) | 879,703 | | | $ | 2,523,316,993 | | |
| Total | 908,829 | | (1) | $ | 136.10 | | (1) | 879,703 | | | $ | 2,523,316,993 | | |
1. In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 3,808 in October; 845 in November; and 24,473 in December.
|
| | | | | | | | | | | | | | |
| Period | (a) Total Number of Shares (or Units) Purchased | | (b) Average Price Paid per Share (or Unit) | | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | |
| October 1, 2018 - October 31, 2018 | 4,246 |
| (1) | $ | 88.24 |
| (1) | — |
| | $ | 1,500,000,050 |
| |
| November 1, 2018 - November 30, 2018 | 17,119,956 |
| (1) | $ | 87.62 |
| (1) | 17,118,625 |
| | $ | 8,924 |
| |
| December 1, 2018 - December 31, 2018 | 8,546,698 |
| (1) | $ | 87.89 |
| (1) | 8,533,255 |
| | $ | 4,250,016,122 |
| (2) |
| Total | 25,670,900 |
| (1) | $ | 87.71 |
| (1) | 25,651,880 |
| | $ | 4,250,016,122 |
| (2) |
| |
1. | In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 4,246 in October; 1,331 in November; and 13,443 in December. |
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
| | | | | | | | | | | |
2. | On December 13, 2018, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase program. The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management’s discretion. The program has no time limit and can be discontinued at any time. | 2021 Form 10-K | | 30 |
|
| | | | | | | | | | |
2431
| |20182021 Form 10-K
| | |
ITEM 6. SELECTED FINANCIAL DATA
The selected financial information should be read in conjunction with the financial statements and accompanying notes included under Item 8, "Financial Statements and Supplementary Data" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."
|
| | | | | | | | | | | | | | | | | | | |
| as of and for the years ended December 31 (in millions, except per share data) | 2018 | | 2017 | | 2016 | | 2015 | | 2014 |
| Statement of earnings data | | | | | | | | | |
| Net revenues | $ | 32,753 |
| | $ | 28,216 |
| | $ | 25,638 |
| | $ | 22,859 |
| | $ | 19,960 |
|
| Net earnings | 5,687 |
| | 5,309 |
| | 5,953 |
| | 5,144 |
| | 1,774 |
|
| Basic earnings per share | $ | 3.67 |
| | $ | 3.31 |
| | $ | 3.65 |
| | $ | 3.15 |
| | $ | 1.11 |
|
| Diluted earnings per share | $ | 3.66 |
| | $ | 3.30 |
| | $ | 3.63 |
| | $ | 3.13 |
| | $ | 1.10 |
|
| Cash dividends declared per common share | $ | 3.95 |
| | $ | 2.63 |
| | $ | 2.35 |
| | $ | 2.10 |
| | $ | 1.75 |
|
| Weighted-average basic shares outstanding | 1,541 |
| | 1,596 |
| | 1,622 |
| | 1,625 |
| | 1,595 |
|
| Weighted-average diluted shares outstanding | 1,546 |
| | 1,603 |
| | 1,631 |
| | 1,637 |
| | 1,610 |
|
| Balance sheet data | | | | | | | | | |
Total assets (a)(b) | $ | 59,352 |
| | $ | 70,786 |
| | $ | 66,099 |
| | $ | 53,050 |
| | $ | 27,513 |
|
Long-term debt and lease obligations (a)(b)(c) | 36,611 |
| | 36,968 |
| | 36,465 |
| | 31,265 |
| | 14,552 |
|
| |
(a) | In May 2015, AbbVie acquired Pharmacyclics for approximately $20.8 billion, including cash consideration of $12.4 billion and equity consideration of approximately 128 million shares of AbbVie common stock valued at $8.4 billion. In connection with the acquisition, AbbVie issued $16.7 billion aggregate principal amount of unsecured senior notes, of which approximately $11.5 billion was used to finance the acquisition and approximately $5.0 billion was used to finance an accelerated share repurchase (ASR) program. |
| |
(b) | In June 2016, AbbVie acquired Stemcentrx for approximately $6.4 billion, including cash consideration of $1.9 billion, equity consideration of approximately 62.4 million shares of AbbVie common stock valued at $3.9 billion and contingent consideration of approximately $620 million. In connection with the acquisition, AbbVie issued $7.8 billion aggregate principal amount of unsecured senior notes. Of the $7.7 billion net proceeds, approximately $1.9 billion was used to finance the acquisition, approximately $3.8 billion was used to finance an ASR and approximately $2.0 billion was used to repay the company's outstanding term loan that was due to mature in November 2016. See Note 5 to the Consolidated Financial Statements for information regarding the acquisition of Stemcentrx, Note 9 for information on the senior notes and Note 12 for information on the ASR.
|
| |
(c) | Includes current portion of both long-term debt and lease obligations. |
|
| | |
| | 2018 Form 10-K | 25
|
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of December 31, 2018 and 2017 and results of operations for each of the three years in the period ended December 31, 2018.. This commentary should be read in conjunction with the consolidated financial statementsConsolidated Financial Statements and accompanying notes appearing in Item 8, "Financial Statements and Supplementary Data." This section of this Form 10-K generally discusses 2021 and 2020 items and year-to-year comparisons between 2021 and 2020. Discussions of 2019 items and year-to-year comparisons between 2020 and 2019 that are not included in this Form 10-K can be found in “Management's Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
EXECUTIVE OVERVIEW
Company Overview
AbbVie is a global, diversified research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories (Abbott).positioned for success with a comprehensive product portfolio that has leadership positions across immunology, hematologic oncology, neuroscience, aesthetics and eye care. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world'sworld’s most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, and patients.patients or other customers. Outside the United States, AbbVie sells products are sold primarily to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies. AbbVie has approximately 30,00050,000 employees. AbbVie operates in oneas a single global business segment—pharmaceutical products.segment.
20182021 Financial Results
AbbVie's strategy has focused on delivering strong financial results, maximizing the benefits of the Allergan acquisition, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company's financial performance in 20182021 included delivering worldwide net revenues of $32.8$56.2 billion, operating earnings of $6.4$17.9 billion, diluted earnings per share of $3.66$6.45 and cash flows from operations of $13.4$22.8 billion. Worldwide net revenues grewincreased by 16%, or 15%23% on a reported basis and 22% on a constant currency basis, driven primarily by revenuereflecting growth relatedacross its immunology, hematologic oncology, neuroscience, aesthetics and eye care portfolios as well as a full period of Allergan results in 2021 compared to MAVYRET, IMBRUVICA and VENCLEXTA, and the continued strength of HUMIRA.prior year.
Diluted earnings per share in 20182021 was $3.66$6.45 and included the following after-tax costs: (i) a Stemcentrx-related impairment charge$6.4 billion related to the amortization of $4.1intangible assets; (ii) $2.7 billion net offor the relatedchange in fair value adjustment toof contingent consideration liabilities; (ii) $1.1 billion of intangible asset amortization; (iii) $948 million for acquired in-process research and development (IPR&D); (iv) $500 million as a result of a collaboration agreement extension with Calico Life Sciences LLC (Calico); (iv) $424LLC; (v) $307 million for acquired in-processmilestones and other research and development (IPR(R&D); (v) $478 expenses; (vi) $253 million for the change in fair valuecharges related to litigation matters; and (vii) $215 million of contingent consideration liabilities excluding the fair value adjustment associated with the Stemcentrx-related impairment; (vi) litigation reserve chargesacquisition and integration expenses. These costs were partially offset by $265 million of $282 million; (vii) charitable contributions of $271 million as part of AbbVie's previously announced plan to make contributions to U.S. not-for-profit organizations in 2018; and (viii) milestone payments of $137 million. 2018 financial results were also impacted by U.S.certain tax reform and the timing of the new legislation's phase in on certain subsidiaries.benefits. Additionally, financial results reflected continued added funding to support all stages of AbbVie’s emerging pipeline assets and continued investment in AbbVie’s growthon-market brands.
In November 2018,October 2021, AbbVie's board of directors declared a quarterly cash dividend of $1.07$1.41 per share of common stock payable in February 2019.2022. This reflectedreflects an increase of approximately 11.5%8.5% over the previous quarterly dividend of $0.96$1.30 per share of common stock.
Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. The integration plan is expected to realize approximately $2.5 billion of annual cost synergies in 2022.
|
| | | | | | | | | | |
| | 26 |20182021 Form 10-K| | | 32 |
To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.
Impact of the Coronavirus Disease 2019 (COVID-19)
In response to the ongoing public health crisis posed by COVID-19, AbbVie continues to focus on ensuring the safety of employees. Throughout the pandemic, AbbVie has followed health and safety guidance from state and local health authorities and implemented safety measures for those employees who are returning to the workplace.
AbbVie also continues to closely manage manufacturing and supply chain resources around the world to help ensure that patients continue to receive an uninterrupted supply of their medicines. Clinical trial sites are being monitored locally to protect the safety of study participants, staff and employees. While the impact of COVID-19 on AbbVie's operations to date has not been material, AbbVie continues to experience lower new patient starts in certain products and markets. AbbVie expects this matter could continue to negatively impact its results of operations throughout the duration of the pandemic.
The extent to which COVID-19 may impact AbbVie's financial condition and results of operations remains uncertain and is dependent on numerous evolving factors, including the measures being taken by authorities to mitigate against the spread of COVID-19, the emergence of new variants and the availability and successful administration of effective vaccines.
2022 Strategic Objectives
AbbVie's mission is to be an innovation-driven, patient-focused specialty biopharmaceutical company capablediscover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution and a consistent stream of innovative new medicines.execution. AbbVie intends to continue to advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) growing revenues by diversifying revenue streams, driving late-stage pipeline assets to the marketleveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (ii) continued investment(iii) continuing to invest in and expansion inexpand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and neuroscience, with additional targeted investment in cystic fibrosis and women's healtheye care as well as continued investment in key on-market products; (iii)(iv) expanding operating margins; and (iv)(v) returning cash to shareholders via dividendsa strong and share repurchases.growing dividend while also reducing debt. In addition, AbbVie anticipates several regulatory submissions and key data readouts from key clinical trials in the next twelve12 months.
AbbVie expects to achieve its strategic objectives through:
•Immunology revenue growth driven by increasing market share and indication expansion of Skyrizi and Rinvoq, as well as Humira U.S. sales growth.
•Hematologic oncology revenue growth from both IMBRUVICAdriven by increasing market share and VENCLEXTA.indication expansion of Venclexta, as well as maintaining the strong leadership position of Imbruvica.
The strong execution•Aesthetics revenue growth driven by global expansion and increasing market penetration of new product launches across multiple therapeutic areas.Botox and Juvederm Collection.
HUMIRA U.S. sales•Neuroscience revenue growth driven by driving biologic penetration across disease categoriesVraylar, Botox Therapeutic, Ubrelvy and maintaining market leadership.recently launched Qulipta.
Effective management of HUMIRA international biosimilar erosion.•Sustaining eye care leadership by maximizing AbbVie's current eye care portfolio.
•The favorable impact of pipeline products and indications recently approved or currently under regulatory review where approval is expected in 2019.2022. These products are described in greater detail in the section labeled "Research and Development" included as part of this Item 7.
7.AbbVie remains committed to driving continued expansion of operating margins and expects to achieve this objective through continued realization of expense synergies from the Allergan acquisition, leverage from revenue growth, the reduction of HUMIRA royalty expense, productivity initiatives in supply chain and ongoing efficiency programs to optimize manufacturing, commercial infrastructure, administrative costs and general corporate expenses.
| | | | | | | | | | | |
33 | |2021 Form 10-K | | |
Research and Development
Research and innovation are the cornerstones of AbbVie's business as a global biopharmaceutical company. AbbVie's long-term success depends to a great extent on its ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.
AbbVie's pipeline currently includes more than 60approximately 90 compounds, devices or indications in clinical development individually or under collaboration or license agreements and is focused on such important medical specialties as immunology, oncology, aesthetics, neuroscience and neuroscience along with targeted investments in cystic fibrosis and women's health.eye care. Of these programs, more than 3050 are in mid- and late-stage development.
The following sections summarize transitions of significant programs from Phase 2mid-stage development to Phase 3late-stage development as well as developments in significant Phase 3late-stage and registration programs. AbbVie expects multiple Phase 2mid-stage programs to transition into Phase 3late-stage programs in the next twelve12 months.
Significant Programs and Developments
Immunology
UpadacitinibSkyrizi
•In January 2018,2021, AbbVie announced top-line results from its Phase 3 KEEPsAKE-1 and KEEPsAKE-2 clinical trials of Skyrizi in adults with active psoriatic arthritis (PsA) met the primary and ranked secondary endpoints.
•In January 2021, AbbVie announced top-line results from its Phase 3 ADVANCE and MOTIVATE induction studies of Skyrizi in patients with Crohn’s disease met the primary and key secondary endpoints.
•In April 2021, AbbVie received U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for upadacitinib, an investigational oral JAK1-selective inhibitor,approval of Skyrizi in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.a single dose pre-filled syringe and pre-filled pen. This approval will reduce the number of injections administered per treatment.
•In April 2018,June 2021, AbbVie announced that top-line results from theits Phase 3 SELECT-COMPARE clinical trial evaluating upadacitinib met all primary and ranked secondary endpointsFORTIFY study for Skyrizi in patients with moderate to severe rheumatoid arthritis (RA) who are onCrohn’s disease met the co-primary endpoints.
•In September 2021, AbbVie submitted a stable backgroundsupplemental New Drug Application (sNDA) to the FDA for Skyrizi for the treatment of methotrexatepatients 16 years and who have an inadequate response. The safety profile of upadacitinib was consistent with previously reported clinical trials and no new safety signals were detected.
|
| | |
| | 2018 Form 10-K | 27
|
In June 2018, AbbVie announced that top-line results from the Phase 3 SELECT-EARLY clinical trial evaluating upadacitinib versus methotrexate in adult patientsolder with moderate to severe RA who were methotrexate-naïve met all primary and ranked secondary endpoints. The safety profile of upadacitinib was consistent with previously reported clinical trials and no new safety signals were detected.Crohn’s disease.
•In July 2018, AbbVie initiated two Phase 3 clinical trials to evaluate the efficacy and safety of upadacitinib in subjects with moderate to severe atopic dermatitis.
In September 2018, AbbVie initiated a Phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with moderate to severe ulcerative colitis.
In December 2018, November 2021, AbbVie submitted a New Drug Application (NDA) to the FDA and a marketing authorisationauthorization application (MAA) to the European Medicines Agency (EMA) for upadacitinibSkyrizi for the treatment of patients 16 years or older with moderate to severe active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
•In November 2021, AbbVie announced that the European Commission (EC) approved Skyrizi alone or in combination with methotrexate for the treatment of active PsA in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.
•In January 2022, AbbVie announced that the FDA approved Skyrizi for the treatment of adults with active PsA.
Rinvoq
•In January 2021, AbbVie announced that the EC approved Rinvoq for the treatment of adults with active PsA and ankylosing spondylitis (AS).
•In February 2021, AbbVie announced its Phase 3 U-ACCOMPLISH induction study of Rinvoq for the treatment of adult patients with moderate to severe RA.ulcerative colitis (UC) met the primary and all ranked secondary endpoints.
Risankizumab
•In January 2018, AbbVie initiated two Phase 3 clinical trials to evaluate the efficacy and safety of risankizumab, an investigational interleukin-23 (IL-23) inhibitor, versus placebo during induction therapy in subjects with moderately to severely active Crohn’s disease.
In February 2018,June 2021, AbbVie announced that top-line results from two Phase 3 clinical trials evaluating risankizumab with 12-week dosing compared to ustekinumab met ranked additional secondary endpointsthe FDA will not meet the Prescription Drug User Fee Act action dates for the sNDA of Rinvoq for the treatment of adults with active AS. No formal regulatory action has been taken on the sNDA for Rinvoq in AS.
•In June 2021, AbbVie announced the results from its Phase 3 maintenance study of Rinvoq in patients with UC met the primary and all secondary endpoints.
•In August 2021, AbbVie announced that the EC approved Rinvoq for the treatment of moderate to severe chronic plaque psoriasis. The initial results from these clinical trials were previously announcedatopic dermatitis (AD) in October 2017. The safety profile was consistent with all previously reported studies,adults and there were no new safety signals detected across the two studies.adolescents 12 years and older who are candidates for systemic therapy.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 34 |
•In April 2018,September 2021, AbbVie submitted a Biologics License Application (BLA)an sNDA to the FDA and an MAA to the EMA for risankizumabRinvoq for the treatment of plaque psoriasis in adults.
In May 2018, AbbVie initiated a Phase 2b/3 clinical trial to evaluate the efficacy and safety of risankizumab versus placebo in subjectsadults with moderately to severely active ulcerative colitis.UC.
Oncology
IMBRUVICA
•In April 2018, AbbVie initiated a Phase 3 clinical trial to evaluateOctober 2021, AbbVie announced the safety and efficacy of IMBRUVICA in combination with VENCLEXTA versus chlorambucil plus GAZYVA (obinutuzumab) for the first-line treatment of subjects with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
In May 2018, AbbVie announced that results from the Phase 3 iLLUMINATE study evaluating IMBRUVICA in combination with GAZYVA in previously untreated CLL/SLL met its primary endpoint. In December 2018, AbbVie announced additional results from the Phase 3 iLLUMINATE study that demonstrated significantly prolonged progression-free survival (PFS).
In June 2018, AbbVie announced that results from an interim analysisStudy 1 of the Phase 3 iNNOVATE study evaluating IMBRUVICA plus Rituxan (rituximab)SELECT-AXIS 2 clinical trial for Rinvoq in previously untreated and relapsed/refractory (R/R) patients with Waldenström’s macroglobulinemia (WM)active AS and inadequate response to biologic disease-modifying antirheumatic drugs met itsthe primary endpoint.and all ranked secondary endpoints.
•In July 2018, October 2021, AbbVie announced the results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial for Rinvoq in adults with non-radiographic axial spondyloarthritis met the primary and 12 of 14 ranked secondary endpoints.
•In December 2021, AbbVie announced thattop-line results from aits Phase 3 U-EXCEED induction study evaluatingfor Rinvoq in patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy met the addition of IMBRUVICAprimary and key secondary endpoints.
•In December 2021, AbbVie announced an update to a chemotherapy regimen consisting of five different agents used in combination did not meet its primary endpoint in a subset of untreated diffuse large B-cell lymphoma patients identified to have the non-germinal center B-cell or activated B-cell subtypes of this disease.
In August 2018, the FDA approved IMBRUVICA, in combination with Rituxan,U.S. Prescribing Information and Medication Guide for Rinvoq for the treatment of adultadults with moderate to severe rheumatoid arthritis (RA). This update follows a Drug Safety Communication (DSC) issued by the FDA in September 2021 based on its final review of the post-marketing study evaluating another JAK inhibitor (tofacitinib) in patients with WM.RA. The DSC and this label update apply to the class of systematically administered FDA-approved JAK inhibitors for the treatment of RA and other inflammatory diseases. Based on this class-wide update, the U.S. label for Rinvoq will now include additional information about risks within the Boxed Warnings and Warnings Precautions sections. The indication has also been updated to be indicated for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
•In December 2018, AbbVie2021, AbbVie announced that results from an interim analysis of the Phase 3 ECOG1912E study evaluating IMBRUVICA in combination with Rituxan versus the chemoimmunotherapy FCR (fludarabine, cyclophosphamide and rituximab) in previously untreated and younger CLL patients met its primary endpoint.
In January 2019, AbbVie announced an update on the Phase 3 RESOLVE study evaluating IMBRUVICA in combination with nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine combination in patients
|
| | |
28 |2018 Form 10-K
| | |
with metastatic pancreatic adenocarcinoma. Results showed the study did not meet its primary endpoint of improving PFS or overall survival (OS) benefit among the study population. Safety data collected from the study were consistent with the existing safety information for the study therapies.
In January 2019, the FDA approved IMBRUVICA, in combinationRinvoq for the treatment of adults with GAZYVA, for adult patients with previously untreated CLL/SLL.active PsA who have had an inadequate response or intolerance to one or more TNF blockers.
VENCLEXTA
•In January 2018, AbbVie submitted2022, AbbVie announced its submission of an sNDA to the FDA and an MAA to the EMA for VENCLEXTA monotherapy in patients with CLL who are refractory to or have relapsed B-cell receptor pathway inhibitors.
In June 2018, the FDA approved VENCLEXTA in combination with RituxanRinvoq for the treatment of patientsadults with CLL/SLL,active nr-axSpA with or without 17p deletion,objective signs of inflammation who have received at least one prior therapy. VENCLEXTA plus Rituxan is the first oral-based, chemotherapy-free combination in CLLresponded inadequately to nonsteroidal anti-inflammatory drugs.
•In January 2022, AbbVie announced that allows patients an option for fixed treatment duration.
In September 2018, the FDA expanded the label for VENCLEXTA in combination with Rituxan to include information about patients with previously-treated CLL who achieved minimal residual disease (MRD)-negativity in the Phase 3 MURANO trial.
In October 2018, the European Commission approved the type-II variation application for VENCLYXTO in combination with RituxanRinvoq for the treatment of patientsmoderate to severe AD in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with R/R CLL who have received at least one prior therapy. other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.
•In November, February 2022, AbbVie received notificationwas notified that the EC is requesting the EMA to assess safety concerns associated with JAK inhibitor products authorized in inflammatory diseases and to evaluate the impact of these events on their benefit-risk balance. The assessment covers all JAK inhibitors approved for use in inflammatory diseases. The request is for an opinion from the European Commission that conditions of the original conditional marketing authorisation have been fulfilled, granting VENCLYXTO official receipt of approval.EMA by September 30, 2022.
Oncology
Imbruvica
•In October 2018,June 2021, AbbVie announced that the results from theits Phase 3 CLL14GLOW study comparing the efficacy and safety of VENCLEXTAImbruvica in combination with Venclexta versus chlorambucil plus obinutuzumab versus obinutuzumab plus chlorambucilfor first-line treatment in previously untreated patients with CLL and coexisting medical conditionschronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma met its primary endpoint.
Venclexta
•In November 2018,May 2021, AbbVie received European Commission approval for Venclyxto in combination with a hypomethylating agent for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
| | | | | | | | | | | |
35 | |2021 Form 10-K | | |
•In July 2021, AbbVie announced that the FDA granted accelerated approval for VENCLEXTABreakthrough Therapy Designation to Venclexta in combination with azacitidine or decitabine, or low dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Rova-T
In March 2018, AbbVie announced top-line results from the Phase 2 TRINITY study evaluating rovalpituzumab tesirine (Rova-T) for third-line R/R small cell lung cancer (SCLC). Although Rova-T demonstrated single agent responses in advanced SCLC patients, after consulting with the FDA, based on the magnitude of effect across multiple parameters in this single-arm study, the company will not seek accelerated approval for Rova-T in third-line R/R SCLC.
In December 2018, AbbVie announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rova-T as a second-line therapy for advanced SCLC. An Independent Data Monitoring Committee recommended stopping enrollment in TAHOE due to shorter overall survival in the Rova-T arm compared with the topotecan control arm. AbbVie will continue its ongoing Phase 3 study of Rova-T in first-line SCLC.
Other
In November 2018, Bristol-Myers Squibb Company (BMS) announced that the FDA expanded the label for Empliciti in combination with pomalidomide and dexamethasone for thepotential treatment of adult patients with multiple myeloma who havepreviously untreated intermediate-, high- and very high-risk myelodysplastic syndromes.
Teliso-V
•In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.
Neuroscience
Botox Therapeutic
•In February 2021, AbbVie received at leastFDA approval of Botox for the treatment of detrusor overactivity associated with a neurological condition in certain pediatric patients 5 years of age and older.
Qulipta
•In September 2021, AbbVie announced that the FDA approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.
Vraylar
•In October 2021, AbbVie announced top-line results from two prior therapies. BMSPhase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). In Study 3111-301-001, Vraylar met its primary endpoint demonstrating statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo in patients with MDD. In Study 3111-302-001, Vraylar demonstrated numerical improvement in depressive symptoms from baseline to week six in MADRS total score compared with placebo but did not achieve statistical significance. Safety data were consistent with the established safety profile of Vraylar across indications with no new safety signals identified.
ABBV-951
•In October 2021, AbbVie announced that results from its pivotal Phase 3 M15-736 study of ABBV-951 (foslevodopa/foscarbidopa) in patients with advanced Parkinson’s disease met its primary endpoint in a 12-week study.
Eye Care
Vuity
•In October 2021,AbbVie are co-developing Empliciti, with BMS solely responsibleannounced that the FDA approved Vuity (pilocarpine HCl ophthalmic solution) for commercial activities.the treatment of presbyopia.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |29
| 36 |
Virology/Liver Disease
In November 2018, AbbVie presented EXPEDITION 8 data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), in which 8 weeks of MAVYRET in treatment naïve, cirrhotic patients was safe and effective with no virologic failures reported.
Neuroscience
In March 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of marketing authorizations for ZINBRYTA, a prescription medicine used to treat adults with relapsing forms of multiple sclerosis.
Other
In February 2018, AbbVie announced that top-line results from the Phase 3 ELARIS UF-I study evaluating elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated in combination with low-dose hormone (add-back) therapy for uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints.
In March 2018, AbbVie announced that top-line results from the Phase 3 ELARIS UF-II study evaluating elagolix in combination with low-dose hormone (add-back) therapy for uterine fibroids met its primary efficacy endpoint and all ranked secondary endpoints.
In July 2018, the FDA approved ORILISSA (elagolix) for the management of moderate to severe pain associated with endometriosis.
In August 2018, AbbVie announced that top-line results from the Phase 3 ELARIS UF-EXTEND study evaluating elagolix in combination with low-dose hormone (add-back) therapy for uterine fibroids were consistent with findings observed in the ELARIS UF-I and ELARIS UF-II Phase 3 studies.
In October 2018, AbbVie announced that it will assume full development and commercial responsibility for its collaboration with Galapagos to discover and develop new therapies to treat cystic fibrosis (CF). Under a revised agreement, AbbVie will assume full development and commercial responsibility over the investigational program comprising several clinical and pre-clinical compounds originally discovered and developed jointly by AbbVie and Galapagos. Galapagos will not pursue further research and development in CF, but is eligible for future milestones and royalties on commercialized programs.
RESULTS OF OPERATIONS
Net Revenues
The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year's foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and the current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company's operations and can facilitate analysis of the company's results of operations, particularly in evaluating performance from one period to another. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | Percent change |
| | | | | | | At actual currency rates | | At constant currency rates |
| years ended (dollars in millions) | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2021 | | 2020 |
| United States | $ | 43,510 | | | $ | 34,879 | | | $ | 23,907 | | | 24.7 | % | | 45.9 | % | | 24.7 | % | | 45.9 | % |
| International | 12,687 | | | 10,925 | | | 9,359 | | | 16.1 | % | | 16.7 | % | | 12.6 | % | | 17.8 | % |
| Net revenues | $ | 56,197 | | | $ | 45,804 | | | $ | 33,266 | | | 22.7 | % | | 37.7 | % | | 21.9 | % | | 38.0 | % |
|
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Percent change |
| | | | | | | | At actual currency rates | | At constant currency rates |
| for the years ended (dollars in millions) | 2018 | | 2017 | | 2016 | | 2018 | | 2017 | | 2018 | | 2017 |
| United States | $ | 21,524 |
| | $ | 18,251 |
| | $ | 15,947 |
| | 17.9 | % | | 14.4 | % | | 17.9 | % | | 14.4 | % |
| International | 11,229 |
| | 9,965 |
| | 9,691 |
| | 12.8 | % | | 2.8 | % | | 10.4 | % | | 2.1 | % |
| Net revenues | $ | 32,753 |
| | $ | 28,216 |
| | $ | 25,638 |
| | 16.1 | % | | 10.1 | % | | 15.2 | % | | 9.8 | % |
|
| | | | | | | | | | |
3037
| |20182021 Form 10-K
| | |
The following table details AbbVie's worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | Percent change |
| | | | | | | | | At actual currency rates | | At constant currency rates |
| years ended December 31 (dollars in millions) | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2021 | | 2020 |
| Immunology | | | | | | | | | | | | | | |
| Humira | United States | | $ | 17,330 | | | $ | 16,112 | | | $ | 14,864 | | | 7.6 | % | | 8.4 | % | | 7.6 | % | | 8.4 | % |
| International | | 3,364 | | | 3,720 | | | 4,305 | | | (9.6) | % | | (13.6) | % | | (12.8) | % | | (12.5) | % |
| Total | | $ | 20,694 | | | $ | 19,832 | | | $ | 19,169 | | | 4.3 | % | | 3.5 | % | | 3.7 | % | | 3.7 | % |
| Skyrizi | United States | | $ | 2,486 | | | $ | 1,385 | | | $ | 311 | | | 79.6 | % | | >100.0% | | 79.6 | % | | >100.0% |
| International | | 453 | | | 205 | | | 44 | | | >100.0 % | | >100.0% | | >100.0 % | | >100.0% |
| Total | | $ | 2,939 | | | $ | 1,590 | | | $ | 355 | | | 84.9 | % | | >100.0% | | 84.0 | % | | >100.0% |
| Rinvoq | United States | | $ | 1,271 | | | $ | 653 | | | $ | 47 | | | 94.8 | % | | >100.0% | | 94.8 | % | | >100.0% |
| International | | 380 | | | 78 | | | — | | | >100.0 % | | >100.0% | | >100.0 % | | >100.0% |
| Total | | $ | 1,651 | | | $ | 731 | | | $ | 47 | | | >100.0 % | | >100.0% | | >100.0 % | | >100.0% |
| Hematologic Oncology | | | | | | | | | | | | | | |
| Imbruvica | United States | | $ | 4,321 | | | $ | 4,305 | | | $ | 3,830 | | | 0.4 | % | | 12.4 | % | | 0.4 | % | | 12.4 | % |
| Collaboration revenues | | 1,087 | | | 1,009 | | | 844 | | | 7.7 | % | | 19.5 | % | | 7.7 | % | | 19.5 | % |
| Total | | $ | 5,408 | | | $ | 5,314 | | | $ | 4,674 | | | 1.8 | % | | 13.7 | % | | 1.8 | % | | 13.7 | % |
| Venclexta | United States | | $ | 934 | | | $ | 804 | | | $ | 521 | | | 16.1 | % | | 54.4 | % | | 16.1 | % | | 54.4 | % |
| International | | 886 | | | 533 | | | 271 | | | 66.2 | % | | 97.0 | % | | 60.9 | % | | 97.8 | % |
| Total | | $ | 1,820 | | | $ | 1,337 | | | $ | 792 | | | 36.1 | % | | 69.0 | % | | 34.0 | % | | 69.3 | % |
| Aesthetics | | | | | | | | | | | | | | |
Botox Cosmetic (a) | United States | | $ | 1,424 | | | $ | 687 | | | $ | — | | | >100.0 % | | n/m | | >100.0 % | | n/m |
| International | | 808 | | | 425 | | | — | | | 90.0 | % | | n/m | | 83.9 | % | | n/m |
| Total | | $ | 2,232 | | | $ | 1,112 | | | $ | — | | | >100.0 % | | n/m | | 98.4 | % | | n/m |
Juvederm Collection (a) | United States | | $ | 658 | | | $ | 318 | | | $ | — | | | >100.0 % | | n/m | | >100.0 % | | n/m |
| International | | 877 | | | 400 | | | — | | | >100.0 % | | n/m | | >100.0 % | | n/m |
| Total | | $ | 1,535 | | | $ | 718 | | | $ | — | | | >100.0 % | | n/m | | >100.0 % | | n/m |
Other Aesthetics (a) | United States | | $ | 1,268 | | | $ | 666 | | | $ | — | | | 90.2 | % | | n/m | | 90.2 | % | | n/m |
| International | | 198 | | | 94 | | | — | | | >100.0 % | | n/m | | >100.0 % | | n/m |
| Total | | $ | 1,466 | | | $ | 760 | | | $ | — | | | 93.0 | % | | n/m | | 91.9 | % | | n/m |
| Neuroscience | | | | | | | | | | | | | | | |
Botox Therapeutic (a) | United States | | $ | 2,012 | | | $ | 1,155 | | | $ | — | | | 74.3 | % | | n/m | | 74.3 | % | | n/m |
| International | | 439 | | | 232 | | | — | | | 89.0 | % | | n/m | | 78.8 | % | | n/m |
| Total | | $ | 2,451 | | | $ | 1,387 | | | $ | — | | | 76.7 | % | | n/m | | 75.0 | % | | n/m |
Vraylar (a) | United States | | $ | 1,728 | | | $ | 951 | | | $ | — | | | 81.7 | % | | n/m | | 81.7 | % | | n/m |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Duodopa | United States | | $ | 102 | | | $ | 103 | | | $ | 97 | | | (1.0) | % | | 5.9 | % | | (1.0) | % | | 5.9 | % |
| International | | 409 | | | 391 | | | 364 | | | 4.6 | % | | 7.4 | % | | (0.1) | % | | 6.3 | % |
| Total | | $ | 511 | | | $ | 494 | | | $ | 461 | | | 3.4 | % | | 7.1 | % | | (0.3) | % | | 6.2 | % |
Ubrelvy (a) | United States | | $ | 552 | | | $ | 125 | | | $ | — | | | >100.0 % | | n/m | | >100.0 % | | n/m |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
Other Neuroscience (a) | United States | | $ | 667 | | | $ | 528 | | | $ | — | | | 26.3 | % | | n/m | | 26.3 | % | | n/m |
| International | | 18 | | | 11 | | | — | | | 77.4 | % | | n/m | | 64.7 | % | | n/m |
| Total | | $ | 685 | | | $ | 539 | | | $ | — | | | 27.2 | % | | n/m | | 27.0 | % | | n/m |
|
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | Percent change |
| | | | | | | | At actual currency rates | | At constant currency rates |
years ended December 31 (dollars in millions) | 2018 | | 2017 | | 2016 | | 2018 | | 2017 | | 2018 | | 2017 |
| Immunology | | | | | | | | | | | | | |
| HUMIRA | | | | | | | | | | | | | |
| United States | $ | 13,685 |
| | $ | 12,361 |
| | $ | 10,432 |
| | 10.7 | % | | 18.5 | % | | 10.7 | % | | 18.5 | % |
| International | 6,251 |
| | 6,066 |
| | 5,646 |
| | 3.1 | % | | 7.4 | % | | 0.6 | % | | 6.7 | % |
| Total | $ | 19,936 |
| | $ | 18,427 |
| | $ | 16,078 |
| | 8.2 | % | | 14.6 | % | | 7.4 | % | | 14.4 | % |
| Hematologic Oncology | | | | | | | | | | | | | |
| IMBRUVICA | | | | | | | | | | | | | |
| United States | $ | 2,968 |
| | $ | 2,144 |
| | $ | 1,580 |
| | 38.4 | % | | 35.8 | % | | 38.4 | % | | 35.8 | % |
| Collaboration revenues | 622 |
| | 429 |
| | 252 |
| | 45.0 | % | | 70.0 | % | | 45.0 | % | | 70.0 | % |
| Total | $ | 3,590 |
| | $ | 2,573 |
| | $ | 1,832 |
| | 39.5 | % | | 40.5 | % | | 39.5 | % | | 40.5 | % |
| VENCLEXTA | | | | | | | | | | | | | |
| United States | $ | 247 |
| | $ | 89 |
| | $ | 17 |
| | >100.0% |
| | >100.0% |
| | >100.0% |
| | >100.0% |
|
| International | 97 |
| | 33 |
| | 1 |
| | >100.0% |
| | >100.0% |
| | >100.0% |
| | >100.0% |
|
| Total | $ | 344 |
| | $ | 122 |
| | $ | 18 |
| | >100.0% |
| | >100.0% |
| | >100.0% |
| | >100.0% |
|
| HCV | | | | | | | | | | | | | |
| MAVYRET | | | | | | | | | | | | | |
| United States | $ | 1,614 |
| | $ | 277 |
| | $ | — |
| | >100.0% |
| | n/m |
| | >100.0% |
| | n/m |
|
| International | 1,824 |
| | 213 |
| | — |
| | >100.0% |
| | n/m |
| | >100.0% |
| | n/m |
|
| Total | $ | 3,438 |
| | $ | 490 |
| | $ | — |
| | >100.0% |
| | n/m |
| | >100.0% |
| | n/m |
|
| VIEKIRA | | | | | | | | | | | | | |
| United States | $ | 3 |
| | $ | 61 |
| | $ | 342 |
| | (96.7 | )% | | (82.8 | )% | | (96.7 | )% | | (82.8 | )% |
| International | 175 |
| | 723 |
| | 1,180 |
| | (75.6 | )% | | (38.7 | )% | | (74.8 | )% | | (38.6 | )% |
| Total | $ | 178 |
| | $ | 784 |
| | $ | 1,522 |
| | (77.2 | )% | | (48.6 | )% | | (76.5 | )% | | (48.5 | )% |
| Other Key Products | | | | | | | | | | | | | |
| Creon | | | | | | | | | | | | | |
| United States | $ | 928 |
| | $ | 831 |
| | $ | 730 |
| | 11.7 | % | | 13.9 | % | | 11.7 | % | | 13.9 | % |
| Lupron | | | | | | | | | | | | | |
| United States | $ | 726 |
| | $ | 669 |
| | $ | 663 |
| | 8.6 | % | | 0.8 | % | | 8.6 | % | | 0.8 | % |
| International | 166 |
| | 160 |
| | 158 |
| | 3.4 | % | | 1.4 | % | | 4.7 | % | | 0.5 | % |
| Total | $ | 892 |
| | $ | 829 |
| | $ | 821 |
| | 7.6 | % | | 0.9 | % | | 7.9 | % | | 0.7 | % |
| Synthroid | | | | | | | | | | | | | |
| United States | $ | 776 |
| | $ | 781 |
| | $ | 763 |
| | (0.6 | )% | | 2.3 | % | | (0.6 | )% | | 2.3 | % |
| Synagis | | | | | | | | | | | | | |
| International | $ | 726 |
| | $ | 738 |
| | $ | 730 |
| | (1.6 | )% | | 1.2 | % | | (2.8 | )% | | 0.6 | % |
| AndroGel | | | | | | | | | | | | | |
| United States | $ | 469 |
| | $ | 577 |
| | $ | 675 |
| | (18.8 | )% | | (14.5 | )% | | (18.8 | )% | | (14.5 | )% |
| Duodopa | | | | | | | | | | | | | |
| United States | $ | 80 |
| | $ | 61 |
| | $ | 37 |
| | 31.4 | % | | 66.1 | % | | 31.4 | % | | 66.1 | % |
| International | 350 |
| | 294 |
| | 256 |
| | 19.1 | % | | 14.6 | % | | 14.8 | % | | 13.1 | % |
| Total | $ | 430 |
| | $ | 355 |
| | $ | 293 |
| | 21.2 | % | | 21.1 | % | | 17.7 | % | | 19.8 | % |
| Sevoflurane | | | | | | | | | | | | | |
| United States | $ | 74 |
| | $ | 78 |
| | $ | 80 |
| | (6.2 | )% | | (2.1 | )% | | (6.2 | )% | | (2.1 | )% |
| International | 317 |
| | 332 |
| | 348 |
| | (4.4 | )% | | (4.6 | )% | | (4.3 | )% | | (3.7 | )% |
| Total | $ | 391 |
| | $ | 410 |
| | $ | 428 |
| | (4.7 | )% | | (4.1 | )% | | (4.6 | )% | | (3.4 | )% |
| Kaletra | | | | | | | | | | | | | |
| United States | $ | 55 |
| | $ | 71 |
| | $ | 116 |
| | (22.1 | )% | | (38.6 | )% | | (22.1 | )% | | (38.6 | )% |
| International | 281 |
| | 352 |
| | 433 |
| | (20.2 | )% | | (18.8 | )% | | (20.1 | )% | | (21.1 | )% |
| Total | $ | 336 |
| | $ | 423 |
| | $ | 549 |
| | (20.5 | )% | | (22.9 | )% | | (20.4 | )% | | (24.7 | )% |
| All other | $ | 319 |
| | $ | 876 |
| | $ | 1,199 |
| | (63.6 | )% | | (26.9 | )% | | (71.9 | )% | | (27.9 | )% |
| Total net revenues | $ | 32,753 |
| | $ | 28,216 |
| | $ | 25,638 |
| | 16.1 | % | | 10.1 | % | | 15.2 | % | | 9.8 | % |
n/m – Not meaningful
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |31
| 38 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | Percent change |
| | | | | | | | | At actual currency rates | | At constant currency rates |
| years ended December 31 (dollars in millions) | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2021 | | 2020 |
| Eye Care | | | | | | | | | | | | | | |
Lumigan/Ganfort (a) | United States | | $ | 273 | | | $ | 165 | | | $ | — | | | 64.7 | % | | n/m | | 64.7 | % | | n/m |
| International | | 306 | | | 213 | | | — | | | 44.1 | % | | n/m | | 38.1 | % | | n/m |
| Total | | $ | 579 | | | $ | 378 | | | $ | — | | | 53.1 | % | | n/m | | 49.7 | % | | n/m |
Alphagan/Combigan (a) | United States | | $ | 373 | | | $ | 223 | | | $ | — | | | 66.5 | % | | n/m | | 66.5 | % | | n/m |
| International | | 156 | | | 103 | | | — | | | 52.5 | % | | n/m | | 50.6 | % | | n/m |
| Total | | $ | 529 | | | $ | 326 | | | $ | — | | | 62.1 | % | | n/m | | 61.5 | % | | n/m |
Restasis (a) | United States | | $ | 1,234 | | | $ | 755 | | | $ | — | | | 63.3 | % | | n/m | | 63.3 | % | | n/m |
| International | | 56 | | | 32 | | | — | | | 75.3 | % | | n/m | | 80.1 | % | | n/m |
| Total | | $ | 1,290 | | | $ | 787 | | | $ | — | | | 63.8 | % | | n/m | | 64.0 | % | | n/m |
Other Eye Care (a) | United States | | $ | 523 | | | $ | 305 | | | $ | — | | | 72.7 | % | | n/m | | 72.7 | % | | n/m |
| International | | 646 | | | 388 | | | — | | | 66.1 | % | | n/m | | 61.0 | % | | n/m |
| Total | | $ | 1,169 | | | $ | 693 | | | $ | — | | | 69.0 | % | | n/m | | 66.1 | % | | n/m |
| Women's Health | | | | | | | | | | | | | | |
Lo Loestrin (a) | United States | | $ | 423 | | | $ | 346 | | | $ | — | | | 21.9 | % | | n/m | | 21.9 | % | | n/m |
| International | | 14 | | | 10 | | | — | | | 43.3 | % | | n/m | | 33.0 | % | | n/m |
| Total | | $ | 437 | | | $ | 356 | | | $ | — | | | 22.5 | % | | n/m | | 22.2 | % | | n/m |
| Orilissa/Oriahnn | United States | | $ | 139 | | | $ | 121 | | | $ | 91 | | | 15.4 | % | | 33.3 | % | | 15.4 | % | | 33.3 | % |
| International | | 6 | | | 4 | | | 2 | | | 57.7 | % | | 96.1 | % | | 47.6 | % | | 97.7 | % |
| Total | | $ | 145 | | | $ | 125 | | | $ | 93 | | | 16.7 | % | | 34.6 | % | | 16.4 | % | | 34.6 | % |
Other Women's Health (a) | United States | | $ | 209 | | | $ | 181 | | | $ | — | | | 16.2 | % | | n/m | | 16.2 | % | | n/m |
| International | | 5 | | | 11 | | | — | | | (57.5) | % | | n/m | | (61.5) | % | | n/m |
| Total | | $ | 214 | | | $ | 192 | | | $ | — | | | 11.7 | % | | n/m | | 11.5 | % | | n/m |
| Other Key Products | | | | | | | | | | | | | | |
| Mavyret | United States | | $ | 754 | | | $ | 785 | | | $ | 1,473 | | | (4.0) | % | | (46.7) | % | | (4.0) | % | | (46.7) | % |
| International | | 956 | | | 1,045 | | | 1,420 | | | (8.5) | % | | (26.4) | % | | (10.8) | % | | (26.8) | % |
| Total | | $ | 1,710 | | | $ | 1,830 | | | $ | 2,893 | | | (6.5) | % | | (36.7) | % | | (7.8) | % | | (36.9) | % |
| Creon | United States | | $ | 1,191 | | | $ | 1,114 | | | $ | 1,041 | | | 6.9 | % | | 6.9 | % | | 6.9 | % | | 6.9 | % |
| Lupron | United States | | $ | 604 | | | $ | 600 | | | $ | 720 | | | 0.5 | % | | (16.6) | % | | 0.5 | % | | (16.6) | % |
| International | | 179 | | | 152 | | | 167 | | | 18.0 | % | | (9.1) | % | | 15.0 | % | | (5.4) | % |
| Total | | $ | 783 | | | $ | 752 | | | $ | 887 | | | 4.0 | % | | (15.2) | % | | 3.4 | % | | (14.5) | % |
Linzess/Constella (a) | United States | | $ | 1,006 | | | $ | 649 | | | $ | — | | | 55.1 | % | | n/m | | 55.1 | % | | n/m |
| International | | 32 | | | 18 | | | — | | | 77.3 | % | | n/m | | 66.4 | % | | n/m |
| Total | | $ | 1,038 | | | $ | 667 | | | $ | — | | | 55.7 | % | | n/m | | 55.4 | % | | n/m |
| Synthroid | United States | | $ | 767 | | | $ | 771 | | | $ | 786 | | | (0.6) | % | | (1.9) | % | | (0.6) | % | | (1.9) | % |
| All other | | | $ | 2,673 | | | $ | 2,923 | | | $ | 2,068 | | | (8.6) | % | | 41.3 | % | | (9.7) | % | | 42.4 | % |
| Total net revenues | | $ | 56,197 | | | $ | 45,804 | | | $ | 33,266 | | | 22.7 | % | | 37.7 | % | | 21.9 | % | | 38.0 | % |
n/m – Not meaningful
(a)Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.
The following discussion and analysis of AbbVie's net revenues by product is presented on a constant currency basis.
Global HUMIRAHumira sales increased 7%4% in 2018 and 14% in 2017. The sales increases in 2018 and 2017 were2021 primarily driven primarily by market growth across therapeutic categories, and geographies as well as favorable pricing in certain geographies. In the United States, HUMIRA sales increased 11% in 2018 and 18% in 2017. The sales increase in 2018 and 2017 was driven by market growth across all indications and favorable pricing. Internationally, HUMIRA revenues increased 1% in 2018 and 7% in 2017. The sales increase in 2018 was driven primarily by market growth across indications partially offset by direct biosimilar competition in Europe following the expiration of the European Union composition of matter patent for adalimumab in October 2018. Due to the entry of biosimilar competition, AbbVie expectscertain international HUMIRA net revenues to decline in 2019. Biosimilar competition for HUMIRA is not expected inmarkets. In the United States, until 2023. AbbVie continues to pursue strategies intended to further differentiate HUMIRA from competing productsHumira sales increased 8% in 2021 driven by market growth across all indications. This increase was partially offset by slightly lower market share following corresponding market share gains of Skyrizi and add to the sustainability of HUMIRA.Rinvoq. Internationally, Humira revenues decreased 13% in 2021 primarily driven by direct biosimilar competition in certain international markets.
Net revenues for IMBRUVICASkyrizi increased 84% in 2021 primarily driven by continued strong volume and market share uptake since launch in 2019 as a treatment for plaque psoriasis as well as market growth over the prior year.
Net revenues for Rinvoq increased by more than 100% in 2021 primarily driven by continued strong volume and market share uptake since launch in 2019 for the treatment of moderate to severe rheumatoid arthritis as well as market growth over the prior year. Net revenues were also favorably impacted by recent regulatory approvals and expansion of Rinvoq for the treatment of psoriatic arthritis, atopic dermatitis and ankylosing spondylitis in certain international markets.
| | | | | | | | | | | |
39 | |2021 Form 10-K | | |
Net revenues for Imbruvica represent product revenues in the United States and collaboration revenues outside of the United States related to AbbVie's 50% share of IMBRUVICAImbruvica profit. AbbVie's global IMBRUVICAImbruvica revenues increased 39%2% in 2018 and 40% in 20172021 as a result of continued penetration of IMBRUVICA as a first-line treatment for patients with CLL as well asmodest favorable pricing.pricing in the United States and increased collaboration revenues, partially offset by lower new patient starts due to the COVID-19 pandemic and share loss in the United States.
Net revenues for VENCLEXTAVenclexta increased 34% in 2021 primarily due to continued expansion of Venclexta for the treatment of patients with first-line CLL, relapsed/refractory CLL and first-line AML.
Net revenues for Botox Cosmetic used in facial aesthetics increased 98% in 2021 due to increased brand investment and strong recovery from the COVID-19 pandemic. Net revenues were also favorably impacted by a full period of Allergan results in 2021 compared to the prior year.
Net revenues for Juvederm Collection (including Juvederm Ultra XC, Juvederm Voluma XC and other Juvederm products) used in facial aesthetics increased by more than 100% in 2018 primarily2021 due to increased brand investment and strong recovery from the COVID-19 pandemic. Net revenues were also favorably impacted by a full period of Allergan results in 2021 compared to the prior year.
Net revenues for Botox Therapeutic used primarily in neuroscience and urology therapeutic areas increased 75% in 2021 due to a strong recovery from the COVID-19 pandemic. Net revenues were also favorably impacted by a full period of Allergan results in 2021 compared to the prior year.
Net revenues for Vraylar for the treatment of schizophrenia, bipolar I disorder and bipolar depression increased 82% in 2021 due to higher market share gains following FDA and EMA approvalsmarket growth. Net revenues were also favorably impacted by a full period of VENCLEXTAAllergan results in combination2021 compared to the prior year.
Net revenues for Ubrelvy for the acute treatment of migraine with Rituxan for certain patients with R/R CLL.
Global MAVYRET salesor without aura in adults increased by more than 100% in 2018 as a result of market share gains following the FDA and EMA approvals of MAVYRET in the second half of 2017 as well as further geographic expansion in 2018. Global VIEKIRA sales decreased by 76% in 2018 and 49% in 20172021 primarily due to lowerincreased volume and market share following theuptake since launch of MAVYRET.in 2020.
Net revenues for Creon increased 12%Mavyret decreased 8% in 2018 and 14% in 2017,2021 primarily driven primarily by the continued market growth, higher market share and favorable pricing. Creon maintains market leadership in the pancreatic enzyme market.
AndroGel net revenues decreased 19% in 2018 and 14% in 2017 primarilydisruption of global HCV markets due to market contraction and the entry of generic competition for the AndroGel 1.62% formulation in October 2018. AbbVie expects net revenues for AndroGel to continue to decline in 2019.COVID-19 pandemic.
Net revenues for Duodopa increased 18% in 2018 and 20% in 2017, primarily as a result of market penetration.
Gross Margin
|
| | | | | | | | | | | | | | | | | |
| | | | | | | | Percent change |
| years ended December 31 (dollars in millions) | 2018 | | 2017 | | 2016 | | 2018 | | 2017 |
| Gross margin | $ | 25,035 |
| | $ | 21,174 |
| | $ | 19,806 |
| | 18 | % | | 7 | % |
| as a percent of net revenues | 76 | % | | 75 | % | | 77 | % | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | Percent change |
| years ended December 31 (dollars in millions) | 2021 | | 2020 | | 2019 | | 2021 | | 2020 |
| Gross margin | $ | 38,751 | | | $ | 30,417 | | | $ | 25,827 | | | 27 | % | | 18 | % |
| as a percent of net revenues | 69 | % | | 66 | % | | 78 | % | | | | |
Gross margin as a percentage of net revenues in 20182021 increased from 20172020 primarily due to the reduction of HUMIRA royalty expense and a 2017 intangible asset impairment charge of $354 million partially offset by the IMBRUVICA profit sharing arrangement.
Gross margin as a percentage of net revenues in 2017 decreased from 2016 primarily due to an intangible asset impairment charge of $354 million in 2017, as well as the unfavorable impacts of higher intangible asset amortization and the IMBRUVICA profit sharing arrangement. These drivers were partially offset by lower amortization of theinventory fair market value step-up of acquisition-date inventory of Pharmacyclics as well asadjustment associated with the Allergan acquisition and favorable changes in product mix, and operational efficiencies.partially offset by higher amortization of intangible assets associated with the Allergan acquisition.
Selling, General and Administrative | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | Percent change |
| years ended December 31 (dollars in millions) | 2021 | | 2020 | | 2019 | | 2021 | | 2020 |
| Selling, general and administrative | $ | 12,349 | | | $ | 11,299 | | | $ | 6,942 | | | 9 | % | | 63 | % |
| as a percent of net revenues | 22 | % | | 25 | % | | 21 | % | | | | |
|
| | | | | | | | | | | | | | | | | |
| | | | | | | | Percent change |
| years ended December 31 (dollars in millions) | 2018 | | 2017 | | 2016 | | 2018 | | 2017 |
| Selling, general and administrative | $ | 7,399 |
| | $ | 6,295 |
| | $ | 5,881 |
| | 18 | % | | 7 | % |
| as a percent of net revenues | 23 | % | | 22 | % | | 23 | % | | | | |
Selling, general and administrative (SG&A)SG&A expenses as a percentage of net revenues in 2018 increased from 20172021 decreased primarily due to lower transaction and integration costs related to the unfavorable impactsacquisition of new product launch expensesAllergan as well as leverage from revenue growth and charitable contributionssynergies realized in the period subsequent to completion of $350 million to
the Allergan acquisition.
|
| | | | | | | | | | |
| | 32 |20182021 Form 10-K| | | 40 |
select U.S. not-for-profit organizations in 2018 as part of AbbVie's previously announced plan partially offset by continued leverage from revenue growth.
SG&A expense percentage in 2017 decreased from 2016. SG&A expense percentage in 2017 was favorably impacted by continued leverage from revenue growth partially offset by litigation reserves charges that increased by $370 million in 2017 compared to the prior year and new product launch expenses.
Research and Development and Acquired In-Process Research and Development | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | Percent change |
| years ended December 31 (dollars in millions) | 2021 | | 2020 | | 2019 | | 2021 | | 2020 |
| Research and development | $ | 7,084 | | | $ | 6,557 | | | $ | 6,407 | | | 8 | % | | 2 | % |
| as a percent of net revenues | 13 | % | | 14 | % | | 19 | % | | | | |
| Acquired in-process research and development | $ | 962 | | | $ | 1,198 | | | $ | 385 | | | (20) | % | | >100% |
|
| | | | | | | | | | | | | | | | | |
| | | | | | | | Percent change |
| years ended December 31 (dollars in millions) | 2018 | | 2017 | | 2016 | | 2018 | | 2017 |
| Research and development | $ | 10,329 |
| | $ | 5,007 |
| | $ | 4,385 |
| | >100% |
| | 14 | % |
| as a percent of net revenues | 32 | % | | 18 | % | | 17 | % | | | | |
| Acquired in-process research and development | $ | 424 |
| | $ | 327 |
| | $ | 200 |
| | 30 | % | | 64 | % |
Research and Development(R&D)R&D expenses as a percentage of net revenues decreased in 2018 increased from 2017 principally due to a $5.1 billion intangible asset impairment charge related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial. The impairment was2021 primarily due to lower probabilities of success of achieving regulatory approval across Rova-T and other early-stage assets obtained in the acquisition. The remaining increase reflected greater funding to support all stagesincreased scale of the company's pipeline assets. See Note 7combined company and synergies realized for the period subsequent to completion of the Allergan acquisition as well as lower integration costs related to the Consolidated Financial Statements for additional information regarding the impairment charge.
R&D expenses in 2017 increased from 2016 principally due to increased funding to support all stagesacquisition of the company’s pipeline assets, the impact of the post-acquisition R&D expenses of Stemcentrx and Boehringer Ingelheim (BI) compounds and an increase in development milestones of $63 million. These factors were partially offset by a decrease in acquisition related costs of $135 million.Allergan.
Acquired IPR&D expenses reflect upfront payments relatedrepresent initial costs to various collaborations. There were no individually significant transactionsacquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or cash flows during 2018.other asset acquisitions. Acquired IPR&D expense in 20172021 included a charge of $205$400 million as a result of exercising the company's exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma and a charge of $370 million as a result of entering into a global strategic collaboration agreement with Alector,REGENXBIO Inc. (Alector)for the development and commercialization of RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. Acquired IPR&D expense in 2020 included a charge of $750 million as a result of entering into a collaboration agreement with Genmab A/S to research, develop and commercialize medicines to treat Alzheimer’s diseaseinvestigational bispecific antibody therapeutics for the treatment of cancer. Acquired IPR&D expense in 2020 also included a charge of $200 million as a result of entering into a collaboration agreement with I-Mab Biopharma for the development and other neurodegenerative disorders. There were no individually significant transactions or cash flows during 2016.commercialization of lemzoparlimab for the treatment of multiple cancers. See Note 5 to the Consolidated Financial Statements for additional information regarding the Alector agreement.information.
Other Operating ExpensesExpense (Income), Net
Other operating expensesexpense in 20182021 included a $500 million charge related to the extension of the previously announced Calico collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer.
Other Non-Operating Expenses
|
| | | | | | | | | | | | |
| years ended December 31 (in millions) | | 2018 | | 2017 | | 2016 |
| Interest expense | | $ | 1,348 |
| | $ | 1,150 |
| | $ | 1,047 |
|
| Interest income | | (204 | ) | | (146 | ) | | (82 | ) |
| Interest expense, net | | $ | 1,144 |
| | $ | 1,004 |
|
| $ | 965 |
|
| | | | | | | |
| Net foreign exchange loss | | $ | 24 |
| | $ | 348 |
| | $ | 303 |
|
| Other expense, net | | 18 |
| | 466 |
| | 188 |
|
| | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | | 2021 | | 2020 | | 2019 |
| Interest expense | | $ | 2,423 | | | $ | 2,454 | | | $ | 1,784 | |
| Interest income | | (39) | | | (174) | | | (275) | |
| Interest expense, net | | $ | 2,384 | | | $ | 2,280 | | | $ | 1,509 | |
| | | | | | |
| Net foreign exchange loss | | $ | 51 | | | $ | 71 | | | $ | 42 | |
| Other expense, net | | 2,500 | | | 5,614 | | | 3,006 | |
Interest expense in 2018 increased2021 decreased compared to 20172020 primarily due to the unfavorablefavorable impact of higherlower interest rates on the company'scompany’s floating rate debt obligations and deleveraging, partially offset by a higher average outstanding debt balance during 2018. Interest expense in 2017 increased compared to 2016 due to a full year of expense associated with the May 2016 issuance of $7.8 billion aggregate principal amount of senior notes which were issued primarily to finance the acquisition of Stemcentrx and to repay an outstanding term loan.incremental Allergan debt acquired.
Interest income in 2018 increased2021 decreased compared to 20172020 primarily due to highera lower average cash and cash equivalents balance as a result of the cash paid for the Allergan acquisition and the unfavorable impact of lower interest rates. Interest income in 2017 increased compared to 2016 primarily due to growth in the company’s investment securities.
|
| | |
| | 2018 Form 10-K | 33
|
Net foreign exchange loss in 2017 included $316 million of historical currency translation losses that were reclassified from accumulated other comprehensive income (AOCI) related to the liquidation of certain foreign entities following the enactment of U.S. tax reform. Net foreign exchange loss in 2016 included losses totaling $298 million related to the devaluation of AbbVie’s net monetary assets denominated in the Venezuelan bolivar. See Note 10 to the Consolidated Financial Statements for additional information regarding the Venezuelan devaluation.
Other expense, net included charges related to the changechanges in fair value of the BI and Stemcentrx contingent consideration liabilities of $49 million$2.7 billion in 2018, $626 million2021 and $5.8 billion in 2017 and $228 million in 2016.2020. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory/commercial milestones, discount rates, the estimated amount of future sales of the acquired products still in development and other market-based factors. In 2018, the BI contingent consideration liability increased due to the passage of time and higher estimated future sales partially offset by the effect of rising interest rates. The increase in the BI contingent consideration liability was primarily offset by a $428 million decrease in the Stemcentrx contingent consideration liability recorded during the fourth quarter of 2018 due to a reduction in probabilities of success of achieving regulatory approval across Rova-T and other early-stage assets obtained in the acquisition. In 2017,2021, the change in fair value represented mainly higher probabilities of success,included the passage of time and declining interest rates. In 2016,increase in the change in fair value represented mainly the passage of time, as increases to the BISkyrizi contingent consideration liability due to higher probabilitiesestimated sales driven by stronger market share uptake, favorable clinical trial results and the passage of success were fullytime, partially offset by higher discount rates. In 2020, the effectschange in fair value primarily included the increase in the Skyrizi contingent consideration liability due to higher estimated sales driven by stronger market share uptake, lower discount rates, the passage of rising interest ratestime and changes in other market-based assumptions. See Note 5 to the Consolidated Financial Statements for additional information regarding the acquisitions of Stemcentrx and BI compounds. Other expense, net for 2017 also included realized gains on available-for-sale investment securities of $90 million.favorable clinical trial results.
| | | | | | | | | | | |
41 | |2021 Form 10-K | | |
Income Tax Expense
The effective income tax rate was 11% in 2021, negative 9%36% in 2018, was 31%2020 and 6% in 2017 and was 24% in 2016.2019. The effective income tax rate in each periodrates differed from the statutory tax rate principally due to the allocationimpact of the company's taxable earnings among jurisdictions, the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, and business development activities.activities, changes in enacted tax rates and laws and related restructuring, tax audit settlements and accretion on contingent consideration. The effective tax rate for 2018 reflects the impact of the effective date of provisions of the Tax Cuts and Jobs Act (the Act) related to the earnings from certain foreign subsidiaries and the effects of Stemcentrx intangible impairment related expenses. Given these factors, the2020 effective income tax rate may change significantlyincluded the recognition of a net tax benefit of $1.7 billion related to changes in future periods.
tax laws and related restructuring, including certain intra-group transfers of intellectual property and deferred tax remeasurement. The effective tax rate in 2017 includedrates for these periods also reflected the benefit from U.S. tax expense of $4.5 billion on the one-time mandatory repatriation of previously untaxed earnings of foreign subsidiaries, partially offset by a $3.6 billion net tax benefit for the remeasurement of deferred taxescredits principally related to research and development credits, the Actorphan drug tax credit and foreignPuerto Rico excise tax law changes.
credits. The Act significantly changed the U.S. corporatePuerto Rico excise tax system. The Act reduced the U.S. federal corporatecredits relate to legislation enacted by Puerto Rico that assesses an excise tax rate from 35% to 21% and created a territorial tax system that included new taxes on certain foreign sourcedproducts manufactured in Puerto Rico. The tax is levied on gross inventory purchases from entities in Puerto Rico and is included in cost of products sold in the consolidated statements of earnings. See Note 13 to the Consolidated Financial Statements for additional information regarding the Act.
The effective tax rate in 2016 included additional expense of $187 million related to the recognitionmajority of the tax effect of regulations issued by the Internal Revenue Service on December 7, 2016 that changed the determination of theis creditable for U.S. taxability of foreign currency gains and losses related to certain foreign operations.income tax purposes.
FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Cash flows from: | | | | | |
| Operating activities | $ | 13,427 |
| | $ | 9,960 |
| | $ | 7,041 |
|
| Investing activities | (1,006 | ) | | (274 | ) | | (6,074 | ) |
| Financing activities | (14,396 | ) | | (5,512 | ) | | (3,928 | ) |
| | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Cash flows provided by (used in) | | | | | |
| Operating activities | $ | 22,777 | | | $ | 17,588 | | | $ | 13,324 | |
| Investing activities | (2,344) | | | (37,557) | | | 596 | |
| Financing activities | (19,039) | | | (11,501) | | | 18,708 | |
Operating cash flows in 20182021 increased from 2017 primarily due to improved results of operations from revenue growth and a decrease in income tax payments.2020. Operating cash flows in 2017 increased from 2016 primarily due to improved results2021 were favorably impacted by higher net revenues of operations resulting from revenue growth, an improvement in operating earningsthe combined company and a decrease inlower acquisition-related cash expenses, partially offset by higher income tax payments. Realized excess tax benefits associated with stock-based compensation totaled $78 million in 2018payments and $71 million in 2017 and were presented within operatingthe timing of working capital cash flows as a result of the adoption of a new accounting pronouncement. Prior to the adoption of the new accounting pronouncement, realized excess benefits of $55 million in 2016 were presented within cash flows from financing activities.flows. Operating cash flows also reflected AbbVie’s contributions to its defined benefit plans of $873$376 million in 2018, $2462021 and $367 million in 2017 and $273 million in 2016.
|
| | |
34 |2018 Form 10-K
| | |
2020.
Investing cash flows in 20182021 included $535 million cash consideration paid to acquire Soliton, Inc. offset by cash acquired, payments made for other acquisitions and investments of $736 million and$1.4 billion, capital expenditures of $638$787 million partiallyand net purchases of investment securities totaling $21 million. Investing cash flows in 2020 included $39.7 billion cash consideration paid to acquire Allergan offset by cash acquired of $1.5 billion, net sales and maturities of investment securities totaling $368 million. Investing cash flows in 2017 included capital expenditures of $529 million and$1.5 billion, payments made for other acquisitions and investments of $308 million, partially offset by net sales and maturities of investment securities totaling $563 million. Investing cash flows in 2016 primarily included $1.9 billion of cash consideration paid to acquire Stemcentrx in June 2016, a $595 million upfront payment to acquire certain rights from BI in April 2016, net purchases of investment securities totaling $3.0$1.4 billion and capital expenditures of $479$798 million.
In 2018, 2017 and 2016, the company issued and redeemed commercial paper. The balance of commercial paper outstanding was $699 million as of December 31, 2018 and $400 million as of December 31, 2017. AbbVie may issue additional commercial paper or retire commercial paper to meet liquidity requirements as needed.
Financing cash flows in 2018 also2021 included proceeds from the issuanceearly repayments of a $3.0 billion 364-day term loan credit agreement (term loan) entered into in May 2018. In June 2018, the company drew on this term loan and as of December 31, 2018, $3.0 billion was outstanding and was included in short-term borrowings on the consolidated balance sheet. Borrowings under the term loan bear interest at one month LIBOR plus applicable margin. The term loan may be prepaid without penalty upon prior notice and contains customary covenants, all of which the company was in compliance with as of December 31, 2018. In September 2018, the company issued $6.0 billion aggregate principal amount of unsecured senior notes. Of the $5.9 billion net proceeds, $2.0 billion was used to repay the company's outstanding three-year term loan credit agreement in September 2018 and $1.0 billion was used to repay the aggregate principal amount of 2.00% senior notes at maturity in November 2018. The company intends to use the remaining proceeds to repay term loan obligations in 2019 as they become due. Financing cash flows in 2018 also included the May 2018 repayment of $3.0$1.8 billion aggregate principal amount of the company's 1.80% senior2.3% principal notes, at maturity.
In November 2016, the company issued €3.6$1.2 billion aggregate principal amount of unsecuredthe company's 5.0% senior notes and €750 million aggregate principal amount of the company's 0.5% senior Euro notes. The company usedFinancing cash flows also included the proceeds to redeem $4.0May 2021 repayment of $750 million aggregate principal amount of floating rate senior notes and the November 2021 repayment of $1.3 billion aggregate principal amount of 1.75%3.375% senior notes, that were due to mature in November 2017. In May 2016, the company issued $7.8$1.8 billion aggregate principal amount of 2.15% senior notes. Approximately $2.0notes and $750 million aggregate principal amount of floating rate senior notes at maturity. Additionally, financing cash flows included repayment of a $1.0 billion floating rate term loan due May 2023 and issuance of a new $1.0 billion floating rate term loan as part of the net proceeds were used to repay an outstanding term loan that was due to maturerefinancing in November 2016, approximately $1.9September 2021.
Financing cash flows in 2020 included the issuance of term loans totaling $3.0 billion ofunder the net proceedsexisting $6.0 billion term loan credit agreement which were used to finance the acquisition of Stemcentrx and approximatelyAllergan. Subsequent to these borrowings, AbbVie terminated the unused commitments of the lenders under the term loan. Additionally, financing cash flows included the May 2020 repayment of $3.8 billion aggregate principal amount of the net proceeds were used to finance an accelerated share repurchase (ASR). See Note 12 tocompany's 2.50% senior notes, the Consolidated Financial Statements for additional information onSeptember 2020 repayment of $650 million aggregate principal amount of 3.375% senior notes and the 2016 ASR transaction.November 2020 repayments of €700 million aggregate principal amount of floating rate senior Euro notes at maturity as well as the $450 million aggregate principal amount of 4.875% senior notes due February 2021.
CashFinancing cash flows also included cash dividend payments totaled $5.6of $9.3 billion in 2018, $4.12021 and $7.7 billion in 2017 and $3.7 billion in 2016.2020. The increase in cash dividend payments was primarily driven by an increase inof the dividend rate. On November 2, 2018,rate and higher outstanding shares following the 286 million shares of AbbVie announced that its board of directors declared an increasecommon stock issued to Allergan shareholders in theMay 2020.
The company's quarterly cash dividend from $0.96 per share to $1.07 per share beginning with the dividend payable on February 15, 2019 to stockholders of record as of January 15, 2019. This reflects an increase of approximately 11.5% over the previous quarterly rate. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie's financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie's debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.
On February 15, 2018, AbbVie's board of directors authorized a new $10.0 billion stock repurchase program, which superseded AbbVie's previous stock repurchase program. On December 13, 2018, AbbVie's board of directors authorized a $5.0 billion increase to the existing $10.0 billion stock repurchase program. The new stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management’s discretion. The program has no time limit and can be discontinued at any time. Under this authorization, AbbVie repurchased approximately 1096 million shares for $10.7 billion$670 million in 2018. AbbVie cash-settled $2012021 and 8 million of its December 2018 open market purchasesshares for $757 million in January 2019.2020. AbbVie's remaining stock repurchase authorization was $4.3$2.5 billion as of December 31, 2018.
Under previous stock repurchase programs, AbbVie made open market share repurchases of approximately 11 million shares for $1.3 billion in 2018, approximately 13 million shares for $1.0 billion in 2017 and approximately 34 million shares for $2.1 billion in 2016. AbbVie cash-settled $285 million of its December 2016 open market purchases in January 2017 and cash-settled $300 million of its December 2015 open market purchases in January 2016.
In 2018, AbbVie paid $100 million of contingent consideration to BI related to BLA and MAA acceptance milestones. $78 million of these payments were included in financing cash flows and $22 million of the payments were included in operating cash flows. In 2017, AbbVie paid $305 million of contingent consideration to BI related to a Phase 3 enrollment milestone. $268 million of this milestone was included in financing cash flows and $37 million was included in operating cash flows.
2021.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |35
| 42 |
CashNo commercial paper borrowings were issued during 2021. In 2020, the company issued and equivalentsredeemed commercial paper. There were impacted by net unfavorable exchange rate changes totaling $39 million in 2018, net favorable exchange rate changes totaling $29 million in 2017 and net unfavorable exchange rate changes totaling $338 million in 2016. The unfavorable exchange rate changes in 2018 were primarily dueno commercial paper borrowings outstanding as of December 31, 2021 or December 31, 2020. AbbVie may issue additional commercial paper or retire commercial paper to the weakening of the Euro and other foreign currencies on the translation of the company's Euro-denominated assets and cash denominated in foreign currencies. The favorable exchange rate changes in 2017 were primarily due to the strengthening of the Euro and other foreign currencies on the translation of the company's Euro-denominated assets and cash denominated in foreign currencies. The unfavorable exchange rate changes in 2016 were primarily due to the devaluation of AbbVie's net monetary assets denominated in the Venezuelan bolivar.meet liquidity requirements as needed.
Credit Risk
AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance againstfor credit losses equal to the estimate of future losses over the contractual life of outstanding accounts receivable when it is probable they will not be collected. Global economic conditions and customer-specific factors may require the company to periodically re-evaluate the collectability of its receivables and the company could potentially incur credit losses.receivable. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.
Credit Facility, Access to Capital and Credit Ratings
Credit Facility
In August 2018, AbbVie replaced its existing revolving credit facility withcurrently has a new $3.0$4.0 billion five-year revolving credit facility. The revolving creditfacility that matures in August 2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At December 31, 2018,2021, the company was in compliance with all its credit facility covenants. Commitmentcovenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facility as of December 31, 20182021 and 2017.2020.
Access to Capital
The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or by issuinghas the ability to issue additional debt. The company's ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company's products or in the solvency of its customers or suppliers, deterioration in the company's key financial ratios or credit ratings, or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company's growth objectives.
Credit Ratings
There were no changes into the company’scompany's credit ratings during 2018. 2021. Following the acquisition of Allergan in 2020, S&P Global Ratings revised its ratings outlook to stable from negative and lowered the issuer credit rating by one notch to BBB+ from A- and the short-term rating to A-2 from A-1. There were no changes in Moody's Investor Service of its Baa2 senior unsecured long-term rating and Prime-2 short-term rating with a stable outlook.
Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company'scompany’s ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company'scompany’s outstanding debt obligations.debt.
Future Cash Requirements
Contractual Obligations
The following table summarizes AbbVie's estimated material contractual obligations as of December 31, 2018:2021: | | | | | | | | | | | | | | | | | |
| (in millions) | Total | | Current | | Long-term |
| Long-term debt, including current portion | $ | 75,962 | | | $ | 12,428 | | | $ | 63,534 | |
Interest on long-term debt(a) | 30,002 | | | 2,392 | | | 27,610 | |
Contingent consideration liabilities(b) | 14,887 | | | 1,249 | | | 13,638 | |
|
| | | | | | | | | | | | | | | | | | | |
| (in millions) | Total | | Less than one year | | One to three years | | Three to five years | | More than five years |
| Short-term borrowings | $ | 3,699 |
| | $ | 3,699 |
| | $ | — |
| | $ | — |
| | $ | — |
|
| Long-term debt and capital lease obligations, including current portion | 37,360 |
| | 1,612 |
| | 6,808 |
| | 6,370 |
| | 22,570 |
|
Interest on long-term debt(a) | 17,204 |
| | 1,433 |
| | 2,613 |
| | 2,024 |
| | 11,134 |
|
| Future minimum non-cancelable operating lease commitments | 809 |
| | 116 |
| | 205 |
| | 145 |
| | 343 |
|
Purchase obligations and other(b) | 1,843 |
| | 1,710 |
| | 110 |
| | 21 |
| | 2 |
|
Other long-term liabilities(c) (d) (e) (f) | 9,994 |
| | 736 |
| | 1,392 |
| | 1,478 |
| | 6,388 |
|
| Total | $ | 70,909 |
| | $ | 9,306 |
| | $ | 11,128 |
| | $ | 10,038 |
| | $ | 40,437 |
|
(a)Includes estimated future interest payments on long-term debt. Interest payments on debt are calculated for future periods using forecasted interest rates in effect at the end of 2021. Projected interest payments include the related effects of interest rate swap agreements. Certain of these projected interest payments may differ in the future based on changes in floating interest rates or other factors or events. The projected interest payments only pertain to obligations and agreements outstanding at December 31, 2021. See Note 10 to the Consolidated Financial Statements for additional information regarding the company's debt instruments and Note 11 for additional information on the interest rate swap agreements outstanding at December 31, 2021.
|
| | | | | | | | | | |
3643
| |20182021 Form 10-K
| | |
(b)Includes contingent consideration liabilities which are recorded at fair value on the consolidated balance sheet. Potential contingent consideration payments that exceed the fair value recorded on the consolidated balance sheet are not included in the table of contractual obligations. See Note 11 to the Consolidated Financial Statements for additional information regarding these liabilities.
| |
(a) | Includes estimated future interest payments on long-term debt and capital lease obligations. Interest payments on debt are calculated for future periods using forecasted interest rates in effect at the end of 2018. Projected interest payments include the related effects of interest rate swap agreements. Certain of these projected interest payments may differ in the future based on changes in floating interest rates or other factors or events. The projected interest payments only pertain to obligations and agreements outstanding at December 31, 2018. See Note 9 to the Consolidated Financial Statements for additional information regarding the company's debt instruments and Note 10 for additional information on the interest rate swap agreements outstanding at December 31, 2018.
|
| |
(b) | Includes the company's significant unconditional purchase obligations. These commitments do not exceed the company's projected requirements and are made in the normal course of business. |
| |
(c) | Amounts less than one year includes a voluntary contribution of $150 million that AbbVie made to its principal domestic defined benefit plan subsequent to December 31, 2018. Amounts otherwise exclude pension and other post-employment benefits and related deferred compensation cash outflows. Timing of future funding is uncertain and dependent on future movements in interest rates and investment returns, changes in laws and regulations and other variables. Also included in this amount are components of other long-term liabilities including restructuring. See Note 8 to the Consolidated Financial Statements for additional information on restructuring and Note 11 for additional information on the pension and other post-employment benefit plans.
|
| |
(d) | Excludes liabilities associated with the company's unrecognized tax benefits as it is not possible to reliably estimate the timing of the future cash outflows related to these liabilities. See Note 13 to the Consolidated Financial Statements for additional information on these unrecognized tax benefits.
|
| |
(e) | Includes $4.5 billion of contingent consideration liabilities primarily related to the acquisition of BI compounds which are recorded at fair value on the consolidated balance sheet. Potential contingent consideration payments that exceed the fair value recorded on the consolidated balance sheet are not included in the table of contractual obligations. See Notes 5 and 10 to the Consolidated Financial Statements for additional information regarding these liabilities.
|
| |
(f) | Includes a one-time transition tax liability on a mandatory deemed repatriation of previously untaxed earnings of foreign subsidiaries resulting from U.S. tax reform enacted in 2017. The one-time transition tax is generally payable in eight annual installments. See Note 13 to the Consolidated Financial Statements for additional information regarding these tax liabilities.
|
AbbVie enters into R&D collaborationcertain unconditional purchase obligations and other commitments in the normal course of business. There have been no changes to these commitments that would have a material impact on the company’s ability to meet either short-term or long-term future cash requirements.
Income Taxes
Future income tax cash requirements include a one-time transition tax liability on a mandatory deemed repatriation of previously untaxed earnings of foreign subsidiaries resulting from U.S. tax reform enacted in 2017. The one-time transition tax liability was $3.9 billion as of December 31, 2021 and is payable in five future annual installments.
Liabilities for unrecognized tax benefits totaled $6.0 billion as of December 31, 2021. It is not possible to reliably estimate the timing of the future cash outflows related to these liabilities. See Note 14 to the Consolidated Financial Statements for additional information on these unrecognized tax benefits.
Quarterly Cash Dividend
On October 29, 2021, AbbVie announced that its board of directors declared an increase in the quarterly cash dividend from $1.30 per share to $1.41 per share beginning with the dividend payable on February 15, 2022 to stockholders of record as of January 14, 2022. This reflects an increase of approximately 8.5% over the previous quarterly rate. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie's financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie's debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.
Collaborations, Licensing and Other Arrangements
AbbVie enters into collaborative, licensing, and other arrangements with third parties that may require future milestone payments to third parties contingent upon the achievement of certain development, regulatory, or commercial milestones. Individually, these arrangements are insignificant in any one annual reporting period. However, if milestones for multiple products covered by these arrangements would happen to be reached in the same reporting period, the aggregate charge to expense could be material to the results of operations in that period. From a business perspective, the payments are viewed as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate future cash flows from product sales. It is not possible to predict with reasonable certainty whether these milestones will be achieved or the timing for achievement. As a result, these potential payments are not included in the table of contractual obligations. See Note 5 to the Consolidated Financial Statements for additional information on these collaboration arrangements.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. A summary of the company's significant accounting policies is included in Note 2 to the Consolidated Financial Statements. Certain of these policies are considered critical as these most significantly impact the company's financial condition and results of operations and require the most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Actual results may vary from these estimates.
Revenue Recognition
AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |37
| 44 |
Rebates
AbbVie provides rebates to pharmacy benefit managers, state government Medicaid programs, insurance companies that administer Medicare drug plans, wholesalers, group purchasing organizations and other government agencies and private entities.
Rebate and chargeback accruals are accounted for as variable consideration and are recorded as a reduction to revenue in the period the related product is sold. RebatesProvisions for rebates and chargebacks totaled $16.4$33.9 billion in 2018, $12.92021, $27.0 billion in 20172020 and $10.8$18.8 billion in 2016.2019. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, the factors used in the calculations of the accrual for that rebate include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant.
In order to establish its rebate and chargeback accruals, the company uses both internal and external data to estimate the level of inventory in the distribution channel and the rebate claims processing lag time for each type of rebate. To estimate the rebate percentage or net price, the company tracks sales by product and by customer or payer. The company evaluates inventory data reported by wholesalers, available prescription volume information, product pricing, historical experience and other factors in order to determine the adequacy of its reserves. AbbVie regularly monitors its reserves and records adjustments when rebate trends, rebate programs and contract terms, legislative changes, or other significant events indicate that a change in the reserve is appropriate. Historically, adjustments to rebate accruals have not been material to net earnings.
The following table is an analysis of the three largest rebate accruals for rebates and chargeback allowances,chargebacks, which comprise approximately 91%95% of the total consolidated rebate and chargebacks recorded as reductions to revenues in 2018.2021. Remaining rebate provisions charged against gross revenues are not significant in the determination of operating earnings. | | | | | | | | | | | | | | | | | |
| (in millions) | Medicaid
and
Medicare
Rebates | | Managed
Care
Rebates | | Wholesaler
Chargebacks |
| Balance at December 31, 2018 | $ | 1,645 | | | $ | 1,439 | | | $ | 656 | |
| Provisions | 4,035 | | | 5,772 | | | 7,947 | |
| Payments | (3,915) | | | (5,275) | | | (7,917) | |
| Balance at December 31, 2019 | 1,765 | | | 1,936 | | | 686 | |
Additions(a) | 1,266 | | | 649 | | | 71 | |
| Provisions | 6,715 | | | 8,656 | | | 8,677 | |
| Payments | (6,801) | | | (8,334) | | | (8,693) | |
| Balance at December 31, 2020 | 2,945 | | | 2,907 | | | 741 | |
| Provisions | 9,622 | | | 11,306 | | | 11,286 | |
| Payments | (8,751) | | | (11,116) | | | (11,125) | |
| Balance at December 31, 2021 | $ | 3,816 | | | $ | 3,097 | | | $ | 902 | |
|
| | | | | | | | | | | |
| (in millions) | Medicaid and Medicare Rebates | | Managed Care Rebates | | Wholesaler Chargebacks |
| Balance at December 31, 2015 | $ | 1,032 |
| | $ | 920 |
| | $ | 363 |
|
| Provisions | 2,606 |
| | 3,146 |
| | 3,987 |
|
| Payments | (2,471 | ) | | (2,899 | ) | | (3,967 | ) |
| Balance at December 31, 2016 | 1,167 |
| | 1,167 |
| | 383 |
|
| Provisions | 2,909 |
| | 3,990 |
| | 5,026 |
|
| Payments | (2,736 | ) | | (3,962 | ) | | (4,887 | ) |
| Balance at December 31, 2017 | 1,340 |
| | 1,195 |
| | 522 |
|
| Provisions | 3,493 |
| | 4,729 |
| | 6,659 |
|
| Payments | (3,188 | ) | | (4,485 | ) | | (6,525 | ) |
| Balance at December 31, 2018 | $ | 1,645 |
| | $ | 1,439 |
| | $ | 656 |
|
Cash Discounts and Product Returns
Cash discounts and product returns, which totaled $3.6 billion in 2021, $2.4 billion in 2020 and $1.6 billion in 2018, $1.3 billion in 2017 and $964 million in 2016,2019, are accounted for as variable consideration and are recorded as a reduction to revenue in the same period the related product is sold. The reserve for cash discounts is readily determinable because the company's experience of payment history is fairly consistent. Product returns can be reliably estimated based on the company's historical return experience.
Pension and Other Post-Employment Benefits
AbbVie engages outside actuaries to assist in the determination of the obligations and costs under the pension and other post-employment benefit plans that are direct obligations of AbbVie. The valuation of the funded status and the net periodic benefit cost for these plans are calculated using actuarial assumptions. The significant assumptions, which are reviewed annually, include the discount rate, the expected long-term rate of return on plan assets and the health care cost trend rates, and are disclosed in Note 1112 to the Consolidated Financial Statements.
|
| | | | | | | | | | |
3845
| |20182021 Form 10-K
| | |
The discount rate is selected based on current market rates on high-quality, fixed-income investments at December 31 each year. AbbVie employs a yield-curve approach for countries where a robust bond market exists. The yield curve is developed using high-quality bonds. The yield-curve approach reflects the plans' specific cash flows (i.e. duration) in calculating the benefit obligations by applying the corresponding individual spot rates along the yield curve. Beginning in 2016, AbbVie also reflectedreflects the plans' specific cash flows and appliedapplies them to the corresponding individual spot rates along the yield curve in calculating the service cost and interest cost portions of expense. For other countries, AbbVie reviews various indices such as corporate bond and government bond benchmarks to estimate the discount rate.
AbbVie's assumed discount rates have a significant effect on the amounts reported for defined benefit pension and other post-employment plans as of December 31, 2018.2021. A 50 basis point change in the assumed discount rate would have had the following effects on AbbVie's calculation of net periodic benefit costs in 20192022 and projected benefit obligations as of December 31, 2018:
|
| | | | | | | |
| | 50 basis point |
| (in millions) (brackets denote a reduction) | Increase | | Decrease |
| Defined benefit plans | | | |
| Service and interest cost | $ | (54 | ) | | $ | 64 |
|
| Projected benefit obligation | (512 | ) | | 578 |
|
| Other post-employment plans | | | |
| Service and interest cost | $ | (2 | ) | | $ | 4 |
|
| Projected benefit obligation | (47 | ) | | 54 |
|
| | | | | | | | | | | |
| 50 basis point |
| (in millions) (brackets denote a reduction) | Increase | | Decrease |
| Defined benefit plans | | | |
| Service and interest cost | $ | (90) | | | $ | 100 | |
| Projected benefit obligation | (1,014) | | | 1,159 | |
| Other post-employment plans | | | |
| Service and interest cost | $ | (7) | | | $ | 7 | |
| Projected benefit obligation | (61) | | | 69 | |
The expected long-term rate of return is based on the asset allocation, historical performance and the current view of expected future returns. AbbVie considers these inputs with a long-term focus to avoid short-term market influences. The current long-term rate of return on plan assets for each plan is supported by the historical performance of the trust's actual and target asset allocation. AbbVie's assumed expected long-term rate of return has a significant effect on the amounts reported for defined benefit pension plans as of December 31, 20182021 and will be used in the calculation of net periodic benefit cost in 2019.2022. A one percentage point change in assumed expected long-term rate of return on plan assets would increase or decrease the net period benefit cost of these plans in 20192022 by $62$101 million.
The health care cost trend rate is selected by reviewing historical trends and current views on projected future health care cost increases. The current health care cost trend rate is supported by the historical trend experience of each plan. Assumed health care cost trend rates have a significant effect on the amounts reported for health care plans as of December 31, 20182021 and will be used in the calculation of net periodic benefit cost in 2019. A one percentage point change in assumed health care cost trend rates would have the following effects on AbbVie's calculation of net periodic benefit costs in 2019 and the projected benefit obligation as of December 31, 2018:
|
| | | | | | | |
| | One percentage point |
| (in millions) (brackets denote a reduction) | Increase | | Decrease |
| Service and interest cost | $ | 17 |
| | $ | (9 | ) |
| Projected benefit obligation | 110 |
| | (87 | ) |
Income Taxes
AbbVie accounts for income taxes under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pretax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amount of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized.
Litigation
The company is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. See Note 1415 to the Consolidated Financial Statements for additional information. Loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. Accordingly, AbbVie is often initially unable to develop a best estimate of loss and therefore, the minimum amount, which could be zero, is recorded. As information becomes known, either the minimum
|
| | |
| | 2018 Form 10-K | 39
|
loss amount is increased, resulting in additional loss provisions, or a best estimate can be made, also resulting in additional loss provisions. Occasionally, a best estimate amount is changed to a lower amount when events result in an expectation of a more favorable outcome than previously expected.
Valuation of Goodwill and Intangible Assets
AbbVie has acquired and may continue to acquire significant intangible assets in connection with business combinations that AbbVie records at fair value. Transactions involving the purchase or sale of intangible assets occur with some frequency between companies in
| | | | | | | | | | | |
| | 2021 Form 10-K | | 46 |
the pharmaceuticals industry and valuations are usually based on a discounted cash flow analysis incorporating the stage of completion. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, cost of capital, terminal values and market participants. Each of these factors can significantly affect the value of the intangible asset. IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off. IPR&D acquired in transactions that are not business combinations is expensed immediately, unless deemed to have an alternative future use. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life.
AbbVie reviews the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Goodwill and indefinite-lived intangible assets are reviewed for impairment annually or when an event occurs that could result in an impairment. See Note 2 to the Consolidated Financial Statements for furtheradditional information.
Annually, the company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. Some of the factors considered in the assessment include general macro-economic conditions, conditions specific to the industry and market, cost factors, the overall financial performance and whether there have been sustained declines in the company's share price. If the company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. AbbVie tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test is performed.
For its quantitative impairment tests, the company uses an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are consistent with the company's business plans and a market participant's views. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of the assets and could potentially impact the company's results of operations. Actual results may differ from the company's estimates.
ContingentConsideration
The fair value measurements of contingent consideration liabilities are determined as of the acquisition date based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products still in development.products. Contingent consideration liabilities are revalued to fair value at each subsequent reporting date until the related contingency is resolved. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs.inputs, which are disclosed in Note 11 to the Consolidated Financial Statements. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At December 31, 2018, a 50 basis point increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately $160 million. Additionally, at December 31, 2018, a five percentage point increase/decrease in the assumed probability of success across all potential indications would have increased/decreased the value of the contingent consideration liabilities by approximately $420 million.
Recent Accounting Pronouncements
See Note 2 to the Consolidated Financial Statements for additional information on recent accounting pronouncements.
|
| | | | | | | | | | |
4047
| |20182021 Form 10-K
| | |
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The company is exposed to risk that its earnings, cash flows and equity could be adversely impacted by changes in foreign exchange rates and interest rates. Certain derivative instruments are used when available on a cost-effective basis to hedge the company's underlying economic exposures. See Note 1011 to the Consolidated Financial Statements for additional information regarding the company's financial instruments and hedging strategies.
Foreign Currency Risk
AbbVie's primary net foreign currency exposures are the Euro, Japanese yen, Canadian dollar, Chinese yuan and British pound. The following table reflects the total foreign currency forward exchange contracts outstanding at December 31, 20182021 and 2017:
|
| | | | | | | | | | | | | | | | | | | | | |
| | 2018 | | 2017 |
| (in millions) | Contract amount | | Weighted average exchange rate | | Fair and carrying value receivable/(payable) | | Contract amount | | Weighted average exchange rate | | Fair and carrying value receivable/(payable) |
| Receive primarily U.S. dollars in exchange for the following currencies: | | | | | | | | | | | |
| Euro | $ | 6,660 |
| | 1.157 |
| | $ | 68 |
| | $ | 6,366 |
| | 1.175 |
| | $ | (88 | ) |
| Japanese yen | 1,076 |
| | 111.5 |
| | (12 | ) | | 940 |
| | 112.4 |
| | 2 |
|
| British pound | 499 |
| | 1.328 |
| | 21 |
| | 760 |
| | 1.310 |
| | (22 | ) |
| All other currencies | 1,776 |
| | n/a |
| | 29 |
| | 1,877 |
| | n/a |
| | (18 | ) |
| Total | $ | 10,011 |
| | | | $ | 106 |
| | $ | 9,943 |
| | | | $ | (126 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2021 | | 2020 |
| as of December 31 (in millions) | Contract amount | | Weighted average exchange rate | | Fair and carrying value receivable/(payable) | | Contract amount | | Weighted average exchange rate | | Fair and carrying value receivable/(payable) |
| Receive primarily U.S. dollars in exchange for the following currencies: | | | | | | | | | | | |
| Euro | $ | 10,253 | | | 1.155 | | | $ | 195 | | | $ | 7,818 | | | 1.213 | | | $ | (39) | |
| Chinese yuan | 673 | | | 6.400 | | | (1) | | | 247 | | | 6.584 | | | (1) | |
| British pound | 605 | | | 1.331 | | | 9 | | | 275 | | | 1.341 | | | 3 | |
| Japanese yen | 602 | | | 113.3 | | | 9 | | | 837 | | | 103.9 | | | (7) | |
| Canadian dollar | 571 | | | 1.258 | | | 9 | | | 591 | | | 1.328 | | | (23) | |
| All other currencies | 1,549 | | | n/a | | 5 | | | 1,459 | | n/a | | (14) | |
| Total | $ | 14,253 | | | | | $ | 226 | | | $ | 11,227 | | | | | $ | (81) | |
The company estimates that a 10% appreciation in the underlying currencies being hedged from their levels against the U.S. dollar, with all other variables held constant, would decrease the fair value of foreign exchange forward contracts by $1.0$1.4 billion at December 31, 2018.2021. If realized, this appreciation would negatively affect earnings over the remaining life of the contracts. However, gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders' equity volatility relating to foreign exchange. A 10% appreciation is believed to be a reasonably possible near-term change in foreign currencies.
In November 2016,As of December 31, 2021, the company issued €3.6has €5.9 billion aggregate principal amount of unsecured senior Euro notes outstanding, which are exposed to foreign currency risk. The company has designated these foreign currency denominated notes as hedges of its net investments in certain foreign subsidiaries and affiliates. As a result, any foreign currency translation gains or losses related to the Euro notes will be included in accumulated other comprehensive income.loss. See Note 9 to the Consolidated Financial Statements for additional information related to the senior Euro note issuance and Note 10 to the Consolidated Financial Statements for additional information relatedregarding to the senior Euro notes and Note 11 to the Consolidated Financial Statements for additional information regarding to the net investment hedging program.
Interest Rate Risk
The company estimates that an increase in interest rates of 100 basis points would adversely impact the fair value of AbbVie's interest rate swap contracts by approximately $403$244 million at December 31, 2018.2021. If realized, the fair value reduction would affect earnings over the remaining life of the contracts. The company estimates that an increase of 100 basis points in long-term interest rates would decrease the fair value of long-term debt by $2.4$5.0 billion at December 31, 2018.2021. A 100 basis point change is believed to be a reasonably possible near-term change in interest rates.
Market Price Risk
AbbVie’s debt securities investment portfolio (the portfolio) is its main exposure to market price risk. The portfolio is subject to changes in fair value as a result of interest rate fluctuations and other market factors. It is AbbVie’s policy to mitigate market price risk by maintaining a diversified portfolio that limits the amount of exposure to a particular issuer and security type while placing limits on the amount of time to maturity. AbbVie’s investment policy limits investments to investment grade credit ratings. The company estimates that an increase in interest rates of 100 basis points would decrease the fair value of the portfolio by approximately $16 million as of December 31, 2018. If the portfolio were to be liquidated, the fair value reduction would affect the statement of earnings in the period sold.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |41
| 48 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
| | | | |
| Page |
| Consolidated Financial Statements | |
| |
| |
| |
| |
| |
| |
| |
|
| | | | | | | | | | |
4249
| |20182021 Form 10-K
| | |
AbbVie Inc. and Subsidiaries
Consolidated Statements of Earnings
| | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions, except per share data) | 2021 | | 2020 | | 2019 |
| Net revenues | $ | 56,197 | | | $ | 45,804 | | | $ | 33,266 | |
| | | | | |
| Cost of products sold | 17,446 | | | 15,387 | | | 7,439 | |
| Selling, general and administrative | 12,349 | | | 11,299 | | | 6,942 | |
| Research and development | 7,084 | | | 6,557 | | | 6,407 | |
| Acquired in-process research and development | 962 | | | 1,198 | | | 385 | |
| Other operating expense (income), net | 432 | | | — | | | (890) | |
| Total operating costs and expenses | 38,273 | | | 34,441 | | | 20,283 | |
| Operating earnings | 17,924 | | | 11,363 | | | 12,983 | |
| | | | | |
| Interest expense, net | 2,384 | | | 2,280 | | | 1,509 | |
| Net foreign exchange loss | 51 | | | 71 | | | 42 | |
| Other expense, net | 2,500 | | | 5,614 | | | 3,006 | |
| Earnings before income tax expense | 12,989 | | | 3,398 | | | 8,426 | |
| Income tax expense (benefit) | 1,440 | | | (1,224) | | | 544 | |
| Net earnings | 11,549 | | | 4,622 | | | 7,882 | |
| Net earnings attributable to noncontrolling interest | 7 | | | 6 | | | — | |
| Net earnings attributable to AbbVie Inc. | $ | 11,542 | | | $ | 4,616 | | | $ | 7,882 | |
| | | | | |
| Per share data | | | | | |
| Basic earnings per share attributable to AbbVie Inc. | $ | 6.48 | | | $ | 2.73 | | | $ | 5.30 | |
| Diluted earnings per share attributable to AbbVie Inc. | $ | 6.45 | | | $ | 2.72 | | | $ | 5.28 | |
| | | | | |
| Weighted-average basic shares outstanding | 1,770 | | | 1,667 | | | 1,481 | |
| Weighted-average diluted shares outstanding | 1,777 | | | 1,673 | | | 1,484 | |
|
| | | | | | | | | | | |
| years ended December 31 (in millions, except per share data) | 2018 | | 2017 | | 2016 |
| Net revenues | $ | 32,753 |
| | $ | 28,216 |
| | $ | 25,638 |
|
| | | | | | |
| Cost of products sold | 7,718 |
| | 7,042 |
| | 5,832 |
|
| Selling, general and administrative | 7,399 |
| | 6,295 |
| | 5,881 |
|
| Research and development | 10,329 |
| | 5,007 |
| | 4,385 |
|
| Acquired in-process research and development | 424 |
| | 327 |
| | 200 |
|
| Other expense | 500 |
| | — |
| | — |
|
| Total operating costs and expenses | 26,370 |
| | 18,671 |
| | 16,298 |
|
| Operating earnings | 6,383 |
| | 9,545 |
| | 9,340 |
|
| | | | | | |
| Interest expense, net | 1,144 |
| | 1,004 |
| | 965 |
|
| Net foreign exchange loss | 24 |
| | 348 |
| | 303 |
|
| Other expense, net | 18 |
| | 466 |
| | 188 |
|
| Earnings before income taxes | 5,197 |
| | 7,727 |
| | 7,884 |
|
| Income tax expense (benefit) | (490 | ) | | 2,418 |
| | 1,931 |
|
| Net earnings | $ | 5,687 |
| | $ | 5,309 |
| | $ | 5,953 |
|
| | | | | | |
| Per share data | | | | | |
| Basic earnings per share | $ | 3.67 |
| | $ | 3.31 |
| | $ | 3.65 |
|
| Diluted earnings per share | $ | 3.66 |
| | $ | 3.30 |
| | $ | 3.63 |
|
| | | | | | |
| Weighted-average basic shares outstanding | 1,541 |
| | 1,596 |
| | 1,622 |
|
| Weighted-average diluted shares outstanding | 1,546 |
| | 1,603 |
| | 1,631 |
|
The accompanying notes are an integral part of these consolidated financial statements.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |43
| 50 |
AbbVie Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
| | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Net earnings | $ | 11,549 | | | $ | 4,622 | | | $ | 7,882 | |
| | | | | |
| Foreign currency translation adjustments, net of tax expense (benefit) of $(35) in 2021, $28 in 2020 and $(4) in 2019 | (1,153) | | | 1,511 | | | (98) | |
| Net investment hedging activities, net of tax expense (benefit) of $193 in 2021, $(221) in 2020 and $22 in 2019 | 699 | | | (799) | | | 74 | |
| Pension and post-employment benefits, net of tax expense (benefit) of $124 in 2021, $(47) in 2020 and $(323) in 2019 | 521 | | | (102) | | | (1,243) | |
| Marketable security activities, net of tax expense (benefit) of $— in 2021, $— in 2020 and $— in 2019 | — | | | — | | | 10 | |
| Cash flow hedging activities, net of tax expense (benefit) of $20 in 2021, $(23) in 2020 and $70 in 2019 | 151 | | | (131) | | | 141 | |
| Other comprehensive income (loss) | $ | 218 | | | $ | 479 | | | $ | (1,116) | |
| Comprehensive income | 11,767 | | | 5,101 | | | 6,766 | |
| Comprehensive income attributable to noncontrolling interest | 7 | | | 6 | | | — | |
| Comprehensive income attributable to AbbVie Inc. | $ | 11,760 | | | $ | 5,095 | | | $ | 6,766 | |
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Net earnings | $ | 5,687 |
| | $ | 5,309 |
| | $ | 5,953 |
|
| | | | | | |
| Foreign currency translation adjustments, net of tax expense (benefit) of $(18) in 2018, $34 in 2017 and $(31) in 2016 | (391 | ) | | 996 |
| | (165 | ) |
| Net investment hedging activities, net of tax expense (benefit) of $40 in 2018, $(194) in 2017 and $79 in 2016 | 138 |
| | (343 | ) | | 140 |
|
| Pension and post-employment benefits, net of tax expense (benefit) of $35 in 2018, $(94) in 2017 and $(75) in 2016 | 197 |
| | (406 | ) | | (135 | ) |
| Marketable security activities, net of tax expense (benefit) of $— in 2018, $(8) in 2017 and $(11) in 2016 | (10 | ) | | (46 | ) | | (1 | ) |
| Cash flow hedging activities, net of tax expense (benefit) of $23 in 2018, $(26) in 2017 and $18 in 2016 | 313 |
| | (342 | ) | | 136 |
|
| Other comprehensive income (loss) | 247 |
| | (141 | ) | | (25 | ) |
| Comprehensive income | $ | 5,934 |
| | $ | 5,168 |
| | $ | 5,928 |
|
The accompanying notes are an integral part of these consolidated financial statements.
|
| | | | | | | | | | |
4451
| |20182021 Form 10-K
| | |
AbbVie Inc. and Subsidiaries
Consolidated Balance Sheets
| | | | | | | | | | | |
| as of December 31 (in millions, except share data) | 2021 | | 2020 |
| Assets | | | |
| Current assets | | | |
| Cash and equivalents | $ | 9,746 | | | $ | 8,449 | |
| Short-term investments | 84 | | | 30 | |
| Accounts receivable, net | 9,977 | | | 8,822 | |
| Inventories | 3,128 | | | 3,310 | |
| Prepaid expenses and other | 4,993 | | | 3,562 | |
| Total current assets | 27,928 | | | 24,173 | |
| | | |
| Investments | 277 | | | 293 | |
| Property and equipment, net | 5,110 | | | 5,248 | |
| Intangible assets, net | 75,951 | | | 82,876 | |
| Goodwill | 32,379 | | | 33,124 | |
| Other assets | 4,884 | | | 4,851 | |
| Total assets | $ | 146,529 | | | $ | 150,565 | |
| | | |
| Liabilities and Equity | | | |
| Current liabilities | | | |
| Short-term borrowings | $ | 14 | | | $ | 34 | |
| Current portion of long-term debt and finance lease obligations | 12,481 | | | 8,468 | |
| Accounts payable and accrued liabilities | 22,699 | | | 20,159 | |
| Total current liabilities | 35,194 | | | 28,661 | |
| | | |
| Long-term debt and finance lease obligations | 64,189 | | | 77,554 | |
| Deferred income taxes | 3,009 | | | 3,646 | |
| Other long-term liabilities | 28,701 | | | 27,607 | |
| | | |
| Commitments and contingencies | 0 | | 0 |
| | | |
| Stockholders' equity (deficit) | | | |
| Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,803,195,293 shares issued as of December 31, 2021 and 1,792,140,764 as of December 31, 2020 | 18 | | | 18 | |
| Common stock held in treasury, at cost, 34,857,597 shares as of December 31, 2021 and 27,007,945 as of December 31, 2020 | (3,143) | | | (2,264) | |
| Additional paid-in capital | 18,305 | | | 17,384 | |
| Retained earnings | 3,127 | | | 1,055 | |
| Accumulated other comprehensive loss | (2,899) | | | (3,117) | |
| Total stockholders' equity | 15,408 | | | 13,076 | |
| Noncontrolling interest | 28 | | | 21 | |
| Total equity | 15,436 | | | 13,097 | |
| | | |
| Total liabilities and equity | $ | 146,529 | | | $ | 150,565 | |
|
| | | | | | | |
| as of December 31 (in millions, except share data) | 2018 | | 2017 |
| Assets | | | |
| Current assets | | | |
| Cash and equivalents | $ | 7,289 |
| | $ | 9,303 |
|
| Short-term investments | 772 |
| | 486 |
|
| Accounts receivable, net | 5,384 |
| | 5,088 |
|
| Inventories | 1,605 |
| | 1,605 |
|
| Prepaid expenses and other | 1,895 |
| | 4,741 |
|
| Total current assets | 16,945 |
| | 21,223 |
|
| | | | |
| Investments | 1,420 |
| | 2,090 |
|
| Property and equipment, net | 2,883 |
| | 2,803 |
|
| Intangible assets, net | 21,233 |
| | 27,559 |
|
| Goodwill | 15,663 |
| | 15,785 |
|
| Other assets | 1,208 |
| | 1,326 |
|
| Total assets | $ | 59,352 |
| | $ | 70,786 |
|
| | | | |
| Liabilities and Equity | | | |
| Current liabilities | | | |
| Short-term borrowings | $ | 3,699 |
| | $ | 400 |
|
| Current portion of long-term debt and lease obligations | 1,609 |
| | 6,015 |
|
| Accounts payable and accrued liabilities | 11,931 |
| | 10,226 |
|
| Total current liabilities | 17,239 |
| | 16,641 |
|
| | | | |
| Long-term debt and lease obligations | 35,002 |
| | 30,953 |
|
| Deferred income taxes | 1,067 |
| | 2,490 |
|
| Other long-term liabilities | 14,490 |
| | 15,605 |
|
| | | | |
| Commitments and contingencies |
|
| |
|
|
| | | | |
| Stockholders’ equity (deficit) | | | |
| Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,776,510,871 shares issued as of December 31, 2018 and 1,768,738,550 as of December 31, 2017 | 18 |
| | 18 |
|
| Common stock held in treasury, at cost, 297,686,473 shares as of December 31, 2018 and 176,607,525 as of December 31, 2017 | (24,108 | ) | | (11,923 | ) |
| Additional paid-in-capital | 14,756 |
| | 14,270 |
|
| Retained earnings | 3,368 |
| | 5,459 |
|
| Accumulated other comprehensive loss | (2,480 | ) | | (2,727 | ) |
| Total stockholders’ equity (deficit) | (8,446 | ) | | 5,097 |
|
| | | | |
| Total liabilities and equity | $ | 59,352 |
| | $ | 70,786 |
|
The accompanying notes are an integral part of these consolidated financial statements.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |45
| 52 |
AbbVie Inc. and Subsidiaries
Consolidated Statements of Equity
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | Common shares outstanding | | Common stock | | Treasury stock | | Additional paid-in capital | | Retained earnings | | Accumulated other comprehensive loss | | Noncontrolling interest | | Total |
| Balance at December 31, 2018 | 1,479 | | | $ | 18 | | | $ | (24,108) | | | $ | 14,756 | | | $ | 3,368 | | | $ | (2,480) | | | $ | — | | | $ | (8,446) | |
| Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 7,882 | | | — | | | — | | | 7,882 | |
| Other comprehensive loss, net of tax | — | | | — | | | — | | | — | | | — | | | (1,116) | | | — | | | (1,116) | |
| Dividends declared | — | | | — | | | — | | | — | | | (6,533) | | | — | | | — | | | (6,533) | |
| Purchases of treasury stock | (5) | | | — | | | (428) | | | — | | | — | | | — | | | — | | | (428) | |
| Stock-based compensation plans and other | 5 | | | — | | | 32 | | | 437 | | | — | | | — | | | — | | | 469 | |
| Balance at December 31, 2019 | 1,479 | | | 18 | | | (24,504) | | | 15,193 | | | 4,717 | | | (3,596) | | | — | | | (8,172) | |
| Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 4,616 | | | — | | | — | | | 4,616 | |
| Other comprehensive income, net of tax | — | | | — | | | — | | | — | | | — | | | 479 | | | — | | | 479 | |
| Dividends declared | — | | | — | | | — | | | — | | | (8,278) | | | — | | | — | | | (8,278) | |
| Common shares and equity awards issued for acquisition of Allergan plc | 286 | | | — | | | 23,166 | | | 1,243 | | | — | | | — | | | — | | | 24,409 | |
| Purchases of treasury stock | (10) | | | — | | | (978) | | | — | | | — | | | — | | | — | | | (978) | |
| Stock-based compensation plans and other | 10 | | | — | | | 52 | | | 948 | | | — | | | — | | | — | | | 1,000 | |
| Change in noncontrolling interest | — | | | — | | | — | | | — | | | — | | | — | | | 21 | | | 21 | |
| Balance at December 31, 2020 | 1,765 | | | 18 | | | (2,264) | | | 17,384 | | | 1,055 | | | (3,117) | | | 21 | | | 13,097 | |
| Net earnings attributable to AbbVie Inc. | — | | | — | | | — | | | — | | | 11,542 | | | — | | | — | | | 11,542 | |
| Other comprehensive income, net of tax | — | | | — | | | — | | | — | | | — | | | 218 | | | — | | | 218 | |
| Dividends declared | — | | | — | | | — | | | — | | | (9,470) | | | — | | | — | | | (9,470) | |
| Purchases of treasury stock | (8) | | | — | | | (934) | | | — | | | — | | | — | | | — | | | (934) | |
| Stock-based compensation plans and other | 11 | | | — | | | 55 | | | 921 | | | — | | | — | | | — | | | 976 | |
| Change in noncontrolling interest | — | | | — | | | — | | | — | | | — | | | — | | | 7 | | | 7 | |
| Balance at December 31, 2021 | 1,768 | | | $ | 18 | | | $ | (3,143) | | | $ | 18,305 | | | $ | 3,127 | | | $ | (2,899) | | | $ | 28 | | | $ | 15,436 | |
|
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | Common shares outstanding | | Common stock | | Treasury stock | | Additional paid-in capital | | Retained earnings | | Accumulated other comprehensive loss | | Total |
| Balance at December 31, 2015 | 1,610 |
| | $ | 17 |
| | $ | (8,839 | ) | | $ | 13,080 |
| | $ | 2,248 |
| | $ | (2,561 | ) | | $ | 3,945 |
|
| Net earnings | — |
| | — |
| | — |
| | — |
| | 5,953 |
| | — |
| | 5,953 |
|
| Other comprehensive loss, net of tax | — |
| | — |
| | — |
| | — |
| | — |
| | (25 | ) | | (25 | ) |
| Dividends declared | — |
| | — |
| | — |
| | — |
| | (3,823 | ) | | — |
| | (3,823 | ) |
| Common shares issued to Stemcentrx stockholders | 63 |
| | — |
| | 3,958 |
| | (35 | ) | | — |
| | — |
| | 3,923 |
|
| Purchases of treasury stock | (94 | ) | | — |
| | (6,018 | ) | | — |
| | — |
| | — |
| | (6,018 | ) |
| Stock-based compensation plans and other | 14 |
| | 1 |
| | 47 |
| | 633 |
| | — |
| | — |
| | 681 |
|
| Balance at December 31, 2016 | 1,593 |
| | 18 |
| | (10,852 | ) | | 13,678 |
| | 4,378 |
| | (2,586 | ) | | 4,636 |
|
| Net earnings | — |
| | — |
| | — |
| | — |
| | 5,309 |
| | — |
| | 5,309 |
|
| Other comprehensive loss, net of tax | — |
| | — |
| | — |
| | — |
| | — |
| | (141 | ) | | (141 | ) |
| Dividends declared | — |
| | — |
| | — |
| | — |
| | (4,221 | ) | | — |
| | (4,221 | ) |
| Purchases of treasury stock | (15 | ) | | — |
| | (1,125 | ) | | — |
| | — |
| | — |
| | (1,125 | ) |
| Stock-based compensation plans and other | 14 |
| | — |
| | 54 |
| | 592 |
| | (7 | ) | | — |
| | 639 |
|
| Balance at December 31, 2017 | 1,592 |
| | 18 |
| | (11,923 | ) | | 14,270 |
| | 5,459 |
| | (2,727 | ) | | 5,097 |
|
Adoption of new accounting standards(a) | — |
| | — |
| | — |
| | — |
| | (1,733 | ) | | — |
| | (1,733 | ) |
| Net earnings | — |
| | — |
| | — |
| | — |
| | 5,687 |
| | — |
| | 5,687 |
|
| Other comprehensive income, net of tax | — |
| | — |
| | — |
| | — |
| | — |
| | 247 |
| | 247 |
|
| Dividends declared | — |
| | — |
| | — |
| | — |
| | (6,045 | ) | | — |
| | (6,045 | ) |
| Purchases of treasury stock | (121 | ) | | — |
| | (12,215 | ) | | — |
| | — |
| | — |
| | (12,215 | ) |
| Stock-based compensation plans and other | 8 |
| | — |
| | 30 |
| | 486 |
| | — |
| | — |
| | 516 |
|
| Balance at December 31, 2018 | 1,479 |
| | $ | 18 |
| | $ | (24,108 | ) | | $ | 14,756 |
| | $ | 3,368 |
| | $ | (2,480 | ) | | $ | (8,446 | ) |
| |
(a) | See Note 2 for additional information regarding the cumulative effect of the adoption of accounting standards in 2018. |
The accompanying notes are an integral part of these consolidated financial statements.
|
| | | | | | | | | | |
4653
| |20182021 Form 10-K
| | |
AbbVie Inc. and Subsidiaries
Consolidated Statements of Cash Flows | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) (brackets denote cash outflows) | 2021 | | 2020 | | 2019 |
| Cash flows from operating activities | | | | | |
| Net earnings | $ | 11,549 | | | $ | 4,622 | | | $ | 7,882 | |
| Adjustments to reconcile net earnings to net cash from operating activities: | | | | | |
| Depreciation | 803 | | | 666 | | | 464 | |
| Amortization of intangible assets | 7,718 | | | 5,805 | | | 1,553 | |
| Deferred income taxes | (898) | | | (2,325) | | | 122 | |
| Change in fair value of contingent consideration liabilities | 2,679 | | | 5,753 | | | 3,091 | |
| Stock-based compensation | 692 | | | 753 | | | 430 | |
| Upfront costs and milestones related to collaborations | 1,624 | | | 1,376 | | | 490 | |
| Gain on divestitures | (68) | | | — | | | (330) | |
| Stemcentrx impairment | — | | | — | | | 1,030 | |
| | | | | |
| Other, net | — | | | 832 | | | 43 | |
| Changes in operating assets and liabilities, net of acquisitions: | | | | | |
| Accounts receivable | (1,321) | | | (929) | | | (74) | |
| Inventories | (142) | | | (40) | | | (231) | |
| Prepaid expenses and other assets | (197) | | | 134 | | | (225) | |
| Accounts payable and other liabilities | 1,628 | | | 1,514 | | | 97 | |
| Income tax assets and liabilities, net | (1,290) | | | (573) | | | (1,018) | |
| Cash flows from operating activities | 22,777 | | | 17,588 | | | 13,324 | |
| | | | | |
| Cash flows from investing activities | | | | | |
| Acquisition of businesses, net of cash acquired | (525) | | | (38,260) | | | — | |
| Other acquisitions and investments | (1,377) | | | (1,350) | | | (1,135) | |
| Acquisitions of property and equipment | (787) | | | (798) | | | (552) | |
| Purchases of investment securities | (119) | | | (61) | | | (583) | |
| Sales and maturities of investment securities | 98 | | | 1,525 | | | 2,699 | |
| Other, net | 366 | | | 1,387 | | | 167 | |
| Cash flows from investing activities | (2,344) | | | (37,557) | | | 596 | |
| | | | | |
| Cash flows from financing activities | | | | | |
| Net change in commercial paper borrowings | — | | | — | | | (699) | |
| | | | | |
| Repayments of other short-term borrowings | — | | | — | | | (3,000) | |
| Proceeds from issuance of long-term debt | 1,000 | | | 3,000 | | | 31,482 | |
| Repayments of long-term debt and finance lease obligations | (9,414) | | | (5,683) | | | (1,536) | |
| Debt issuance costs | — | | | (20) | | | (424) | |
| Dividends paid | (9,261) | | | (7,716) | | | (6,366) | |
| Purchases of treasury stock | (934) | | | (978) | | | (629) | |
| Proceeds from the exercise of stock options | 244 | | | 209 | | | 8 | |
| Payments of contingent consideration liabilities | (698) | | | (321) | | | (163) | |
| Other, net | 24 | | | 8 | | | 35 | |
| Cash flows from financing activities | (19,039) | | | (11,501) | | | 18,708 | |
| Effect of exchange rate changes on cash and equivalents | (97) | | | (5) | | | 7 | |
| Net change in cash and equivalents | 1,297 | | | (31,475) | | | 32,635 | |
| Cash and equivalents, beginning of year | 8,449 | | | 39,924 | | | 7,289 | |
| | | | | |
| Cash and equivalents, end of year | $ | 9,746 | | | $ | 8,449 | | | $ | 39,924 | |
| | | | | |
| Other supplemental information | | | | | |
| Interest paid, net of portion capitalized | $ | 2,712 | | | $ | 2,619 | | | $ | 1,794 | |
| Income taxes paid | 3,648 | | | 1,674 | | | 1,447 | |
| Supplemental schedule of non-cash investing and financing activities | | | | | |
| Issuance of common shares associated with acquisitions of businesses | — | | | 23,979 | | | — | |
|
| | | | | | | | | | | |
| years ended December 31 (in millions) (brackets denote cash outflows) | 2018 | | 2017 | | 2016 |
| Cash flows from operating activities | | | | | |
| Net earnings | $ | 5,687 |
| | $ | 5,309 |
| | $ | 5,953 |
|
| Adjustments to reconcile net earnings to net cash from operating activities: | | | | | |
| Depreciation | 471 |
| | 425 |
| | 425 |
|
| Amortization of intangible assets | 1,294 |
| | 1,076 |
| | 764 |
|
| Change in fair value of contingent consideration liabilities | 49 |
| | 626 |
| | 228 |
|
| Stock-based compensation | 421 |
| | 365 |
| | 353 |
|
| Upfront costs and milestones related to collaborations | 1,061 |
| | 470 |
| | 280 |
|
| Devaluation loss related to Venezuela | — |
| | — |
| | 298 |
|
| Intangible asset impairment | 5,070 |
| | 354 |
| | 39 |
|
| Impacts related to U.S. tax reform | 424 |
| | 1,242 |
| | — |
|
| Other, net | 76 |
| | 84 |
| | 390 |
|
| Changes in operating assets and liabilities, net of acquisitions: | | | | | |
| Accounts receivable | (591 | ) | | (391 | ) | | (71 | ) |
| Inventories | (226 | ) | | 93 |
| | (38 | ) |
| Prepaid expenses and other assets | (499 | ) | | (118 | ) | | (393 | ) |
| Accounts payable and other liabilities | 190 |
| | 425 |
| | (1,187 | ) |
| Cash flows from operating activities | 13,427 |
| | 9,960 |
| | 7,041 |
|
| | | | | | |
| Cash flows from investing activities | | | | | |
| Acquisition of businesses, net of cash acquired | — |
| | — |
| | (2,495 | ) |
| Other acquisitions and investments | (736 | ) | | (308 | ) | | (262 | ) |
| Acquisitions of property and equipment | (638 | ) | | (529 | ) | | (479 | ) |
| Purchases of investment securities | (1,792 | ) | | (2,230 | ) | | (5,315 | ) |
| Sales and maturities of investment securities | 2,160 |
| | 2,793 |
| | 2,359 |
|
| Other | — |
| | — |
| | 118 |
|
| Cash flows from investing activities | (1,006 | ) | | (274 | ) | | (6,074 | ) |
| | | | | | |
| Cash flows from financing activities | | | | | |
| Net change in commercial paper borrowings | 299 |
| | 23 |
| | (23 | ) |
| Proceeds from issuance of other short-term borrowings | 3,002 |
| | — |
| | — |
|
| Proceeds from issuance of long-term debt | 5,963 |
| | — |
| | 11,627 |
|
| Repayments of long-term debt and lease obligations | (6,035 | ) | | (25 | ) | | (6,010 | ) |
| Debt issuance costs | (40 | ) | | — |
| | (69 | ) |
| Dividends paid | (5,580 | ) | | (4,107 | ) | | (3,717 | ) |
| Purchases of treasury stock | (12,014 | ) | | (1,410 | ) | | (6,033 | ) |
| Proceeds from the exercise of stock options | 73 |
| | 254 |
| | 268 |
|
| Payments of contingent consideration liabilities | (78 | ) | | (268 | ) | | — |
|
| Other, net | 14 |
| | 21 |
| | 29 |
|
| Cash flows from financing activities | (14,396 | ) | | (5,512 | ) | | (3,928 | ) |
| Effect of exchange rate changes on cash and equivalents | (39 | ) | | 29 |
| | (338 | ) |
| Net change in cash and equivalents | (2,014 | ) | | 4,203 |
| | (3,299 | ) |
| Cash and equivalents, beginning of year | 9,303 |
| | 5,100 |
| | 8,399 |
|
| | | | | | |
| Cash and equivalents, end of year | $ | 7,289 |
| | $ | 9,303 |
| | $ | 5,100 |
|
| | | | | | |
| Other supplemental information | | | | | |
| Interest paid, net of portion capitalized | $ | 1,215 |
| | $ | 1,099 |
| | $ | 986 |
|
| Income taxes paid (received) | (35 | ) | | 1,696 |
| | 3,563 |
|
| Supplemental schedule of non-cash investing and financing activities | | | | | |
| Issuance of common shares associated with acquisitions of businesses | — |
| | — |
| | 3,923 |
|
The accompanying notes are an integral part of these consolidated financial statements.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |47
| 54 |
AbbVie Inc. and Subsidiaries
Notes to Consolidated Financial Statements
Note 1 Background
Background
The principal business of AbbVie Inc. (AbbVie or the company) is the discovery, development, manufacturemanufacturing and sale of a broad line of pharmaceutical products.therapies that address some of the world's most complex and serious diseases. AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, and patients.patients or other customers. Outside the United States, AbbVie sells products are sold primarily to customers or through distributors, depending on the market served.
AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.
On May 8, 2020, AbbVie completed its acquisition of Allergan plc (Allergan). Refer to Note 5 for additional information regarding this acquisition. Note 2 Summary of Significant Accounting Policies
Use of Estimates
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for rebates, pension and other post-employment benefits, income taxes, litigation, valuation of goodwill and intangible assets, contingent consideration liabilities, financial instruments and inventory and accounts receivable exposures.
Basis of Consolidation
The consolidated financial statements include the accounts of AbbVie and all of its subsidiaries in which a controlling interest is maintained. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, where AbbVie is determined to be the primary beneficiary. Investments in companies over which AbbVie has a significant influence but not a controlling interest are accounted for using the equity method with AbbVie's share of earnings or losses reported in other expense, net in the consolidated statements of earnings. Intercompany balances and transactions are eliminated.
Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation.
Revenue Recognition
AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less.
Discounts, rebates, sales incentives to customers, returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are
| | | | | | | | | | | |
55 | |2021 Form 10-K | | |
typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. Sales incentives to customers are insignificant.
|
| | |
48 |2018 Form 10-K
| | |
In addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborationcollaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 1516 for disaggregation of revenue by product and geography.
Research and Development Expenses
Internal research and development (R&D) costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaborations, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product.
Collaborations and Other Arrangements
The company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include joint research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements during the development stage are expensed to acquired in-process research and development (IPR&D) expenses in the consolidated statements of earnings. Subsequent payments made to the partner for the achievement of milestones during the development stage are expensed to R&D expense in the consolidated statements of earnings when the milestone is achieved. Milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred.
Advertising
Costs associated with advertising are expensed as incurred and are included in selling, general and administrative (SG&A) expense in the consolidated statements of earnings. Advertising expenses were $2.1 billion in 2021, $1.8 billion in 2020 and $1.1 billion in 2018, $846 million in 2017 and $764 million in 2016.2019.
Pension and Other Post-Employment Benefits
AbbVie records annual expenses relating to its defined benefit pension and other post-employment benefit plans based on calculations which utilize various actuarial assumptions, including discount rates, rates of return on assets, compensation increases, turnover rates and health care cost trend rates. AbbVie reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends. Actuarial gains and losses are deferred in accumulated other comprehensive lossincome (loss) (AOCI), net of tax and are amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return are generally amortized to net periodic benefit cost over a five-year period.
Income Taxes
Income taxes are accounted for under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pretax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized.
Cash and Equivalents
Cash and equivalents include money market funds and time deposits with original maturities of three months or less.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 56 |
Investments
Investments consist primarily of time deposits, marketable debtequity securities, held-to-maturity debt securities, and equity securities. Investments in marketable debt securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in AOCI on the consolidated balance sheets until realized, at which time the gains or losses are recognized in earnings.deposits. Investments in equity securities that have readily determinable fair values are recorded at fair value. Investments in equity securities that do not have readily determinable fair values are recorded at cost and are remeasured to fair value based on certain observable price changes or impairment events as they occur. Held-to-
|
| | |
| | 2018 Form 10-K | 49
|
maturityHeld-to-maturity debt securities are recorded at cost. Gains or losses on investments are included in other expense, net in the consolidated statements of earnings. Investments in marketable debt securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in AOCI on the consolidated balance sheets until realized, at which time the gains or losses are recognized in earnings.
AbbVie periodically assesses its marketable debt securities for other-than-temporary impairment and credit losses. This evaluation is based onWhen a number of factors, including the length of time and the extent to which thedecline in fair value has been belowof marketable debt security is due to credit related factors, an allowance for credit losses is recorded with a corresponding charge to other expense, net in the cost basis and adverse conditions related specifically to the security, including any changes to the credit ratingconsolidated statements of the security, intent to sell, or whether AbbVie will more likely than not be required to sell the security before recovery of its amortized cost basis. AbbVie also considers industry factors and general market trends.earnings. When AbbVie determines that an other-than-temporary declinea non-credit related impairment has occurred, the amortized cost basis of the investment, net of allowance for credit losses, is written down with a charge to other expense, net in the consolidated statements of earnings and an available-for-sale investment's unrealized loss is reclassified from AOCI to other expense, net in the consolidated statements of earnings. Realized gains and losses on sales of investments are computed using the first-in, first-out method adjusted for any other-than-temporary declines in fair valueimpairments and credit losses that were recorded in net earnings.
Accounts Receivable
Accounts receivable are stated at their net realizable value.amortized cost less allowance for credit losses. The allowance for doubtful accountscredit losses reflects the best estimate of probablefuture losses inherent inover the receivables portfoliocontractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, and other currently available information. Accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. The allowance for doubtful accounts was $51 million at December 31, 2018information including customer financial condition, and $58 million at December 31, 2017.both current and forecasted economic conditions.
Inventories
Inventories are valued at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. Inventories consisted of the following: | | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Finished goods | $ | 932 | | | $ | 1,318 | |
| Work-in-process | 1,193 | | | 1,201 | |
| Raw materials | 1,003 | | | 791 | |
| Inventories | $ | 3,128 | | | $ | 3,310 | |
|
| | | | | | | |
| as of December 31 (in millions) | 2018 | | 2017 |
| Finished goods | $ | 473 |
| | $ | 610 |
|
| Work-in-process | 862 |
| | 822 |
|
| Raw materials | 270 |
| | 173 |
|
| Inventories | $ | 1,605 |
| | $ | 1,605 |
|
Property and Equipment
|
| | | | | | | |
| as of December 31 (in millions) | 2018 | | 2017 |
| Land | $ | 73 |
| | $ | 48 |
|
| Buildings | 1,603 |
| | 1,428 |
|
| Equipment | 6,362 |
| | 5,991 |
|
| Construction in progress | 358 |
| | 604 |
|
| Property and equipment, gross | 8,396 |
| | 8,071 |
|
| Less accumulated depreciation | (5,513 | ) | | (5,268 | ) |
| Property and equipment, net | $ | 2,883 |
| | $ | 2,803 |
|
| | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Land | $ | 287 | | | $ | 288 | |
| Buildings | 2,791 | | | 2,555 | |
| Equipment | 6,850 | | | 6,976 | |
| Construction in progress | 799 | | | 1,040 | |
| Property and equipment, gross | 10,727 | | | 10,859 | |
| Less accumulated depreciation | (5,617) | | | (5,611) | |
| Property and equipment, net | $ | 5,110 | | | $ | 5,248 | |
Depreciation for property and equipment is recorded on a straight-line basis over the estimated useful lives of the assets. The estimated useful life for buildings ranges from 10 to 50 years. Buildings include leasehold improvements which are amortized over the life of the related facility lease (including any renewal periods, if appropriate) or the asset, whichever is shorter. The estimated useful life for equipment ranges from 2 to 25 years. Equipment includes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use and is amortized over 3 to 10 years. Depreciation expense was $471$803 million in 2018, $4252021, $666 million in 20172020 and $425$464 million in 2016. Assets related2019.
| | | | | | | | | | | |
57 | |2021 Form 10-K | | |
Leases
Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.
The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to capital leases were insignificant at December 31, 2018discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option.
Variable lease payments include payments to lessors for taxes, maintenance, insurance and 2017.other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
Litigation and Contingencies
Loss contingency provisions are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. When a best estimate cannot be made, the minimum loss contingency amount in a probable range is recorded. Legal fees are expensed as incurred. AbbVie accrues for product liability claims on an undiscounted basis. The liabilities are evaluated quarterly and adjusted if necessary as additional information
|
| | |
50 |2018 Form 10-K
| | |
becomes available. Receivables for insurance recoveries for product liability claims, if any, are recorded as assets on an undiscounted basis when it is probable that a recovery will be realized.
Business Combinations
AbbVie utilizes the acquisition method of accounting for business combinations. This method requires, among other things, that resultsresults of operations of acquired companies are included in AbbVie's results of operations beginning on the respective acquisition dates and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other expense, net in the consolidated statements of earnings. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed twelve12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.
Goodwill and Intangible Assets
Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital and terminal values of market participants. Definite-lived intangibles are amortized over their estimated useful lives using the estimated pattern of economic benefit. AbbVie reviews the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. AbbVie first compares the projected undiscounted cash flows to be generated by the asset to its carrying value. If the undiscounted cash flows of an intangible asset are less than the carrying value, the intangible asset is written down to its fair value. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest level for which cash flows are largely independent of the cash flows of other assets and liabilities.
Goodwill and indefinite-lived assets are not amortized, but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeded the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value.
The company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. AbbVie tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test is performed. For its quantitative impairment tests, the company uses an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are consistent with the company's business plans and a market participant's views. The use of alternative estimates and assumptions could increase or decrease
| | | | | | | | | | | |
| | 2021 Form 10-K | | 58 |
the estimated fair value of the assets and potentially result in different impacts to the company's results of operations. Actual results may differ from the company's estimates.
Acquired In-Process Research and Development
In an asset acquisition, the initial costs ofto acquire rights to IPR&D projects acquired are expensed as IPR&D in the consolidated statements of earnings unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. In a business combination, the fair value of IPR&D projects acquired are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be written off. R&D costs incurred after the acquisition are expensed as incurred.
Foreign Currency Translation
Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using period-end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recognized in other comprehensive income (loss) (OCI) in the consolidated statements of comprehensive income. The net assets of subsidiaries in highly inflationary economies are
|
| | |
| | 2018 Form 10-K | 51
|
remeasured as if the functional currency were the reporting currency. The remeasurement is recognized in net foreign exchange loss in the consolidated statements of earnings.
Derivatives
All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument.
For derivatives formally designated as hedges, the company assesses at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in AOCI and are subsequently recognized in earnings consistent with the underlying hedged item. If it is determined that a derivative is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from AOCI to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings.
The company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in AOCI.
Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing section of the consolidated statements of cash flows.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
ASU No. 2014-092019-12
In May 2014,December 2019, the Financial Accounting Standards Board (FASB)FASB issued Accounting Standards Update (ASU)ASU No. 2014-09, Summary and Amendments That Create Revenue from Contracts with Customers2019-12, Income Taxes (Topic 606) and Other Assets and Deferred Costs - Contracts with Customers (Subtopic 340-40)740). The amendmentsstandard includes simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in this standard superseded most existing revenue recognition requirements. The core principlea step-up in the tax basis of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.goodwill. AbbVie adopted the standard in the first quarter of 2018 using the modified retrospective method. Results for reporting periods beginning after December 31, 2017 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie’s historical accounting. The cumulative effect of initially applying the new revenue standard was recognized as an adjustment to the opening balance of retained earnings as of January 1, 2018.
There were no significant changes to the amounts or timing of revenue recognition for product sales, the company's primary revenue stream. For certain licensing arrangements where revenue was previously deferred and recognized over time, revenue is now recognized at the point in time when the license is granted. Additionally, for certain contract manufacturing arrangements where revenue was previously recognized at a point in time at the end of the manufacturing process, revenue is now recognized over time throughout the manufacturing process.
Under the new standard, on January 1, 2018, the company recognized a cumulative-effect adjustment to retained earnings primarily related to certain deferred license revenues that were originally expected to be recognized through early 2020. The adjustment to the consolidated balance sheet included: (i) a $42 million increase to prepaid expenses and other; (ii) a $39 million decrease to inventories; (iii) a $57 million decrease to accounts payable and accrued liabilities; (iv) a $75 million decrease to other long-term liabilities; (v) a $22 million increase to deferred income taxes; and (vi) a $124 million increase to retained earnings. Other cumulative-effect adjustments to the consolidated balance sheet were insignificant.
|
| | |
52 |2018 Form 10-K
| | |
The impact of adoption on the company’s consolidated statements of earnings in 2018 was as follows:
|
| | | | | | | | | | | | |
| year ended December 31, 2018 (in millions, except per share data) | | As Reported | | Balances Without Adoption of ASU 2014-09 | | Effect of Change Higher/(Lower) |
| Net revenues | | $ | 32,753 |
| | $ | 32,812 |
| | $ | (59 | ) |
| Cost of products sold | | 7,718 |
| | 7,730 |
| | (12 | ) |
| Income tax benefit | | (490 | ) | | (487 | ) | | (3 | ) |
| Net earnings | | 5,687 |
| | 5,731 |
| | (44 | ) |
| Diluted earnings per share | | $ | 3.66 |
| | $ | 3.69 |
| | $ | (0.03 | ) |
As of December 31, 2018, due to the impact of the adoption of ASU 2014-09, prepaid expenses and other were $40 million higher, inventories were $27 million lower, accounts payable and accrued liabilities were $53 million lower, other long-term liabilities were $18 million lower, deferred income taxes were $11 million higher and retained earnings were $80 million higher on the company’s consolidated balance sheet than they would have been had ASU 2014-09 not been adopted. Other impacts to the consolidated balance sheet were insignificant.
ASU No. 2016-01
In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The standard requires several targeted changes including that equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) be measured at fair value with changes in fair value recognized in net earnings. AbbVie adopted the standard in the first quarter of 2018. The adoption did not impact the accounting for AbbVie's investments in debt securities and did not have a material impact on the company's consolidated financial statements.
ASU No. 2016-16
In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The standard requires entities to recognize the income tax consequences of an intercompany transfer of an asset other than inventory when the transfer occurs. Under previous U.S. GAAP, the income tax consequences of these intercompany asset transfers were deferred until the asset was sold to a third party or otherwise recovered through use. AbbVie adopted the standard in the first quarter of 2018 using the modified retrospective method. As a result, on January 1, 2018, the company recorded a cumulative-effect adjustment to its consolidated balance sheet that included a $1.9 billion decrease to retained earnings, a $1.4 billion decrease to prepaid expenses and other and a $0.5 billion decrease to other assets.
ASU No. 2017-07
In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The standard requires that an employer continue to report the service cost component of net periodic benefit cost in the same income statement line item or items as other employee compensation costs arising from services rendered during the period. The other components of net periodic benefit cost are required to be presented separately outside of income from operations and are not eligible for capitalization. AbbVie adopted the standard in the first quarter of 2018 and applied the income statement classification provisions of this standard retrospectively. As a result, the company reclassified income of $47 million from operating earnings to non-operating income in 2017 and $44 million in 2016. Additionally, the company recorded approximately $34 million of non-operating income in 2018 which would have been recorded in operating earnings under the previous guidance.
ASU No. 2017-12
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The standard simplifies the application of hedge accounting and more closely aligns the accounting with an entity’s risk management activities. AbbVie elected to early adopt the standard in the first quarter of 2018.2021. The adoption did not have a material impact on the company's consolidated financial statements.
|
| | |
| | 2018 Form 10-K | 53
|
Recent Accounting Pronouncements Not Yet Adopted
ASU No. 2016-02
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard outlines a comprehensive lease accounting model that supersedes the current lease guidance and requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changes the definition of a lease and expands the disclosure requirements of lease arrangements. AbbVie has substantially completed its assessment of the new standard as of December 31, 2018. AbbVie will adopt the standard effective in the first quarter of 2019 and will not restate comparative periods upon adoption. AbbVie will elect a package of practical expedients for leases that commenced prior to January 1, 2019 and will not reassess: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases. AbbVie does not expect the adoption will have a material impact on its consolidated statement of earnings. However, the new standard will require AbbVie to establish liabilities and corresponding right-of-use assets on its consolidated balance sheet of approximately $0.3 billion to $0.5 billion for operating leases that exist as of the adoption date.
ASU No. 2016-13
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326). The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. Early adoption beginning in the first quarter of 2019 is permitted. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact and timing of adopting this guidance on its consolidated financial statements.
ASU No. 2018-02
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from AOCI to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act. The standard will be effective for AbbVie starting with the first quarter of 2019. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.
| | | | | | | | | | | |
59 | |2021 Form 10-K | | |
Note 3 Supplemental Financial Information | | |
54 |2018 Form 10-K
| | |
Note 3 Supplemental Financial Information
Interest Expense, Net | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Interest expense | $ | 2,423 | | | $ | 2,454 | | | $ | 1,784 | |
| Interest income | (39) | | | (174) | | | (275) | |
| Interest expense, net | $ | 2,384 | | | $ | 2,280 | | | $ | 1,509 | |
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Interest expense | $ | 1,348 |
| | $ | 1,150 |
| | $ | 1,047 |
|
| Interest income | (204 | ) | | (146 | ) | | (82 | ) |
| Interest expense, net | $ | 1,144 |
| | $ | 1,004 |
| | $ | 965 |
|
Accounts Payable and Accrued Liabilities | | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Sales rebates | $ | 8,254 | | | $ | 7,188 | |
| Dividends payable | 2,543 | | | 2,335 | |
| Accounts payable | 2,882 | | | 2,276 | |
| Salaries, wages and commissions | 1,785 | | | 1,669 | |
| Royalty and license arrangements | 661 | | | 483 | |
| Other | 6,574 | | | 6,208 | |
| Accounts payable and accrued liabilities | $ | 22,699 | | | $ | 20,159 | |
|
| | | | | | | |
| as of December 31 (in millions) | 2018 | | 2017 |
| Sales rebates | $ | 3,939 |
| | $ | 3,069 |
|
| Dividends payable | 1,607 |
| | 1,143 |
|
| Accounts payable | 1,546 |
| | 1,474 |
|
| Salaries, wages and commissions | 787 |
| | 763 |
|
| Royalty and license arrangements | 304 |
| | 514 |
|
| Other | 3,748 |
| | 3,263 |
|
| Accounts payable and accrued liabilities | $ | 11,931 |
| | $ | 10,226 |
|
Other Long-Term Liabilities | | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Contingent consideration liabilities | $ | 13,638 | | | $ | 12,289 | |
| Liabilities for unrecognized tax benefits | 5,970 | | | 5,680 | |
| Income taxes payable | 3,442 | | | 3,847 | |
| Pension and other post-employment benefits | 3,153 | | | 3,413 | |
| Other | 2,498 | | | 2,378 | |
| Other long-term liabilities | $ | 28,701 | | | $ | 27,607 | |
|
| | | | | | | |
| as of December 31 (in millions) | 2018 | | 2017 |
| Income taxes payable | $ | 4,311 |
| | $ | 4,675 |
|
| Contingent consideration liabilities | 4,306 |
| | 4,266 |
|
| Liabilities for unrecognized tax benefits | 2,726 |
| | 2,683 |
|
| Pension and other post-employment benefits | 1,840 |
| | 2,740 |
|
| Other | 1,307 |
| | 1,241 |
|
| Other long-term liabilities | $ | 14,490 |
| | $ | 15,605 |
|
| | | | | | | | | | | |
| | 2021 Form 10-K | | 60 |
Note 4 Earnings Per Share
AbbVie grants certain restricted stock awards (RSAs) and restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.
|
| | |
| | 2018 Form 10-K | 55
|
The following table summarizes the impact of the two-class method:
|
| | | | | | | | | | | |
| | Years ended December 31, |
| (in millions, except per share information) | 2018 | | 2017 | | 2016 |
| Basic EPS | | | | | |
| Net earnings | $ | 5,687 |
| | $ | 5,309 |
| | $ | 5,953 |
|
| Earnings allocated to participating securities | 30 |
| | 26 |
| | 30 |
|
| Earnings available to common shareholders | $ | 5,657 |
|
| $ | 5,283 |
|
| $ | 5,923 |
|
| Weighted-average basic shares outstanding | 1,541 |
| | 1,596 |
| | 1,622 |
|
| Basic earnings per share | $ | 3.67 |
| | $ | 3.31 |
| | $ | 3.65 |
|
| | | | | | |
| Diluted EPS | | | | | |
| Net earnings | $ | 5,687 |
| | $ | 5,309 |
| | $ | 5,953 |
|
| Earnings allocated to participating securities | 30 |
| | 26 |
| | 30 |
|
| Earnings available to common shareholders | $ | 5,657 |
| | $ | 5,283 |
| | $ | 5,923 |
|
| Weighted-average shares of common stock outstanding | 1,541 |
| | 1,596 |
| | 1,622 |
|
| Effect of dilutive securities | 5 |
| | 7 |
| | 9 |
|
| Weighted-average diluted shares outstanding | 1,546 |
| | 1,603 |
| | 1,631 |
|
| Diluted earnings per share | $ | 3.66 |
| | $ | 3.30 |
| | $ | 3.63 |
|
As further described in Note 12, AbbVie entered into and executed an accelerated share repurchase agreement (ASR) with a third party financial institution in 2016. For purposes of calculating EPS, AbbVie reflected the ASR as a repurchase of AbbVie common stock. | | | | | | | | | | | | | | | | | |
| Years ended December 31, |
| (in millions, except per share data) | 2021 | | 2020 | | 2019 |
| Basic EPS | | | | | |
| Net earnings attributable to AbbVie Inc. | $ | 11,542 | | | $ | 4,616 | | | $ | 7,882 | |
| Earnings allocated to participating securities | 74 | | | 60 | | | 40 | |
| Earnings available to common shareholders | $ | 11,468 | | | $ | 4,556 | | | $ | 7,842 | |
| Weighted average basic shares of common stock outstanding | 1,770 | | | 1,667 | | | 1,481 | |
| Basic earnings per share attributable to AbbVie Inc. | $ | 6.48 | | | $ | 2.73 | | | $ | 5.30 | |
| | | | | |
| Diluted EPS | | | | | |
| Net earnings attributable to AbbVie Inc. | $ | 11,542 | | | $ | 4,616 | | | $ | 7,882 | |
| Earnings allocated to participating securities | 74 | | | 60 | | | 40 | |
| Earnings available to common shareholders | $ | 11,468 | | | $ | 4,556 | | | $ | 7,842 | |
| Weighted average shares of common stock outstanding | 1,770 | | | 1,667 | | | 1,481 | |
| Effect of dilutive securities | 7 | | | 6 | | | 3 | |
| Weighted average diluted shares of common stock outstanding | 1,777 | | | 1,673 | | | 1,484 | |
| Diluted earnings per share attributable to AbbVie Inc. | $ | 6.45 | | | $ | 2.72 | | | $ | 5.28 | |
Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
Note 5 Licensing, Acquisitions and Other Arrangements
Acquisition of Stemcentrx
Allergan
On June 1, 2016,May 8, 2020, AbbVie acquiredcompleted its acquisition of all of the outstanding equity interests in Stemcentrx,Allergan in a privately-held biotechnology company.cash and stock transaction. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The transaction expanded AbbVie’scombination created a diverse entity with leadership positions across immunology, hematologic oncology, aesthetics, neuroscience, eye care and women's health. AbbVie's existing product portfolio and pipeline by addingis enhanced with numerous Allergan assets and Allergan's product portfolio benefits from AbbVie's commercial strength, expertise and international infrastructure. Under the late-stage asset rovalpituzumab tesirine (Rova-T), four additional early-stage clinical compoundsterms of the acquisition, each ordinary share of Allergan common stock was converted into the right to receive (i) $120.30 in solid tumor indicationscash and (ii) 0.8660 of a significant portfolioshare of pre-clinical assets. Rova-TAbbVie common stock.
Total consideration for the acquisition of Allergan is currently in registrational trialssummarized as follows: | | | | | |
| (in millions) | |
Cash consideration paid to Allergan shareholders (a) | $ | 39,675 | |
Fair value of AbbVie common stock issued to Allergan shareholders (b) | 23,979 | |
Fair value of AbbVie equity awards issued to Allergan equity award holders (c) | 430 | |
| Total consideration | $ | 64,084 | |
(a)Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing.
| | | | | | | | | | | |
61 | |2021 Form 10-K | | |
(b)Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for small cell lung cancer.each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share.
(c)Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.
The acquisition of Stemcentrx wasAllergan has been accounted for as a business combination using the acquisition method of accounting. The aggregate upfront consideration foracquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of Stemcentrx consistedassets acquired and liabilities assumed was finalized during the second quarter of approximately 62.4 million shares2021. Measurement period adjustments to the preliminary purchase price allocation during 2021 included (i) an increase to intangible assets of AbbVie common stock, issued$710 million; (ii) an increase to deferred income tax liabilities of $148 million; (iii) other individually insignificant adjustments for a net increase to identifiable net assets of $2 million; and (iv) a corresponding decrease to goodwill of $564 million. The measurement period adjustments primarily resulted from common stock held in treasury,the completion of the valuation of certain license agreement intangible assets based on facts and cash. AbbVie may make certain contingent payments upon the achievement of defined development and regulatory milestones. Ascircumstances that existed as of the acquisition date and did not result from intervening events subsequent to such date. These adjustments did not have a significant impact on AbbVie's results of operations in 2021 and would not have had a significant impact on prior period results if these adjustments had been made as of the maximum aggregate amount payable for development and regulatory milestones was $4.0 billion. The acquisition-date fair value of these milestones was $620 million and was estimated using a combination of probability-weighted discounted cash flow models and Monte Carlo simulation models. The estimate was determined based on significant inputs that are not observable in the market, referred to as Level 3 inputs, as described in more detail in Note 10.acquisition date.
The following table summarizes total consideration:
|
| | | |
| (in millions) | |
| Cash | $ | 1,883 |
|
| Fair value of AbbVie common stock | 3,923 |
|
| Contingent consideration | 620 |
|
| Total consideration | $ | 6,426 |
|
|
| | |
56 |2018 Form 10-K
| | |
The following table summarizes the final fair valuesvalue of assets acquired and liabilities assumed as of the June 1, 2016 acquisition date: | | | | | |
| (in millions) | |
| Assets acquired and liabilities assumed | |
| Cash and equivalents | $ | 1,537 | |
| Short-term investments | 1,421 | |
| Accounts receivable | 2,374 | |
| Inventories | 2,340 | |
| Prepaid expenses and other current assets | 1,982 | |
| Investments | 137 | |
| Property and equipment | 2,129 | |
| Intangible assets | |
| Definite-lived intangible assets | 68,190 | |
| In-process research and development | 1,600 | |
| Other noncurrent assets | 1,395 | |
| Short-term borrowings | (60) | |
| Current portion of long-term debt and finance lease obligations | (1,899) | |
| Accounts payable and accrued liabilities | (5,852) | |
| Long-term debt and finance lease obligations | (18,937) | |
| Deferred income taxes | (3,940) | |
| Other long-term liabilities | (4,765) | |
| |
| Total identifiable net assets | 47,652 | |
| Goodwill | 16,432 | |
| Total assets acquired and liabilities assumed | $ | 64,084 | |
|
| | | |
| (in millions) | |
| Assets acquired and liabilities assumed | |
| Accounts receivable | $ | 1 |
|
| Prepaid expenses and other | 7 |
|
| Property and equipment | 17 |
|
| Intangible assets - Indefinite-lived research and development | 6,100 |
|
| Accounts payable and accrued liabilities | (31 | ) |
| Deferred income taxes | (1,933 | ) |
| Other long-term liabilities | (7 | ) |
| Total identifiable net assets | 4,154 |
|
| Goodwill | 2,272 |
|
| Total assets acquired and liabilities assumed | $ | 6,426 |
|
The fair value step-up adjustment to inventories of $1.2 billion was amortized to cost of products sold when the inventory was sold to customers and was fully amortized as of December 31, 2021.
Intangible assets were relatedrelate to IPR&D for Rova-T, four additional early-stage clinical compounds in solid tumor indications$68.2 billion of definite-lived intangible assets and several additional pre-clinical compounds.$1.6 billion of IPR&D. The acquired definite-lived intangible assets consist of developed product rights and license agreements and are being amortized over a weighted-average estimated useful life of approximately twelve years using the estimated pattern of economic benefit. The estimated fair valuevalues of the acquired IPR&D wasidentifiable intangible assets were determined using the multi-period excess earnings model of the “income approach,”"income approach" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of thosethese asset valuations include the estimated annualnet cash flows for each year for each asset or product, (including net revenues, cost of sales, R&D costs, selling and marketing costs and working capital/contributory asset charges), the appropriate discount rate to select in ordernecessary to measure the risk inherent in each future cash flow stream, the assessmentlife cycle of each asset’s life cycle,asset, the potential regulatory approval probabilities,and commercial success risks,risk, competitive landscapetrends impacting the asset and each cash flow stream, as well as other factors. See Note 7 for additional information on the 2018 partial impairment of Stemcentrx-related intangible assets.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 62 |
The fair value of long-term debt was determined by quoted market prices as of the acquisition date and the total purchase price adjustment of $1.3 billion is being amortized as a reduction to interest expense, net over the lives of the related debt.
Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized represented expectedfrom the acquisition of Allergan represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies includingand cost savings from the ability to: (i) leverage the respective strengths of each business; (ii) expand the combined company’s product portfolio; (iii) accelerate AbbVie's clinical and commercial presence in oncology; and (iv) establish a strong leadership position in oncology. Goodwill was also impacted by the establishmentcreation of a deferred tax liability for the acquired identifiable intangible assets which have no tax basis.single combined global organization. The goodwill is not deductible for tax purposes.
Following the acquisition date, the operating results of StemcentrxAllergan have been included in the company'sconsolidated financial statements. AbbVie’sFor the period from the acquisition date through December 31, 2020, net revenues attributable to Allergan were $10.3 billion and operating losses attributable to Allergan were $1.1 billion, inclusive of $4.0 billion of intangible asset amortization and $1.2 billion of inventory fair value step-up amortization.
Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $781 million for the year ended December 31, 2020 and $103 million for the year ended December 31, 2019 which were included in SG&A expenses in the consolidated statements of earnings. In the fourth quarter of 2021, AbbVie recovered certain acquisition-related regulatory fees totaling $401 million which was recorded as a reduction to SG&A expenses in the consolidated statement of earnings for the year ended December 31, 2016 included no net revenues and an operating loss of $165 million associated with Stemcentrx's operations. This operating loss included $43 million of post-acquisition stock-based compensation expense for Stemcentrx options and excluded interest expense and certain acquisition costs.2021.
Pro Forma Financial Information
The following table presents the unaudited pro forma combined results of operations of AbbVie and StemcentrxAllergan for the year ended December 31, 20162020 and 2019 as if the acquisition of StemcentrxAllergan had occurred on January 1, 2015:
|
| | | |
| year ended December 31 (in millions, except per share information) | 2016 |
| Net revenues | $ | 25,641 |
|
| Net earnings | 5,907 |
|
| Basic earnings per share | $ | 3.58 |
|
| Diluted earnings per share | $ | 3.56 |
|
2019: | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | | 2020 | | 2019 |
| Net revenues | | $ | 50,521 | | | $ | 49,028 | |
| Net earnings (loss) | | 6,746 | | | (38) | |
The unaudited pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of AbbVie and Stemcentrx.Allergan. In order to reflect the occurrence of the acquisition on January 1, 20152019 as required, the unaudited pro forma financial information includes adjustments to reflect incremental amortization expense to be incurred based on the final fair values of the identifiable intangible assets acquired; the incremental cost of products sold related to the fair value adjustments associated with acquisition date inventory; the additional interest expense associated with the issuance of debt to finance the acquisitionacquisition; and the reclassification of acquisition, integration and financing-relatedacquisition-related costs incurred during the year ended December 31, 20162020 to the year ended December 31,
|
| | |
| | 2018 Form 10-K | 57
|
2015. 2019. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2015.2019. In addition, the unaudited pro forma financial information is not a projection of the future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings or synergies associated with the acquisition.
Acquisition of BI 655066Soliton, Inc.
In December 2021, AbbVie completed its previously announced acquisition of Soliton, Inc. (Soliton). Soliton's RESONIC (Rapid Acoustic Pulse device) has U.S. Food and BI 655064 from Boehringer Ingelheim
On April 1, 2016, AbbVie acquired all rights to risankizumab (BI 655066), an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis, from Boehringer Ingelheim (BI) pursuant to a global collaboration agreement. AbbVie is also evaluating the potential of this biologic therapy in other indications, including Crohn’s disease, psoriatic arthritis and ulcerative colitis. In addition to risankizumab, AbbVie also gained rights to an anti-CD40 antibody, BI 655064, currently in Phase 1 development. BI will retain responsibility for further development of BI 655064, and AbbVie may elect to advance the program after completion of certain clinical achievements. The acquired assets include all patents, data, know-how, third-party agreements, regulatory filings and manufacturing technology related to BI 655066 and BI 655064.
The company concluded that the acquired assets met the definition of a business and accountedDrug Administration (FDA) 510(k) clearance for the long-term improvement in the appearance of cellulite up to one year. The transaction was accounted for as a business combination using the acquisition method of accounting. UnderTotal consideration transferred allocated to the termspurchase price consisted of cash consideration of $535 million paid to holders of Soliton common stock, equity-based awards and warrants. As of the agreement,transaction date, AbbVie made an upfront payment of $595 million. Additionally, $18acquired $407 million of paymentsintangible assets for developed product rights and assumed deferred tax liabilities totaling $63 million. Other assets and liabilities were insignificant. The acquisition resulted in the recognition of $177 million of goodwill which is not deductible for tax purposes.
Acquisition of Luminera
In October 2020, AbbVie entered into an agreement with Luminera, a privately held aesthetics company based in Israel, to BI, pursuant toacquire Luminera's full dermal filler portfolio and R&D pipeline including HArmonyCa, a contractual obligation to reimburse BIdermal filler intended for certain development costs it incurred prior tofacial soft tissue augmentation. The aggregate accounting purchase price of $186 million was comprised of a $122 million upfront cash payment and $64 million for the acquisition date were initially deferred.fair value of contingent consideration liabilities, for which AbbVie may make certain contingentowe up to $90 million in future payments upon the achievement of defined development, regulatory andcertain commercial milestones,milestones. The agreement was accounted for as well as royalty payments based on net revenuesa business combination using the acquisition method of licensed products.accounting. As of the acquisition date, the maximum aggregate amount payableAbbVie acquired $127 million of intangible assets for in-process research and development and regulatory milestones was approximately $1.6 billion. The acquisition-date fair value$33 million of these milestones was $606 million. The acquisition-date fair value of contingent royalty payments was $2.8 billion. The potential contingent consideration payments were estimated by applying a probability-weighted expected payment modelintangible assets for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which were then discounted to present value. The fair value measurements were based on Level 3 inputs.developed
The following table summarizes total consideration:
|
| | | |
| (in millions) | |
| Cash | $ | 595 |
|
| Deferred consideration payable | 18 |
|
| Contingent consideration | 3,365 |
|
| Total consideration | $ | 3,978 |
|
| | | | | | | | | | | |
63 | |2021 Form 10-K | | |
The following table summarizes fair values of assets acquired as of the April 1, 2016 acquisition date:
|
| | | |
| (in millions) | |
| Assets acquired | |
| Identifiable intangible assets - Indefinite-lived research and development | $ | 3,890 |
|
| Goodwill | 88 |
|
| Total assets acquired | $ | 3,978 |
|
product rights. Other assets and liabilities assumed were insignificant. The estimated fair valueacquisition resulted in the recognition of the acquired IPR&D was determined using the multi-period excess earnings model$12 million of the “income approach.” The goodwill recognized represented expected synergies, including an expansion of the company’s immunology product portfolio.
Pro forma results of operationswhich is not deductible for this acquisition have not been presented because this acquisition was insignificant to AbbVie’s consolidated results of operations.tax purposes.
Other Licensing & Acquisitions Activity
Excluding the acquisitions above, cashCash outflows related to other acquisitions and investments totaled $736 million$1.4 billion in 2018, $308 million2021, $1.4 billion in 20172020 and $262 million$1.1 billion in 2016.2019. AbbVie recorded acquired IPR&D charges of $424$962 million in 2018, $3272021, $1.2 billion in 2020 and $385 million in 2017 and $200 million in 2016.2019. Significant arrangements impacting 2018, 20172021, 2020 and 2016,2019, some of which require contingent milestone payments, are summarized below.
|
| | |
58 |2018 Form 10-K
| | |
Calico Life Sciences LLC
In June 2018,July 2021, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of atheir collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second collaboration extension and builds on the partnership established in 2014 and extended in 2018. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million to the collaboration and the term is extended for an additional 3three years. AbbVie’s contribution is payable in two equal installments beginning in 2023. Calico will be responsible for research and early development until 20222025 and will advance collaboration projects throughinto Phase 2a through 2027.2030. Following completion of the Phase 2a studies, AbbVie will have the option to exclusively license the collaboration compounds. Upon exercise, AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During 2018,the third quarter of 2021, AbbVie recorded $500 million inas other operating expense in the consolidated statement of earnings related to its commitments under the agreement.
Alector, Inc.TeneoOne and TNB-383B
In October 2017,September 2021, AbbVie acquired TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered into a global strategic collaboration with Alector, Inc. (Alector)transaction to develop and commercialize medicinesTNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to treat Alzheimer’s diseasedirect the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study and accounted for the transaction as an asset acquisition. Under the terms of the agreement, AbbVie made an exercise payment of $400 million which was recorded to IPR&D in the consolidated statement of earnings in the third quarter of 2021. The agreement also included additional payments of up to $250 million upon the achievement of certain development, regulatory and commercial milestones.
REGENXBIO Inc.
In September 2021, AbbVie and REGENXBIO Inc. (REGENXBIO) entered into a collaboration to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other neurodegenerative disorders.chronic retinal diseases. The collaboration provides AbbVie with an exclusive global license to develop and commercialize RGX-314. REGENXBIO will be responsible for completion of ongoing trials, AbbVie and Alector have agreed to research a portfolioREGENXBIO will collaborate and share costs of antibody targetsadditional trials, and AbbVie has an option to globalwill lead the clinical development and commercialization of RGX-314 globally. REGENXBIO and AbbVie will share equally in pre-tax profits from net revenues of RGX-314 in the U.S. and AbbVie will pay REGENXBIO tiered royalties on net revenues outside the U.S. Upon closing in the fourth quarter of 2021, AbbVie made an upfront payment of $370 million to exclusively license RGX-314 which was recorded to IPR&D in the consolidated statement of earnings for the year ended December 31, 2021. The agreement also included additional payments of up to $1.4 billion upon the achievement of certain development, regulatory and commercial rightsmilestones.
I-Mab Biopharma
In September 2020, AbbVie and I-Mab Biopharma (I-Mab) entered into a collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. Both companies will collaborate to two targets.design and conduct further global clinical trials to evaluate lemzoparlimab. The collaboration provides AbbVie an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The agreement also allows for potential collaboration on future CD47-related therapeutic agents, subject to further licenses to explore each other's related programs in their respective territories. The terms of the arrangement includedinclude an initial upfront payment of $205$180 million to exclusively license lemzoparlimab along with a milestone payment of $20 million based on the Phase I results, for a total of $200 million, which was expensedrecorded to IPR&D in the consolidated statement of earnings in the fourth quarter of 2017. Alector2020 after regulatory approval of the transaction. In addition, I-Mab will be eligible to receive up to $1.7 billion upon the achievement of certain clinical development, regulatory and
| | | | | | | | | | | |
| | 2021 Form 10-K | | 64 |
commercial milestones, and AbbVie will pay tiered royalties from low-to-mid teen percentages on global net revenues outside of greater China.
Genmab A/S
In June 2020, AbbVie and Genmab A/S (Genmab) entered into a collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody therapeutics and entered into a discovery research collaboration for future differentiated antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab granted to AbbVie an exclusive license to its epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 programs. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will record net revenues in the U.S. and Japan, and the parties will share equally in pre-tax profits from these sales. Genmab will receive tiered royalties on remaining global sales. For the discovery research partnership, Genmab will conduct exploratory research, drug discoveryPhase 1 studies for these programs and development for lead programs upAbbVie retains the right to opt-in to program development. During 2020, AbbVie made an upfront payment of $750 million, which was recorded to IPR&D in the conclusionconsolidated statement of the proof of concept studies. If the option is exercised,earnings. AbbVie will lead development and commercialization activities and could make additional payments to Alector of up to $986 million$3.2 billion upon the achievement of certain development, regulatory and regulatory milestones. Alectorcommercial milestones for all programs.
Reata Pharmaceuticals, Inc.
In October 2019, AbbVie and Reata Pharmaceuticals, Inc. (Reata) entered into an amended and restated license agreement. Under the terms of the agreement, Reata reacquired exclusive development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie for territories outside of the United States with respect to bardoxolone methyl and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators. As consideration for the rights reacquired by Reata, AbbVie received a total of $250 million as of December 31, 2020 and $80 million in cash in 2021. Total consideration of $330 million was recognized in other operating (income) expense in the consolidated statement of earnings in 2019. In addition, AbbVie will co-fund developmentreceive low single-digit, tiered royalties from worldwide sales of omaveloxolone and commercialization and will share global profits equally.certain next-generation Nrf2 activators.
Other Arrangements
In addition to the significant arrangements described above, AbbVie entered into several other arrangements resulting in charges to IPR&D of $424$192 million in 2018, $1222021, $248 million in 20172020 and $200$385 million in 2016.2019. In connection with the other individually insignificant early-stage arrangements entered into in 2018,2021, AbbVie could make additional payments of up to $4.8$5.5 billion upon the achievement of certain development, regulatory and commercial milestones.
The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting 2021, 2020 and 2019.
Collaboration with Janssen Biotech, Inc.
In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA,Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA,Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.
The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICAImbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.
| | | | | | | | | | | |
65 | |2021 Form 10-K | | |
In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICAImbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.
Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA.Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.
|
| | |
| | 2018 Form 10-K | 59
|
The following table shows the profit and cost sharing relationship between Janssen and AbbVie:
|
| | | | | | | | | | | | |
| years ended December 31 (in millions) | | 2018 | | 2017 | | 2016 |
| United States - Janssen's share of profits (included in cost of products sold) | | $ | 1,372 |
| | $ | 1,001 |
| | $ | 735 |
|
| International - AbbVie's share of profits (included in net revenues) | | 622 |
| | 429 |
| | 252 |
|
| Global - AbbVie's share of other costs (included in respective line items) | | 326 |
| | 288 |
| | 262 |
|
| | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| United States - Janssen's share of profits (included in cost of products sold) | $ | 2,018 | | | $ | 2,012 | | | $ | 1,803 | |
| International - AbbVie's share of profits (included in net revenues) | 1,087 | | | 1,009 | | | 844 | |
| Global - AbbVie's share of other costs (included in respective line items) | 304 | | | 295 | | | 321 | |
AbbVie’s receivable from Janssen, included in accounts receivable, net, was $177$294 million at December 31, 20182021 and $124$283 million at December 31, 2017.2020. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $376$509 million at December 31, 20182021 and $253$562 million at December 31, 2017.2020.
Collaboration with Genentech, Inc. AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States.
AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie's net revenues. Genentech's share of United States profits is included in AbbVie's cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of SG&A expenses and global development costs as part of R&D expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold.
The following table shows the profit and cost sharing relationship between Genentech and AbbVie: | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Genentech's share of profits, including royalties (included in cost of products sold) | $ | 703 | | | $ | 533 | | | $ | 320 | |
| AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) | 40 | | | 46 | | | 41 | |
| AbbVie's share of development costs (included in R&D) | 140 | | | 129 | | | 128 | |
| | | | | | | | | | | |
| | 2021 Form 10-K | | 66 |
Note 7 Goodwill and Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill: | | | | | |
| (in millions) | |
| Balance as of December 31, 2019 | $ | 15,604 | |
Additions(a) | 17,008 | |
| Foreign currency translation adjustments | 512 | |
| Balance as of December 31, 2020 | 33,124 | |
Additions(b) | 177 | |
Measurement period adjustments(c) | (564) | |
| Foreign currency translation adjustments and other | (358) | |
| Balance as of December 31, 2021 | $ | 32,379 | |
(a)Goodwill additions related to the acquisition of Allergan in the second quarter of 2020 and the acquisition of Luminera in the fourth quarter of 2020 (see Note 5). |
| | | |
| (in millions) | |
| Balance as of December 31, 2016 | $ | 15,416 |
|
| Foreign currency translation | 369 |
|
| Balance as of December 31, 2017 | 15,785 |
|
| Foreign currency translation | (122 | ) |
| Balance as of December 31, 2018 | $ | 15,663 |
|
(c)Measurement period adjustments recorded in 2021 related to the acquisition of Allergan (see Note 5).
The latestcompany performs its annual goodwill impairment assessment of goodwill was completed in the third quarter of 2018. As of December 31, 2018, there were no accumulated goodwill impairment losses. Future impairment tests for goodwill will be performed annually in the third quarter, or earlier if impairment indicators exist. As of December 31, 2021, there were no accumulated goodwill impairment losses.
Intangible Assets, Net
The following table summarizes intangible assets: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2021 | | 2020 |
| as of December 31 (in millions) | Gross
carrying
amount | | Accumulated
amortization | | Net
carrying
amount | | Gross
carrying
amount | | Accumulated
amortization | | Net
carrying
amount |
| Definite-lived intangible assets | | | | | | | | | | | |
| Developed product rights | $ | 88,945 | | | $ | (18,463) | | | $ | 70,482 | | | $ | 87,707 | | | $ | (11,620) | | | $ | 76,087 | |
| License agreements | 8,487 | | | (3,688) | | | 4,799 | | | 7,828 | | | (2,916) | | | 4,912 | |
| Total definite-lived intangible assets | 97,432 | | | (22,151) | | | 75,281 | | | 95,535 | | | (14,536) | | | 80,999 | |
| Indefinite-lived research and development | 670 | | | — | | | 670 | | | 1,877 | | | — | | | 1,877 | |
| Total intangible assets, net | $ | 98,102 | | | $ | (22,151) | | | $ | 75,951 | | | $ | 97,412 | | | $ | (14,536) | | | $ | 82,876 | |
|
| | | | | | | | | | | | | | | | | | | | | | | |
| | 2018 | | 2017 |
| as of December 31 (in millions) | Gross carrying amount | | Accumulated amortization | | Net carrying amount | | Gross carrying amount | | Accumulated amortization | | Net carrying amount |
| Definite-lived intangible assets | | | | | | | | | | | |
| Developed product rights | $ | 15,872 |
| | $ | (5,614 | ) | | $ | 10,258 |
| | $ | 16,138 |
| | $ | (4,982 | ) | | $ | 11,156 |
|
| License agreements | 7,865 |
| | (1,810 | ) | | 6,055 |
| | 7,822 |
| | (1,409 | ) | | 6,413 |
|
| Total definite-lived intangible assets | 23,737 |
| | (7,424 | ) | | 16,313 |
| | 23,960 |
| | (6,391 | ) | | 17,569 |
|
| Indefinite-lived research and development | 4,920 |
| | — |
| | 4,920 |
| | 9,990 |
| | — |
| | 9,990 |
|
| Total intangible assets, net | $ | 28,657 |
| | $ | (7,424 | ) | | $ | 21,233 |
| | $ | 33,950 |
| | $ | (6,391 | ) | | $ | 27,559 |
|
Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. Indefinite-lived intangible assets as of December 31, 2018 and 2017 related to the acquisitions of Stemcentrx and BI compounds. See Note 5 for additional information. The latest annual impairment assessment of indefinite-lived intangible assets was completed in the third quarter of 2018 which supported that no impairment existed at that time.
During the fourth quarter of 2018, the company made a decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rova-T as a second-line therapy for advanced small cell lung cancer following a recommendation from an Independent Data Monitoring Committee. This decision lowered the probabilities of success of achieving regulatory approval across Rova-T and other early-stage assets and represented a triggering event which required the company to evaluate for impairment the IPR&D assets associated with the Stemcentrx acquisition. The company utilized multi-period excess earnings models of the “income approach” and determined that the current fair value was $1.0 billion as of December 31, 2018, which was lower than the carrying value of $6.1 billion and resulted in a pre-tax impairment charge of $5.1 billion ($4.5 billion after
|
| | |
60 |2018 Form 10-K
| | |
tax). The fair value measurements were based on Level 3 inputs. Some of the more significant assumptions inherent in the development of the models included the estimated annual cash flows for each asset (including net revenues, cost of sales, R&D costs, selling and marketing costs and working capital/contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the regulatory approval probabilities, commercial success risks, competitive landscape as well as other factors. This impairment charge was recorded to R&D expense in the consolidated statement of earnings for the year ended December 31, 2018. AbbVie continues to evaluate information as it becomes available with respect to the Stemcentrx-related clinical development programs and will monitor the remaining IPR&D assets for further impairment.
No indefinite-lived intangible asset impairment charges were recorded in 2017 and 2016. Future impairment tests for indefinite-lived intangible assets will be performed annually in the third quarter, or earlier if impairment indicators exist.
Definite-Lived Intangible Assets
The increase in definite-lived intangible assets during 2021 was primarily due to the measurement period adjustments from the completion of the valuation of certain license agreements acquired in the Allergan acquisition as well as the acquisition of Soliton. Refer to Note 5 for additional information regarding these acquisitions and related adjustments. In 2021, AbbVie also reclassified $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving certain regulatory approvals for Vuity, Qulipta, and HArmonyCa.
Definite-lived intangible assets are amortized over their estimated useful lives, which range between 21 to 16 years with an average of 1112 years for both developed product rights and 11 years for license agreements. Amortization expense was $1.3$7.7 billion in 2018, $1.12021, $5.8 billion in 20172020 and $764 million$1.6 billion in 20162019 and was included in cost of products sold in the consolidated statements of earnings. The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 20182021 is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in billions) | 2022 | | 2023 | | 2024 | | 2025 | | 2026 |
| Anticipated annual amortization expense | $ | 7.2 | | | $ | 7.5 | | | $ | 8.0 | | | $ | 8.4 | | | $ | 7.9 | |
|
| | | | | | | | | | | | | | | | | | | |
| (in billions) | 2019 | | 2020 | | 2021 | | 2022 | | 2023 |
| Anticipated annual amortization expense | $ | 1.5 |
| | $ | 1.7 |
| | $ | 1.9 |
| | $ | 2.1 |
| | $ | 2.2 |
|
No definite-lived | | | | | | | | | | | |
67 | |2021 Form 10-K | | |
Indefinite-Lived Intangible Assets
Indefinite-lived intangible assetassets represent acquired IPR&D associated with products that have not yet received regulatory approval. Indefinite-lived intangible assets as of December 31, 2021 primarily relate to the acquisition of Allergan.
The company performs its annual impairment charges wereassessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.
In 2019, following the announcement of the decision to terminate the rovalpituzumab tesirine (Rova-T) R&D program, the company recorded in 2018. In 2017, an impairment charge of $354 million$1.0 billion which represented the remaining value of the IPR&D acquired as part of the 2016 Stemcentrx acquisition. The impairment charge was recorded related to ZINBRYTA that reduced both the gross carrying amount and net carrying amount of the underlying intangible assets due to lower expected future cash flows for the product. In 2016, an impairment charge of $39 million was recorded related to certain developed product rights in the United States due to a decline in the market for the product. The 2017 and 2016 impairment charges were based on discounted cash flow analyses and were included in cost of products soldR&D expense in the consolidated statements of earnings.earnings in 2019.
Note 8 Integration and Restructuring Plans
Allergan Integration Plan
Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion of charges through 2022. These costs will consist of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.
The following table summarizes the charges associated with the Allergan acquisition integration plan: | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Severance and employee benefits | | Other integration |
| year ended December 31 (in millions) | | 2021 | | 2020 | | 2021 | | 2020 |
| Cost of products sold | | $ | 5 | | | $ | 109 | | | $ | 127 | | | $ | 21 | |
| Research and development | | — | | | 199 | | | 102 | | | 177 | |
| Selling, general and administrative | | 64 | | | 388 | | | 289 | | | 237 | |
| Total charges | | $ | 69 | | | $ | 696 | | | $ | 518 | | | $ | 435 | |
The following table summarizes the cash activity in the recorded liability associated with the integration plan: | | | | | | | | | | | | |
| year ended December 31 (in millions) | Severance and employee benefits | | | Other integration |
| | | | |
| Charges | $ | 594 | | | | $ | 435 | |
| Payments and other adjustments | (227) | | | | (415) | |
| Accrued balance as of December 31, 2020 | $ | 367 | | | | $ | 20 | |
| Charges | 65 | | | | 461 | |
| Payments and other adjustments | (210) | | | | (448) | |
| Accrued balance as of December 31, 2021 | $ | 222 | | | | $ | 33 | |
Other Restructuring
AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. In 2018, 20172021, 2020 and 2016,2019, no such plans were individually significant. Restructuring charges recorded were $70$59 million in 2018, $862021, $60 million in 20172020 and $52$234 million in 20162019 and were primarily related to employee severance and contractual obligations. These charges were recorded in cost of products sold, R&D expense and SG&A expenses in the consolidated statements of earnings based on the classification of the affected employees or operations.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 68 |
The following table summarizes the cash activity in the restructuring reserve for 2018, 20172021, 2020 and 2016:2019:
|
| | | |
| (in millions) | |
| Accrued balance as of December 31, 2015 | $ | 148 |
|
| 2016 restructuring charges | 52 |
|
| Payments and other adjustments | (113 | ) |
| Accrued balance as of December 31, 2016 | 87 |
|
| 2017 restructuring charges | 86 |
|
| Payments and other adjustments | (87 | ) |
| Accrued balance as of December 31, 2017 | 86 |
|
| 2018 restructuring charges | 59 |
|
| Payments and other adjustments | (46 | ) |
| Accrued balance as of December 31, 2018 | $ | 99 |
|
| | | | | |
| (in millions) | |
| Accrued balance as of December 31, 2018 | $ | 99 | |
| Restructuring charges | 219 | |
| Payments and other adjustments | (178) | |
| Accrued balance as of December 31, 2019 | 140 | |
| Restructuring charges | 58 | |
| Payments and other adjustments | (108) | |
| Accrued balance as of December 31, 2020 | 90 | |
| Restructuring charges | 54 | |
| Payments and other adjustments | (111) | |
| Accrued balance as of December 31, 2021 | $ | 33 | |
AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets:
| | | | | | | | | | | | | | |
| as of December 31 (in millions) | Balance sheet caption | 2021 | | 2020 |
| Assets | | | | |
| Operating | Other assets | $ | 762 | | | $ | 895 | |
| Finance | Property and equipment, net | 33 | | | 27 | |
| Total lease assets | | $ | 795 | | | $ | 922 | |
| Liabilities | | | | |
| Operating | | | | |
| Current | Accounts payable and accrued liabilities | $ | 178 | | | $ | 175 | |
| Noncurrent | Other long-term liabilities | 713 | | | 832 | |
| Finance | | | | |
| Current | Current portion of long-term debt and finance lease obligations | 9 | | | 8 | |
| Noncurrent | Long-term debt and finance lease obligations | 25 | | | 21 | |
| Total lease liabilities | | $ | 925 | | | $ | 1,036 | |
The following table summarizes the lease costs recognized in the consolidated statements of earnings:
| | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | | 2021 | | 2020 | | 2019 |
| Operating lease cost | | $ | 226 | | | $ | 192 | | | $ | 124 | |
| | | | | | |
| | | | | | |
| | | | | | |
| Short-term lease cost | | 56 | | | 59 | | | 34 | |
| Variable lease cost | | 71 | | | 60 | | | 62 | |
| Total lease cost | | $ | 353 | | | $ | 311 | | | $ | 220 | |
Sublease income and finance lease costs were insignificant in 2021, 2020 and 2019.
| | | | | | | | | | | |
69 | 2018|2021 Form 10-K | | |
The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: | | | | | | | | | | | | | | | | | |
| years ended December 31 | 2021 | | 2020 | | 2019 |
| Weighted-average remaining lease term (years) | | | | | |
| Operating | 7 | | 8 | | 5 |
| Finance | 3 | | 3 | | 3 |
| Weighted-average discount rate | | | | | |
| Operating | 2.4 | % | | 2.5 | % | | 3.9 | % |
| Finance | 1.1 | % | | 1.4 | % | | 3.9 | % |
The following table presents supplementary cash flow information regarding the company's leases: | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Cash paid for amounts included in the measurement of lease liabilities | | | | | |
| Operating cash flows from operating leases | $ | 236 | | | $ | 185 | | | $ | 125 | |
| | | | | |
| | | | | |
| | | | | |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 66 | | | 692 | | | 26 | |
Finance lease cash flows were insignificant in 2021, 2020 and 2019. Right-of-use assets obtained in exchange for new operating lease liabilities as of December 31, 2020 included $453 million of right-of-use assets acquired in the Allergan acquisition.
The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2021: | | | | | | | | | | | | | | | | | |
| (in millions) | Operating
leases | | Finance
leases | | Total (a) |
| 2022 | $ | 179 | | | $ | 9 | | | $ | 188 | |
| 2023 | 162 | | | 9 | | | 171 | |
| 2024 | 126 | | | 7 | | | 133 | |
| 2025 | 105 | | | 5 | | | 110 | |
| 2026 | 91 | | | 9 | | | 100 | |
| Thereafter | 317 | | | — | | | 317 | |
| Total lease payments | 980 | | | 39 | | | 1,019 | |
| Less: Interest | 89 | | | 5 | | | 94 | |
| Present value of lease liabilities | $ | 891 | | | $ | 34 | | | $ | 925 | |
(a)Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
| | | | | | | | | | | |
| | 2021 Form 10-K |61
| 70 |
Note 910 Debt, Credit Facilities and Commitments and Contingencies
The following table summarizes long-term debt: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| as of December 31 (dollars in millions) | Effective interest rate in 2021(a) | | 2021 | | Effective interest rate in 2020(a) | | 2020 | | | | | |
| Senior notes issued in 2012 | | | | | | | | | | | | |
| 2.90% notes due 2022 | 2.97 | % | | $ | 3,100 | | | 2.97 | % | | $ | 3,100 | | | | | | |
| 4.40% notes due 2042 | 4.46 | % | | 2,600 | | | 4.46 | % | | 2,600 | | | | | | |
| Senior notes issued in 2015 | | | | | | | | | | | | |
| 3.20% notes due 2022 | 3.28 | % | | 1,000 | | | 3.28 | % | | 1,000 | | | | | | |
| 3.60% notes due 2025 | 3.66 | % | | 3,750 | | | 3.66 | % | | 3,750 | | | | | | |
| 4.50% notes due 2035 | 4.58 | % | | 2,500 | | | 4.58 | % | | 2,500 | | | | | | |
| 4.70% notes due 2045 | 4.73 | % | | 2,700 | | | 4.73 | % | | 2,700 | | | | | | |
| Senior notes issued in 2016 | | | | | | | | | | | | |
| 2.30% notes due 2021 | 2.40 | % | | — | | | 2.40 | % | | 1,800 | | | | | | |
| 2.85% notes due 2023 | 2.91 | % | | 1,000 | | | 2.91 | % | | 1,000 | | | | | | |
| 3.20% notes due 2026 | 3.28 | % | | 2,000 | | | 3.28 | % | | 2,000 | | | | | | |
| 4.30% notes due 2036 | 4.37 | % | | 1,000 | | | 4.37 | % | | 1,000 | | | | | | |
| 4.45% notes due 2046 | 4.50 | % | | 2,000 | | | 4.50 | % | | 2,000 | | | | | | |
| Senior Euro notes issued in 2016 | | | | | | | | | | | | |
| 1.375% notes due 2024 (€1,450 principal) | 1.46 | % | | 1,643 | | | 1.46 | % | | 1,783 | | | | | | |
| 2.125% notes due 2028 (€750 principal) | 2.18 | % | | 850 | | | 2.18 | % | | 922 | | | | | | |
| Senior notes issued in 2018 | | | | | | | | | | | | |
| 3.375% notes due 2021 | 3.51 | % | | — | | | 3.51 | % | | 1,250 | | | | | | |
| 3.75% notes due 2023 | 3.84 | % | | 1,250 | | | 3.84 | % | | 1,250 | | | | | | |
| 4.25% notes due 2028 | 4.38 | % | | 1,750 | | | 4.38 | % | | 1,750 | | | | | | |
| 4.875% notes due 2048 | 4.94 | % | | 1,750 | | | 4.94 | % | | 1,750 | | | | | | |
| Senior Euro notes issued in 2019 | | | | | | | | | | | | |
| 0.75% notes due 2027 (€750 principal) | 0.86 | % | | 850 | | | 0.86 | % | | 922 | | | | | | |
| 1.25% notes due 2031 (€650 principal) | 1.30 | % | | 737 | | | 1.30 | % | | 799 | | | | | | |
| Senior notes issued in 2019 | | | | | | | | | | | | |
| Floating rate notes due May 2021 | 0.74 | % | | — | | | 1.33 | % | | 750 | | | | | | |
| Floating rate notes due November 2021 | 0.78 | % | | — | | | 1.42 | % | | 750 | | | | | | |
| Floating rate notes due 2022 | 0.99 | % | | 750 | | | 1.62 | % | | 750 | | | | | | |
| 2.15% notes due 2021 | 2.23 | % | | — | | | 2.23 | % | | 1,750 | | | | | | |
| 2.30% notes due 2022 | 2.42 | % | | 3,000 | | | 2.42 | % | | 3,000 | | | | | | |
| 2.60% notes due 2024 | 2.69 | % | | 3,750 | | | 2.69 | % | | 3,750 | | | | | | |
| 2.95% notes due 2026 | 3.02 | % | | 4,000 | | | 3.02 | % | | 4,000 | | | | | | |
| 3.20% notes due 2029 | 3.25 | % | | 5,500 | | | 3.25 | % | | 5,500 | | | | | | |
| 4.05% notes due 2039 | 4.11 | % | | 4,000 | | | 4.11 | % | | 4,000 | | | | | | |
| 4.25% notes due 2049 | 4.29 | % | | 5,750 | | | 4.29 | % | | 5,750 | | | | | | |
| Term loan facilities | | | | | | | | | | | | |
| Floating rate notes due 2023 | 1.23 | % | | — | | | 1.29 | % | | 1,000 | | | | | | |
| Floating rate notes due 2023 | 0.81 | % | | 1,000 | | | — | % | | — | | | | | | |
| Floating rate notes due 2025 | 1.36 | % | | 2,000 | | | 1.42 | % | | 2,000 | | | | | | |
|
| | | | | | | | | | | | | |
| as of December 31 (dollars in millions) | Effective interest rate in 2018(a) | | 2018 | | Effective interest rate in 2017(a) | | 2017 |
| Senior notes issued in 2012 | | | | | | | |
| 2.00% notes due 2018 | 2.15 | % | | $ | — |
| | 2.15 | % | | $ | 1,000 |
|
| 2.90% notes due 2022 | 2.97 | % | | 3,100 |
| | 2.97 | % | | 3,100 |
|
| 4.40% notes due 2042 | 4.46 | % | | 2,600 |
| | 4.46 | % | | 2,600 |
|
| Senior notes issued in 2015 | | | | | | | |
| 1.80% notes due 2018 | 1.92 | % | | — |
| | 1.92 | % | | 3,000 |
|
| 2.50% notes due 2020 | 2.65 | % | | 3,750 |
| | 2.65 | % | | 3,750 |
|
| 3.20% notes due 2022 | 3.28 | % | | 1,000 |
| | 3.28 | % | | 1,000 |
|
| 3.60% notes due 2025 | 3.66 | % | | 3,750 |
| | 3.66 | % | | 3,750 |
|
| 4.50% notes due 2035 | 4.58 | % | | 2,500 |
| | 4.58 | % | | 2,500 |
|
| 4.70% notes due 2045 | 4.73 | % | | 2,700 |
| | 4.73 | % | | 2,700 |
|
| Senior notes issued in 2016 | | | | | | | |
| 2.30% notes due 2021 | 2.40 | % | | 1,800 |
| | 2.40 | % | | 1,800 |
|
| 2.85% notes due 2023 | 2.91 | % | | 1,000 |
| | 2.91 | % | | 1,000 |
|
| 3.20% notes due 2026 | 3.28 | % | | 2,000 |
| | 3.28 | % | | 2,000 |
|
| 4.30% notes due 2036 | 4.37 | % | | 1,000 |
| | 4.37 | % | | 1,000 |
|
| 4.45% notes due 2046 | 4.50 | % | | 2,000 |
| | 4.50 | % | | 2,000 |
|
| Senior Euro notes issued in 2016 | | | | | | | |
| 0.38% notes due 2019 (€1,400 principal) | 0.55 | % | | 1,604 |
| | 0.55 | % | | 1,673 |
|
| 1.38% notes due 2024 (€1,450 principal) | 1.46 | % | | 1,661 |
| | 1.46 | % | | 1,733 |
|
| 2.13% notes due 2028 (€750 principal) | 2.18 | % | | 859 |
| | 2.18 | % | | 896 |
|
| Senior notes issued in 2018 | | | | | | | |
| 3.375% notes due 2021 | 3.51 | % | | 1,250 |
| | — | % | | — |
|
| 3.75% notes due 2023 | 3.84 | % | | 1,250 |
| | — | % | | — |
|
| 4.25% notes due 2028 | 4.38 | % | | 1,750 |
| | — | % | | — |
|
| 4.875% notes due 2048 | 4.94 | % | | 1,750 |
| | — | % | | — |
|
| Term loan facilities | | | | | | | |
| Floating rate notes due 2018 | 3.06 | % | | — |
| | 2.26 | % | | 2,000 |
|
| Other |
|
| | 36 |
| |
|
| | 110 |
|
| Fair value hedges | | | (466 | ) | | | | (401 | ) |
| Unamortized bond discounts | | | (120 | ) | | | | (97 | ) |
| Unamortized deferred financing costs | | | (163 | ) | | | | (146 | ) |
| Total long-term debt and lease obligations | | | 36,611 |
| | | | 36,968 |
|
| Current portion | | | 1,609 |
| | | | 6,015 |
|
| Noncurrent portion | | | $ | 35,002 |
| | | | $ | 30,953 |
|
| | | | | | | | | | | |
(a)71 | Excludes the effect of any related interest rate swaps.|2021 Form 10-K | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| as of December 31 (dollars in millions) | Effective interest rate in 2021(a) | | 2021 | | Effective interest rate in 2020(a) | | 2020 | | | | | |
| Senior notes acquired in 2020 | | | | | | | | | | | | |
| 5.000% notes due 2021 | 1.53 | % | | — | | | 1.53 | % | | 1,200 | | | | | | |
| 3.450% notes due 2022 | 1.97 | % | | 2,878 | | | 1.97 | % | | 2,878 | | | | | | |
| 3.250% notes due 2022 | 1.92 | % | | 1,700 | | | 1.92 | % | | 1,700 | | | | | | |
| 2.800% notes due 2023 | 2.13 | % | | 350 | | | 2.13 | % | | 350 | | | | | | |
| 3.850% notes due 2024 | 2.07 | % | | 1,032 | | | 2.07 | % | | 1,032 | | | | | | |
| 3.800% notes due 2025 | 2.09 | % | | 3,021 | | | 2.09 | % | | 3,021 | | | | | | |
| 4.550% notes due 2035 | 3.52 | % | | 1,789 | | | 3.52 | % | | 1,789 | | | | | | |
| 4.625% notes due 2042 | 4.00 | % | | 457 | | | 4.00 | % | | 457 | | | | | | |
| 4.850% notes due 2044 | 4.11 | % | | 1,074 | | | 4.11 | % | | 1,074 | | | | | | |
| 4.750% notes due 2045 | 4.20 | % | | 881 | | | 4.20 | % | | 881 | | | | | | |
| Senior Euro notes acquired in 2020 | | | | | | | | | | | | |
| 0.500% notes due 2021 (€750 principal) | 0.72 | % | | — | | | 0.72 | % | | 922 | | | | | | |
| 1.500% notes due 2023 (€500 principal) | 0.49 | % | | 567 | | | 0.49 | % | | 615 | | | | | | |
| 1.250% notes due 2024 (€700 principal) | 0.65 | % | | 793 | | | 0.65 | % | | 861 | | | | | | |
| 2.625% notes due 2028 (€500 principal) | 1.20 | % | | 567 | | | 1.20 | % | | 615 | | | | | | |
| 2.125% notes due 2029 (€550 principal) | 1.19 | % | | 623 | | | 1.19 | % | | 677 | | | | | | |
| Other | | | 33 | | | | | 29 | | | | | | |
| Fair value hedges | | | 102 | | | | | 278 | | | | | | |
| Unamortized bond discounts | | | (130) | | | | | (146) | | | | | | |
| Unamortized deferred financing costs | | | (251) | | | | | (287) | | | | | | |
Unamortized bond premiums (b) | | | 954 | | | | | 1,200 | | | | | | |
| Total long-term debt and finance lease obligations | | | 76,670 | | | | | 86,022 | | | | | | |
| Current portion | | | 12,481 | | | | | 8,468 | | | | | | |
| Noncurrent portion | | | $ | 64,189 | | | | | $ | 77,554 | | | | | | |
(a)Excludes the effect of any related interest rate swaps.
(b)Represents unamortized purchase price adjustments of Allergan debt.
In September 2018,April 2021, the company issued $6.0repaid $1.8 billion aggregate principal amount of unsecured2.3% senior notes consistingthat were scheduled to mature in May 2021. In May 2021, the company repaid €750 million aggregate principal amount of $1.250.5% senior Euro notes that were scheduled to mature in June 2021. These repayments were made by exercising, under the terms of the notes, 30-day early redemptions at 100% of the principal amounts. The company also repaid $750 million aggregate principal amount of floating rate senior notes at maturity in May 2021.
In September 2021, the company refinanced its $1.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $1.0 billion term loan due May 2023 and borrowed $1.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.
In September 2021, the company repaid $1.2 billion aggregate principal amount of 5.0% senior notes that were scheduled to mature in December 2021. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.
In November 2021, the company repaid $1.3 billion aggregate principal amount of 3.375% senior notes due 2021, $1.25and $1.8 billion aggregate principal amount of 3.75%2.15% senior notes due 2023, $1.75at maturity. The company also repaid $750 million aggregate principal amount of floating rate senior notes at maturity in November 2021.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 72 |
In January 2022, the company repaid $2.9 billion aggregate principal amount of 4.25%3.450% senior notes due 2028that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.
In connection with the acquisition of Allergan, in May 2020, the company borrowed $3.0 billion under a $6.0 billion term loan credit agreement, of which $1.0 billion was outstanding under a floating rate three-year term loan tranche and $1.75$2.0 billion outstanding under a floating rate five-year term loan tranche as of December 31, 2021. Subsequent to these borrowings, AbbVie terminated the unused commitments of the lenders under the term loan.
In May 2020, AbbVie completed its previously announced offers to exchange any and all outstanding notes of certain series issued by Allergan for new notes to be issued by AbbVie and cash. Following the settlement of the exchange offers, AbbVie issued $14.0 billion and €3.1 billion of new notes in exchange for the Allergan notes tendered in the exchange offers. The aggregate principal amount of Allergan notes that remained outstanding following the settlement of the exchange offers was approximately $1.5 billion and €635 million. The exchange transaction was accounted for as a modification of the assumed debt instruments.
In May 2020, the company repaid $3.8 billion aggregate principal amount of 2.5% senior notes at maturity.
In September 2020, the company repaid $650 million aggregate principal amount of 3.375% senior notes at maturity.
In November 2020, the company repaid €700 million aggregate principal amount of floating rate senior Euro notes at maturity and $450 million aggregate principal amount of 4.875% senior notes due 2048. These senior notes rank equally with all other unsecured and
|
| | |
62 |2018 Form 10-K
| | |
unsubordinated indebtedness of the company. AbbVie may redeem the senior notes prior to maturity at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium, and except for the 3.375% notes dueFebruary 2021 AbbVie may redeem the senior notes at par between one and sixthree months prior to maturity.
In connection with the offering, debt issuance costs incurred totaled $37 million and debt discounts totaled $37 million and are being amortized over the respective terms of the senior notes to interest expense, net in the consolidated statements of earnings. Of the $5.9 billion net proceeds, $2.0 billion was used to repay the company's outstanding three-year term loan credit agreement in September 2018 and $1.0 billion was used to repay the aggregate principal amount of 2.00% senior notes at maturity in November 2018. The company intends to use the remaining proceeds to repay term loan obligations in 2019, as they become due.
In May 2018, the company also repaid $3.0 billion aggregate principal amount of 1.80% senior notes at maturity.
In November 2016, the company issued €3.6€1.4 billion aggregate principal amount of unsecured senior Euro notes. These senior notes rank equally with all other unsecured and unsubordinated indebtedness of the company. AbbVie may redeem the senior notes prior to maturity at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium. AbbViepremium and may redeem the senior notes at par between one and three months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $17$9 million and debt discounts totaled $9$5 million and are being amortized over the respective terms of the senior notes to interest expense, net in the consolidated statements of earnings. TheIn October 2019, the company used the proceeds to redeem $4.0€1.4 billion aggregate principal amount of 1.75%0.375% senior Euro notes that were due to mature in November 2017. As a result of this redemption, the company incurred a charge of $39 million ($25 million after tax) related to the make-whole premium, write-off of unamortized debt issuance costs and other expenses. The charge was recorded in interest expense, net in the consolidated statement of earnings.2019.
In May 2016,November 2019, the company issued $7.8$30.0 billion aggregate principal amount of unsecured senior notes. These senior notes rank equally with all other unsecured and unsubordinated indebtedness of the company. AbbVie may redeem the fixed-rate senior notes prior to maturity at a redemption price equal to the greater of the principal amount or the sum of present values of the remaining scheduled payments of principal and interest on the fixed-rate senior notes to be redeemed plus a make-whole premium. With exception of the fixed-rate notes due 2021 and 2022, AbbVie may also redeem the fixed-rate senior notes at par between one and six months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $173 million and debt discounts totaled $52 million, which are being amortized over the respective terms of the notes to interest expense, net in the consolidated statements of earnings. AbbVie used the net proceeds to fund a portion of the aggregate cash consideration due to Allergan shareholders in connection with the acquisition described in Note 5 and to pay related fees and expenses.
AbbVie has outstanding $4.8 billion aggregate principal amount of unsecured senior notes which were issued in 2018. AbbVie may redeem the senior notes prior to maturity at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium.premium and AbbVie may redeem the senior notes at par between one month and six months prior to maturity. In connection with
AbbVie has outstanding €2.2 billion aggregate principal amount of unsecured senior Euro notes which were issued in 2016. AbbVie may redeem the offering, debt issuance costs incurred totaled $52 million and debt discounts totaled $29 million and are being amortized oversenior notes prior to maturity at a redemption price equal to the respective termsprincipal amount of the senior notes redeemed plus a make-whole premium and AbbVie may redeem the senior notes at par between one and three months prior to interest expense, net in the consolidated statementsmaturity.
AbbVie has outstanding $6.0 billion aggregate principal amount of earnings. Of the $7.7 billion net proceeds, $2.0 billion was used to repay the company’s outstanding term loan that was due to mature in November 2016, approximately $1.9 billion was used to finance the acquisition of Stemcentrx and approximately $3.8 billion was used to finance an ASR with a third party financial institution. See Note 5 for additional information related to the acquisition of Stemcentrx and Note 12 for additional information related to the ASR. In connection with the May 2016 unsecured senior notes issuance, AbbVie repaid a $2.0 billion 364-day term loan credit agreement.
AbbVie has outstanding $13.7which were issued in 2016 and $10.0 billion aggregate principal amount of unsecured senior notes which were issued in 2015. AbbVie may redeem the senior notes, at any time, prior to maturity at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium and AbbVie may redeem the senior notes at par between one and six months prior to maturity.
AbbVie has outstanding $5.7 billion aggregate principal amount of unsecured senior notes which were issued in 2012. AbbVie may redeem all of the senior notes of each series, at any time, or some of the senior notes of each series, from time to time, at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium.
| | | | | | | | | | | |
73 | |2021 Form 10-K | | |
At December 31, 2018,2021, the company was in compliance with its senior note covenants and term loan covenants.
Short-Term Borrowings
Short-term borrowings includedThere were no commercial paper borrowings outstanding as of $699 million at December 31, 20182021 and $400 million at December 31, 2017.2020. No commercial paper borrowings were issued during 2021. The weighted-average interest rate on commercial paper borrowings was 2.0%1.8% in 2018, 1.3%2020 and 2.5% in 2017 and 0.6% in 2016.2019.
In August 2018,2019, AbbVie replaced its existing revolving credit facility with a new $3.0entered into an amended and restated $4.0 billion five-year revolving credit facility that matures in August 2023. The new2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At December 31, 2018, the company was in compliance with all its credit facility covenants. Commitment fees under AbbVie's revolving credit facilities were insignificant in 2018, 2017 and 2016. No amounts were outstanding under the credit facility as of December 31, 2018 and December 31, 2017.
In May 2018, AbbVie entered into a $3.0 billion 364-day term loan credit agreement (term loan). In June 2018, the company drew on this term loan and as of December 31, 2018, $3.0 billion was outstanding and was included in short-term borrowings on the consolidated balance sheet. Borrowings under the term loan bear interest at one month LIBOR plus
|
| | |
| | 2018 Form 10-K | 63
|
applicable margin. The term loan may be prepaid without penalty upon prior notice and contains customary covenants, all of which the company was in compliance with as of December 31, 2018.2021. Commitment fees under AbbVie's revolving credit facilities were insignificant in 2021, 2020 and 2019. No amounts were outstanding under the company's credit facilities as of December 31, 2021 and December 31, 2020.
In March 2019, AbbVie repaid a $3.0 billion 364-day term loan credit agreement that was drawn on in June 2018 and was scheduled to mature in June 2019.
Maturities of Long-Term Debt and Capital Lease Obligations
The following table summarizes AbbVie's future minimum lease payments under non-cancelable operating leases, debt maturities and future minimum lease payments for capital lease obligations as of December 31, 2018:
|
| | | | | | | |
| as of and for the years ending December 31 (in millions) | Operating leases | | Debt maturities and capital leases |
| 2019 | $ | 116 |
| | $ | 1,612 |
|
| 2020 | 105 |
| | 3,755 |
|
| 2021 | 100 |
| | 3,053 |
|
| 2022 | 81 |
| | 4,120 |
|
| 2023 | 64 |
| | 2,250 |
|
| Thereafter | 343 |
| | 22,570 |
|
| Total obligations and commitments | 809 |
| | 37,360 |
|
| Fair value hedges, unamortized bond discounts and deferred financing costs |
|
| | (749 | ) |
| Total long-term debt and lease obligations | $ | 809 |
| | $ | 36,611 |
|
Lease expense was $161 million in 2018, $169 million in 2017 and $159 million in 2016. AbbVie's operating leases generally include renewal options and provide for the company to pay taxes, maintenance, insurance and other operating costs of the leased property. As of December 31, 2018, annual future minimum lease payments for capital lease obligations were insignificant.2021: | | | | | |
| as of and for the years ending December 31 (in millions) | |
| 2022 | $ | 12,428 | |
| 2023 | 4,167 | |
| 2024 | 7,219 | |
| 2025 | 8,771 | |
| 2026 | 6,000 | |
| Thereafter | 37,377 | |
| Total obligations and commitments | 75,962 | |
| Fair value hedges, unamortized bond premiums and discounts, deferred financing costs and finance lease obligations | 708 | |
| Total long-term debt and finance lease obligations | $ | 76,670 | |
Contingencies and Guarantees
In connection with the separation, AbbVie has indemnified Abbott for all liabilities resulting from the operation of AbbVie's business other than income tax liabilities with respect to periods prior to the distribution date and other liabilities as agreed to by AbbVie and Abbott. AbbVie has no material exposures to off-balance sheet arrangements and no special-purpose entities. In the ordinary course of business, AbbVie has periodically entered into third-party agreements, such as the assignment of product rights, which have resulted in AbbVie becoming secondarily liable for obligations for which AbbVie had previously been primarily liable. Based upon past experience, the likelihood of payments under these agreements is remote.
Note 1011 Financial Instruments and Fair Value Measures Risk Management Policy
The company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. AbbVie's hedging policy attempts to manage these risks to an acceptable level based on the company's judgment of the appropriate trade-off between risk, opportunity and costs. The company uses derivative and nonderivative instruments to reduce its exposure to foreign currency exchange rates. AbbVie also periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. Derivative instruments are not used for trading purposes or to manage exposure to changes in interest rates for investment securities, and none of the company's outstanding derivative instruments contain credit risk related contingent features; collateral is generally not required.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 74 |
Financial Instruments
Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.4$1.1 billion at December 31, 20182021 and $2.2$1.5 billion at December 31, 2017,2020, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than eighteen18 months. Accumulated gains and losses as of December 31, 20182021 will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.
In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 resulting in a pre-tax gain of $383 million recognized in other comprehensive income (loss). This gain is reclassified to interest expense, net over the term of the related debt.
|
| | |
64 |2018 Form 10-K
| | |
The company is a party to interest rate swap contracts designed as cash flow hedges with notional amounts totaling $750 million at December 31, 2021 and $2.3 billion at December 31, 2020. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.
The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $8.2 billion at December 31, 2021 and $8.6 billion at December 31, 2018 and $7.7 billion at December 31, 2017.2020.
The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. In the fourth quarter of 2016, theThe company issued €3.6 billionhad an aggregate principal amount of senior Euro notes and designated the principal amounts of this foreign denominated debt as net investment hedges. Concurrently,hedges of €5.9 billion at December 31, 2021 and €6.6 billion at December 31, 2020. In addition, the company settledhad foreign currency forward exchange contracts designated as net investment hedges with aggregate notional amounts totaling €4.3 billion at December 31, 2021 and €971 million at December 31, 2020. The company uses the spot method of €3.5 billion that wereassessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.
AbbVieThe company is a party to interest rate hedgeswap contracts designated as fair value hedges with notional amounts totaling $10.8$4.5 billion at December 31, 20182021 and $11.8$4.8 billion at December 31, 2017.2020. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
No amounts are excluded from the assessment of effectiveness for cash flow hedges net investment hedges or fair value hedges.
| | | | | | | | | | | |
75 | |2021 Form 10-K | | |
The following table summarizes the amounts and location of AbbVie's derivative instruments on the consolidated balance sheets:
|
| | | | | | | | | | | | | | | |
| | Fair value - Derivatives in asset position | | Fair value - Derivatives in liability position |
| as of December 31 (in millions) | Balance sheet caption | 2018 | 2017 | | Balance sheet caption | 2018 | 2017 |
| Foreign currency forward exchange contracts | | | | | | | |
| Designated as cash flow hedges | Prepaid expenses and other | $ | 113 |
| $ | 1 |
| | Accounts payable and accrued liabilities | $ | — |
| $ | 120 |
|
| Not designated as hedges | Prepaid expenses and other | 19 |
| 22 |
| | Accounts payable and accrued liabilities | 26 |
| 29 |
|
| Interest rate swaps designated as fair value hedges | Prepaid expenses and other | — |
| — |
| | Accounts payable and accrued liabilities | — |
| 8 |
|
| Interest rate swaps designated as fair value hedges | Other assets | — |
| — |
| | Other long-term liabilities | 466 |
| 393 |
|
| Total derivatives | | $ | 132 |
| $ | 23 |
| | | $ | 492 |
| $ | 550 |
|
| | | | | | | | | | | | | | | | | | | | | | | |
| Fair value - Derivatives in asset position | | Fair value -
Derivatives in liability position |
| as of December 31 (in millions) | Balance sheet caption | 2021 | 2020 | | Balance sheet caption | 2021 | 2020 |
| Foreign currency forward exchange contracts | | | | | | | |
| Designated as cash flow hedges | Prepaid expenses and other | $ | 51 | | $ | 2 | | | Accounts payable and accrued liabilities | $ | 2 | | $ | 82 | |
| | | | | | | |
| Designated as cash flow hedges | Other assets | — | | — | | | Other long-term liabilities | — | | 6 | |
| Designated as net investment hedges | Prepaid expenses and other | 149 | | — | | | Accounts payable and accrued liabilities | — | | 11 | |
| Designated as net investment hedges | Other assets | 15 | | — | | | Other long-term liabilities | — | | — | |
| Not designated as hedges | Prepaid expenses and other | 26 | | 49 | | | Accounts payable and accrued liabilities | 13 | | 33 | |
| Interest rate swap contracts | | | | | | | |
| Designated as cash flow hedges | Prepaid expenses and other | — | | — | | | Accounts payable and accrued liabilities | 7 | | 14 | |
| Designated as cash flow hedges | Other assets | — | | — | | | Other long-term liabilities | — | | 20 | |
| Designated as fair value hedges | Prepaid expenses and other | — | | 7 | | | Accounts payable and accrued liabilities | — | | — | |
| Designated as fair value hedges | Other assets | 26 | | 131 | | | Other long-term liabilities | 15 | | — | |
| Total derivatives | | $ | 267 | | $ | 189 | | | | $ | 37 | | $ | 166 | |
While certain derivatives are subject to netting arrangements with the company's counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheets.
The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2018 | | 2017 | | 2016 |
| years ended December 31 (in millions) | | Cash Flow Hedges | Net Investment Hedges | Total | | Cash Flow Hedges | Net Investment Hedges | Total | | Cash Flow
Hedges | Net Investment Hedges | Total |
| Foreign currency forward exchange contracts | | $ | 175 |
| $ | — |
| $ | 175 |
| | $ | (250 | ) | $ | — |
| $ | (250 | ) | | $ | 174 |
| $ | 118 |
| $ | 292 |
|
| | | | | | | | | | | | | | | | | | | | |
| years ended in December 31 (in millions) | | 2021 | | 2020 | | 2019 |
| Foreign currency forward exchange contracts | | | | | | |
| Designated as cash flow hedges | | $ | 82 | | | $ | (71) | | | $ | (5) | |
| Designated as net investment hedges | | 341 | | | (95) | | | 33 | |
| Interest rate swap contracts designated as cash flow hedges | | 2 | | | (53) | | | 4 | |
| Treasury rate lock agreements designated as cash flow hedges | | — | | | — | | | 383 | |
Assuming market rates remain constant through contract maturities, the company expects to transferreclassify pre-tax gains of $159$65 million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $7 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.
The company recognized, in other comprehensive loss, pre-tax gains of $178 million in 2018, pre-tax losses of $537 million in 2017 and pre-tax gains of $101 million in 2016 relatedRelated to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges.
hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $577 million in 2021, pre-tax losses of $907 million in 2020 and pre-tax gains of $90 million in 2019.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |65
| 76 |
The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 1213 for the amount of net gains (losses) reclassified out of AOCI.
|
| | | | | | | | | | | | |
| years ended December 31 (in millions) | Statement of earnings caption | 2018 | | 2017 | | 2016 |
| Foreign currency forward exchange contracts | | | | | | |
| Designated as cash flow hedges | Cost of products sold | $ | (161 | ) | | $ | 118 |
| | $ | 20 |
|
| Not designated as hedges | Net foreign exchange loss | 83 |
| | (96 | ) | | 6 |
|
| Non-designated treasury rate lock agreements | Other expense, net | — |
| | — |
| | (12 | ) |
| Interest rate swaps designated as fair value hedges | Interest expense, net | (71 | ) | | (63 | ) | | (266 | ) |
| Debt designated as hedged item in fair value hedges | Interest expense, net | 71 |
| | 63 |
| | 266 |
|
| | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | Statement of earnings caption | 2021 | | 2020 | | 2019 |
| Foreign currency forward exchange contracts | | | | | | |
| Designated as cash flow hedges | Cost of products sold | $ | (87) | | | $ | 23 | | | $ | 167 | |
| Designated as net investment hedges | Interest expense, net | 26 | | | 18 | | | 27 | |
| Not designated as hedges | Net foreign exchange loss | (100) | | | 58 | | | (70) | |
| Treasury rate lock agreements designated as cash flow hedges | Interest expense, net | 24 | | | 24 | | | 3 | |
| Interest rate swap contracts | | | | | | |
| Designated as cash flow hedges | Interest expense, net | (24) | | | (17) | | | 1 | |
| Designated as fair value hedges | Interest expense, net | (127) | | | 365 | | | 418 | |
| Debt designated as hedged item in fair value hedges | Interest expense, net | 127 | | | (365) | | | (418) | |
Fair Value Measures
The fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;
•Level 2—Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and
•Level 3—Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.
| | | | | | | | | | | |
77 | |2021 Form 10-K | | |
The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2018:2021: | | | | | | | | | | | | | | | | | | | | | | | |
| | | Basis of fair value measurement |
| (in millions) | Total | | Quoted prices in active markets for
identical assets
(Level 1) | | Significant other observable
inputs
(Level 2) | | Significant unobservable inputs
(Level 3) |
| Assets | | | | | | | |
| Cash and equivalents | $ | 9,746 | | | $ | 4,451 | | | $ | 5,295 | | | $ | — | |
| Money market funds and time deposits | 45 | | | — | | | 45 | | | — | |
| Debt securities | 46 | | | — | | | 46 | | | — | |
| Equity securities | 121 | | | 100 | | | 21 | | | — | |
| Interest rate swap contracts | 26 | | | — | | | 26 | | | — | |
| Foreign currency contracts | 241 | | | — | | | 241 | | | — | |
| | | | | | | |
| Total assets | $ | 10,225 | | | $ | 4,551 | | | $ | 5,674 | | | $ | — | |
| Liabilities | | | | | | | |
| Interest rate swap contracts | $ | 22 | | | $ | — | | | $ | 22 | | | $ | — | |
| Foreign currency contracts | 15 | | | — | | | 15 | | | — | |
| Contingent consideration | 14,887 | | | — | | | — | | | 14,887 | |
| Total liabilities | $ | 14,924 | | | $ | — | | | $ | 37 | | | $ | 14,887 | |
|
| | | | | | | | | | | | | | | |
| | | | Basis of fair value measurement |
| (in millions) | Total | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable Inputs (Level 3) |
| Assets | | | | | | | |
| Cash and equivalents | $ | 7,289 |
| | $ | 1,209 |
| | $ | 6,080 |
| | $ | — |
|
| Time deposits | 568 |
| | — |
| | 568 |
| | — |
|
| Debt securities | 1,536 |
| | — |
| | 1,536 |
| | — |
|
| Equity securities | 4 |
| | 4 |
| | — |
| | — |
|
| Foreign currency contracts | 132 |
| | — |
| | 132 |
| | — |
|
| Total assets | $ | 9,529 |
| | $ | 1,213 |
| | $ | 8,316 |
| | $ | — |
|
| Liabilities | | | | | | | |
| Interest rate hedges | $ | 466 |
| | $ | — |
| | $ | 466 |
| | $ | — |
|
| Foreign currency contracts | 26 |
| | — |
| | 26 |
| | — |
|
| Contingent consideration | 4,483 |
| | — |
| | — |
| | 4,483 |
|
| Total liabilities | $ | 4,975 |
| | $ | — |
| | $ | 492 |
| | $ | 4,483 |
|
|
| | |
66 |2018 Form 10-K
| | |
The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2017:2020: | | | | | | | | | | | | | | | | | | | | | | | |
| | | Basis of fair value measurement |
| (in millions) | Total | | Quoted prices in active markets for identical assets
(Level 1) | | Significant other observable
inputs
(Level 2) | | Significant unobservable inputs
(Level 3) |
| Assets | | | | | | | |
| Cash and equivalents | $ | 8,449 | | | $ | 2,758 | | | $ | 5,691 | | | $ | — | |
| Money market funds and time deposits | 12 | | | — | | | 12 | | | — | |
| Debt securities | 50 | | | — | | | 50 | | | — | |
| Equity securities | 159 | | | 149 | | | 10 | | | — | |
| Interest rate swap contracts | 138 | | | — | | | 138 | | | — | |
| Foreign currency contracts | 51 | | | — | | | 51 | | | — | |
| Total assets | $ | 8,859 | | | $ | 2,907 | | | $ | 5,952 | | | $ | — | |
| Liabilities | | | | | | | |
| Interest rate swap contracts | $ | 34 | | | $ | — | | | $ | 34 | | | $ | — | |
| Foreign currency contracts | 132 | | | — | | | 132 | | | — | |
| Contingent consideration | 12,997 | | | — | | | — | | | 12,997 | |
| Total liabilities | $ | 13,163 | | | $ | — | | | $ | 166 | | | $ | 12,997 | |
|
| | | | | | | | | | | | | | | |
| | | | Basis of fair value measurement |
| (in millions) | Total | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable Inputs (Level 3) |
| Assets | | | | | | | |
| Cash and equivalents | $ | 9,303 |
| | $ | 849 |
| | $ | 8,454 |
| | $ | — |
|
| Debt securities | 2,524 |
| | — |
| | 2,524 |
| | — |
|
| Equity securities | 4 |
| | 4 |
| | — |
| | — |
|
| Foreign currency contracts | 23 |
| | — |
| | 23 |
| | — |
|
| Total assets | $ | 11,854 |
| | $ | 853 |
| | $ | 11,001 |
| | $ | — |
|
| Liabilities | | | | | | | |
| Interest rate hedges | $ | 401 |
| | $ | — |
| | $ | 401 |
| | $ | — |
|
| Foreign currency contracts | 149 |
| | — |
| | 149 |
| | — |
|
| Contingent consideration | 4,534 |
| | — |
| | — |
| | 4,534 |
|
| Total liabilities | $ | 5,084 |
| | $ | — |
| | $ | 550 |
| | $ | 4,534 |
|
TheEquity securities primarily consist of investments for which the fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based onby using the published market prices obtained from commercial pricing services.per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published spot curves for interest rate hedgescurves and publishedboth forward curvesand spot prices for foreign currency contracts. currencies.
The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products still in development.products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones
| | | | | | | | | | | |
| | 2021 Form 10-K | | 78 |
and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At December 31, 2018, a 50 basis point increase/decrease in
The fair value of the assumed discount rate would have decreased/increasedcompany's contingent consideration liabilities was calculated using the following significant unobservable inputs: | | | | | | | | | | | | | | | | | |
| 2021 | | 2020 |
| years ended December 31 (in millions) | Range | Weighted Average(a) | | Range | Weighted Average(a) |
| Discount rate | 0.2% - 2.6% | 1.7% | | 0.1% - 2.2% | 1.1 | % |
| Probability of payment for unachieved milestones | 89% - 100% | 90% | | 56% - 92% | 64 | % |
Probability of payment for royalties by indication(b) | 56% - 100% | 96% | | 56% - 100% | 91 | % |
| | | | | |
| Projected year of payments | 2022 - 2034 | 2027 | | 2021 - 2034 | 2027 |
(a)Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities by approximately $160 million. Additionally,liabilities.
(b)Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at December 31, 2018, a five percentage point increase/decrease in the assumed probability of success across all potential indications would have increased/decreased the value of the contingent consideration liabilities by approximately $420 million.2021 and 56% to 89% at December 31, 2020.
There have been no transfers of assets or liabilities betweeninto or out of Level 3 of the fair value measurement levels.hierarchy. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Beginning balance | $ | 12,997 | | | $ | 7,340 | | | $ | 4,483 | |
Additions(a) | — | | | 225 | | | — | |
| Change in fair value recognized in net earnings | 2,679 | | | 5,753 | | | 3,091 | |
| Payments | (789) | | | (321) | | | (234) | |
| Ending balance | $ | 14,887 | | | $ | 12,997 | | | $ | 7,340 | |
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Beginning balance | $ | 4,534 |
| | $ | 4,213 |
| | $ | — |
|
| Additions (See Note 5) | — |
| | — |
| | 3,985 |
|
| Change in fair value recognized in net earnings | 49 |
| | 626 |
| | 228 |
|
| Milestone payments | (100 | ) | | (305 | ) | | — |
|
| Ending balance | $ | 4,483 |
| | $ | 4,534 |
| | $ | 4,213 |
|
The change in fair value recognized in net earnings is recorded in other expense, net in the consolidated statements of earnings. During the fourth quarter of 2018,year-ended December 31, 2021, the company recorded a $428$2.7 billion increase in the Skyrizi contingent consideration liability due to higher estimated sales driven by stronger market share uptake, favorable clinical trial results and the passage of time, partially offset by higher discount rates. During the year-ended December 31, 2020, the company recorded a $5.7 billion increase in the Skyrizi contingent consideration liability due to higher estimated future sales driven by stronger market share uptake, lower discount rates, the passage of time and favorable clinical trial results. During the second quarter of 2019, the company recorded a $2.3 billion increase in the Skyrizi contingent consideration liability due to higher probabilities of success, higher estimated future sales and lower discount rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of Skyrizi for the treatment of moderate to severe plaque psoriasis. During the third quarter of 2019, the company recorded a $91 million decrease in the Stemcentrx contingent consideration liability due to a reduction in probabilitiesthe termination of success of achieving regulatory approval.
the Rova-T R&D program.
|
| | | | | | | | | | |
| 79 | 2018|2021 Form 10-K| 67
| | |
Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 20182021 are shown in the table below: | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Basis of fair value measurement |
| (in millions) | Book value | Approximate fair values | | Quoted prices in active markets for identical assets
(Level 1) | | Significant other observable inputs
(Level 2) | | Significant unobservable inputs
(Level 3) |
| Liabilities | | | | | | | | |
| Short-term borrowings | $ | 14 | | $ | 14 | | | $ | — | | | $ | 14 | | | $ | — | |
| Current portion of long-term debt and finance lease obligations, excluding fair value hedges | 12,455 | | 11,830 | | | 11,329 | | | 501 | | | — | |
| Long-term debt and finance lease obligations, excluding fair value hedges | 64,113 | | 71,810 | | | 70,757 | | | 1,053 | | | — | |
| Total liabilities | $ | 76,582 | | $ | 83,654 | | | $ | 82,086 | | | $ | 1,568 | | | $ | — | |
|
| | | | | | | | | | | | | | | | | | |
| | | | | Basis of fair value measurement |
| (in millions) | Book value | Approximate fair values | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable Inputs (Level 3) |
| Liabilities | | | | | | | | |
| Short-term borrowings | $ | 3,699 |
| $ | 3,693 |
| | $ | — |
| | $ | 3,693 |
| | $ | — |
|
| Current portion of long-term debt and lease obligations, excluding fair value hedges | 1,609 |
| 1,617 |
| | 1,609 |
| | 8 |
| | — |
|
| Long-term debt and lease obligations, excluding fair value hedges | 35,468 |
| 34,052 |
| | 34,024 |
| | 28 |
| | — |
|
| Total liabilities | $ | 40,776 |
| $ | 39,362 |
| | $ | 35,633 |
| | $ | 3,729 |
| | $ | — |
|
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Basis of fair value measurement |
| (in millions) | Book value | Approximate fair values | | Quoted prices in active markets for identical assets
(Level 1) | | Significant other observable inputs
(Level 2) | | Significant unobservable inputs
(Level 3) |
| Liabilities | | | | | | | | |
| Short-term borrowings | $ | 34 | | $ | 34 | | | $ | — | | | $ | 34 | | | $ | — | |
| Current portion of long-term debt and finance lease obligations, excluding fair value hedges | $ | 8,461 | | $ | 8,542 | | | $ | 8,249 | | | $ | 293 | | | $ | — | |
| Long-term debt and finance lease obligations, excluding fair value hedges | 77,283 | | 87,761 | | | 86,137 | | | 1,624 | | | — | |
| Total liabilities | $ | 85,778 | | $ | 96,337 | | | $ | 94,386 | | | $ | 1,951 | | | $ | — | |
AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $84$149 million as of December 31, 2018.2021 and $102 million as of December 31, 2020. No significant cumulative upward or downward adjustments have been recorded for these investments as of December 31, 2018. Prior to the adoption of ASU No. 2016-01 discussed in Note 2, these investments were accounted for under the cost method and disclosed in the table below as of December 31, 2017.
The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2017 are shown in the table below:
|
| | | | | | | | | | | | | | | | | | |
| | | | | Basis of fair value measurement |
| (in millions) | Book value | Approximate fair values | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable Inputs (Level 3) |
| Assets | | | | | | | | |
| Investments | $ | 48 |
| $ | 48 |
| | $ | — |
| | $ | — |
| | $ | 48 |
|
| Total assets | $ | 48 |
| $ | 48 |
| | $ | — |
| | $ | — |
| | $ | 48 |
|
| Liabilities | | | | | | | | |
| Short-term borrowings | $ | 400 |
| $ | 400 |
| | $ | — |
| | $ | 400 |
| | $ | — |
|
| Current portion of long-term debt and lease obligations, excluding fair value hedges | 6,023 |
| 6,034 |
| | 4,004 |
| | 2,030 |
| | — |
|
| Long-term debt and lease obligations, excluding fair value hedges | 31,346 |
| 32,846 |
| | 32,763 |
| | 83 |
| | — |
|
| Total liabilities | $ | 37,769 |
| $ | 39,280 |
| | $ | 36,767 |
| | $ | 2,513 |
| | $ | — |
|
|
| | |
68 |2018 Form 10-K
| | |
Available-for-sale Securities
Substantially all of the company’s investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. Debt securities classified as short-term were $204 million as of December 31, 2018 and $482 million as of December 31, 2017. Long-term debt securities mature primarily within five years. Estimated fair values of available-for-sale debt securities were based on prices obtained from commercial pricing services.
The following table summarizes available-for-sale securities by type as of December 31, 2018:
|
| | | | | | | | | | | | | | | |
| | Amortized cost | | Gross unrealized | | Fair value |
| (in millions) | | Gains | | Losses | |
| Asset backed securities | $ | 423 |
| | $ | — |
| | $ | (2 | ) | | $ | 421 |
|
| Corporate debt securities | 1,042 |
| | 1 |
| | (9 | ) | | 1,034 |
|
| Other debt securities | 81 |
| | — |
| | — |
| | 81 |
|
| Total | $ | 1,546 |
| | $ | 1 |
| | $ | (11 | ) | | $ | 1,536 |
|
The following table summarizes available-for-sale securities by type as of December 31, 2017:
|
| | | | | | | | | | | | | | | |
| | Amortized cost | | Gross unrealized | | Fair value |
| (in millions) | | Gains | | Losses | |
| Asset backed securities | $ | 930 |
| | $ | 1 |
| | $ | (3 | ) | | $ | 928 |
|
| Corporate debt securities | 1,451 |
| | 4 |
| | (2 | ) | | 1,453 |
|
| Other debt securities | 144 |
| | — |
| | (1 | ) | | 143 |
|
| Equity securities | 4 |
| | 2 |
| | (2 | ) | | 4 |
|
| Total | $ | 2,529 |
| | $ | 7 |
| | $ | (8 | ) | | $ | 2,528 |
|
AbbVie had no other-than-temporary impairments as of December 31, 2018. Net realized gains and losses were insignificant in 2018 and 2016. Net realized gains in 2017 were $90 million.2021.
Concentrations of Risk
The company invests excess cash in time deposits, money market funds and debt securities to diversify the concentration of cash among different financial institutions. The company has established credit exposure limits and monitors concentrations of credit risk associated with financial institution deposits.
The functional currency of the company's Venezuela operations is the U.S. dollar due to the hyperinflationary status of the Venezuelan economy. During the first quarter of 2016, in consideration of declining economic conditions in Venezuela and a decline in transactions settled at the official rate, AbbVie determined that its net monetary assets denominated in the Venezuelan bolivar (VEF) were no longer expected to be settled at the official rate of 10 VEF per U.S. dollar, but rather at the Divisa Complementaria (DICOM) rate. Therefore, during the first quarter of 2016, AbbVie recorded a charge of $298 million to net foreign exchange loss to revalue its bolivar-denominated net monetary assets using the DICOM rate then in effect of approximately 270 VEF per U.S. dollar. As of December 31, 2018 and 2017, AbbVie’s net monetary assets in Venezuela were insignificant.
Of total net accounts receivable, three3 U.S. wholesalers accounted for 63%75% as of December 31, 20182021 and 56%72% as of December 31, 2017,2020, and substantially all of AbbVie's pharmaceutical product net revenues in the United States were to these three3 wholesalers.
HUMIRAHumira (adalimumab) is AbbVie's single largest product and accounted for approximately 61%37% of AbbVie's total net revenues in 2018, 65%2021, 43% in 20172020 and 63%58% in 2016.2019.
Note 11 Post-Employment Benefits
|
| | | | | | | | | | |
| | 2021 Form 10-K | | 80 |
Note 12 Post-Employment Benefits AbbVie sponsors various pension and other post-employment benefit plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. In addition, AbbVie provides medical benefits, primarily to eligible retirees in the United States and Puerto Rico, through other post-retirement benefit plans. Net obligations for these plans have been reflected on the consolidated balance sheets as of December 31, 20182021 and 2017.2020.
|
| | |
| | 2018 Form 10-K | 69
|
The following table summarizes benefit plan information for the global AbbVie-sponsored defined benefit and other post-employment plans:
|
| | | | | | | | | | | | | | | |
| | Defined benefit plans | | Other post-employment plans |
| as of and for the years ended December 31 (in millions) | 2018 | | 2017 | | 2018 | | 2017 |
| Projected benefit obligations | | | | | | | |
| Beginning of period | $ | 6,985 |
| | $ | 5,829 |
| | $ | 813 |
| | $ | 627 |
|
| Service cost | 285 |
| | 236 |
| | 26 |
| | 26 |
|
| Interest cost | 227 |
| | 204 |
| | 25 |
| | 24 |
|
| Employee contributions | 2 |
| | 2 |
| | — |
| | — |
|
| Actuarial (gain) loss | (614 | ) | | 714 |
| | (287 | ) | | 149 |
|
| Benefits paid | (191 | ) | | (173 | ) | | (16 | ) | | (15 | ) |
| Other, primarily foreign currency translation adjustments | (76 | ) | | 173 |
| | — |
| | 2 |
|
| End of period | 6,618 |
| | 6,985 |
| | 561 |
| | 813 |
|
| Fair value of plan assets | | | | | | | |
| Beginning of period | 5,399 |
| | 4,572 |
| | — |
| | — |
|
| Actual return on plan assets | (384 | ) | | 684 |
| | — |
| | — |
|
| Company contributions | 873 |
| | 246 |
| | 16 |
| | 15 |
|
| Employee contributions | 2 |
| | 2 |
| | — |
| | — |
|
| Benefits paid | (191 | ) | | (173 | ) | | (16 | ) | | (15 | ) |
| Other, primarily foreign currency translation adjustments | (62 | ) | | 68 |
| | — |
| | — |
|
| End of period | 5,637 |
| | 5,399 |
| | — |
| | — |
|
| Funded status, end of period | $ | (981 | ) | | $ | (1,586 | ) | | $ | (561 | ) | | $ | (813 | ) |
| | | | | | | | |
| Amounts recognized on the consolidated balance sheets | | | | | | | |
| Other assets | $ | 321 |
| | $ | 388 |
| | $ | — |
| | $ | — |
|
| Accounts payable and accrued liabilities | (8 | ) | | (32 | ) | | (15 | ) | | (15 | ) |
| Other long-term liabilities | (1,294 | ) | | (1,942 | ) | | (546 | ) | | (798 | ) |
| Net obligation | $ | (981 | ) | | $ | (1,586 | ) | | $ | (561 | ) | | $ | (813 | ) |
| Actuarial loss, net | $ | 2,516 |
| | $ | 2,471 |
| | $ | 25 |
| | $ | 320 |
|
| Prior service cost (credit) | 11 |
| | 12 |
| | (22 | ) | | (29 | ) |
| Accumulated other comprehensive loss | $ | 2,527 |
| | $ | 2,483 |
| | $ | 3 |
| | $ | 291 |
|
| | | | | | | | | | | | | | | | | | | | | | | |
| Defined benefit plans | | Other post-employment plans |
| as of and for the years ended December 31 (in millions) | 2021 | | 2020 | | 2021 | | 2020 |
| Projected benefit obligations | | | | | | | |
| Beginning of period | $ | 11,792 | | | $ | 8,646 | | | $ | 795 | | | $ | 1,050 | |
| Service cost | 440 | | | 370 | | | 48 | | | 42 | |
| Interest cost | 237 | | | 264 | | | 19 | | | 34 | |
| Employee contributions | 2 | | | 2 | | | — | | | — | |
| Amendments | — | | | — | | | — | | | (397) | |
| Actuarial (gain) loss | (8) | | | 1,105 | | | 10 | | | 40 | |
| Benefits paid | (281) | | | (249) | | | (22) | | | (17) | |
| | | | | | | |
| Acquisition | — | | | 1,409 | | | — | | | 43 | |
| Other, primarily foreign currency translation adjustments | (176) | | | 245 | | | — | | | — | |
| End of period | 12,006 | | | 11,792 | | | 850 | | | 795 | |
| Fair value of plan assets | | | | | | | |
| Beginning of period | 9,702 | | | 7,116 | | | — | | | — | |
| Actual return on plan assets | 1,000 | | | 979 | | | — | | | — | |
| Company contributions | 376 | | | 367 | | | 22 | | | 17 | |
| Employee contributions | 2 | | | 2 | | | — | | | — | |
| Benefits paid | (281) | | | (249) | | | (22) | | | (17) | |
| | | | | | | |
| Acquisition | — | | | 1,296 | | | — | | | — | |
| Other, primarily foreign currency translation adjustments | (144) | | | 191 | | | — | | | — | |
| End of period | 10,655 | | | 9,702 | | | — | | | — | |
| Funded status, end of period | $ | (1,351) | | | $ | (2,090) | | | $ | (850) | | | $ | (795) | |
| | | | | | | |
| Amounts recognized on the consolidated balance sheets | | | | | | | |
| Other assets | $ | 991 | | | $ | 563 | | | $ | — | | | $ | — | |
| Accounts payable and accrued liabilities | (13) | | | (12) | | | (26) | | | (23) | |
| Other long-term liabilities | (2,329) | | | (2,641) | | | (824) | | | (772) | |
| Net obligation | $ | (1,351) | | | $ | (2,090) | | | $ | (850) | | | $ | (795) | |
| Actuarial loss, net | $ | 3,504 | | | $ | 4,163 | | | $ | 461 | | | $ | 482 | |
| Prior service cost (credit) | 5 | | | 8 | | | (370) | | | (408) | |
| Accumulated other comprehensive loss | $ | 3,509 | | | $ | 4,171 | | | $ | 91 | | | $ | 74 | |
The projected benefit obligations (PBO) in the table above included $1.9$3.2 billion at December 31, 20182021 and $2.0$3.5 billion at December 31, 2017,2020, related to international defined benefit plans.
For plans reflected in the table above, the accumulated benefit obligations (ABO) were $6.0$10.5 billion at December 31, 20182021 and $6.3 billion at December 31, 2017. For those plans reflected in the table above in which the ABO exceeded plan assets at December 31, 2018, the ABO was $4.0 billion, the PBO was $4.5 billion and aggregate plan assets were $3.3 billion.
Subsequent to December 31, 2018, the company made a voluntary contribution of $150 million to its principal domestic defined benefit plan, the AbbVie Pension Plan.
2020.
|
| | | | | | | | | | |
7081
| |20182021 Form 10-K
| | |
Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets | | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Accumulated benefit obligation | $ | 6,395 | | | $ | 7,527 | |
| Fair value of plan assets | 5,412 | | | 6,066 | |
Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets | | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Projected benefit obligation | $ | 7,788 | | | $ | 8,719 | |
| Fair value of plan assets | 5,447 | | | 6,066 | |
The 2021 actuarial gain of $8 million for qualified pension plans and actuarial loss of $10 million for other post-employment plans were primarily driven by an increase in the assumed discount rate offset by change in demographic assumptions from 2020. The 2020 actuarial losses of $1.1 billion for qualified pension plans and $40 million for other post-employment plans were primarily driven by a decrease in the assumed discount rate from 2019.
AbbVie's U.S. pension plan was modified to close the plan to new entrants effective January 1, 2022. In addition, a change to AbbVie's U.S. retiree health benefit plan was approved in 2020 and communicated to employees and retirees in October 2020. Beginning in 2022, Medicare-eligible retirees and Medicare-eligible dependents will choose health care coverage from insurance providers through a private Medicare exchange. AbbVie will continue to provide financial support to Medicare-eligible retirees. This change to the U.S. retiree health benefit plan decreased AbbVie's post-employment benefit obligation and increased AbbVie's unrecognized prior service credit as of December 31, 2020 by $397 million.
In connection with the Allergan acquisition, AbbVie assumed certain post-employment benefit obligations which were recorded at fair value. Upon acquisition in the second quarter of 2020, the excess of projected benefit obligations over the plan assets was recognized as a liability totaling $156 million.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 82 |
Amounts Recognized in Other Comprehensive Income (Loss)
The following table summarizes the pre-tax gains and losses (gains) included in other comprehensive income (loss): | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Defined benefit plans | | | | | |
| Actuarial loss (gain) | $ | (345) | | | $ | 701 | | | $ | 1,231 | |
| | | | | |
| Amortization of prior service cost | (2) | | | (2) | | | — | |
| Amortization of actuarial loss | (288) | | | (227) | | | (109) | |
| Foreign exchange loss (gain) and other | (27) | | | 56 | | | (6) | |
| Total loss (gain) | $ | (662) | | | $ | 528 | | | $ | 1,116 | |
| Other post-employment plans | | | | | |
| Actuarial loss | $ | 10 | | | $ | 40 | | | $ | 451 | |
| Prior service credit | — | | | (397) | | | — | |
| Amortization of prior service credit | 39 | | | 4 | | | — | |
| Amortization of actuarial loss | (32) | | | (26) | | | (1) | |
| Total loss (gain) | $ | 17 | | | $ | (379) | | | $ | 450 | |
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Defined benefit plans | | | | | |
| Actuarial loss | $ | 209 |
| | $ | 412 |
| | $ | 284 |
|
| Amortization of actuarial loss and prior service cost | (140 | ) | | (107 | ) | | (85 | ) |
| Foreign exchange gain (loss) and other | (13 | ) | | 46 |
| | (22 | ) |
| Total | $ | 56 |
| | $ | 351 |
| | $ | 177 |
|
| Other post-employment plans | | | | | |
| Actuarial loss (gain) | $ | (287 | ) | | $ | 149 |
| | $ | 33 |
|
| Amortization of actuarial loss and prior service credit | (1 | ) | | — |
| | — |
|
| Total | $ | (288 | ) | | $ | 149 |
| | $ | 33 |
|
Net Periodic Benefit Cost | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Defined benefit plans | | | | | |
| Service cost | $ | 440 | | | $ | 370 | | | $ | 269 | |
| Interest cost | 237 | | | 264 | | | 259 | |
| Expected return on plan assets | (663) | | | (575) | | | (474) | |
| Amortization of prior service cost | 2 | | | 2 | | | — | |
| Amortization of actuarial loss | 288 | | | 227 | | | 109 | |
| Net periodic benefit cost | $ | 304 | | | $ | 288 | | | $ | 163 | |
| Other post-employment plans | | | | | |
| Service cost | $ | 48 | | | $ | 42 | | | $ | 25 | |
| Interest cost | 19 | | | 34 | | | 29 | |
| Amortization of prior service credit | (39) | | | (4) | | | — | |
| Amortization of actuarial loss | 32 | | | 26 | | | 1 | |
| Net periodic benefit cost | $ | 60 | | | $ | 98 | | | $ | 55 | |
The pre-tax amounts included in AOCI at December 31, 2018 expected to be recognized incomponents of net periodic benefit cost other than service cost are included in 2019 consistedother expense, net in the consolidated statements of $103 million of expense related to actuarial losses and prior service costs for defined benefit plans and $5 million of income related to actuarial losses and prior service credits for other post-employment plans.earnings.
Net Periodic Benefit Cost
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Defined benefit plans | | | | | |
| Service cost | $ | 285 |
| | $ | 236 |
| | $ | 210 |
|
| Interest cost | 227 |
| | 204 |
| | 201 |
|
| Expected return on plan assets | (439 | ) | | (382 | ) | | (354 | ) |
| Amortization of actuarial loss and prior service cost | 140 |
| | 107 |
| | 85 |
|
| Net periodic benefit cost | $ | 213 |
| | $ | 165 |
| | $ | 142 |
|
| Other post-employment plans | | | | | |
| Service cost | $ | 26 |
| | $ | 26 |
| | $ | 25 |
|
| Interest cost | 25 |
| | 24 |
| | 24 |
|
| Amortization of actuarial loss and prior service credit | 1 |
| | — |
| | — |
|
| Net periodic benefit cost | $ | 52 |
| | $ | 50 |
| | $ | 49 |
|
Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date
|
| | | | | |
| as of December 31 | 2018 | | 2017 |
| Defined benefit plans | | | |
| Discount rate | 4.0 | % | | 3.4 | % |
| Rate of compensation increases | 4.6 | % | | 4.5 | % |
| Other post-employment plans | | | |
| Discount rate | 4.6 | % | | 3.9 | % |
| | | | | | | | | | | |
| as of December 31 | 2021 | | 2020 |
| Defined benefit plans | | | |
| Discount rate | 2.8 | % | | 2.4 | % |
| Rate of compensation increases | 5.2 | % | | 4.6 | % |
| Cash balance interest crediting rate | 2.7 | % | | 2.8 | % |
| Other post-employment plans | | | |
| Discount rate | 3.1 | % | | 2.8 | % |
The assumptions used in calculating the December 31, 20182021 measurement date benefit obligations will be used in the calculation of net periodic benefit cost in 2019.
2022.
|
| | | | | | | | | | |
| 83 | 2018|2021 Form 10-K| 71
| | |
Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost
|
| | | | | | | | |
| years ended December 31 | 2018 | | 2017 | | 2016 |
| Defined benefit plans | | | | | |
| Discount rate for determining service cost | 3.4 | % | | 3.9 | % | | 4.4 | % |
| Discount rate for determining interest cost | 3.1 | % | | 3.7 | % | | 4.0 | % |
| Expected long-term rate of return on plan assets | 7.7 | % | | 7.8 | % | | 7.9 | % |
| Expected rate of change in compensation | 4.4 | % | | 4.4 | % | | 4.4 | % |
| Other post-employment plans | | | | | |
| Discount rate for determining service cost | 4.0 | % | | 4.9 | % | | 5.1 | % |
| Discount rate for determining interest cost | 3.7 | % | | 4.1 | % | | 4.3 | % |
| | | | | | | | | | | | | | | | | |
| years ended December 31 | 2021 | | 2020 | | 2019 |
| Defined benefit plans | | | | | |
| Discount rate for determining service cost | 2.6 | % | | 3.1 | % | | 4.0 | % |
| Discount rate for determining interest cost | 2.2 | % | | 3.0 | % | | 4.0 | % |
| Expected long-term rate of return on plan assets | 7.1 | % | | 7.1 | % | | 7.6 | % |
| Expected rate of change in compensation | 4.6 | % | | 4.6 | % | | 4.6 | % |
| Cash balance interest crediting rate | 2.8 | % | | 2.8 | % | | 2.8 | % |
| Other post-employment plans | | | | | |
| Discount rate for determining service cost | 3.0 | % | | 3.7 | % | | 4.7 | % |
| Discount rate for determining interest cost | 2.2 | % | | 3.2 | % | | 4.3 | % |
For the December 31, 20182021 post-retirement health care obligations remeasurement, the company assumed a 6.6%5.9% pre-65 (7.3%(2.1% post-65) annual rate of increase in the per capita cost of covered health care benefits. The pre-65 rate was assumed to decrease gradually to 4.5% (1.8% post-65) in 20502029 and remain at that level thereafter. For purposes of measuring the 20182021 post-retirement health care costs, the company assumed a 7.7%6.0% pre-65 (9.5%(2.3% post-65) annual rate of increase in the per capita cost of covered health care benefits. The pre-65 rate was assumed to decrease gradually to 4.5% (2.0% post-65) for 20502029 and remain at that level thereafter.
Assumed health care cost trend rates have a significant effect on the amounts reported for health care plans. As of December 31, 2018, a one percentage point change in assumed health care cost trend rates would have the following effects:
|
| | | | | | | |
| | One percentage point |
| year ended December 31, 2018 (in millions) (brackets denote a reduction) | Increase | | Decrease |
| Service cost and interest cost | $ | 13 |
| | $ | (10 | ) |
| Projected benefit obligation | 110 |
| | (87 | ) |
| | | | | | | | | | | |
| | 2021 Form 10-K | | 84 |
Defined Benefit Pension Plan Assets | | | | | | | | | | | | | | | | | | | | | | | |
| | | Basis of fair value measurement |
| as of December 31 (in millions) | 2021 | | Quoted prices in active markets for identical assets
(Level 1) | | Significant other observable inputs
(Level 2) | | Significant unobservable inputs
(Level 3) |
| Equities | | | | | | | |
U.S. large cap(a) | $ | 1,428 | | | $ | 1,428 | | | $ | — | | | $ | — | |
U.S. mid cap(b) | 198 | | | 198 | | | — | | | — | |
International(c) | 458 | | | 458 | | | — | | | — | |
| Fixed income securities | | | | | | | |
U.S. government securities(d) | 228 | | | 95 | | | 133 | | | — | |
Corporate debt instruments(d) | 945 | | | 179 | | | 766 | | | — | |
Non-U.S. government securities(d) | 602 | | | 445 | | | 157 | | | — | |
Other(d) | 273 | | | 268 | | | 5 | | | — | |
Absolute return funds(e) | 100 | | | 5 | | | 95 | | | — | |
| Real assets | 10 | | | 10 | | | — | | | — | |
Other(f) | 261 | | | 216 | | | 45 | | | — | |
| Total | $ | 4,503 | | | $ | 3,302 | | | $ | 1,201 | | | $ | — | |
| Total assets measured at NAV | 6,152 | | | | | | | |
| Fair value of plan assets | $ | 10,655 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | |
| | | Basis of fair value measurement |
| as of December 31 (in millions) | 2020 | | Quoted prices in active markets for identical assets
(Level 1) | | Significant other observable inputs
(Level 2) | | Significant unobservable inputs
(Level 3) |
| Equities | | | | | | | |
U.S. large cap(a) | $ | 1,143 | | | $ | 1,143 | | | $ | — | | | $ | — | |
U.S. mid cap(b) | 164 | | | 164 | | | — | | | — | |
International(c) | 524 | | | 524 | | | — | | | — | |
| Fixed income securities | | | | | | | |
U.S. government securities(d) | 132 | | | 18 | | | 114 | | | — | |
Corporate debt instruments(d) | 854 | | | 178 | | | 676 | | | — | |
Non-U.S. government securities(d) | 544 | | | 397 | | | 147 | | | — | |
Other(d) | 297 | | | 294 | | | 3 | | | — | |
Absolute return funds(e) | 310 | | | 4 | | | 306 | | | — | |
| Real assets | 10 | | | 10 | | | — | | | — | |
Other(f) | 252 | | | 250 | | | 2 | | | — | |
| Total | $ | 4,230 | | | $ | 2,982 | | | $ | 1,248 | | | $ | — | |
| Total assets measured at NAV | 5,472 | | | | | | | |
| Fair value of plan assets | $ | 9,702 | | | | | | | |
|
| | | | | | | | | | | | | | | |
| | | | Basis of fair value measurement |
| as of December 31 (in millions) | 2018 | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) |
| Equities | | | | | | | |
U.S. large cap(a) | $ | 719 |
| | $ | 719 |
| | $ | — |
| | $ | — |
|
U.S. mid cap(b) | 67 |
| | 67 |
| | — |
| | — |
|
International(c) | 226 |
| | 226 |
| | — |
| | — |
|
| Fixed income securities | | | | | | | |
U.S. government securities(d) | 140 |
| | 21 |
| | 119 |
| | — |
|
Corporate debt instruments(d) | 385 |
| | 123 |
| | 262 |
| | — |
|
Non-U.S. government securities(d) | 175 |
| | 48 |
| | 127 |
| | — |
|
Other(d) | 232 |
| | 225 |
| | 7 |
| | — |
|
Absolute return funds(e) | 261 |
| | 3 |
| | 258 |
| | — |
|
| Real assets | 7 |
| | 7 |
| | — |
| | — |
|
Other(f) | 147 |
| | 147 |
| | — |
| | — |
|
| Total | $ | 2,359 |
| | $ | 1,586 |
| | $ | 773 |
| | $ | — |
|
| Total assets measured at NAV | 3,278 |
| | | | | | |
| Fair value of plan assets | $ | 5,637 |
| |
|
| |
|
| |
|
|
(b)A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices.
(c)A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.
(d)Securities held by actively managed accounts, index funds and mutual funds.
|
| | | | | | | | | | |
7285
| |20182021 Form 10-K
| | |
(e)Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets.
(f)Investments in cash and cash equivalents.
|
| | | | | | | | | | | | | | | |
| | | | Basis of fair value measurement |
| as of December 31 (in millions) | 2017 | | Quoted prices in active markets for identical assets (Level 1) | | Significant other observable inputs (Level 2) | | Significant unobservable inputs (Level 3) |
| Equities | | | | | | | |
U.S. large cap(a) | $ | 597 |
| | $ | 597 |
| | $ | — |
| | $ | — |
|
U.S. mid cap(b) | 74 |
| | 74 |
| | — |
| | — |
|
International(c) | 63 |
| | 63 |
| | — |
| | — |
|
| Fixed income securities | | | | | | | |
U.S. government securities(d) | 110 |
| | 6 |
| | 104 |
| | — |
|
Corporate debt instruments(d) | 238 |
| | 132 |
| | 106 |
| | — |
|
Non-U.S. government securities(d) | 59 |
| | 25 |
| | 34 |
| | — |
|
Other(d) | 265 |
| | 260 |
| | 5 |
| | — |
|
Absolute return funds(e) | 262 |
| | 4 |
| | 258 |
| | — |
|
| Real assets | 7 |
| | 7 |
| | — |
| | — |
|
Other(f) | 40 |
| | 40 |
| | — |
| | — |
|
| Total | $ | 1,715 |
| | $ | 1,208 |
| | $ | 507 |
| | $ | — |
|
| Total assets measured at NAV | 3,684 |
| | | | | | |
| Fair value of plan assets | $ | 5,399 |
| |
|
| |
|
| |
|
|
| |
(a) | A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. |
| |
(b) | A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices. |
| |
(c) | A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. |
| |
(d) | Securities held by actively managed accounts, index funds and mutual funds. |
| |
(e) | Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets. |
| |
(f) | Investments in cash and cash equivalents. |
Equities and registered investment companies having quoted prices are valued at the published market prices. Fixed income securities that are valued using significant other observable inputs are quoted at prices obtained from independent financial service industry-recognized vendors. Investments held in pooled investment funds, common collective trusts or limited partnerships are valued at the net asset value (NAV) practical expedient to estimate fair value. The NAV is provided by the fund administrator and is based on the value of the underlying assets owned by the fund minus its liabilities.
The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a desired return, balancing higher return, more volatile equity securities and lower return, less volatile fixed income securities. Investment allocations are established for each plan and are generally made across a range of markets, industry sectors, capitalization sizes and in the case of fixed income securities, maturities and credit quality. The 2021 target investment allocationsallocation for the AbbVie Pension Plan is 35%was 62.5% in equity securities, 20%22.5% in fixed income securities and 45%15% in asset allocation strategies and other holdings. There are no known significant concentrations of risk in the plan assets of the AbbVie Pension Plan or of any other plans.
The expected return on plan assets assumption for each plan is based on management's expectations of long-term average rates of return to be achieved by the underlying investment portfolio. In establishing this assumption, management considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic and capital market conditions.
|
| | |
| | 2018 Form 10-K | 73
|
Expected Benefit Payments
The following table summarizes total benefit payments expected to be paid to plan participants including payments funded from both plan and company assets:
|
| | | | | | | |
| years ending December 31 (in millions) | Defined benefit plans | | Other post-employment plans |
| 2019 | $ | 209 |
| | $ | 16 |
|
| 2020 | 221 |
| | 19 |
|
| 2021 | 235 |
| | 21 |
|
| 2022 | 249 |
| | 21 |
|
| 2023 | 265 |
| | 22 |
|
| 2024 to 2028 | 1,589 |
| | 135 |
|
| | | | | | | | | | | |
| years ending December 31 (in millions) | Defined
benefit plans | | Other
post-employment plans |
| 2022 | $ | 293 | | | $ | 27 | |
| 2023 | 312 | | | 30 | |
| 2024 | 334 | | | 31 | |
| 2025 | 356 | | | 34 | |
| 2026 | 379 | | | 36 | |
| 2027 to 2031 | 2,291 | | | 224 | |
Defined Contribution Plan
AbbVie's principalAbbVie maintains defined contribution plan issavings plans for the AbbVie Savings Plan. AbbVie recordedbenefit of its eligible employees. The expense of $89recognized for these plans was $267 million in 2018, $822021, $191 million in 20172020 and $75$102 million in 2016 related to this plan.2019. AbbVie provides certain other post-employment benefits, primarily salary continuation arrangements, to qualifying employees and accrues for the related cost over the service lives of the employees.
Note 1213 Equity
Stock-Based Compensation
In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program (2013 ISP). AbbVie grants stock-based awards to eligible employees pursuant to the AbbVie 2013 Incentive Stock Program (2013 ISP),Amended Plan, which provides for several different forms of benefits, including nonqualifiednon-qualified stock options, RSAs, RSUs and various performance-based awards. Under the 2013 ISP, 100Amended Plan, a total of 144 million shares of AbbVie common stock werehave been reserved for issuance as awards to AbbVie employees. The 2013 ISP also facilitated the assumption of certain awards granted under Abbott’s incentive stock program, which were adjusted and converted into Abbott and AbbVie stock-based awards as a result of AbbVie's separation from Abbott.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 86 |
AbbVie measures compensation expense for stock-based awards based on the grant date fair value of the awards and the estimated number of awards that are expected to vest. Forfeitures are estimated based on historical experience at the time of grant and are revised in subsequent periods if actual forfeitures differ from those estimates. Compensation cost for stock-based awards is amortized over the service period, which could be shorter than the vesting period if an employee is retirement eligible. Retirement eligible employees generally are those who are age 55 or older and have at least ten10 years of service.
Stock-based compensation expense is principally related to awards issued pursuant to the 2013 ISP and the Amended Plan and is summarized as follows:
|
| | | | | | | | | | | |
| | Years ended December 31, |
| (in millions) | 2018 | | 2017 | | 2016 |
| Cost of products sold | $ | 27 |
| | $ | 23 |
| | $ | 22 |
|
| Research and development | 169 |
| | 159 |
| | 193 |
|
| Selling, general and administrative | 225 |
| | 183 |
| | 181 |
|
| Pre-tax compensation expense | 421 |
| | 365 |
| | 396 |
|
| Tax benefit | 73 |
| | 73 |
| | 104 |
|
| After-tax compensation expense | $ | 348 |
| | $ | 292 |
| | $ | 292 |
|
| | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Cost of products sold | $ | 46 | | | $ | 47 | | | $ | 29 | |
| Research and development | 226 | | | 247 | | | 171 | |
| Selling, general and administrative | 420 | | | 459 | | | 230 | |
| Pre-tax compensation expense | 692 | | | 753 | | | 430 | |
| Tax benefit | 126 | | | 131 | | | 80 | |
| After-tax compensation expense | $ | 566 | | | $ | 622 | | | $ | 350 | |
Realized excess tax benefits associated with stock-based compensation totaled $78$50 million in 2018, $712021, $34 million in 20172020 and $55$15 million in 2016. Since 2017, all excess tax benefits associated with stock-based awards have been recognized in the statement of earnings when the awards vest or settle, rather than in stockholders' equity as a result of the adoption of a new accounting pronouncement.
|
| | |
74 |2018 Form 10-K
| | |
2019.
Stock Options
Stock options awarded to employees typically have a contractual term of 10 years and generally vest in one-third increments over a three-year period. The exercise price is equal to at least 100% of the market value on the date of grant. The fair value is determined using the Black-Scholes model. The weighted-average grant-date fair values of stock options granted were $21.63$16.28 in 2018, $9.802021, $12.14 in 20172020 and $9.29$12.54 in 2016.2019.
In connection with the Allergan acquisition, during the second quarter of 2020, AbbVie issued 11.2 million stock options to holders of Allergan options as a result of the conversion of such options. These options were fair-valued using a lattice valuation model. Refer to Note 5 for additional information regarding the Allergan acquisition.
The following table summarizes AbbVie stock option activity in 2018:
|
| | | | | | | | | | | | |
| (options in thousands, aggregate intrinsic value in millions) | Options | | Weighted- average exercise price | | Weighted- average remaining life (in years) | | Aggregate intrinsic value |
| Outstanding at December 31, 2017 | 8,316 |
| | $ | 41.69 |
| | 5.1 | | $ | 458 |
|
| Granted | 634 |
| | 114.36 |
| | | | |
| Exercised | (2,781 | ) | | 28.75 |
| | | | |
| Lapsed | (26 | ) | | 17.03 |
| | | | |
| Outstanding at December 31, 2018 | 6,143 |
| | $ | 55.05 |
| | 6.2 | | $ | 242 |
|
| Exercisable at December 31, 2018 | 4,293 |
| | $ | 45.23 |
| | 5.3 | | $ | 202 |
|
| | | | | | | | | | | | | | | | | | | | | | | |
| (options in thousands, aggregate intrinsic value in millions) | Options | | Weighted- average
exercise price | | Weighted-average remaining
life (in years) | | Aggregate intrinsic value |
| Outstanding at December 31, 2020 | 15,691 | | | $ | 73.90 | | | 4.7 | | $ | 559 | |
| Granted | 1,147 | | | 105.94 | | | | | |
| Exercised | (4,278) | | | 57.77 | | | | | |
| Lapsed and forfeited | (186) | | | 105.28 | | | | | |
| Outstanding at December 31, 2021 | 12,374 | | | $ | 81.98 | | | 4.7 | | $ | 661 | |
| Exercisable at December 31, 2021 | 9,424 | | | $ | 78.03 | | | 3.6 | | $ | 541 | |
The total intrinsic value of options exercised was $215$239 million in 2018, $3712021, $186 million in 20172020 and $325$22 million in 2016.2019. The total fair value of options vested during 20182021 was $22$21 million. As of December 31, 2018, $62021, $10 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.
RSAs, RSUs and Performance Shares
RSUs awarded to employees other than senior executives and other key employees generally vest in one-thirdratable increments over a three year or four-year period. Recipients of these RSUs are entitled to receive dividend equivalents as dividends are declared and paid during the RSU vesting period.
The majority of the equity awards AbbVie grants to its senior executives and other key employees are performance-based. Such awards granted before 2016 consisted of RSAs or RSUs for which vesting was contingent upon AbbVie achieving a minimum annual return on equity (ROE). Since 2016, equityEquity awards granted to senior executives and other key employees consist of a combination of performance-vested RSUs and performance shares as well as non-qualified stock options described above. The performance-vested RSUs have the potential to vest in one-third increments during a three-year performance periodperiod. For awards granted in 2021 and 2020, performance is based on AbbVie's return on invested capital relative to a defined peer group of pharmaceutical, biotech and life science companies. For awards granted in 2019, the tranches tied to 2021 performance are based on AbbVie’s ROEreturn on
| | | | | | | | | | | |
87 | |2021 Form 10-K | | |
equity relative to a defined peer group of pharmaceutical, biotech and life sciences companies. The recipient may receive one1 share of AbbVie common stock for each vested award. The performance shares have the potential to vest over a three-year performance period and may be earned based on AbbVie’s EPS achievement and AbbVie’s total stockholder return (TSR) (a market condition) relative to a defined peer group of pharmaceutical, biotech and life sciences companies. Dividend equivalents on performance-vested RSUs and performance shares accrue during the performance period and are payable at vesting only to the extent that shares are earned.
The weighted-average grant-date fair value of RSAs, RSUs and performance shares generally is determined based on the number of shares/units granted and the quoted price of AbbVie’s common stock on the date of grant. The weighted-average grant-date fair values of performance shares with a TSR market condition are determined using the Monte Carlo simulation model.
The following table summarizes AbbVie RSA, RSU and performance share activity for 2018:
|
| | | | | | |
| (share units in thousands) | Share units | | Weighted-average grant date fair value |
| Outstanding at December 31, 2017 | 10,682 |
| | $ | 59.47 |
|
| Granted | 4,771 |
| | 103.31 |
|
| Vested | (5,073 | ) | | 59.41 |
|
| Forfeited | (512 | ) | | 73.45 |
|
| Outstanding at December 31, 2018 | 9,868 |
| | $ | 79.90 |
|
| | | | | | | | | | | |
| (share units in thousands) | Share units | | Weighted-average grant date fair value |
| Outstanding at December 31, 2020 | 15,918 | | | $ | 87.03 | |
| Granted | 7,556 | | | 105.79 | |
| Vested | (6,735) | | | 91.63 | |
| Forfeited | (1,849) | | | 83.35 | |
| Outstanding at December 31, 2021 | 14,890 | | | $ | 94.93 | |
The fair market value of RSAs, RSUs and performance shares (as applicable) vested was $583$718 million in 2018, $3482021, $618 million in 20172020 and $362$371 million in 2016.2019.
|
| | |
| | 2018 Form 10-K | 75
|
In connection with the Allergan acquisition, during the second quarter of 2020, AbbVie issued 8.2 million RSUs to holders of Allergan equity awards based on a conversion factor described in the transaction agreement. Refer to Note 5 for additional information regarding the Allergan acquisition.
As of December 31, 2018, $3072021, $592 million of unrecognized compensation cost related to RSAs, RSUs and performance shares is expected to be recognized as expense over approximately the next two years.
Cash Dividends
Cash dividends declared per common share totaled $3.95$5.31 in 2018, $2.632021, $4.84 in 20172020 and $2.35$4.39 in 2016.2019. The following table summarizes quarterly cash dividends declared during 2018, 20172021, 2020 and 2016:
|
| | | | | | | | | | | | | | | | |
| 2018 | | 2017 | | 2016 |
| Date Declared | | Payment Date | | Dividend Per Share | | Date Declared | | Payment Date | | Dividend Per Share | | Date Declared | | Payment Date | | Dividend Per Share |
| 11/02/18 | | 02/15/19 | | $1.07 | | 10/27/17 | | 02/15/18 | | $0.71 | | 10/28/16 | | 02/15/17 | | $0.64 |
| 09/07/18 | | 11/15/18 | | $0.96 | | 09/08/17 | | 11/15/17 | | $0.64 | | 09/09/16 | | 11/15/16 | | $0.57 |
| 06/14/18 | | 08/15/18 | | $0.96 | | 06/22/17 | | 08/15/17 | | $0.64 | | 06/16/16 | | 08/15/16 | | $0.57 |
| 02/15/18 | | 05/15/18 | | $0.96 | | 02/16/17 | | 05/15/17 | | $0.64 | | 02/18/16 | | 05/16/16 | | $0.57 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2021 | | 2020 | | 2019 |
| Date Declared | | Payment Date | | Dividend Per Share | | Date Declared | | Payment Date | | Dividend Per Share | | Date Declared | | Payment Date | | Dividend Per Share |
| 10/29/21 | | 02/15/22 | | $1.41 | | 10/30/20 | | 02/16/21 | | $1.30 | | 11/01/19 | | 02/14/20 | | $1.18 |
| 09/10/21 | | 11/15/21 | | $1.30 | | 09/11/20 | | 11/16/20 | | $1.18 | | 09/06/19 | | 11/15/19 | | $1.07 |
| 06/17/21 | | 08/16/21 | | $1.30 | | 06/17/20 | | 08/14/20 | | $1.18 | | 06/20/19 | | 08/15/19 | | $1.07 |
| 02/18/21 | | 05/14/21 | | $1.30 | | 02/20/20 | | 05/15/20 | | $1.18 | | 02/21/19 | | 05/15/19 | | $1.07 |
Stock Repurchase Program
The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management’s discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under these programs are recorded at acquisition cost, including related expenses and are available for general corporate purposes.
On February 15, 2018, AbbVie's board of directors authorized a new $10.0 billion stock repurchase program, which superseded AbbVie's previous stock repurchase program. On December 13, 2018, AbbVie's board of directors authorized a $5.0 billion increase to the existing $10.0 billion stock repurchase program. Under this authorization, AbbVie repurchased approximately 1096 million shares for $10.7 billion$670 million in 2018.2021, 8 million shares for $757 million in 2020 and 4 million shares for $300 million in 2019. AbbVie's remaining sharestock repurchase authorization was $4.3$2.5 billion as of December 31, 2018.
Under previous stock repurchase programs, AbbVie made open-market share repurchases of approximately 11 million shares for $1.3 billion in 2018, approximately 13 million shares for $1.0 billion in 2017 and approximately 34 million shares for $2.1 billion in 2016. Additionally, in 2016, AbbVie executed an ASR in connection with the Stemcentrx acquisition and repurchased approximately 60 million shares for $3.8 billion.
2021.
|
| | | | | | | | | | |
| | 76 |20182021 Form 10-K| | | 88 |
Accumulated Other Comprehensive Loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2018, 20172021, 2020 and 2016:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| (in millions) (brackets denote losses) | Foreign currency translation adjustments | | Net investment hedging activities | | Pension and post- employment benefits | | Marketable security activities | | Cash flow hedging activities | | Total |
| Balance as of December 31, 2015 | $ | (1,270 | ) | | $ | — |
| | $ | (1,378 | ) | | $ | 47 |
| | $ | 40 |
| | $ | (2,561 | ) |
| Other comprehensive income (loss) before reclassifications | (165 | ) | | 140 |
| | (194 | ) | | 7 |
| | 160 |
| | (52 | ) |
| Net losses (gains) reclassified from accumulated other comprehensive loss | — |
| | — |
| | 59 |
| | (8 | ) | | (24 | ) | | 27 |
|
| Net current-period other comprehensive income (loss) | (165 | ) | | 140 |
| | (135 | ) | | (1 | ) | | 136 |
| | (25 | ) |
| Balance as of December 31, 2016 | (1,435 | ) | | 140 |
| | (1,513 | ) | | 46 |
| | 176 |
| | (2,586 | ) |
| Other comprehensive income (loss) before reclassifications | 680 |
| | (343 | ) | | (480 | ) | | 29 |
| | (230 | ) | | (344 | ) |
| Net losses (gains) reclassified from accumulated other comprehensive loss | 316 |
| | — |
| | 74 |
| | (75 | ) | | (112 | ) | | 203 |
|
| Net current-period other comprehensive income (loss) | 996 |
| | (343 | ) | | (406 | ) | | (46 | ) | | (342 | ) | | (141 | ) |
| Balance as of December 31, 2017 | (439 | ) | | (203 | ) | | (1,919 | ) | | — |
| | (166 | ) | | (2,727 | ) |
| Other comprehensive income (loss) before reclassifications | (391 | ) | | 138 |
| | 84 |
| | (14 | ) | | 156 |
| | (27 | ) |
Net losses reclassified from accumulated other comprehensive loss | — |
| | — |
| | 113 |
| | 4 |
| | 157 |
| | 274 |
|
| Net current-period other comprehensive income (loss) | (391 | ) | | 138 |
| | 197 |
| | (10 | ) | | 313 |
| | 247 |
|
| Balance as of December 31, 2018 | $ | (830 | ) | | $ | (65 | ) | | $ | (1,722 | ) | | $ | (10 | ) | | $ | 147 |
| | $ | (2,480 | ) |
2019: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in millions) (brackets denote losses) | Foreign currency translation adjustments | | Net investment hedging activities | | Pension
and post-employment benefits | | Marketable security activities | | Cash flow hedging activities | | Total |
| Balance as of December 31, 2018 | $ | (830) | | | $ | (65) | | | $ | (1,722) | | | $ | (10) | | | $ | 147 | | | $ | (2,480) | |
| Other comprehensive income (loss) before reclassifications | (98) | | | 95 | | | (1,330) | | | 12 | | | 298 | | | (1,023) | |
| Net losses (gains) reclassified from accumulated other comprehensive loss | — | | | (21) | | | 87 | | | (2) | | | (157) | | | (93) | |
| Net current-period other comprehensive income (loss) | (98) | | | 74 | | | (1,243) | | | 10 | | | 141 | | | (1,116) | |
| Balance as of December 31, 2019 | (928) | | | 9 | | | (2,965) | | | — | | | 288 | | | (3,596) | |
| Other comprehensive income (loss) before reclassifications | 1,511 | | | (785) | | | (300) | | | — | | | (108) | | | 318 | |
| Net losses (gains) reclassified from accumulated other comprehensive loss | — | | | (14) | | | 198 | | | — | | | (23) | | | 161 | |
| Net current-period other comprehensive income (loss) | 1,511 | | | (799) | | | (102) | | | — | | | (131) | | | 479 | |
| Balance as of December 31, 2020 | 583 | | | (790) | | | (3,067) | | | — | | | 157 | | | (3,117) | |
| Other comprehensive income (loss) before reclassifications | (1,153) | | | 720 | | | 298 | | | — | | | 76 | | | (59) | |
| Net losses (gains) reclassified from accumulated other comprehensive loss | — | | | (21) | | | 223 | | | — | | | 75 | | | 277 | |
| Net current-period other comprehensive income (loss) | (1,153) | | | 699 | | | 521 | | | — | | | 151 | | | 218 | |
| Balance as of December 31, 2021 | $ | (570) | | | $ | (91) | | | $ | (2,546) | | | $ | — | | | $ | 308 | | | $ | (2,899) | |
Other comprehensive loss in 2018income (loss) for 2021 included foreign currency translation adjustments totaling a losslosses of $391$1.2 billion and the offsetting impact of net investment hedging activities totaling gains of $699 million, which waswere principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets. In 2017, AbbVie reclassified $316 million of historical currency translation losses from AOCI related to the liquidation of certain foreign entities following the enactment of U.S. tax reform. These losses were included in net foreign exchange loss in the consolidated statement of earnings and had no related income tax impacts. Other comprehensive loss in 2017 alsoincome (loss) for 2020 included foreign currency translation adjustments totaling a gaingains of $680$1.5 billion and the offsetting impact of net investment hedging activities totaling losses of $799 million, which waswere principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets. Other comprehensive loss in 2016 included foreign currency translation adjustments totaling a loss of $165 million, which was principally due to the impact of the weakening of the Euro on the translation of the company’scompany's Euro-denominated assets.
Other comprehensive income (loss) for 2019 included pension and post-employment benefit plan losses of $1.2 billion primarily due to an actuarial loss driven by lower discount rates. See Note 12 for additional information.
|
| | | | | | | | | | |
| 89 | 2018|2021 Form 10-K| 77
| | |
The table below presents the impact on AbbVie's consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) (brackets denote gains) | 2021 | | 2020 | | 2019 |
| Net investment hedging activities | | | | | |
Gains on derivative amount excluded from effectiveness testing(a) | $ | (26) | | | $ | (18) | | | $ | (27) | |
| Tax expense | 5 | | | 4 | | | 6 | |
| Total reclassifications, net of tax | $ | (21) | | | $ | (14) | | | $ | (21) | |
| Pension and post-employment benefits | | | | | |
Amortization of actuarial losses and other(b) | $ | 283 | | | $ | 251 | | | $ | 110 | |
| Tax benefit | (60) | | | (53) | | | (23) | |
| Total reclassifications, net of tax | $ | 223 | | | $ | 198 | | | $ | 87 | |
| Cash flow hedging activities | | | | | |
Losses (gains) on foreign currency forward exchange contracts(c) | $ | 87 | | | $ | (23) | | | $ | (167) | |
Gains on treasury rate lock agreements(a) | (24) | | | (24) | | | (3) | |
Losses (gains) on interest rate swap contracts(a) | 24 | | | 17 | | | (1) | |
| Tax expense (benefit) | (12) | | | 7 | | | 14 | |
| Total reclassifications, net of tax | $ | 75 | | | $ | (23) | | | $ | (157) | |
(a)Amounts are included in interest expense, net (see Note 11). |
| | | | | | | | | | | |
| years ended December 31 (in millions) (brackets denote gains) | 2018 | | 2017 | | 2016 |
| Pension and post-employment benefits | | | | | |
Amortization of actuarial losses and other(a) | $ | 141 |
| | $ | 107 |
| | $ | 85 |
|
| Tax benefit | (28 | ) | | (33 | ) | | (26 | ) |
| Total reclassifications, net of tax | $ | 113 |
| | $ | 74 |
| | $ | 59 |
|
| | | | | | |
| Cash flow hedging activities | | | | | |
Losses (gains) on designated cash flow hedges(b) | $ | 161 |
| | $ | (118 | ) | | $ | (20 | ) |
| Tax expense (benefit) | (4 | ) | | 6 |
| | (4 | ) |
| Total reclassifications, net of tax | $ | 157 |
| | $ | (112 | ) | | $ | (24 | ) |
| |
(a) | Amounts are included in the computation of net periodic benefit cost (see Note 11).(c)Amounts are included in cost of products sold (see Note 11). |
| |
(b) | Amounts are included in cost of products sold (see Note 10).
|
Other
In addition to common stock, AbbVie's authorized capital includes 200 million shares of preferred stock, par value $0.01. As of December 31, 2018, no2021, 0 shares of preferred stock were issued or outstanding.
Note 13 Income Taxes
Earnings Before Income Tax Expense
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Domestic | $ | (4,274 | ) | | $ | (2,678 | ) | | $ | (1,651 | ) |
| Foreign | 9,471 |
| | 10,405 |
| | 9,535 |
|
| Total earnings before income tax expense | $ | 5,197 |
| | $ | 7,727 |
| | $ | 7,884 |
|
Income Tax Expense
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Current | | | | | |
| Domestic | $ | 593 |
| | $ | 6,204 |
| | $ | 2,229 |
|
| Foreign | 434 |
| | 376 |
| | 498 |
|
| Total current taxes | $ | 1,027 |
| | $ | 6,580 |
| | $ | 2,727 |
|
| Deferred | | | | | |
| Domestic | $ | (1,497 | ) | | $ | (4,898 | ) | | $ | (792 | ) |
| Foreign | (20 | ) | | 736 |
| | (4 | ) |
| Total deferred taxes | $ | (1,517 | ) | | $ | (4,162 | ) | | $ | (796 | ) |
| Total income tax expense (benefit) | $ | (490 | ) | | $ | 2,418 |
| | $ | 1,931 |
|
Impacts Related to U.S. Tax Reform
The Tax Cuts and Jobs Act (the Act) was signed into law in December 2017, resulting in significant changes to the U.S. corporate tax system. The Act reduced the U.S. federal corporate tax rate from 35% to 21% and required companies to pay a one-time transition tax on a mandatory deemed repatriation of earnings of certain foreign subsidiaries that were previously untaxed. These changes were generally effective for tax years beginning in 2018.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 90 |
Note 14 Income Taxes | | |
78 |2018 Form 10-K
| | |
Earnings Before Income Tax Expense | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Domestic | $ | (1,644) | | | $ | (4,467) | | | $ | (2,784) | |
| Foreign | 14,633 | | | 7,865 | | | 11,210 | |
| Total earnings before income tax expense | $ | 12,989 | | | $ | 3,398 | | | $ | 8,426 | |
Income Tax Expense | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Current | | | | | |
| Domestic | $ | 1,987 | | | $ | 907 | | | $ | 102 | |
| Foreign | 351 | | | 194 | | | 320 | |
| Total current taxes | $ | 2,338 | | | $ | 1,101 | | | $ | 422 | |
| Deferred | | | | | |
| Domestic | $ | (839) | | | $ | (58) | | | $ | (137) | |
| Foreign | (59) | | | (2,267) | | | 259 | |
| Total deferred taxes | $ | (898) | | | $ | (2,325) | | | $ | 122 | |
| Total income tax expense (benefit) | $ | 1,440 | | | $ | (1,224) | | | $ | 544 | |
The Act also created a minimum tax on certain foreign sourced earnings. The taxability of the foreign earnings and the applicable tax rates are dependent on future events. The company’s accounting policy for the minimum tax on foreign sourced earnings is to report the tax effects on the basis that the minimum tax will be recognized in tax expense in the year it is incurred as a period expense.
Additionally, the Act significantly changed the timing and manner in which earnings of foreign subsidiaries are subject to U.S. tax. Therefore, unremitted foreign earnings previously considered indefinitely reinvested that were subject to the Act’s transition tax are no longer considered indefinitely reinvested. Post-2017 earnings subject to the U.S. minimum tax on foreign sourced earnings and the 100 percent foreign dividends received deduction are also not considered indefinitely reinvested earnings. As such, the company records foreign withholding tax liabilities related to the future cash repatriation of such earnings. However, the company considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon reversal (e.g., capital gain distribution) to be permanent in duration. The unrecognized tax liability is not practicable to determine.
Prior to the enactment of the Act, the company did not provide deferred income taxes on undistributed earnings of foreign subsidiaries that were indefinitely reinvested for continued use in foreign operations. Due to the provision of the Act that required a one-time deemed repatriation of earnings of foreign subsidiaries, in 2017, the company recorded a transition tax expense of $4.5 billion. The company also recognized income tax expense of $338 million related to transition tax on income from the sale of inventory in 2018. The transition tax is generally payable in eight annual installments.
Additionally, in 2017, the company remeasured certain deferred tax assets and liabilities based on tax rates at which they were expected to reverse in the future. In 2017, the net tax benefit of U.S. tax reform from the remeasurement of deferred taxes related to the Act and foreign tax law changes was $3.6 billion.
Given the complexity of the Act and anticipated guidance from the U.S. Treasury about implementing the Act, the SEC staff issued Staff Accounting Bulletin No. 118 (SAB 118) which allowed companies to record provisional amounts during a measurement period not extending beyond one year from the enactment date of the Act. As a result, in 2017, the company’s analysis and accounting for the tax effects of the Act was preliminary. In 2017, as a direct result of the Act, the company recorded $4.5 billion of transition tax expense, as well as $4.1 billion of net tax benefit for deferred tax remeasurement. Both of these amounts were provisional estimates, as the company had not fully completed its analysis and calculation of foreign earnings subject to the transition tax or its analysis of certain other aspects of the Act that impacted the remeasurement of deferred tax balances. In 2018, the company finalized its provisional estimates and recognized income tax expense related to the Act of $86 million, which primarily related to the transition tax expense on the one-time mandatory repatriation of previously untaxed earnings of foreign subsidiaries.
Effective Tax Rate Reconciliation
|
| | | | | | | | |
| years ended December 31 | 2018 | | 2017 | | 2016 |
| Statutory tax rate | 21.0 | % | | 35.0 | % | | 35.0 | % |
| Effect of foreign operations | (28.7 | ) | | (12.2 | ) | | (10.3 | ) |
| U.S. tax credits | (7.3 | ) | | (4.0 | ) | | (4.4 | ) |
| Impacts related to U.S. tax reform | 8.2 |
| | 12.0 |
| | — |
|
| Tax law change related to foreign currency | — |
| | — |
| | 2.4 |
|
| Stock-based compensation excess tax benefit | (1.5 | ) | | (0.9 | ) | | — |
|
| Tax audit settlements | (2.5 | ) | | (1.2 | ) | | — |
|
| All other, net | 1.4 |
| | 2.6 |
| | 1.8 |
|
| Effective tax rate | (9.4 | )% | | 31.3 | % | | 24.5 | % |
| | | | | | | | | | | | | | | | | |
| years ended December 31 | 2021 | | 2020 | | 2019 |
| Statutory tax rate | 21.0 | % | | 21.0 | % | | 21.0 | % |
| Effect of foreign operations | (5.4) | | | 2.4 | | | (8.4) | |
| U.S. tax credits | (2.8) | | | (10.6) | | | (3.3) | |
| Impacts related to U.S. tax reform | — | | | (1.1) | | | (1.6) | |
| Non-deductible expenses | 0.3 | | | 7.2 | | | 1.0 | |
| Tax law changes and related restructuring | (2.0) | | | (48.5) | | | 3.1 | |
| Tax audit settlements | (0.4) | | | (5.1) | | | (4.7) | |
| | | | | |
| All other, net | 0.4 | | | (1.3) | | | (0.6) | |
| Effective tax rate | 11.1 | % | | (36.0 | %) | | 6.5 | % |
The effective income tax rate fluctuates year to year due to the allocation of the company's taxable earnings among jurisdictions, as well as certain discrete factors and events in each year, including changes in tax law, acquisitions and collaborations. The effective income tax rates in 2018, 20172021, 2020 and 20162019 differed from the statutory tax rate principally due to changes in enacted tax rates and laws, the benefit fromimpact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities, changes in enacted tax rates and laws and related restructuring, tax audit settlements and accretion on contingent consideration. The 2020 effective income tax rate included the costrecognition of repatriation decisionsa net tax benefit of $1.7 billion related to changes in tax laws and Stemcentrx impairment related expenses.restructuring, including certain intra-group transfers of intellectual property and deferred tax remeasurement. The effective tax rates for these periods also reflected the benefit from U.S. tax credits principally related to research and development credits, the orphan drug tax credit and Puerto Rico excise tax credits. The Puerto Rico excise tax credits relate to legislation enacted by Puerto Rico that assesses an excise tax on certain products manufactured in Puerto Rico. The tax is levied on gross inventory purchases from entities in Puerto Rico and is included in cost of products sold in the consolidated statements of earnings. The majority of the tax is creditable for U.S. income tax purposes.
|
| | |
| | 2018 Form 10-K | 79
|
The effective income tax rate in 20182020 and 20172019 included impacts related to U.S. tax reform. Specific to 2018, thereThe Tax Cuts and Jobs Act (the Act) was a favorable impact of the effective date of provisions of the Act relatedsigned into law in December 2017, resulting in significant changes to the U.S. corporate tax system, including a one-time transition tax on a mandatory deemed repatriation of earnings fromof certain foreign subsidiaries.subsidiaries that were previously untaxed. The 2018Act also created a minimum tax on certain foreign sourced earnings. The company’s accounting policy for the minimum tax on foreign sourced earnings is to report the tax effects on the basis that the minimum tax will be recognized in tax expense in the year it is incurred as a period expense. The effective income tax raterates for 2019 also reflectsincluded the effects of Stemcentrx impairment related expenses. In addition, the company recognized a net tax benefit of $131 million in 2018 and $91 million in 2017 related to the resolution of various tax positions pertaining to prior years.
The effective income tax rate in 2016 included additional expense of $187 million related to the recognition of the tax effect of regulations issued by the Internal Revenue Service on December 7, 2016 that changed the determination of the U.S. taxability of foreign currency gains and losses related to certain foreign operations. | | | | | | | | | | | |
91 | |2021 Form 10-K | | |
Deferred Tax Assets and Liabilities | | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| Deferred tax assets | | | |
| Compensation and employee benefits | $ | 937 | | | $ | 1,109 | |
| Accruals and reserves | 667 | | | 438 | |
| Chargebacks and rebates | 837 | | | 555 | |
| Advance payments | 809 | | | 324 | |
| Net operating losses and other credit carryforwards | 10,095 | | | 2,765 | |
| Other | 1,234 | | | 1,371 | |
| Total deferred tax assets | 14,579 | | | 6,562 | |
| Valuation allowances | (9,391) | | | (1,203) | |
| Total net deferred tax assets | 5,188 | | | 5,359 | |
| Deferred tax liabilities | | | |
| Excess of book basis over tax basis of intangible assets | (4,711) | | | (5,274) | |
| Excess of book basis over tax basis in investments | (308) | | | (335) | |
| Other | (904) | | | (982) | |
| Total deferred tax liabilities | (5,923) | | | (6,591) | |
| Net deferred tax liabilities | $ | (735) | | | $ | (1,232) | |
|
| | | | | | | |
| as of December 31 (in millions) | 2018 | | 2017 |
| Deferred tax assets | | | |
| Compensation and employee benefits | $ | 529 |
| | $ | 556 |
|
| Accruals and reserves | 371 |
| | 315 |
|
| Chargebacks and rebates | 417 |
| | 305 |
|
| Advance payments | 867 |
| | 219 |
|
| Net operating losses and other credit carryforwards | 228 |
| | 208 |
|
| Other | 353 |
| | 429 |
|
| Total deferred tax assets | 2,765 |
| | 2,032 |
|
| Valuation allowances | (103 | ) | | (108 | ) |
| Total net deferred tax assets | 2,662 |
| | 1,924 |
|
| Deferred tax liabilities | | | |
| Excess of book basis over tax basis of intangible assets | (2,940 | ) | | (3,762 | ) |
| Excess of book basis over tax basis in investments | (211 | ) | | (181 | ) |
| Other | (250 | ) | | (203 | ) |
| Total deferred tax liabilities | (3,401 | ) | | (4,146 | ) |
| Net deferred tax liabilities | $ | (739 | ) | | $ | (2,222 | ) |
AsThe decrease in net deferred tax assets is primarily related to the utilization of December 31, 2018, gross state net operating losses were $717 million and other carryforwards offset by an increase in advance payments. The decrease in deferred tax credit carryforwards were $210 million. The state tax carryforwards expire between 2019 and 2038. Asliabilities is primarily related to amortization of December 31, 2018,intangible assets.
In connection with the Allergan acquisition, the company recorded adjustments within the measurement period in 2021 related to foreign net operating losslosses and other credit carryforwards were $427 million. Foreignthat are not expected to be realized. The adjustments reflected an increase of $8.2 billion to deferred tax assets and an offsetting increase to valuation allowances, resulting in no net operating loss carryforwards of $350 million expire between 2020 and 2028 and the remaining do not have an expiration period.impact to deferred tax assets.
The company had valuation allowances of $103 million$9.4 billion as of December 31, 20182021 and $108 million$1.2 billion as of December 31, 2017.2020. These were principally related to foreign and state net operating losses and other credit carryforwards that are not expected to be realized.
Current income taxes receivable were $488 million asAs of December 31, 20182021, the company had U.S. federal and $2.1state credit carryforwards of $214 million as well as U.S. federal, state and foreign net operating loss carryforwards of $34.4 billion, aswhich will expire at various times through 2041. The remaining U.S. federal and foreign loss carryforwards of December 31, 2017$3.2 billion have no expiration.
The Act significantly changed the timing and were includedmanner in prepaid expenses and otherwhich earnings of foreign subsidiaries are subject to U.S. tax. Therefore, unremitted foreign earnings subject to the Act’s transition tax are not considered indefinitely reinvested. Post-2017 earnings subject to the U.S. minimum tax on foreign sourced earnings or eligible for the consolidated balance sheets.
Unrecognized Tax Benefits
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Beginning balance | $ | 2,701 |
| | $ | 1,168 |
| | $ | 954 |
|
| Increase due to current year tax positions | 163 |
| | 1,768 |
| | 118 |
|
| Increase due to prior year tax positions | 110 |
| | 16 |
| | 111 |
|
| Decrease due to prior year tax positions | (36 | ) | | (2 | ) | | (7 | ) |
| Settlements | (79 | ) | | (233 | ) | | — |
|
| Lapse of statutes of limitations | (7 | ) | | (16 | ) | | (8 | ) |
| Ending balance | $ | 2,852 |
| | $ | 2,701 |
| | $ | 1,168 |
|
100 percent foreign dividends received deduction are also not considered indefinitely reinvested earnings. However, the company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon reversal (e.g., capital gain distribution) to be permanent in duration. The unrecognized tax liability is not practicable to determine.
|
| | | | | | | | | | |
| | 80 |20182021 Form 10-K| | | 92 |
AbbVie and Abbott entered into a tax sharing agreement, effective on the date of separation, which provides that Abbott is liable for and has indemnified AbbVie against all income tax liabilities for periods prior to the separation. AbbVie will be responsible for unrecognized tax benefits and related interest and penalties for periods after separation or in instances where an existing entity was transferred to AbbVie upon separation.Unrecognized Tax Benefits | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Beginning balance | $ | 5,264 | | | $ | 2,661 | | | $ | 2,852 | |
| Increase due to acquisition | — | | | 2,674 | | | — | |
| Increase due to current year tax positions | 208 | | | 91 | | | 113 | |
| Increase due to prior year tax positions | 137 | | | 59 | | | 499 | |
| Decrease due to prior year tax positions | (62) | | | (7) | | | (21) | |
| Settlements | (24) | | | (141) | | | (749) | |
| Lapse of statutes of limitations | (34) | | | (73) | | | (33) | |
| Ending balance | $ | 5,489 | | | $ | 5,264 | | | $ | 2,661 | |
If recognized, the net amount of potential tax benefits that would impact the company's effective tax rate is $2.7$5.2 billion in 20182021 and $2.6$5.0 billion in 2017.2020. Of the unrecognized tax benefits recorded in the table above as of December 31, 2018,2021, AbbVie would be indemnified for approximately $84$79 million. The “Increase"Increase due to current year tax positions”positions" and "Increase due to prior year tax positions" in the table above include amounts related to federal, state and international tax items. "Increase due to acquisition" in the table above includes amounts related to federal, state and international tax items. The "Increase dueitems recorded in acquisition accounting related to prior year tax positions" in the table above includes amounts relating to federal, state and international items as well as prior positions acquired through business development activities during the year.Allergan acquisition.
AbbVie recognizes interest and penalties related to income tax matters in income tax expense in the consolidated statements of earnings. AbbVie recognized gross income tax expense of $73$161 million in 2018, $242021, $142 million in 20172020 and $35$51 million in 2016,2019, for interest and penalties related to income tax matters. AbbVie had an accrual for the payment of gross interest and penalties of $190$803 million at December 31, 2018, $1202021, $642 million at December 31, 20172020 and $112$191 million at December 31, 2016.2019.
The company is routinely audited by the tax authorities in significant jurisdictions and a number of audits are currently underway. It is reasonably possible during the next twelve12 months that uncertain tax positions may be settled, which could result in a decrease in the gross amount of unrecognized tax benefits. Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitation, the company's gross unrecognized tax benefits balance may change within the next twelve12 months up to $486$225 million. All significant federal, state, local and international matters have been concluded for years through 2010.2008. The company believes adequate provision has been made for all income tax uncertainties.
Note 1415 Legal Proceedings and Contingencies
AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balanceFor litigation matters discussed below for litigation was approximately $350 million aswhich a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of December 31, 2018 and approximately $445 million as of December 31, 2017.loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows.
Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.
Several pending lawsuits filed against Unimed Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as In re: AndroGel Antitrust Litigation, MDL No. 2084. These cases, brought by private plaintiffs and the Federal Trade Commission (FTC), generally allege Solvay's patent litigation involving AndroGel was sham litigation and the 2006 patent litigation settlement agreements and related agreements with three generic companies violate federal antitrust laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. These cases include: (a) four individual plaintiff lawsuits; (b) three purported class actions; and (c) Federal Trade Commission v. Actavis, Inc. et al. Following the district court's dismissal of all plaintiffs' claims, appellate proceedings led to the reinstatement of the claims regarding the patent litigation settlements, which are proceeding in the district court. In July 2018, the court denied the private plaintiffs' motion for class certification.
Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits
|
| | | | | | | | | | |
| 93 | 2018|2021 Form 10-K| 81
| | |
pending in federal court consist of four4 individual plaintiff lawsuits and two2 consolidated purported class actions: one1 brought by three namedNiaspan direct purchasers of Niaspan and the other1 brought by ten named end-payer purchasers of Niaspan.Niaspan end-payors. The cases are consolidated for pre-trial proceedingspending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees.
In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with 3 generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. In May 2018, the California Court of Appeals ruled that the District Attorney’s Office may not bring monetary claims beyond the scope of Orange County.
In September 2014, the FTC2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that theAbbott's 2011 AndroGel patent litigation with two generic companies regarding AndroGellawsuit filed against Perrigo was sham litigation andlitigation. In October 2020, the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million, plus prejudgment interest. The court denied the FTC’s request for injunctive relief. AbbVie is appealing the court’s liability and disgorgement rulings and, based on an assessment of the merits of that appeal, no liability has been accrued for this matter. The FTC is also appealing aspects of the court’s trial ruling and the dismissal of its settlement-related claim. In July and August 2018, several direct AndroGel purchasers brought two individual and one class action cases inPerrigo lawsuit was transferred to the United States District Court for New Jersey. In September 2021, the Eastern District of Pennsylvania alleging sham litigation basedNew Jersey court granted AbbVie's motion for judgment on the court’s trial rulingpleadings in the FTC’s case. Those cases are stayed pendingPerrigo lawsuit, dismissing it with prejudice. Perrigo has appealed the appeals in the FTC’s case.dismissal.
InBetween March 2015, the State of Louisiana filed a lawsuit, State of Louisiana v. Fournier Industrie et Sante, et al., against AbbVie, Abbott and affiliated Abbott entities in Louisiana state court. Plaintiff alleges that patent applications and patent litigation filed and other alleged conduct from the early 2000's and before related to the drug TriCor violated Louisiana State antitrust and unfair trade practices laws. The lawsuit seeks monetary damages and attorneys' fees. Plaintiff has filed a writ of certiorari with the Louisiana Supreme Court seeking to appeal the August 2018 dismissal of this lawsuit by the Louisiana Court of Appeal.
In November 2014, aMay 2019, 12 putative class action lawsuit, Medical Mutual of Ohio v. AbbVie Inc., et al., waslawsuits were filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insuranceby indirect Humira purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as In re: Humira (Adalimumab) Antitrust Litigation. In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal.
Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act andconduct by Forest involving Namenda, violated state consumer fraudantitrust, unfair and deceptive trade practices, and unjust enrichment laws. The complaint seeksPlaintiffs generally seek monetary damages, injunctive relief and injunctive relief. attorneys’ fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as In July 2018,re: Namenda Indirect Purchaser Antitrust Litigation in the court deniedUnited States District Court for the plaintiff’s motion for class certification.Southern District of New York.
Product liability casesLawsuits are pending in which plaintiffsagainst Allergan Inc. generally allegealleging that AbbVieAllergan’s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys’ fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to final court approval.
Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with 6 generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief, and attorneys’ fees. The lawsuits, purported class actions filed on behalf of TRTs did not adequately warn about risksdirect and indirect purchasers of certain injuries, primarily heart attacks, strokesBystolic, are consolidated as In re: Bystolic Antitrust Litigation in the United States District Court for the Southern District of New York.
Government Proceedings
Lawsuits are pending against Allergan and blood clots.several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 4,000 claims3,130 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of IllinoisOhio under the MDL Rulesrules as In re: Testosterone Replacement Therapy Products LiabilityNational Prescription Opiate Litigation, MDL No. 2545.2804. Approximately 200251 of the claims against AbbVie are pending in various state courts. PlaintiffsThe plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals, and personal injury claimants, generally seek compensatory and punitive damages. Six cases have gone to trial. Four of those have resulted in complete verdicts In December 2021, a California state court reached a judgment for AbbVie: three by juriesAllergan and other defendants in the United States District Court fortrial of an opioid lawsuit by Orange, Los Angeles, and Santa Clara Counties and the Northern DistrictCity of Illinois in January, May,Oakland. In December 2021, Allergan reached an agreement to settle a lawsuit brought by the State of New York and June 2018,two New York counties, which also provides all other New York counties and one by a jurypolitical subdivisions the opportunity to participate in the Cook County, Illinois Circuit Court in August 2017. Another case in the United States District Court for the Northern District of Illinois resulted in a March 2018 jury verdict for AbbVie on strict liability and fraud and for the plaintiff on negligence and awarded $200,000 in compensatory damages and $3 million in punitive damages, which is the subject of post-trial proceedings. Another case in the United States District Court for the Northern District of Illinois resulted in a jury verdict for AbbVie on strict liability and for the plaintiff on remaining claims and an award of $140,000 in compensatory damages and $140 million in punitive damages in August 2017. In July 2018, the court vacated that verdict and ordered a new trial. In November 2018, AbbVie entered into a Master Settlement Agreement with the Plaintiffs’ Steering Committee in the MDL encompassing all existing claims in all courts. All proceedings in pending cases are effectively stayed, including post-trial proceedings in cases that had been tried to verdict with appellate rights preserved.
Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately 404 cases are pending in the United States District Court for the Southern District of Illinois, and approximately six others are pending in various other federal and state courts. Plaintiffs generally seek compensatory and punitive damages. Over ninety percent of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice. To date, approximately 185 cases have been dismissed with prejudice.
In November 2014, five individuals filed a putative class action lawsuit, Rubinstein, et al. v Gonzalez, et al., on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made
settlement.
|
| | | | | | | | | | |
| | 82 |20182021 Form 10-K| | | 94 |
In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al., in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico’s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act.
and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire.Shareholder and Securities Litigation
In June 2016, a lawsuit,Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five5 investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 20182019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages.
In May 2017, a shareholder derivative lawsuit, Ellis v. Gonzalez, et al., was filed in Delaware Chancery Court, alleging that AbbVie's directors breached their fiduciary duties in connection with statements made regarding the Shire transaction. The lawsuit sought unspecified compensatory damages for AbbVie, among other relief. In July 2018, the court dismissed this case with prejudice. In August 2018, plaintiff appealed that dismissal to the Delaware Supreme Court.
In September 2018, the Commissioner of the California Department of Insurance intervened in a qui tam lawsuit, State of California and Lazaro Suarez v. AbbVie Inc., et al., brought under the California Insurance Frauds Prevention Act, in California Superior Court for Alameda County. The Department of Insurance’s complaint alleges that, through patient and reimbursement support services and other services and items of value provided in connection with HUMIRA, AbbVie caused the submission of fraudulent commercial insurance claims for HUMIRA in violation of the California statute. The complaint seeks injunctive relief, an assessment of up to three times the amount ofgranted motions dismissing the claims at issue, and civil penalties.of 3 investment-fund plaintiffs, which they appealed. In addition, two federal securities lawsuits were filed in September (Pippins v. AbbVie Inc., et al.,March 2021, in the United States Districtfirst of those appeals, the dismissal was affirmed. NaN of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the Central DistrictCounty of California) andNew York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals.
In October (2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and then-chiefformer chief financial officer, alleging that reasons stated for HUMIRAHumira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the conduct allegedcourt granted plaintiffs' motion to certify a class.
Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the DepartmentUnited States District Court for the Southern District of Insurance’s complaint. New York as In November 2018,re: Allergan plc Securities Litigation. The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the Pippins case was voluntarily dismissed.court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class.
BeginningLawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan’s former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of 3 purported class actions and 1 individual action that have been consolidated in May 2016, the Patent Trial & Appeal Board of the U.S. Patent & Trademark Office (PTO) instituted five inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to three AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie’s appeal of the decisions is pending in theDistrict Court of Appeals for the Federal Circuit.District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation. In July 2021, the parties reached an agreement to settle the class action lawsuits, which received court approval in November 2021.
Product Liability and General Litigation
In March 2017, AbbVie2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed a lawsuit, AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd., in the United States District Court for the Northern District of California against Novartis Vaccinesseveral Allergan entities and Grifols Worldwide seeking a declaratory judgmentothers, alleging that eleven HCV-related patents licensedtheir conduct before the U.S. Patent Office resulted in false claims for payment being made to AbbViefederal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in 2002 are invalid.the lawsuit.
Intellectual Property Litigation
AbbVie isInc. and AbbVie Biotechnology Ltd are seeking to enforce certaintheir patent rights relatedrelating to adalimumab (a drug AbbVie sells under the trademark HUMIRA®)Humira). In a caseApril 2021 and May 2021, cases were filed in the United States District Court for the Northern District of Delaware in August 2017,Illinois against Alvotech hf. AbbVie alleges that Boehringer Ingelheim International GmbH’s, Boehringer Ingelheim Pharmaceutical, Inc.’s, and Boehringer Ingelheim Fremont, Inc.’sdefendant’s proposed biosimilar adalimumab product infringes certain AbbVie patents. AbbViepatents and seeks declaratory and injunctive relief. In August 2021, the court denied Defendant’s motion to dismiss on jurisdictional grounds in the first case; a motion in the second case remains pending. The court has set a trial on a subset of patents for August 2022. The court order provides that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In October 2021, the May 2021 declaratory judgment action filed by Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. in the United States Eastern District of Virginia was transferred to the Northern District of Illinois and subsequently dismissed.
Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsulestablets (a drug Pharmacyclics sells under the trademark IMBRUVICA®)Imbruvica). In February 2018, four separate casesCases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc.,court issued a decision holding all asserted patents infringed and Fresenius Kabi Oncology Limited; Shilpa Medicare Limited, Sun Pharma Global FZEvalid. The judgment precludes Defendants from obtaining regulatory approval and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., and Lek Pharmaceuticals D.D. In November 2018, Pharmacyclics filed a fifth suitlaunching until the last patent expires in the United States District Court for the District of Delaware against Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit-I and Unit-V. In each case, Pharmacyclics alleges the defendant’s proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief.2036. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA,Imbruvica, is the co-plaintiff in these suits.
| | | | | | | | | | | |
95 | |2021 Form 10-K | | |
Allergan USA, Inc., Allergan Sales, LLC, and Forest Laboratories Holdings Limited, wholly owned subsidiaries of AbbVie, are seeking to enforce patent rights relating to cariprazine (a drug sold under the trademark Vraylar). Litigation was filed in the United States District Court for the District of Delaware in December 2019 against Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE; Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.; and Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited. Allergan alleges defendants' proposed generic cariprazine products infringe certain patents and seeks declaratory and injunctive relief. Gedeon Richter Plc, Inc. which is in a global collaboration with Allergan concerning the development and marketing of Vraylar, is the co-plaintiff in this suit.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 96 |
Note 16 Segment and Geographic Area Information | | |
| | 2018 Form 10-K | 83
|
Note 15 Segment and Geographic Area InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in oneorder to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment—pharmaceutical products. segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
Substantially all of AbbVie's net revenues in the United States are to three3 wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:
|
| | | | | | | | | | | |
| years ended December 31 (in millions) | 2018 | | 2017 | | 2016 |
| Immunology | | | | | |
| HUMIRA | | | | | |
| United States | $ | 13,685 |
| | $ | 12,361 |
| | $ | 10,432 |
|
| International | 6,251 |
| | 6,066 |
| | 5,646 |
|
| Total | $ | 19,936 |
| | $ | 18,427 |
| | $ | 16,078 |
|
| Hematologic Oncology | | | | | |
| IMBRUVICA | | | | | |
| United States | $ | 2,968 |
| | $ | 2,144 |
| | $ | 1,580 |
|
| Collaboration revenues | 622 |
| | 429 |
| | 252 |
|
| Total | $ | 3,590 |
| | $ | 2,573 |
| | $ | 1,832 |
|
| VENCLEXTA | | | | | |
| United States | $ | 247 |
| | $ | 89 |
| | $ | 17 |
|
| International | 97 |
| | 33 |
| | 1 |
|
| Total | $ | 344 |
| | $ | 122 |
| | $ | 18 |
|
| HCV | | | | | |
| MAVYRET | | | | | |
| United States | $ | 1,614 |
| | $ | 277 |
| | $ | — |
|
| International | 1,824 |
| | 213 |
| | — |
|
| Total | $ | 3,438 |
| | $ | 490 |
| | $ | — |
|
| VIEKIRA | | | | | |
| United States | $ | 3 |
| | $ | 61 |
| | $ | 342 |
|
| International | 175 |
| | 723 |
| | 1,180 |
|
| Total | $ | 178 |
| | $ | 784 |
| | $ | 1,522 |
|
| Other Key Products | | | | | |
| Creon | | | | | |
| United States | $ | 928 |
| | $ | 831 |
| | $ | 730 |
|
| Lupron | | | | | |
| United States | $ | 726 |
| | $ | 669 |
| | $ | 663 |
|
| International | 166 |
| | 160 |
| | 158 |
|
| Total | $ | 892 |
| | $ | 829 |
| | $ | 821 |
|
| Synthroid | | | | | |
| United States | $ | 776 |
| | $ | 781 |
| | $ | 763 |
|
| Synagis | | | | | |
| International | $ | 726 |
| | $ | 738 |
| | $ | 730 |
|
| AndroGel | | | | | |
| United States | $ | 469 |
| | $ | 577 |
| | $ | 675 |
|
| Duodopa | | | | | |
| United States | $ | 80 |
| | $ | 61 |
| | $ | 37 |
|
| International | 350 |
| | 294 |
| | 256 |
|
| Total | $ | 430 |
| | $ | 355 |
| | $ | 293 |
|
| Sevoflurane | | | | | |
| United States | $ | 74 |
| | $ | 78 |
| | $ | 80 |
|
| International | 317 |
| | 332 |
| | 348 |
|
| Total | $ | 391 |
| | $ | 410 |
| | $ | 428 |
|
| Kaletra | | | | | |
| United States | $ | 55 |
| | $ | 71 |
| | $ | 116 |
|
| International | 281 |
| | 352 |
| | 433 |
|
| Total | $ | 336 |
| | $ | 423 |
| | $ | 549 |
|
| All other | $ | 319 |
| | $ | 876 |
| | $ | 1,199 |
|
| Total net revenues | $ | 32,753 |
| | $ | 28,216 |
| | $ | 25,638 |
|
| | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Immunology | | | | | |
| Humira | United States | $ | 17,330 | | | $ | 16,112 | | | $ | 14,864 | |
| International | 3,364 | | | 3,720 | | | 4,305 | |
| Total | $ | 20,694 | | | $ | 19,832 | | | $ | 19,169 | |
| Skyrizi | United States | $ | 2,486 | | | $ | 1,385 | | | $ | 311 | |
| International | 453 | | | 205 | | | 44 | |
| Total | $ | 2,939 | | | $ | 1,590 | | | $ | 355 | |
| Rinvoq | United States | $ | 1,271 | | | $ | 653 | | | $ | 47 | |
| International | 380 | | | 78 | | | — | |
| Total | $ | 1,651 | | | $ | 731 | | | $ | 47 | |
| Hematologic Oncology | | | | | |
| Imbruvica | United States | $ | 4,321 | | | $ | 4,305 | | | $ | 3,830 | |
| Collaboration revenues | 1,087 | | | 1,009 | | | 844 | |
| Total | $ | 5,408 | | | $ | 5,314 | | | $ | 4,674 | |
| Venclexta | United States | $ | 934 | | | $ | 804 | | | $ | 521 | |
| International | 886 | | | 533 | | | 271 | |
| Total | $ | 1,820 | | | $ | 1,337 | | | $ | 792 | |
| Aesthetics | | | | | |
Botox Cosmetic (a) | United States | $ | 1,424 | | | $ | 687 | | | $ | — | |
| International | 808 | | | 425 | | | — | |
| Total | $ | 2,232 | | | $ | 1,112 | | | $ | — | |
Juvederm Collection (a) | United States | $ | 658 | | | $ | 318 | | | $ | — | |
| International | 877 | | | 400 | | | — | |
| Total | $ | 1,535 | | | $ | 718 | | | $ | — | |
Other Aesthetics (a) | United States | $ | 1,268 | | | $ | 666 | | | $ | — | |
| International | 198 | | | 94 | | | — | |
| Total | $ | 1,466 | | | $ | 760 | | | $ | — | |
| Neuroscience | | | | | |
Botox Therapeutic (a) | United States | $ | 2,012 | | | $ | 1,155 | | | $ | — | |
| International | 439 | | | 232 | | | — | |
| Total | $ | 2,451 | | | $ | 1,387 | | | $ | — | |
Vraylar (a) | United States | $ | 1,728 | | | $ | 951 | | | $ | — | |
| | | | | | |
| | | | | | |
| Duodopa | United States | $ | 102 | | | $ | 103 | | | $ | 97 | |
| International | 409 | | | 391 | | | 364 | |
| Total | $ | 511 | | | $ | 494 | | | $ | 461 | |
Ubrelvy (a) | United States | $ | 552 | | | $ | 125 | | | $ | — | |
| | | | | | |
| | | | | | |
Other Neuroscience (a) | United States | $ | 667 | | | $ | 528 | | | $ | — | |
| International | 18 | | | 11 | | | — | |
| Total | $ | 685 | | | $ | 539 | | | $ | — | |
|
| | | | | | | | | | |
8497
| |20182021 Form 10-K
| | |
| | | | | | | | | | | | | | | | | | | | |
| years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| Eye Care | | | | | |
Lumigan/Ganfort (a) | United States | $ | 273 | | | $ | 165 | | | $ | — | |
| International | 306 | | | 213 | | | — | |
| Total | $ | 579 | | | $ | 378 | | | $ | — | |
Alphagan/Combigan (a) | United States | $ | 373 | | | $ | 223 | | | $ | — | |
| International | 156 | | | 103 | | | — | |
| Total | $ | 529 | | | $ | 326 | | | $ | — | |
Restasis (a) | United States | $ | 1,234 | | | $ | 755 | | | $ | — | |
| International | 56 | | | 32 | | | — | |
| Total | $ | 1,290 | | | $ | 787 | | | $ | — | |
Other Eye Care (a) | United States | $ | 523 | | | $ | 305 | | | $ | — | |
| International | 646 | | | 388 | | | — | |
| Total | $ | 1,169 | | | $ | 693 | | | $ | — | |
| Women's Health | | | | | |
Lo Loestrin (a) | United States | $ | 423 | | | $ | 346 | | | $ | — | |
| International | 14 | | | 10 | | | — | |
| Total | $ | 437 | | | $ | 356 | | | $ | — | |
| Orilissa/Oriahnn | United States | $ | 139 | | | $ | 121 | | | $ | 91 | |
| International | 6 | | | 4 | | | 2 | |
| Total | $ | 145 | | | $ | 125 | | | $ | 93 | |
Other Women's Health (a) | United States | $ | 209 | | | $ | 181 | | | $ | — | |
| International | 5 | | | 11 | | | — | |
| Total | $ | 214 | | | $ | 192 | | | $ | — | |
| Other Key Products | | | | | |
| Mavyret | United States | $ | 754 | | | $ | 785 | | | $ | 1,473 | |
| International | 956 | | | 1,045 | | | 1,420 | |
| Total | $ | 1,710 | | | $ | 1,830 | | | $ | 2,893 | |
| Creon | United States | $ | 1,191 | | | $ | 1,114 | | | $ | 1,041 | |
| Lupron | United States | $ | 604 | | | $ | 600 | | | $ | 720 | |
| International | 179 | | | 152 | | | 167 | |
| Total | $ | 783 | | | $ | 752 | | | $ | 887 | |
Linzess/Constella (a) | United States | $ | 1,006 | | | $ | 649 | | | $ | — | |
| International | 32 | | | 18 | | | — | |
| Total | $ | 1,038 | | | $ | 667 | | | $ | — | |
| Synthroid | United States | $ | 767 | | | $ | 771 | | | $ | 786 | |
| All other | | $ | 2,673 | | | $ | 2,923 | | | $ | 2,068 | |
| Total net revenues | $ | 56,197 | | | $ | 45,804 | | | $ | 33,266 | |
(a)Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 98 |
Net revenues to external customers by geographic area, based on product shipment destination, were as follows:
| | | years ended December 31 (in millions) | 2018 | | 2017 | | 2016 | years ended December 31 (in millions) | 2021 | | 2020 | | 2019 |
| United States | $ | 21,524 |
| | $ | 18,251 |
| | $ | 15,947 |
| United States | $ | 43,510 | | | $ | 34,879 | | | $ | 23,907 | |
| Canada | | Canada | 1,397 | | | 1,159 | | | 813 | |
| Germany | | Germany | 1,223 | | | 1,049 | | | 909 | |
| Japan | 1,591 |
| | 764 |
| | 770 |
| Japan | 1,090 | | | 1,198 | | | 1,211 | |
| Germany | 1,292 |
| | 1,157 |
| | 1,104 |
| |
| France | | France | 936 | | | 797 | | | 695 | |
| China | | China | 857 | | | 471 | | | 195 | |
| Australia | | Australia | 533 | | | 527 | | | 395 | |
| Spain | | Spain | 519 | | | 453 | | | 472 | |
| Italy | | Italy | 506 | | | 379 | | | 372 | |
| United Kingdom | 855 |
| | 807 |
| | 776 |
| United Kingdom | 497 | | | 509 | | | 372 | |
| France | 783 |
| | 730 |
| | 713 |
| |
| Canada | 730 |
| | 659 |
| | 624 |
| |
| Italy | 652 |
| | 475 |
| | 523 |
| |
| Spain | 611 |
| | 521 |
| | 589 |
| |
| The Netherlands | 352 |
| | 362 |
| | 352 |
| |
| Brazil | 350 |
| | 410 |
| | 355 |
| Brazil | 368 | | | 406 | | | 359 | |
| All other countries | 4,013 |
| | 4,080 |
| | 3,885 |
| All other countries | 4,761 | | | 3,977 | | | 3,566 | |
| Total net revenues | $ | 32,753 |
| | $ | 28,216 |
| | $ | 25,638 |
| Total net revenues | $ | 56,197 | | | $ | 45,804 | | | $ | 33,266 | |
Long-lived assets, primarily net property and equipment, by geographic area were as follows:
| | | | | | | | | | | |
| as of December 31 (in millions) | 2021 | | 2020 |
| United States and Puerto Rico | $ | 3,369 | | | $ | 3,354 | |
| Europe | 1,400 | | | 1,534 | |
| All other | 341 | | | 360 | |
| Total long-lived assets | $ | 5,110 | | | $ | 5,248 | |
Note 17 Fourth Quarter Financial Results (unaudited) |
| | | | | | | |
| as of December 31 (in millions) | 2018 | | 2017 |
| United States and Puerto Rico | $ | 1,993 |
| | $ | 1,862 |
|
| Europe | 599 |
| | 621 |
|
| All other | 291 |
|
| 320 |
|
| Total long-lived assets | $ | 2,883 |
| | $ | 2,803 |
|
| | | | | | | |
| quarter ended December 31 (in millions except per share data) | 2021 | | |
| | |
| | 2018 Form 10-K | 85
|
Note 16 Quarterly Financial Data (unaudited)
|
| | | | | | | | |
| (in millions except per share data) | 2018 | | 2017 | |
| First Quarter | | | | |
| Net revenues | $ | 7,934 |
| | $ | 6,538 |
| |
| Gross margin | 6,007 |
| | 4,922 |
| |
Net earnings(a) | 2,783 |
| | 1,711 |
| |
| Basic earnings per share | $ | 1.74 |
| | $ | 1.07 |
| |
| Diluted earnings per share | $ | 1.74 |
| | $ | 1.06 |
| |
| Cash dividends declared per common share | $ | 0.96 |
| | $ | 0.64 |
| |
Second Quarter | | | | |
| Net revenues | $ | 8,278 |
| | $ | 6,944 |
| |
| Gross margin | 6,344 |
| | 5,415 |
| |
Net earnings(b) | 1,983 |
| | 1,915 |
| |
| Basic earnings per share | $ | 1.26 |
| | $ | 1.20 |
| |
| Diluted earnings per share | $ | 1.26 |
| | $ | 1.19 |
| |
| Cash dividends declared per common share | $ | 0.96 |
| | $ | 0.64 |
| |
Third Quarter | | | | |
| Net revenues | $ | 8,236 |
| | $ | 6,995 |
| |
| Gross margin | 6,401 |
| | 5,379 |
| |
Net earnings(c) | 2,747 |
| | 1,631 |
| |
| Basic earnings per share | $ | 1.81 |
| | $ | 1.02 |
| |
| Diluted earnings per share | $ | 1.81 |
| | $ | 1.01 |
| |
| Cash dividends declared per common share | $ | 0.96 |
| | $ | 0.64 |
| |
Fourth Quarter | | | | |
| Net revenues | $ | 8,305 |
| | $ | 7,739 |
| |
| Gross margin | 6,283 |
| | 5,458 |
| |
Net earnings (loss)(d) | (1,826 | ) | | 52 |
| |
| Basic earnings (loss) per share | $ | (1.23 | ) | | $ | 0.03 |
| |
| Diluted earnings (loss) per share | $ | (1.23 | ) | | $ | 0.03 |
| |
| Cash dividends declared per common share | $ | 1.07 |
| | $ | 0.71 |
| |
| |
(a) | First quarter results in 2018 included an after-tax benefit of $148 million related to the change in fair value of contingent consideration liabilities partially offset by after-tax litigation reserves charges of $100 million. First quarter results in 2017 included after-tax costs of $84 million related to the change in fair value of contingent consideration liabilities.
|
| |
(b) | Second quarter results in 2018 included after-tax charges of $500 million as a result of a collaboration agreement extension with Calico and $485 million related to the change in fair value of contingent consideration liabilities. Second quarter results in 2017 included an after-tax charge of $62 million to increase litigation reserves and after-tax costs of $61 million related to the change in fair value of contingent consideration liabilities.
|
| |
(c) | Third quarter results in 2018 included after-tax litigation reserves charges of $176 million and $95 million related to the change in fair value of contingent consideration liabilities. Third quarter results in 2017 included after-tax costs of $401 million related to the change in fair value of contingent consideration liabilities.
|
| |
(d) | Fourth quarter results in 2018 included an after-tax intangible asset impairment charge of
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Net revenues | $4.5 billion partially offset by an after-tax benefit of $375 million related | 14,886 | | | |
| Gross margin | 10,566 | | | |
Net earnings attributable to the change in fair value of contingent consideration liabilities. Fourth quarter results in 2017 were impacted by net charges relatedAbbVie Inc. | 4,044 | | | |
Basic earnings per share attributable to the December 2017 enactment of the Tax Cuts andAbbVie Inc. | $ | 2.27 | | | |
| Diluted earnings per share attributable to AbbVie Inc. | $ | 2.26 | | | |
| Cash dividends declared per common share | $ | 1.41 | | | |
|
| | | | | | | | | | |
8699
| |20182021 Form 10-K
| | |
Jobs Act, including an after-tax charge of $4.5 billion related to the one-time mandatory repatriation of previously untaxed earnings of foreign subsidiaries, partially offset by after-tax benefits of $3.3 billion due to remeasurement of net deferred tax liabilities and other related impacts. Additional after-tax costs that impacted fourth quarter results in 2017 included $244 million for an intangible asset impairment charge, $221 million for a charge to increase litigation reserves, $205 million as a result of entering into a global strategic collaboration with Alector and $79 million related to the change in fair value of contingent consideration liabilities.
|
| | |
| | 2018 Form 10-K | 87 |
Report Ofof Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of AbbVie Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of AbbVie Inc. and subsidiaries (the Company) as of December 31, 20182021 and 2017,2020, and the related consolidated statements of earnings, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2018,2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 20182021 and 2017,2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018,2021, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2018,2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 27, 201918, 2022 expressed an unqualified opinion thereon.
Adoption of ASU No. 2016-16
As discussed in Note 2 to the financial statements, the Company changed its method of accounting for the income tax consequences of intercompany transfers of assets other than inventory in 2018 due to the adoption of Accounting Standards Update (ASU) No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures tothat respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financialstatements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
| | | | | | | | | | | |
| | 2021 Form 10-K | | 100 |
| | | | | | | | |
| | Sales rebate accruals for Medicaid, Medicare and managed care programs |
| Description of the Matter | | As discussed in Note 2 to the consolidated financial statements under the caption “Revenue Recognition,” the Company established provisions for sales rebates in the same period the related product is sold. At December 31, 2021, the Company had $8,254 million in sales rebate accruals, a large portion of which were for rebates provided to pharmacy benefit managers, state government Medicaid programs, insurance companies that administer Medicare drug plans and private entities for Medicaid, Medicare and managed care programs. In order to establish these sales rebate accruals, the Company estimated its rebates based upon the identification of the products subject to a rebate, the applicable price and rebate terms and the estimated lag time between the sale and payment of the rebate. Auditing the Medicaid, Medicare and managed care sales rebate accruals was complex and required significant auditor judgment because the accruals consider multiple subjective and complex estimates and assumptions. These estimates and assumptions included the estimated inventory in the distribution channel, which impacts the lag time between the sale to the customer and payment of the rebate, and the final payer related to product sales, which impacts the applicable price and rebate terms. In deriving these estimates and assumptions, the Company used both internal and external sources of information to estimate product in the distribution channels, payer mix, prescription volumes and historical experience. Management supplemented its historical data analysis with qualitative adjustments based upon changes in rebate trends, rebate programs and contract terms, legislative changes, or other significant events which indicate a change in the reserve is appropriate. |
| How We Addressed the Matter in Our Audit | | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s sales rebate accruals for Medicaid, Medicare and managed care programs. This included testing controls over management’s review of the significant assumptions and other inputs used in the estimation of Medicaid, Medicare and managed care rebates, among others, including the significant assumptions discussed above. The testing was inclusive of management’s controls to evaluate the accuracy of its reserve judgments to actual rebates paid, rebate validation and processing, and controls to ensure that the data used to evaluate and support the significant assumptions was complete, accurate and, where applicable, verified to external data sources. To test the sales rebate accruals for Medicaid, Medicare, and managed care programs, our audit procedures included, among others, understanding and evaluating the significant assumptions and underlying data used in management’s calculations. Our testing of significant assumptions included corroboration to external data sources. We evaluated the reasonableness of assumptions considering industry and economic trends, product profiles, and other regulatory factors. We assessed the historical accuracy of management’s estimates by comparing actual activity to previous estimates and performed analytical procedures, based on internal and external data sources, to evaluate the completeness of the reserves. For Medicaid, we involved a specialist with an understanding of statutory reimbursement requirements to assess the consistency of the Company’s calculation methodologies with applicable government regulations and policy. |
| | |
| | | | | | | | | | | |
101 | |2021 Form 10-K | | |
| | | | | | | | |
| | Valuation of contingent consideration |
| Description of the Matter | | As discussed in Note 2 to the consolidated financial statements under the caption “Business Combinations” and in Note 11 under the caption “Financial Instruments and Fair Value Measures,” the Company recognized contingent consideration liabilities at the estimated fair value on the acquisition date in connection with applying the acquisition method of accounting for business combinations. Subsequent changes to the fair value of the contingent consideration liabilities were recorded within the consolidated statement of earnings in the period of change. At December 31, 2021, the Company had $14,887 million in contingent consideration liabilities, which represented a ‘Level 3’ fair value measurement in the fair value hierarchy due to the significant unobservable inputs used in determining the fair value and the use of management judgment about the assumptions market participants would use in pricing the liabilities. Auditing the valuation of contingent consideration liabilities was complex and required significant auditor judgment due to the use of a Monte Carlo simulation model and the high degree of subjectivity in evaluating certain assumptions required to estimate the fair value of contingent royalty payments. In particular, the fair value measurement was sensitive to the significant assumptions underlying the estimated amount of future sales of the acquired products. Management utilized its expertise within the industry, including commercial dynamics, trends and utilization, as well as knowledge of clinical development and regulatory approval processes to determine certain of these assumptions. |
| How We Addressed the Matter in Our Audit | | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s contingent consideration liabilities process including, among others, management’s process to establish the significant assumptions and measure the liability. This included testing controls over management’s review of the significant assumptions and other inputs used in the determination of fair value. The testing was inclusive of key management review controls to monitor and evaluate clinical development of the acquired products and estimated future sales, and controls to ensure that the data used to evaluate and support the significant assumptions was complete, accurate and, where applicable, verified to external data sources. To test the estimated fair value of contingent consideration liabilities, our audit procedures included, among others, inspecting the terms of the executed agreement, assessing the Monte Carlo simulation model used and testing the key contractual inputs and significant assumptions discussed above. We evaluated the assumptions and judgments considering observable industry and economic trends and standards, external data sources and regulatory factors. Estimated amounts of future sales were evaluated for reasonableness in relation to internal and external analyses, clinical development progress and timelines, probability of success benchmarks, and regulatory notices. Our procedures included evaluating the data sources used by management in determining its assumptions and, where necessary, included an evaluation of available information that either corroborated or contradicted management’s conclusions. We involved a valuation specialist to assess the Company’s Monte Carlo simulation model and to perform corroborative fair value calculations. |
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Chicago, Illinois
February 27, 201918, 2022
|
| | | | | | | | | | |
| | 88 |20182021 Form 10-K| | | 102 |
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures; Internal Control Over Financial Reporting
Evaluation of disclosure controls and procedures. The Chief Executive Officer, Richard A. Gonzalez, and the Chief Financial Officer, Robert A. Michael, evaluated the effectiveness of AbbVie's disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie's disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to AbbVie's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in internal control over financial reporting. There were no changes in AbbVie's internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) that have materially affected, or are reasonably likely to materially affect, AbbVie's internal control over financial reporting during the quarter ended December 31, 2018.2021.
Inherent limitations on effectiveness of controls. AbbVie's management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie's disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.
The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
Management's annual report on internal control over financial reporting. Management of AbbVie is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. AbbVie's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States. However, all internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting.
Management assessed the effectiveness of AbbVie's internal control over financial reporting as of December 31, 2018.2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on that assessment, management concluded that AbbVie maintained effective internal control over financial reporting as of December 31, 2018,2021, based on the COSO criteria.
The effectiveness of AbbVie's internal control over financial reporting as of December 31, 20182021 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report below, which expresses an unqualified opinion on the effectiveness of AbbVie's internal control over financial reporting as of December 31, 2018.2021.
|
| | |
| | 2018 Form 10-K | 89
|
Report of independent registered public accounting firm. The report of AbbVie's independent registered public accounting firm related to its assessment of the effectiveness of internal control over financial reporting is included below.
|
| | | | | | | | | | |
90103
| |20182021 Form 10-K
| | |
Report Ofof Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of AbbVie Inc.
Opinion on Internal Control over Financial Reporting
We have audited AbbVie Inc. and subsidiaries' internal control over financial reporting as of December 31, 2018,2021, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, AbbVie Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018,2021, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of AbbVie Inc. and subsidiaries as of December 31, 20182021 and 2017,2020, and the related consolidated statements of earnings, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2018,2021, and the related notes and our report dated February 27, 201918, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations on Internal Control Over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 27, 2019
|
| | |
| | 2018 Form 10-K | 91
|
ITEM 9B. OTHER INFORMATION
None.
18, 2022
| | | | | | | | | | | |
| | 2021 Form 10-K | | 104 |
ITEM 9B. OTHER INFORMATION None.
92 | | | | | | | | | | | |
105 | |20182021 Form 10-K
| | |
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Incorporated herein by reference are "Information Concerning Director Nominees," "The Board of Directors and its Committees—Committees of the Board of Directors," "Section 16(a) Beneficial Ownership Reporting Compliance," and "Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting" to be included in the 20192022 AbbVie Inc. Proxy Statement. The 20192022 Definitive Proxy Statement will be filed on or about March 22, 2019.21, 2022. Also incorporated herein by reference is the text found in this Form 10-K under the caption, "Executive Officers of the Registrant."Information about Our Executive Officers."
AbbVie's code of business conduct requires all its business activities to be conducted in compliance with all applicable laws, regulations and ethical principles and values. All directors, officers and employees of AbbVie are required to read, understand and abide by the requirements of the code of business conduct applicable to them. AbbVie's code of business conduct is available in the corporate governance section of AbbVie's investor relations website at www.abbvieinvestor.com.
Any waiver of the code of business conduct for directors or executive officers may be made only by AbbVie's audit committee. AbbVie will disclose any amendment to, or waiver from, a provision of the code of conduct for the principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, on its website within four business days following the date of the amendment or waiver. In addition, AbbVie will disclose any waiver from the code of business conduct for the other executive officers and for directors on the website.
AbbVie has a chief ethics and compliance officer who reports to the Vice Chairman, External Affairs and Chief Legal Officer and to the public policy committee. The chief ethics and compliance officer is responsible for overseeing, administering and monitoring AbbVie's compliance program.
ITEM 11. EXECUTIVE COMPENSATION
The material to be included in the 20192022 AbbVie Inc. Proxy Statement under the headings "Director Compensation," "Executive Compensation," and "Compensation Committee Report" is incorporated herein by reference. The 20192022 Definitive Proxy Statement will be filed on or about March 22, 2019.
21, 2022.
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |93
| 106 |
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
(a) Equity Compensation Plan Information.
The following table presents information as of December 31, 20182021 about AbbVie's equity compensation plans under which AbbVie common stock has been authorized for issuance: | | | | | | | | | | | | | | | | | |
| Plan Category | (a)
Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants and
rights (1) | | (b)
Weighted-
average exercise price of
outstanding options,
warrants and
rights (2) | | (c)
Number of securities remaining available for
future issuance under equity compensation plans (excluding securities
reflected in
column (a)) (3) |
| Equity compensation plans approved by security holders | 27,264,327 | | | $ | 81.98 | | | 74,075,427 | |
| Equity compensation plans not approved by security holders | — | | | — | | | — | |
| Total | 27,264,327 | | | $ | 81.98 | | | 74,075,427 | |
(1)Includes 138,085 shares issuable under AbbVie's Incentive Stock Program pursuant to awards granted by Abbott and adjusted into AbbVie awards in connection with AbbVie's separation from Abbott.
(2)The weighted-average exercise price does not include outstanding restricted stock units, restricted stock awards and performance shares that have no exercise price.
(3)Excludes shares issuable upon the exercise of stock options and pursuant to other rights granted under the Stemcentrx 2011 Equity Incentive Plan, which was assumed by AbbVie upon the consummation of its acquisition of Stemcentrx, Inc. As of December 31, 2021, 44,912 options remained outstanding under this plan. The options have a weighted-average exercise price of $17.63. No further awards will be granted under this plan.
(b)Information Concerning Security Ownership. Incorporated herein by reference is the material under the heading "Securities Ownership—Securities Ownership of Executive Officers and Directors" in the 2022 AbbVie Inc. Proxy Statement. The 2022 Definitive Proxy Statement will be filed on or about March 21, 2022.
|
| | | | | | | | | |
| Plan Category | (a) Number of securities to be issued upon exercise of outstanding options, warrants and rights (1) | | (b) Weighted- average exercise price of outstanding options, warrants and rights (2) | | (c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (3) |
| Equity compensation plans approved by security holders | 16,004,640 |
| | $ | 55.05 |
| | 68,259,802 |
|
| Equity compensation plans not approved by security holders | — |
| | — |
| | — |
|
| Total | 16,004,640 |
| | $ | 55.05 |
| | 68,259,802 |
|
| |
(1) | Includes 1,005,389 shares issuable under AbbVie's Incentive Stock Program pursuant to awards granted by Abbott and adjusted into AbbVie awards in connection with AbbVie's separation from Abbott. |
| |
(2) | The weighted-average exercise price does not include outstanding restricted stock units, restricted stock awards and performance shares that have no exercise price. |
| |
(3) | Excludes shares issuable upon the exercise of stock options and pursuant to other rights granted under the Stemcentrx 2011 Equity Incentive Plan, which was assumed by AbbVie upon the consummation of its acquisition of Stemcentrx, Inc. As of December 31, 2018, 286,634 options remained outstanding under this plan. The options have a weighted-average exercise price of $14.52. No further awards will be granted under this plan.
|
| |
(b) | Information Concerning Security Ownership. Incorporated herein by reference is the material under the heading "Securities Ownership—Securities Ownership of Executive Officers and Directors" in the 2019 AbbVie Inc. Proxy Statement. The 2019 Definitive Proxy Statement will be filed on or about March 22, 2019.
|
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The material to be included in the 20192022 AbbVie Inc. Proxy Statement under the headings "The Board of Directors and its Committees," "Corporate Governance Materials," and "Procedures for Approval of Related Person Transactions" is incorporated herein by reference. The 20192022 Definitive Proxy Statement will be filed on or about March 22, 2019.21, 2022.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The material to be included in the 20192022 AbbVie Inc. Proxy Statement under the headings "Audit Fees and Non-Audit Fees" and "Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Registered Public Accounting Firm" is incorporated herein by reference. The 20192022 Definitive Proxy Statement will be filed on or about March 22, 2019.
21, 2022.
|
| | | | | | | | | | |
94107
| |20182021 Form 10-K
| | |
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)Documents filed as part of this Form 10-K.
(1)Financial Statements: See Item 8, "Financial Statements and Supplementary Data," on page 48 hereof, for a list of financial statements.
(2)Financial Statement Schedules: All schedules omitted are inapplicable or the information required is shown in the consolidated financial statements or notes thereto.
(3)Exhibits Required by Item 601 of Regulation S-K: The information called for by this paragraph is set forth in Item 15(b) below.
(b) Exhibits:
| |
(a) | Documents filed as part of this Form 10-K. |
| |
(1) | Financial Statements: See Item 8, "Financial Statements and Supplementary Data," on page 42 hereof, for a list of financial statements.
|
| |
(2) | Financial Statement Schedules: All schedules omitted are inapplicable or the information required is shown in the consolidated financial statements or notes thereto.
|
| |
(3) | Exhibits Required by Item 601 of Regulation S-K: The information called for by this paragraph is set forth in Item 15(b) below.
|
|
| | | |
Exhibit Number | | Exhibit Description | |
|
| | *Transaction Agreement, and Plan of Merger, dated as of AprilJune 25, 2016, by and among Stemcentrx, Inc.,2019, between AbbVie Inc., Sirius Sonoma Corporation, AbbVie Stemcentrx LLC (formerly Sirius Sonoma LLC)Allergan plc and solely for the purposes set forth therein, Fertile ValleyVenice Subsidiary, LLC (incorporated by reference to Exhibit 2.1 of AbbVie’s Current Report on Form 8-K/A filed on May 6, 2016). |
|
| | *Amendment No. 1, dated as of May 28, 2016, to the Agreement and Plan of Merger, dated as of April 25, 2016, by and among Stemcentrx, Inc., AbbVie Inc., Sirius Sonoma Corporation, AbbVie Stemcentrx LLC (formerly Sirius Sonoma LLC) and, solely for the purposes set forth therein, Fertile Valley LLC (incorporated by reference to Exhibit 2.2 of AbbVie’scompany’s Current Report on Form 8-K filed on June 1, 2016)25, 2019). | |
|
| | | |
| | | |
| | | |
|
| | |
|
| | | |
|
| | | |
|
| | | |
| | | |
|
| | | |
|
| | | |
|
| | | |
|
| | *Supplemental Indenture No. 4, dated as of November 17, 2016, among AbbVie Inc., U.S. Bank National Association, as trustee, Elavon Financial Services DAC, U.K. Branch, as paying agent and Elavon Financial Services DAC, as transfer agent and registrar, including forms of notes (incorporated by reference to Exhibit 4.1 of the company's Current Report on Form 8-K filed on November 17, 2016). | |
|
| | | |
| | | | | | | | | | | |
| | |
| | 20182021 Form 10-K |95
| 108 |
|
| | | | | | | | | | |
Exhibit Number | | Exhibit Description | |
|
| | *Supplemental Indenture No. 6, dated September 26, 2019, among AbbVie Inc., U.S. Bank National Association, as trustee, transfer agent and registrar, and Elavon Financial Services DAC, UK Branch, as paying agent, including forms of notes (incorporated by reference to Exhibit 4.2 of the company’s Current Report on Form 8-K filed on September 26, 2019). | |
| | | |
| | | |
| | *Supplemental Indenture No. 9, dated May 14, 2020, among AbbVie Inc., U.S. Bank and National Association, as trustee, transfer agent and registrar, and Elavon Financial Services DAC, U.K. Branch, as paying agent (incorporated by reference to Exhibit 4.15 of the company's Current Report on Form 8-K filed on May 14, 2020). | |
| | *Agency Agreement, dated as of November 17, 2016, among AbbVie Inc., U.S. Bank National Association, as trustee, Elavon Financial Services DAC, U.K. Branch, as paying agent and Elavon Financial Services DAC, as transfer agent and registrar (incorporated by reference to Exhibit 4.2 of the company's Current Report on Form 8-K filed on November 17, 2016). | |
| | *Agency Agreement, dated September 26, 2019, among AbbVie Inc., U.S. Bank National Association, as trustee, transfer agent and registrar, and Elavon Financial Services DAC, U.K. Branch, as paying agent (incorporated by reference to Exhibit 4.3 of the company’s Current Report on Form 8-K filed on September 26, 2019). | |
| | | |
| | *Agency Agreement, dated May 14, 2020, among AbbVie Inc., U.S. Bank National Association, as trustee, transfer agent and registrar, and Elavon Financial Services DAC, U.K. Branch, as paying agent and calculation agent (incorporated by reference to Exhibit 4.16 of the company’s Current Report on Form 8-K filed on May 14, 2020). | |
| | *Registration Rights Agreement, dated May 14, 2020, among AbbVie Inc. and Morgan Stanley & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., BNP Paribas Securities Corp., HSBC Securities (USA) Inc., Mizuho Securities USA LLC and Wells Fargo Securities, LLC (incorporated by reference to Exhibit 4.23 of the company’s Current Report on Form 8-K filed on May 14, 2020). | |
|
| | | |
|
| | | |
|
| | | |
|
| | | |
|
| | | |
|
| | |
|
| | | |
|
| | |
|
| | | |
|
| | | |
|
| | | |
|
| | |
|
| | |
|
| | |
|
| | |
|
| | |
|
| | |
|
| | | |
|
| | | |
| | | | | | | | | | | |
|
|2021 Form 10-K | | |
| | | | | | | | | | | |
Exhibit Number | | Exhibit Description | |
| | | |
| | | |
| | |
|
| | |
|
| | | |
Exhibit
Number
| | Exhibit Description |
|
| | |
|
| | |
|
| | |
|
| | | |
|
| | | |
|
| | | |
|
| | | |
|
| | | |
| | | |
| | | |
| | | |
|
| | | |
|
| | *Amended and Restated Revolving Credit Agreement, dated as of August 31, 2018,27, 2019, among AbbVie Inc., the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of the company’s Current Report on Form 8-K filed on September 6, 2018)August 30, 2019). | |
|
| | *364-Day Term LoanBridge Credit Agreement, dated as of May 17, 2018,June 25, 2019, among AbbVie Inc., Morgan Stanley Senior Funding, Inc. and the lenders and other parties party thereto and Bank of America, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of the company’s Current Report on Form 8-K filed on May 18, 2018)June 25, 2019). | |
|
| | |
|
| | *Underwriting Agreement, dated as of May 5, 2015, by andSeptember 17, 2019, among AbbVie Inc. and Morgan Stanley & Co. LLC, Barclays Capital Inc., DeutscheInternational plc, HSBC Bank Securities Inc.plc and Merrill Lynch Pierce, Fenner & Smith Incorporated, as representatives of the several other underwriters named therein (incorporated by reference to Exhibit 1.1 of the company's Current Report on Form 8-K filed on May 7, 2015). |
|
| | *Underwriting Agreement, dated as of May 9, 2016, by and among AbbVie Inc., and Barclays Capital Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters named in Schedule II thereto (incorporated by reference to Exhibit 1.1 of AbbVie’s Current Report on Form 8-K filed on May 12, 2016). |
|
| | *Underwriting Agreement, dated as of November 14, 2016, by and among AbbVie Inc., and Barclays Bank PLC, Deutsche Bank AG, London Branch, J.P. Morgan Securities plc, Merrill Lynch International and Morgan Stanley & Co. International plc, as representatives of the several other underwriters named therein (incorporated by reference to Exhibit 1.1 of the company's Current Report on Form 8-K filed on November 17, 2016). |
|
| | *Underwriting Agreement, dated September 13, 2018, by and among AbbVie Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BNP Paribas Securities Corp. (acting for themselves and as representatives of the several underwriters named therein) (incorporated by reference to Exhibit 1.1 of the company’s Current Report on Form 8-K filed on September 18, 2018)23, 2019). | |
| | | |
|
| | |
| | | |
| | | |
| | | |
| | | |
|
| | | |
|
| | | |
|
| | | |
| | | | | | | | | | | |
| | 2021 Form 10-K | | 110 |
| | | | | | | | | | | |
Exhibit Number | | Exhibit Description | |
|
| | | |
|
| | | |
|
| | |
|
| | |
| 101 | | 2018 Form 10-K | 97
|
|
| | | |
Exhibit
Number
| | Exhibit Description |
101 |
| | The following financial statements and notes from the AbbVie Inc. Annual Report on Form 10-K for the year ended December 31, 20182021 filed on February 27, 2019,18, 2022, formatted in XBRL:Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Earnings; (ii) Consolidated Statements of Comprehensive Income; (iii) Consolidated Balance Sheets; (iv) Consolidated Statements of Equity; (v) Consolidated Statements of Cash Flows; and (vi) the Notes to Consolidated Financial Statements. | |
| 104 |
| Cover Page Interactive Data File (the cover page from the AbbVie Inc. Annual Report on Form 10-K formatted as Inline XBRL and contained in Exhibit 101). | |
| | The AbbVie Inc. 20192021 Definitive Proxy Statement will be filed with the Securities and Exchange Commission under separate cover on or about March 22, 2019.21, 2022. | |
| |
* | * Incorporated herein by reference. Commission file number 001-35565. |
| |
** | Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto. |
** Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
Exhibits 32.1 and 32.2, above, are furnished herewith and should not be deemed to be "filed" under the Securities Exchange Act of 1934. AbbVie will furnish copies of any of the above exhibits to a stockholder upon written request to the Secretary, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064.
| | | | | | | | | | | |
111 | |2021 Form 10-K | | |
ITEM 16. FORM 10-K SUMMARY None.
|
| | | | | | | | | | |
| | 98 |20182021 Form 10-K| | | |
ITEM 16. FORM 10-K SUMMARY
None.
|
| | |
| | 2018 Form 10-K | 99
|
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, AbbVie Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| | | | | | | | | | | | | |
| AbbVie Inc. |
| By: | | /s/ RICHARD A. GONZALEZ |
| | Name: | | Richard A. Gonzalez |
| | Title: | | Chairman of the Board and
Chief Executive Officer
|
| Date: | | February 27, 201918, 2022 |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of AbbVie Inc. on February 27, 201918, 2022 in the capacities indicated below.
| | | | | | | | |
| /s/ RICHARD A. GONZALEZ | | /s/ ROBERT A. MICHAEL |
Richard A. Gonzalez
Chairman of the Board and
Chief Executive Officer
(Principal Executive Officer) | | Robert A. Michael
Vice Chairman, Finance and Commercial Operations and
Chief Financial Officer
(Principal Financial Officer) |
| | |
/s/ RICHARD A. GONZALEZ | | /s/ ROBERT A. MICHAEL |
Richard A. Gonzalez
Chairman of the Board and
Chief Executive Officer
(Principal Executive Officer)
| | Robert A. Michael
Senior Vice President,
Chief Financial Officer
(Principal Financial Officer)
|
| | |
| /s/ BRIAN L. DURKIN | | |
Brian L. Durkin
Vice President, Controller
(Principal Accounting Officer)
| | |
| | |
| /s/ ROBERT J. ALPERN, M.D. | | /s/ ROXANNE S. AUSTIN |
Robert J. Alpern, M.D.
Director of AbbVie Inc.
| | Roxanne S. Austin
Director of AbbVie Inc.
|
| | |
| /s/ WILLIAM H.L. BURNSIDE | | /s/ THOMAS C. FREYMAN |
William H.L. Burnside
Director of AbbVie Inc. | | Thomas C. Freyman
Director of AbbVie Inc. |
| | |
| /s/ BRETT J. HART |
William H.L. Burnside
Director of AbbVie Inc.
| | Brett J. Hart
Director of AbbVie Inc.
|
| | |
| /s/ EDWARD M. LIDDY |
Brett J. Hart
Director of AbbVie Inc. | | Edward M. Liddy
Director of AbbVie Inc. |
| | |
| /s/ MELODY B. MEYER |
Edward M. Liddy
Director of AbbVie Inc.
| | Melody B. Meyer
Director of AbbVie Inc.
|
| | |
| /s/ EDWARD J. RAPP |
Melody B. Meyer
Director of AbbVie Inc. | | Edward J. Rapp
Director of AbbVie Inc. |
| | |
| /s/ REBECCA B. ROBERTS |
Edward J. Rapp
Director of AbbVie Inc.
| | Rebecca B. Roberts
Director of AbbVie Inc.
|
| | |
| /s/ GLENN F. TILTON |
Rebecca B. Roberts
Director of AbbVie Inc. | | Glenn F. Tilton
Director of AbbVie Inc. |
| | |
| /s/ FREDERICK H. WADDELL | | |
Glenn F. Tilton
Frederick H. Waddell
Director of AbbVie Inc. | | Frederick H. Waddell
Director of AbbVie Inc.
|
|
| | | | | | | | | | |
100113
| |20182021 Form 10-K
| | |
